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Summary 
Summary 
 
The protein kinase A (PKA) signal transduction pathway is highly conserved from lower unicellular 
eukaryotes such as Saccharomyces cerevisiae to mammals. The evolutionary distance from yeast to 
mammals is, however, relatively low compared to the evolutionary distance to the first primitive 
eukaryotic organisms. In the protozoan parasite Trypanosoma brucei, which belongs to the 
evolutionary early branching order of Kinetoplastida, not a single complete signal transduction 
pathway has been uncovered yet. Since T. brucei is the causative agent of Human African Sleeping 
Sickness, a life threatening neglected tropical disease very difficult to treat, there is a strong demand 
for discovery, design and development of new drugs. Parasite-specific signal transduction components 
might represent promising drug targets. Previous work from this laboratory provided indications for 
retooling of cAMP/PKA signaling in T. brucei. The scope of this work was to identify and 
characterize known and novel components of cAMP/PKA signaling in the parasite. Cyclic AMP is 
produced by a large family of receptor-type adenylate cyclases (ACs) with atypical sequence and 
structural features. We could show that by regulation of cytokinesis and modulation of the host 
immune response, the second messenger plays an important intracellular as well as extracellular role 
in T. brucei. Surprisingly, the parasite PKA orthologue was insensitive to cAMP and thereby 
represents the first example of a PKA uncoupled from this second messenger. Instead, the kinase was 
activated by low temperature, a known inducer in the parasite’s life cycle. T. brucei shuttles between a 
mammalian host and an insect vector and hence faces dramatic and rapid alterations in the 
environmental conditions, e.g. changes in temperature, pH or nutrient availability. We provide 
evidence that T. brucei PKA is involved in signaling during temperature-dependent differentiation 
from the bloodstream to the insect stage in culture. Similarly, in the related kinetoplastid parasite 
Leishmania donovani, the causative agent of visceral leishmaniasis, PKA signaling showed strong 
stage-specificity with a rapid change in the abundance of PKA-specific downstream phosphorylations 
upon induction of promastigote (in the insect vector) to amastigote (in the mammalian host) 
differentiation. Moreover, we observed indirect activation of T. brucei PKA by the adenosine 
antimetabolite dipyridamole in vivo providing strong evidence for activation of PKA by (an) 
endogenous, purine nucleoside-related ligand(s). A small-scale chemical screen aiming to define the 
chemical space of the putative ligand(s) resulted in identification of several activators and inhibitors, 
which were subsequently used as tool to identify downstream components of PKA signaling in T. 
brucei. Expression profiling and phosphoproteomics analysis revealed involvement of the kinase in 
regulation of metabolism, ribosome biogenesis and translation, transport, protein folding, and motility, 
reminiscent of PKA downstream functions in other organisms. However, a substantial amount of the 
identified PKA downstream components were kinetoplastid- or even Trypanosoma-specific with 
mostly unknown function and hence point to parasite-specific functions of the kinase. The absence of 
genes with similarity to any known alternative cAMP receptors from trypanosomal genomes indicated 
the presence of unknown cAMP effectors. By a whole genome RNAi library screen selecting for cells 
resistant to elevated intracellular cAMP levels, we identified several novel cAMP response proteins 
(CARPs). Most importantly, CARP1, a protein exclusively found in kinetoplastids, acts as cAMP 
acceptor and might represent the entry point into a novel, kinetoplastid-specific cAMP signaling 
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Summary 
pathway. Since the discovered peculiarities of cAMP and PKA signaling in T. brucei are likely to be 
conserved within the kinetoplastid order, components of these pathways represent promising targets 
for drug development against kinetoplastid-caused diseases (Human African Sleeping Sickness, 
Chagas disease, Leishmaniasis). 	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Zusammenfassung 
Zusammenfassung 	  
Der Protein Kinase A (PKA) Signaltransduktionsweg ist hoch konserviert von niederen, einzelligen 
Eukaryoten wie z. B. der Bäckerhefe Saccharomyces cerevisiae bis hin zu Säugern. Die evolutionäre 
Distanz der Hefe zum Säuger ist jedoch relativ zur evolutionären Distanz zu den ersten, 
ursprünglichen Eukaryoten ziemlich gering. In Trypanosoma brucei, einem parasitischen Protozoen 
der Ordnung Kinetoplastida, welche sich in der Evolution sehr früh abgespalten hat, konnte bislang 
kein einziger kompletter Signaltransduktionsweg entschlüsselt werden. Da T. brucei die Afrikanische 
Schlafkrankheit versursacht, eine lebensbedrohliche, vernachlässigte tropische Erkrankung, welche 
nur schwer behandelbar ist, herrscht ein enormer Bedarf an der Entdeckung und Entwicklung neuer 
Therapeutika. Hierbei könnten Trypanosomen-spezifische Komponenten von 
Signaltransduktionswegen erfolgversprechende Zielstrukturen darstellen. Da vorhergehende Arbeiten 
aus diesem Labor einen Hinweis auf Besonderheiten der cAMP/PKA Signaltransduktion in T. brucei 
lieferten, war das Ziel der vorliegenden Arbeit, bekannte sowie neue Komponenten dieses 
Signalweges in T. brucei zu identifizieren und zu charakterisieren. Der sekundäre Botenstoff cAMP 
wird in dem Parasiten von einer großen Familie membranständiger, rezeptorartiger Adenylatzyklasen 
hergestellt, welche untypische Sequenz- und Struktureigenschaften aufweisen. Wir konnten zeigen, 
dass die Adenylatzyklasen intrazellulär für die Regulation der Zytokinese verantwortlich sind. 
Darüber hinaus konnten wir nachweisen, dass T. brucei cAMP nutzt, um das Immunsystem des Wirtes 
zu manipulieren und damit seine eigene Verbreitung zu optimieren. Überraschenderweise zeigte die T. 
brucei PKA im Gegensatz zu allen bisher charakterisierten PKAs aus den verschiedensten 
Organismen keine Sensitivität gegenüber cAMP. Stattdessen konnte die Kinase durch 
Temperaturerniedrigung, einem sogenannten Kälteschock, aktiviert werden, ein Stimulus, der eine 
wichtige Rolle bei der Stadiendifferenzierung des Parasiten spielt. T. brucei durchläuft während seines 
komplexen Lebenszyklus einen Wechsel zwischen einem Säugerwirt und einem Insektenvektor und ist 
deshalb gravierenden Änderungen der Umgebungsbedingungen, wie z. B. Temperatur, pH-Wert oder 
Nährstoffangebot, ausgesetzt. Tatsächlich konnten wir zeigen, dass die T. brucei PKA bei der Kälte-
induzierten Differenzierung der Blutstromform (im Säugerwirt) in die prozyklische Form (in der 
Tsetse-Fliege) in Kultur eine Rolle spielt. Auch in dem verwandten Kinetoplastiden Leishmania 
donovani, dem Erreger der viszeralen Leishmaniose, wies der PKA Signalweg eine starke 
Stadienspezifität auf mit rapider Änderung PKA-spezifischer Phosphorylierungen nach Induktion der 
Differenzierung vom promastigoten (im Insektenvektor) zum amastigoten (im Säugerwirt) Stadium, 
was möglicherweise auf eine Beteiligung an der Regulation der Stadiendifferenzierung hinweisen 
könnte. Darüber hinaus konnten wir beobachten, dass die T. brucei PKA in vivo indirekt durch den 
Adenosin-Antimetaboliten Dipyridamol aktiviert wird. Dies deutet auf Regulierbarkeit der Kinase 
durch einen (oder auch mehrere) endogenen Liganden, welcher Ähnlichkeit zu Purin-Nukleosiden 
aufweist, hin. Um die Struktur des/der möglichen endogenen Liganden weiter einzugrenzen, wurde ein 
chemischer Screen durchgeführt, anhand dessen mehrere Aktivatoren und Inhibitoren der T. brucei 
PKA identifiziert wurden. Diese eignen sich als hervorragende Werkzeuge, um nachfolgende 
Komponenten des PKA Signalweges zu identifizieren. Mittels Transkriptom- und 
Phosphoproteomanalysen konnten wir zeigen, dass die Kinase an der Regulierung von Stoffwechsel, 
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Zusammenfassung 
Ribosomen-Biogenese und Translation, Transport, Proteinfaltung und Motilität von T. brucei beteiligt 
ist. Diese Prozesse werden auch in anderen Eukaryoten durch PKA reguliert. Allerdings ist ein 
beträchtlicher Anteil der identifizierten Proteine Kinetoplastiden- oder sogar Trypanosomen-
spezifisch, was auf einzigartige Funktionen der PKA in diesen Organismen hinweist. Da das 
Trypanosomengenom keine Gene mit Ähnlichkeit zu bekannten, alternativen cAMP Rezeptoren aus 
anderen Organismen enthält, ist es sehr wahrscheinlich, dass bislang unbekannte cAMP 
Effektorproteine vorhanden sind. Mittels eines RNAi Screens, welcher auf Selektion von Zellen mit 
Resistenz gegenüber erhöhter intrazellulärer cAMP-Konzentration basierte, konnten wir mehrere neue 
„cAMP response proteins“ (CARPs) identifizieren. Besonders hervorzuheben ist dabei die 
Identifizierung von CARP1, ein cAMP-bindendes Protein, welches ausschließlich in Kinetoplastiden 
vorkommt und damit höchstwahrscheinlich die Eintrittsstelle in einen neuen, Kinetoplastiden-
spezifischen cAMP Signaltransduktionsweg darstellt. Da die Besonderheiten der cAMP und PKA 
Signaltransduktionswege in T. brucei offensichtlich innerhalb der Ordnung der Kinetoplastida 
konserviert sind, stellen Komponenten beider Signalwege vielversprechende Zielstrukturen zur 
Medikamentenentwicklung gegen Krankheiten, welche durch Kinetoplastiden verursacht werden 
(Afrikanische Schlafkrankheit, Chagas Krankheit, Leishmaniose), dar. 	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1. Introduction 
1. Introduction 
1.1 The cAMP/PKA signal transduction pathway 	  
The ability to specifically respond to changes in the extracellular environment is pivotal for unicellular 
as well as multicellular organisms. This is accomplished by various mechanisms of signal transduction 
with protein kinases representing major components of most signaling pathways. The cyclic AMP-
dependent protein kinase PKA has been identified almost 50 years ago (Walsh et al., 1968), ten years 
after the identification of its activator, the second messenger cyclic AMP (cAMP) (Rall and 
Sutherland, 1958), and is now one of the best studied protein kinases from a variety of eukaryotes. 
Together with the cGMP-dependent protein kinase PKG it belongs to the group of cyclic nucleotide-
regulated kinases. Several highly conserved components comprise the conventional cAMP/PKA signal 
transduction pathway of most eukaryotes (Figure 1.1, left): binding of an extracellular ligand, e.g. a 
hormone, to a 7-transmembrane (7-TM) G protein-coupled receptor (GPCR) induces dissociation of 
the alpha subunit (Gsα) of an associated heterotrimeric G protein, which subsequently activates a 
transmembrane adenylate cyclase (AC) to produce the second messenger cAMP. By binding to the 
regulatory subunits of PKA, cAMP induces a conformational change resulting in dissociation of active 
catalytic PKA subunits, which consequently phosphorylate a variety of downstream substrates 
(Skalhegg and Tasken, 2000). Deregulation of the cAMP/PKA signal transduction pathway has been 
implicated in a variety of human diseases including Carney complex (Kirschner et al., 2000), 
Cushing’s syndrome (Groussin et al., 2002; Beuschlein et al., 2014; Cao et al., 2014; Goh et al., 2014; 
Sato et al., 2014), or cancer (Gordge et al., 1996; Cho et al., 2000; Naviglio et al., 2010; Beristain et 
al., 2014). Hence, spatiotemporal specificity is crucial for cellular and organismal viability. This is 
accomplished by generation of cAMP microdomains via several independent mechanisms (Skalhegg 
and Tasken, 2000): 1) cAMP produced by ACs can be hydrolyzed by several different classes of 
phosphodiesterases (PDEs) or can be exported via specific transporters. 2) Distinctive isoforms of 
regulatory (PKAR) and catalytic (PKAC) PKA subunits with differences e.g. in their tissue-specific 
expression pattern, subcellular localization or substrate specificity constitute the PKA holoenzyme. 3) 
A-kinase anchoring proteins (AKAPs) provide spatial control of PKA activation by tethering PKAR 
and other components of the cAMP/PKA signaling pathway to specific subcellular sites (Dessauer, 
2009; Welch et al., 2010). 
 
 
	  	   17	  
1. Introduction 
 
Figure 1.1: Eukaryotic cyclic cAMP signaling pathways. Comparison of the conventional cAMP 
signaling pathway found in most eukaryotes (left) with cAMP signaling in Trypanosoma brucei 
(right). 
 
 
1.1.1 Evolutionary conservation of the cAMP/PKA signal transduction pathway 	  
Whereas ACs, PDEs and cAMP are ubiquitous signaling molecules suggested to be present in all 
kingdoms of life, the occurrence of a cAMP-regulated kinase is restricted to eukaryotes. The 
cAMP/PKA signal transduction pathway including all components described in chapter 1.1 has been 
identified and characterized in many eukaryotes ranging from protozoa like Dictyostelium discoideum 
to humans. However, there are a few exceptions: while in plants the existence of conventional GPCRs 
is under debate, and plant heterotrimeric G proteins are suggested to function independent of 7-TM 
receptors (Lagerstrom and Schioth, 2008; Tuteja, 2009; Urano et al., 2013; Taddese et al., 2014), 
genes encoding these signaling molecules seem to be completely absent from the genomes of parasitic 
protozoa of the order of Kinetoplastida (e.g. Trypanosoma brucei, Trypanosoma cruzi, Leishmania 
donovani) (El-Sayed et al., 2005; Parsons et al., 2005). It is speculated that in these organisms ACs 
might replace the receptor function of GPCRs (Gould and de Koning, 2011). A variable intracellular 
N-terminal domain, two membrane-spanning cassettes composed of six transmembrane domains each, 
and two large cytoplasmic catalytic domains comprise the common secondary structure of mammalian 
transmembrane ACs (Cooper, 2005; Dessauer, 2009) (Figure 1.2). In contrast, kinetoplastid ACs 
consist of a large variable extracellular N-terminal domain, followed by a single membrane-spanning 
region and a well-conserved intracellular, C-terminal catalytic domain (Gould and de Koning, 2011). 
In general, transmembrane ACs are activated by the alpha subunit of heterotrimeric G proteins (Gsα) 
to generate cAMP from ATP. In addition, isoform-specific regulation by the alpha subunit (Giα) of 
inhibitory heterotrimeric G proteins or by G protein βγ subunits has been observed (Defer et al., 2000; 
Hanoune and Defer, 2001). Moreover, AC activity can be controlled by calcium or by phosphorylation 
mediated by kinases such as PKA or PKC (Defer et al., 2000; Hanoune and Defer, 2001). 
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Figure 1.2: Schematic representation of the structures of mammalian (left) compared to 
trypanosomal (right) transmembrane adenylate cyclases. The picture was adapted from Naula and 
Seebeck (2000). Catalytic domains are indicated in red. In mammalian ACs, the two closely related 
subdomains C1 and C2 together form the catalytic domain. 
 
Cyclic nucleotide phosphodiesterases are found in all kingdoms of life and catalyze the hydrolytic 
cleavage of the 3’ phosphodiester bond of cAMP or cGMP, resulting in formation of 5’AMP or 
5’GMP, respectively (Bender and Beavo, 2006; Conti and Beavo, 2007; Francis et al., 2011). 
Typically, PDEs have an N-terminal regulatory domain and a conserved C-terminal catalytic domain 
encompassing several invariant residues. Based on differences in the primary amino acid sequence of 
the catalytic domain, PDEs are grouped into three classes. In unicellular organisms, all classes of 
PDEs have been identified, whereas metazoa express predominantly class I PDEs. The different 
classes can be further subdivided into families with differences in subcellular localization, regulatory 
properties, and catalytic characteristics. PDE activity can be regulated by diverse processes including 
phosphorylation by different kinases such as PKA or PKG, cyclic nucleotide binding to allosteric GAF 
domains, changes in expression levels, or interaction with other proteins. The major downstream 
effector of cAMP in eukaryotes is the cAMP-dependent protein kinase PKA. All PKA orthologues 
analyzed to date consist of regulatory and catalytic subunits. Whereas the mammalian genome 
encodes four different PKAR (RIα, RIβ, RIIα, RIIβ) and two to three different PKAC isoforms (Cα, 
Cβ, Cγ (only in primates)) with differences in their primary amino acid sequence, their tissue-specific 
expression pattern, sub-cellular localization and affinity to cAMP (Skalhegg and Tasken, 2000), the 
genomes of most unicellular eukaryotes contain only one PKAR gene and a variable number of PKAC 
genes. The regulatory PKA subunit PKAR shows a characteristic domain structure: an N-terminal 
dimerization/docking (DD) domain important for homodimerization and for interaction with A kinase 
anchoring proteins (AKAPs) is connected to two C-terminal cyclic nucleotide binding (CNB) 
domains, CNB-A and CNB-B, by a flexible linker, which contains an inhibitory pseudosubstrate 
(PKARI) or autophosphorylation site (PKARII) (Scholten et al., 2008). PKAC isoforms belong to the 
AGC kinase family, which is characterized by specific structural and sequence motifs within the 
kinase core and the C-terminal tail of the kinase. The N-terminal, in contrast, is unique to PKA and 
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highly variable between PKAC isoforms from different organisms (Haste et al., 2012). Almost all 
PKA holoenzymes analyzed to date are heterotetrameric proteins consisting of a dimer of regulatory 
subunits and two associated catalytic subunits. However, in some lower eukaryotes like Dictyostelium 
discoideum (Mutzel et al., 1987), Paramecium tetraurelia (Hochstrasser and Nelson, 1989) or the 
dinoflagellate Amphidinium operculatum (Leighfield et al., 2002), heterodimeric PKA holoenzymes 
have been described. The PKAR orthologue of the apicomplexan parasite Plasmodium falciparum 
lacks the N-terminal DD domain, suggesting either a dimeric R-C holoenzyme or heterotetramer 
formation by a so far unknown mechanism (Haste et al., 2012). Besides mediating homodimerization, 
the DD domain serves as docking site for interaction with AKAPs. AKAPs are important structural 
molecules ensuring spatiotemporal specificity of the cAMP/PKA signal transduction pathway in 
eukaryotes by tethering PKAR as well as other signaling components to defined sub-cellular 
organelles and membranes (Dessauer, 2009; Welch et al., 2010). So far, AKAPs have almost 
exclusively been identified in multicellular eukaryotes. However, in Chlamydomonas reinhardtii and 
Saccharomyces cerevisiae, functional AKAP homologues have been discovered, which structurally 
differ from their counterparts in multicellular eukaryotes (Gaillard et al., 2001; Griffioen et al., 2001; 
Griffioen et al., 2003; Sivadas et al., 2012). Whereas PKA orthologues have been identified in many 
eukaryotes ranging from primitive protozoa to humans, their existence in plants is highly questionable. 
Initially, it was commonly believed that plants completely lack signal transduction via cyclic AMP. 
However, in the last few decades its existence in various plant species has been proposed by a 
considerable number of reports (Lemtiri-Chlieh et al., 2001; Talke et al., 2003; Newton and Smith, 
2004; Bridges et al., 2005; Kaplan et al., 2007; Lomovatskaya et al., 2008; Gehring, 2010). Although 
there is some indirect, biochemical evidence for cAMP-dependent kinase activities in plants (Lemtiri-
Chlieh et al., 2001; Talke et al., 2003; Newton and Smith, 2004), genes with significant sequence 
similarities to putative PKAR orthologues have not been identified in plant genomes. Interestingly, 
however, BLAST searches with the consensus sequence for the CNB domain (Pfam PF00027) 
revealed the existence of two highly similar genes (AT2G20050.1 and AT2G20050.2 
(http://www.arabidopsis.org/)) with a tandem arrangement in the Arabidopsis genome bearing a 
serine/threonine kinase domain, two cAMP-binding domain-like domains, and one phosphatase 
domain (domain analysis tool: http://supfam.cs.bris.ac.uk/SUPERFAMILY/index.html). Whether the 
encoded proteins act as cAMP-dependent kinases is yet to be confirmed. Most of the Arabidopsis 
proteins carrying a CNB domain are annotated as cyclic nucleotide activated ion channels. Several 
studies demonstrate that these channels can be regulated by cyclic nucleotides, are able to conduct 
specific mono- and divalent cations, and are implicated in regulation of diverse cellular processes such 
as Ca2+ homeostasis, development, and defense responses (Balague et al., 2003; Talke et al., 2003; Ali 
et al., 2006; Gao et al., 2014). However, direct binding of cAMP has not been shown by any of these 
studies. It is speculated that a cyclic nucleotide-dependent change in the intracellular Ca2+ 
concentration might regulate calcium-dependent protein kinases and hence provide a crosstalk 
between cyclic nucleotide and calcium signaling (Talke et al., 2003). This would represent an example 
of cyclic nucleotide-dependent signaling involving kinases other than PKA. Apart from plants, cyclic 
nucleotide activated ion channels have also been identified in vertebrates and invertebrates with main 
functions in photo- and chemoreception as well as neuronal signal transmission (Kaupp and Seifert, 
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2002). In recent years, ion channels regulated by cAMP have also been discovered in prokaryotes 
(Karpen, 2004; Caldwell et al., 2010; Brams et al., 2014; Kowal et al., 2014). Another, just recently 
discovered class of cAMP effector proteins is the cAMP-regulated guanine nucleotide exchange factor 
Epac (exchange protein directly activated by cAMP) (isoforms Epac1 and Epac2) that regulates the 
activity of the small G-protein Rap1. Epacs have been identified in vertebrates and some invertebrates 
(Gancedo, 2013) and are implicated in regulation of diverse cellular processes including cell adhesion, 
differentiation, and apoptosis (Cheng et al., 2008). In prokaryotes, the main cAMP downstream 
effectors are transcription factors of the CRP (cAMP receptor protein) family (Kannan et al., 2007; 
Gancedo, 2013), which regulate the expression of a number of downstream genes and thereby control 
processes such as utilization of alternative sugars, motility, or virulence. Interestingly, the processes 
regulated by CRP family proteins are highly diverse between different types of bacteria. Finally, some 
pathogenic bacteria regulate their virulence by excretion of cAMP or ACs into host cells, resulting in 
manipulation of innate immune functions by modulating inflammatory mediator expression 
(McDonough and Rodriguez, 2012). 
 
1.1.2 Activation mechanism of PKA 	  
In the absence of cAMP, PKA exists as an inactive heterotetrameric R2C2 holoenzyme in most 
eukaryotes (exceptional R-C heterodimers in some lower eukaryotes: see chapter 1.1.1). The kinase is 
activated by the cooperative binding of two molecules of cAMP to each PKAR subunit: one molecule 
of cAMP binds to the C-terminal binding pocket (B domain) thereby rendering the N-terminal binding 
pocket (A domain) accessible for cAMP (Skalhegg and Tasken, 2000). This induces a conformational 
change and consequently displacement of the internal pseudosubstrate (PKARI) or 
autophosphorylation motif (PKARII) resulting in the release of an R subunit dimer and two free, 
catalytically active PKAC subunits, which subsequently phosphorylate serine and threonine residues 
on a variety of downstream substrates. The cyclic nucleotide-binding domain (CNB domain) is a 
highly conserved module of all cAMP-binding proteins from both pro- and eukaryotes. The phosphate 
binding cassette (PBC) is the hallmark motif for all CNB domains and ensures proper binding of 
cAMP by the presence of several invariant residues including a conserved arginine interacting with the 
exocyclic phosphate of cAMP and a glutamate mediating binding to the ribose 2’OH (Kannan et al., 
2007). A few examples of cAMP-independent activation of PKA have been described such as cross-
activation of PKA by cGMP (Shabb, 2001; Francis et al., 2010; Shabb, 2011) or activation of PKA via 
TGF-β (Wang et al., 1998; Yang et al., 2013), NFκB/IκB (Zhong et al., 1997) or AKAP110 (Niu et al., 
2001). Moreover, Saccharomyces cerevisiae PKA can be activated independently of cAMP by 
another, as yet unknown mechanism: under conditions of nitrogen or phosphate starvation, the 
addition of the limiting nutrient induces rapid activation of PKA by a cAMP- and PKAR-independent 
mechanism, also called the ‘Fermentable-Growth Medium (FGM) Pathway’ (Fuller and Rhodes, 
2012). 
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1.1.3 Downstream functions of cAMP/PKA signaling 	  
In mammalian cells, PKA is involved in regulation of a large variety of cellular processes including 
metabolism, differentiation, apoptosis, sperm motility, or cell cycle progression (Skalhegg and 
Tasken, 2000; Shabb, 2001; Pearce et al., 2010). Hence, deregulation of the cAMP/PKA signal 
transduction pathway plays a major role in the pathogenesis of cancer and other severe diseases. 
Several of these downstream functions of PKA are even conserved in unicellular eukaryotes. The PKA 
orthologues of the non-pathogenic fungus Saccharomyces cerevisiae and the protozoa Dictyostelium 
discoideum and Plasmodium falciparum are among the best-examined representatives in unicellular 
organisms. In Saccharomyces cerevisiae, the cAMP/PKA pathway is mainly controlled by the 
availability of extracellular nutrients and regulates growth, metabolism, differentiation, apoptosis, cell 
cycle progression, and stress responses (Wilson et al., 2010; Tamanoi, 2011; Fuller and Rhodes, 2012; 
Lastauskiene et al., 2014). In the slime mold Dictyostelium discoideum, the cAMP/PKA signaling 
pathway controls the transition from growth to development as well as the differentiation to 
subsequent developmental stages (Primpke et al., 2000; Saran et al., 2002). The PKA orthologue of 
the protozoan parasite Plasmodium falciparum has been implicated in a number of processes in 
malarial pathogenesis e.g. by modification of membrane permeability of red blood cells thereby 
ensuring survival in the host (Haste et al., 2012). PKA regulates downstream processes either directly 
at the level of substrate phosphorylation or at the level of protein synthesis involving all steps from 
transcriptional (via phosphorylation of transcription factors) (Shabb, 2001), posttranscriptional (via 
phosphorylation of RNA-binding proteins with transcript stabilizing/destabilizing functions) (Huang et 
al., 1995; Mizunuma et al., 2013), or translational control (Vaidyanathan et al., 2014). 
 
1.2 Signal transduction in T. brucei 
1.2.1 The model organism Trypanosoma brucei brucei 	  
Subspecies of Trypanosoma brucei, a unicellular, flagellated protozoan parasite belonging to the 
Kinetoplastida, an evolutionary early branching eukaryotic order, are the causative agents of Human 
African Trypanosomiasis (HAT) (T. brucei gambiense, T. brucei rhodesiense) and Nagana in cattle (T. 
brucei brucei) (Brun et al., 2010). The prevalence of these diseases is restricted to sub-Saharan 
African countries and correlates with the geographical extension of the tsetse fly (Glossina spp.), a 
blood-sucking insect responsible for transmission of T. brucei. HAT is a severe disease, usually fatal if 
untreated and is subdivided into two stages: the early stage is characterized by unspecific symptoms 
such as fever, headache, or itching at the site of the tsetse bite. As soon as the parasites cross the blood 
brain barrier, they infect the central nervous system initiating the late stage of the disease hallmarked 
by severe neurological dysfunctions ultimately resulting in coma and death. Treatment of HAT is 
complicated due to the high costs and the toxicity of some of the available drugs as well as the 
increasing emergence of drug-resistant trypanosome strains (Brun et al., 2010). Since T. brucei 
possesses a highly effective combination of independent and complementary mechanisms of immune 
evasion (Leung et al., 2014), preventive vaccination is not possible against HAT. The T. brucei cell is 
characterized by a single flagellum, which is connected to the cell body along the length of the cell 
(Figure 1.3). The flagellum exits the cytoplasm at the so-called flagellar pocket, an invagination of the 
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plasma membrane and the only site of endo- and exocytosis (Field and Carrington, 2009). The densely 
packed mitochondrial DNA constitutes the name-giving kinetoplast, which is located in close 
proximity to the basal body of the flagellum. The surface of T. brucei bloodstream forms (BSFs) 
living in the mammalian bloodstream is covered by a densely packed coat of variant surface 
glycoproteins (VSGs) (Manna et al., 2014). Whereas the trypanosomal genome encodes >1000 VSG 
genes, only one is expressed at a certain time. As soon as the mammalian immune system produces 
antibodies against the VSG coat, most of the parasites get eliminated. However, by antigenic variation 
involving mechanisms of homologous recombination and transcriptional silencing and activation, 
trypanosomes can exchange their VSG coat (Glover et al., 2013). Hence, periodical switching of the 
VSG coat is accompanied by periodical extinction of most of the parasites resulting in the typical, 
observed waves of parasitemia. This ensures a prolonged survival of the host and thereby increases the 
transmissibility to a new host. In addition, a recent study showed that antibodies against VSGs bound 
to the trypanosomal surface are moved by hydrodynamic forces related to motility to the posterior end 
of the cell and are internalized by endocytosis at the flagellar pocket (Engstler et al., 2007).  
 
 
Figure 1.3: Schematic representation of a T. brucei cell. The picture was adapted from 
http://www.ilri.org/InfoServ/Webpub/fulldocs/Ilrad90/Figures/fig%2025%20p45.gif. The arrow 
indicates the swimming direction. 
 
Its early evolutionary divergence and several special molecular and cellular features such as antigenic 
variation (Glover et al., 2013) or a highly unconventional polycistronic gene expression exclusively 
regulated at the posttranscriptional level (Clayton, 2002; Haile and Papadopoulou, 2007) as well as the 
existence of a subspecies non-pathogenic for humans made T. brucei an interesting model organism. 
Furthermore, complete genome sequences of an increasing number of species and strains 
(www.tritrypdb.org) combined with the available variety of tools for genetic manipulation, e.g. gene 
replacement by homologous recombination (Carruthers et al., 1993; Li and Gottesdiener, 1996; 
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McCulloch et al., 2004) or RNAi-mediated gene silencing (Ngo et al., 1998; Bringaud et al., 2000; Shi 
et al., 2000; Clayton et al., 2005), provide an excellent opportunity to study unique as well as 
evolutionary conserved cellular mechanisms in these evolutionary early branching eukaryotes.  
 
1.2.2  Putative components of the T. brucei cAMP/PKA signal transduction pathway 	  
Whereas conventional cAMP/PKA signaling pathways are found in several unicellular eukaryotes 
such as Saccharomyces cerevisiae (Santangelo, 2006) or Dictyostelium discoideum (Saran et al., 
2002), kinetoplastid cAMP signaling seems to be significantly different (Figure 1.1, right). First 
evidence for the presence of cAMP in trypanosomes dates back to the year 1974 when Walter and co-
workers reported AC and PDE activities in T. b. gambiense (Walter, 1974; Walter et al., 1974) 
followed by the discovery of changes in the intracellular cAMP concentration between different life 
cycle stages of T. lewisi by Strickler and Patton (1975). In the following decades, multiple reports 
analyzed putative components and functions of cAMP signaling in kinetoplastids (e.g. Naula and 
Seebeck, 2000; Seebeck et al., 2001; Seebeck et al., 2004; Laxman and Beavo, 2007; Oberholzer et 
al., 2007; Bhattacharya et al., 2008, 2009; Biswas et al., 2011; Gould and de Koning, 2011; 
Bhattacharya et al., 2012; de Koning et al., 2012; Salmon et al., 2012a; Salmon et al., 2012b; Gould et 
al., 2013; Lopez et al., 2014; Saada et al., 2014; Vij et al., 2014). Apart from the apparent absence of 
genes encoding GPCRs or heterotrimeric G proteins from kinetoplastid genomes (see chapter 1.1.1), 
the existence of a cAMP-dependent kinase activity in kinetoplastids is an open question. As in most 
other eukaryotes, cAMP is produced by ACs and degraded by PDEs. Kinetoplastid ACs, however, 
diverge from their mammalian orthologues in structure and sequence (see chapter 1.1.1) and were 
suggested to replace the receptor function of GPCRs. Yet, no ligand has been identified to date. 
Activation of trypanosomal ACs has been observed upon exposure to stress conditions such as acid 
treatment or osmotic lysis (Voorheis and Martin, 1980; Rolin et al., 1996; Nolan et al., 2000). 
Interestingly, there is a remarkable expansion of the AC family in the genomes of the African 
trypanosomes T. brucei and T. congolense (www.tritrypdb.org), which live extracellularly in the 
mammalian bloodstream, in contrast to T. cruzi or L. donovani, kinetoplastid parasites developing 
intracellularly in host cells. Four families of cAMP-specific class I PDEs have been characterized in T. 
brucei with structural similarities to mammalian PDEs within their catalytic domain (Seebeck et al., 
2001; Seebeck et al., 2004; Laxman and Beavo, 2007; Gould and de Koning, 2011). The two members 
of the T. brucei PDEB family, PDEB1 and PDEB2, are encoded by two tandemly arranged genes with 
high sequence similarity and represent the major cAMP-degrading activity in BSFs. The lethal 
phenotype resulting from genetic or pharmacological inhibition of both enzymes simultaneously in 
contrast to absence of a phenotype upon inhibition of a single PDEB suggests functional redundancy 
and indicates that deregulation of cAMP signaling is detrimental to the parasites (Oberholzer et al., 
2007; Bland et al., 2011; de Koning et al., 2012). This validates the trypanosomal cAMP-specific 
PDEs as excellent drug targets. The reported predominant localization of ACs (Paindavoine et al., 
1992; Salmon et al., 2012b; Saada et al., 2014) and PDEs (Oberholzer et al., 2007) to the parasite 
flagellum suggests this organelle as a center for cAMP signaling. As in most other kinetoplastids, the 
T. brucei genome encodes one orthologue of a regulatory and three isoforms of catalytic subunits of 
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PKA. Two closely related PKAC genes are arranged in tandem and most likely result from a recent 
gene duplication event (Kramer et al., 2007). The few amino acid differences between the two 
isoforms are located at the very N- and C-terminal ends (Bachmaier and Boshart, 2013). The third 
PKAC gene (PKAC3 in T. brucei) is more distant and is located on a different chromosome. 
Surprisingly, it has been shown that in vitro kinase activity is not stimulated by cAMP but by 
unphysiologically high concentrations of cGMP (Shalaby et al., 2001). This is in contrast to the 
Leishmania donovani orthologue, which according to a recent study seems to be activated by cAMP in 
vitro (Bhattacharya et al., 2012). An involvement of cAMP/PKA signaling in kinetoplastid 
differentiation has been shown for Leishmania donovani (Bhattacharya et al., 2012) and suggested for 
Trypanosoma cruzi (Rangel-Aldao et al., 1987; Gonzales-Perdomo et al., 1988; Rangel-Aldao et al., 
1988; Naula and Seebeck, 2000; de Godoy et al., 2012). Several observations led to the assumption 
that cAMP signaling also plays a role in life cycle stage differentiation of T. brucei (see chapter 1.2.3). 
 
1.2.3 Life cycle stage differentiation of T. brucei 	  
The shuttling between a mammal and an insect vector requires the ability to quickly adapt to dramatic 
changes in the environmental conditions. The parasites live in an environment with plenty of glucose 
as energy source (Bringaud et al., 2006) and a constant temperature of 37°C in the mammalian 
bloodstream. Upon uptake by a tsetse fly, the parasites encounter significant environmental changes 
such as a drop in temperature and altered carbon source availability. The host switch is accompanied 
by a complex life cycle involving dividing as well as cell cycle-arrested stages with the latter being 
pre-adapted to the life in the next host compartment (Figure 1.4). In the mammalian bloodstream, T. 
brucei cells proliferate extracellularly as long slender (LS) forms, which differentiate into cell cycle-
arrested short stumpy (SS) forms by a density-dependent, quorum sensing-like mechanism (Reuner et 
al., 1997; MacGregor et al., 2011). This differentiation step is accompanied by morphological, 
biochemical and metabolic changes such as repositioning of nucleus and kinetoplast as well as 
expression of procyclin, the major surface protein of PCFs, and of enzymes crucial for utilization of 
available carbon sources in the fly (Fenn and Matthews, 2007). Upon a blood meal on an infected 
mammal, tsetse flies take up LS and SS trypanosomes. The latter, pre-adapted to the life in the insect 
vector, differentiate within 48-72 hours into the dividing PCF stage characterized by synchronous re-
entry into the cell cycle, exchange of the stage-specific surface coat as well as morphological and 
metabolic changes (Fenn and Matthews, 2007). The fully developed mitochondrion including all 
enzymes required for utilization of proline as main energy source enables ATP generation via 
oxidative phosphorylation. LS cells, in contrast, are attacked and killed by proteases in the fly midgut 
(Nolan et al., 2000). Within the tsetse vector, T. brucei cells differentiate from the procyclic stage 
colonizing the fly midgut to the infectious metacyclic stage inhabiting the tsetse salivary glands via 
several different intermediate stages (Sharma et al., 2009). Until recently, it was not possible to 
reproduce these differentiation steps in vitro. A major break-through was the identification of RBP6, 
an RNA-binding protein, which promotes differentiation of PCFs upon overexpression in culture 
(Kolev et al., 2012).   
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There are many studies investigating life cycle stage differentiation of T. brucei. Several of these 
studies use monomorphic cell lines, i.e. cells that have been passaged several times through rodents 
and as a consequence have lost the ability to differentiate to the short stumpy bloodstream form. 
Instead, they develop into so-called stumpy-like forms. Naturally occurring trypanosomes, which 
efficiently differentiate into stumpy forms, are called pleomorphic. 
 
 
Figure 1.4: Life cycle of T. brucei. The picture was adapted from 
http://www.ilri.org/InfoServ/Webpub/fulldocs/Ilrad90/Figures/fig%2018%20p35.jpg. The VSG 
surface coat is indicated in blue. 
 
 
1.2.3.1 Signaling during LS to SS differentiation 	  
The observation that intracellular cAMP levels change according to the parasitemia in rats led to the 
speculation that cAMP signaling might play a role in the density-dependent differentiation from LS to 
SS (Mancini and Patton, 1981). This hypothesis was strengthened by the discovery of a putative, as 
yet unknown ‘stumpy induction factor’ (SIF), a heat-stable, low molecular weight compound (or 
compounds) extracted from medium of a BSF culture at maximal density (Vassella et al., 1997). The 
effect of SIF could be mimicked by treatment of LS forms with the membrane-permeable cAMP 
derivative 8-pCPT-cAMP (Vassella et al., 1997; Breidbach et al., 2002; Laxman et al., 2006). 
Furthermore, exposure of LS cells to conditioned medium containing SIF resulted in a two- to 
threefold increase in the intracellular cAMP concentration. However, the finding that the effect of SIF 
cannot be mimicked by treatment with hydrolysis-resistant but only with hydrolysable cAMP 
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derivatives and even more effectively with their degradation products, namely the respective 5’AMP 
and adenosine derivatives, indicated that these molecules are likely to be the key players in the 
signaling cascade rather than cAMP (Laxman et al., 2006). A recent whole-genome RNAi library 
screen selecting for cells resistant to 8-pCPT-cAMP or 8-pCPT-2’O-me-5’AMP and hence defective 
in stumpy formation identified several proteins with putative involvement in the process of LS to SS 
differentiation (Mony et al., 2014). Notably, RBP7, an RNA-binding protein identified by the screen, 
is likely to be a positive regulator of stumpy formation, since RNAi-mediated repression of RBP7 
caused loss of LS to SS differentiation and overexpression resulted in cell cycle arrest and increased 
differentiation competence. Apart from these putative positive regulators, several kinases have been 
proposed to negatively regulate stumpy formation such as ZFK (Vassella et al., 2001), MAPK5 
(Domenicali Pfister et al., 2006), and TbTOR4 (Barquilla et al., 2012). A family of putative citrate 
transporters, the PAD (protein associated with differentiation) proteins, has been shown to play an 
important role in the differentiation process from BSF to PCF in the insect host (Dean et al., 2009) 
(see chapter 1.2.3.2). One member of the PAD proteins, PAD1, is only expressed at significant levels 
in differentiation-competent SS cells and hence serves as stage-specific marker. This property of 
PAD1 is currently being exploited to identify small molecule compounds, which either inhibit or 
promote differentiation and hence might serve as promising leads for drug development against 
diseases caused by African trypanosomes (MacGregor et al., 2014). 
 
1.2.3.2 Signaling during SS to PCF differentiation 	  
In vitro, the differentiation process from SS to PCF can be induced by treatment with millimolar 
concentrations of citrate/cis-aconitate (CCA) (Ziegelbauer et al., 1990), mild acid stress (Rolin et al., 
1998), or proteases (Hunt et al., 1994; Sbicego et al., 1999; Szöör et al., 2013). In addition, a 
temperature drop of >15°C (cold shock) sensitizes stumpy trypanosomes to low, putatively 
physiological concentrations of CCA (Engstler and Boshart, 2004). The molecular mechanisms and 
signaling pathways underlying these differentiation processes are only partially uncovered. A family 
of putative citrate transporters, the PAD proteins, is required for perception of the CCA stimulus 
(Dean et al., 2009). PAD proteins are encoded by an array of eight genes, and simultaneous 
knockdown of all members results in reduced ability to differentiate to the insect form and eliminates 
CCA hypersensitivity under cold shock conditions. Stumpy cells exposed to cold shock show 
increased expression as well as surface routing of PAD2, which might act as CCA receptor. Moreover, 
a phosphatase cascade involving PTP1 and PIP39 controls differentiation from SS to PCF (Szöör et 
al., 2006; Szöör et al., 2010) with PTP1 being a negative and PIP39 a positive regulator. 
Phosphorylation of PIP39 at Y278 is a prerequisite for differentiation to the insect stage. As long as 
SS forms reside in the mammalian bloodstream, PTP1 inactivates PIP39 by dephosphorylation at 
Y278 and thereby prevents differentiation. PIP39 activates PTP1 and thereby promotes its own 
inhibition. Szöör et al. (2013) propose a model in which the feedback inhibition of PIP39 by PTP1 is 
blocked by a CCA-dependent mechanism upon uptake of SS cells by a tsetse fly: CCA entering the 
cells via transporters of the PAD family localized at the surface of SS cells promotes interaction 
between PIP39 and PTP1 and independently blocks the ability of PIP39 to enhance PTP1 activity. In 
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addition, expression of PIP39 in SS is induced by cold shock (Szöör et al., 2010). These combined 
events eventually result in increased amounts of phosphorylated PIP39, which localizes to the 
glycosomes and consequently promotes efficient differentiation into PCFs. So far, the kinase 
responsible for phosphorylation of PIP39 at Y278 as well as the downstream pathway ultimately 
resulting in differentiation to the PCF stage is unknown. Kinases negatively regulating BSF to PCF 
differentiation have recently been discovered by a global kinome RNAi library screen (Jones et al., 
2014): RDK1, repressor of differentiation kinase 1, has been shown to act in conjunction with the 
PTP1/PIP39 pathway blocking uncontrolled BSF to PCF differentiation, whereas RDK2 might act 
upstream of RDK1 and PTP1. 	  
1.3 Scope of this thesis 	  
Although multiple studies investigating cAMP/PKA signaling in kinetoplastids have been published in 
recent years (e.g. Naula and Seebeck, 2000; Seebeck et al., 2001; Seebeck et al., 2004; Laxman and 
Beavo, 2007; Oberholzer et al., 2007; Bhattacharya et al., 2008, 2009; Biswas et al., 2011; Gould and 
de Koning, 2011; Bhattacharya et al., 2012; de Koning et al., 2012; Salmon et al., 2012a; Salmon et 
al., 2012b; Gould et al., 2013; Lopez et al., 2014; Saada et al., 2014; Vij et al., 2014) and the general 
interest in this field is increasing, there are still many open questions concerning various putative steps 
in this/these signaling pathway/s.  
 
1) Is T. brucei PKA activated by cAMP? 
Whereas Leishmania donovani PKA is apparently activated by cAMP in vitro (Bhattacharya et al., 
2012), previous work from our laboratory (S. Kramer PhD thesis, 2004) as well as published data from 
Shalaby et al. (2001) indicate that the T. brucei orthologue is cAMP independent. In order to confirm 
these in vitro observations under physiological conditions, a previously established in vivo PKA 
reporter assay will be used to investigate PKA activity when intracellular cAMP levels are elevated 
(chapter 4.1). This assay will be furthermore exploited to identify possible alternative ligands. 
 
2) Are there alternative cAMP downstream effectors? 
A cAMP-independent PKA would suggest uncoupling of cAMP and PKA signaling in T. brucei and 
hence would raise the question about the existence of alternative downstream effectors of cAMP. In 
the absence of genes encoding orthologues of known cAMP receptor proteins of other organisms such 
as CRP, Epac or CNGs from the trypanosomal genome, alternative downstream effectors are most 
likely novel, maybe even kinetoplastid-specific proteins. The study presented in chapter 3 aims at 
identification of cAMP response proteins in T. brucei by a whole-genome RNAi library screen.  
 
3) Which functional role does cAMP play in T. brucei? 
The putative absence of known cAMP receptor proteins raises the question whether cAMP has any 
intracellular function in T. brucei. Since manipulation of the intracellular cAMP concentration by 
simultaneous inhibition of T. brucei PDEB1 and PDEB2 either genetically (by RNAi; Oberholzer et 
al., 2007) or pharmacologically (by the PDE inhibitor CpdA; de Koning et al., 2012) causes 
cytokinesis defects eventually resulting in cell death, increased intracellular cAMP levels seem to be 
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detrimental to the parasites. The studies presented in chapters 2.1 and 2.2 will shed light on 
downstream functions of cAMP in T. brucei by genetic manipulation of ACs, the enzymes producing 
cAMP from ATP. 
 
4) How is T. brucei PKA activated and to which purpose?  
The absence of activation of T. brucei PKA by cAMP asks for the identification of alternative 
activators or activating conditions. Previous work from the laboratory has shown that the kinase is 
activated in vivo by a drop in temperature (S. Kramer PhD thesis, 2004), a known differentiation 
trigger in the parasite’s life cycle (see chapter 1.2.3.2). Chapter 4.2 aims to extend the specificity of 
activation of T. brucei PKA by cold shock as well as to prove the suggested role of the kinase in the 
differentiation from BSF to PCF.  
 
5) Is PKA downstream signaling conserved between T. brucei and other organisms? 
Hundreds of substrates phosphorylated by PKA are known from a variety of eukaryotes (Skalhegg and 
Tasken, 2000). There is even a high overlap between processes regulated by PKA in lower, unicellular 
eukaryotes like Saccharomyces cerevisiae and higher eukaryotes like mammals, such as regulation of 
metabolism or differentiation (Sonneborn et al., 2000; Bockmuhl and Ernst, 2001; Wilson et al., 2010; 
Tamanoi, 2011; Lastauskiene et al., 2014). Since T. brucei PKA has apparently lost its upstream 
activation by cAMP, it is possible that the kinase acts in a completely different pathway thereby 
regulating a different set of downstream processes. Alternatively, the unconventional upstream 
activation mechanism could be combined with a downstream pathway conserved from trypanosomes 
to humans. Chapters 4.1 and 4.2 will provide insight into downstream components of T. brucei PKA 
signaling. 
 
6) Is the unconventional cAMP/PKA signaling in T. brucei conserved in other kinetoplastids? 
T. brucei PKA is the first example of a PKA not regulated by cAMP. The parasite belongs to the order 
of Kinetoplastida, evolutionary early branching eukaryotes. The loss of the evolutionary conserved 
upstream regulatory mechanism of PKA could have occurred directly after the early branching of the 
Kinetoplastida. Alternatively, it could be a unique feature of the T. brucei kinase. Analysis of 
cAMP/PKA signaling in the related kinetoplastid parasites L. donovani and T. cruzi will shed light on 
the evolutionary conservation of these signal transduction pathways (chapter 5 and discussion). 
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2. Cyclic AMP production in T. brucei – the adenylyl cyclases. 
 
 
2.1  Cytokinesis of Trypanosoma brucei bloodstream forms depends on expression of 
adenylyl cyclases of the ESAG4 or ESAG4-like subfamily. 
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Abstract 
 
Antigenic variation of the parasite Trypanosoma brucei operates by monoallelic expression of a 
variant surface glycoprotein (VSG) from a collection of multiple telomeric expression sites (ESs). 
Each of these ESs harbours a long polycistronic transcription unit containing several expression site-
associated genes (ESAGs). ESAG4 copies encode bloodstream stage-specific adenylyl cyclases (AC) 
and belong to a larger gene family of around 80 members, the majority of which, termed genes related 
to ESAG4 (GRESAG4s), are not encoded in ESs and are expressed constitutively in the life cycle. Here 
we report that ablation of ESAG4 from the active ES did not affect parasite growth, neither in culture 
nor upon rodent infection, and did not significantly change total AC activity. In contrast, inducible 
RNAi-mediated knock-down of an AC subfamily that includes ESAG4 and two ESAG4-like 
GRESAG4 (ESAG4L) genes, decreased total AC activity and induced a lethal phenotype linked to 
impaired cytokinesis. In the ∆esag4 line compensatory upregulation of apparently functionally 
redundant ESAG4L genes was observed, suggesting that the ESAG4/ESAG4L-subfamily ACs are 
involved in the control of cell division. How deregulated adenylyl cyclases or cAMP might impair 
cytokinesis is discussed.  
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2.2 Adenylate cyclases of Trypanosoma brucei inhibit the innate immune response of 
the host. 
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Abstract 
 
The parasite Trypanosoma brucei possesses a large family of transmembrane receptor–like adenylate 
cyclases. Activation of these enzymes requires the dimerization of the catalytic domain and typically 
occurs under stress. Using a dominant-negative strategy, we found that reducing adenylate cyclase 
activity by about 50% allowed trypanosome growth but reduced the parasite’s ability to control the 
early innate immune defense of the host. Specifically, activation of trypanosome adenylate cyclase 
resulting from parasite phagocytosis by liver myeloid cells inhibited the synthesis of the trypanosome-
controlling cytokine tumor necrosis factor-α through activation of protein kinase A in these cells. 
Thus, adenylate cyclase activity of lyzed trypanosomes favors early host colonization by live parasites. 
The role of adenylate cyclases at the host-parasite interface could explain the expansion and 
polymorphism of this gene family. 
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3. Cyclic AMP effectors in African trypanosomes revealed by genome-scale 
RNA interference library screening for resistance to the phosphodiesterase 
inhibitor CpdA. 
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Abstract 
 
One of the most promising new targets for trypanocidal drugs to emerge in recent years is the cyclic 
AMP (cAMP) phosphodiesterases (PDE) activity encoded by TbrPDEB1 and TbrPDEB2. These genes 
were genetically confirmed as essential, and a high affinity inhibitor, CpdA, displays potent 
antitrypanosomal activity. To identify effectors of the elevated cAMP levels resulting from CpdA 
action and, consequently, potential sites for adaptations giving resistance to PDE inhibitors, resistance 
to the drug was induced. Selection of mutagenized trypanosomes resulted in resistance to CpdA as 
well as cross-resistance to membrane permeable cAMP analogues but not to currently used 
trypanocidal drugs. Resistance was not due to changes in cAMP levels or in PDEB genes. A second 
approach, a genome-wide RNA interference (RNAi) library screen, returned four genes giving 
resistance to CpdA upon knockdown. Validation by independent RNAi strategies confirmed resistance 
to CpdA and suggested a role for the identified cAMP Response Proteins (CARPs) in cAMP action. 
CARP1 is unique to kinetoplastid parasites and has predicted cyclic nucleotide binding-like domains, 
and RNAi repression resulted in >100-fold resistance. CARP2 and CARP4 are hypothetical conserved 
proteins associated with the eukaryotic flagellar proteome or with flagellar function, with an 
orthologue of CARP4 implicated in human disease. CARP3 is a hypothetical protein, unique to 
Trypanosoma. CARP1 to CARP4 likely represent components of a novel cAMP signaling pathway in 
the parasite. As cAMP metabolism is validated as a drug target in Trypanosoma brucei, cAMP 
effectors highly divergent from the mammalian host, such as CARP1, lend themselves to further 
pharmacological development. 
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4. Unconventional activation of T. brucei PKA. 
 
4.1 Cyclic AMP-independent signaling from a conserved PKA. 
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Abstract 
 
The protein kinase A (PKA) signaling pathway is highly conserved among eukaryotes. Activation by 
cyclic AMP and regulation of a plethora of cellular processes such as metabolism, differentiation or 
cell cycle progression, are hallmarks of PKA in unicellular as well as multicellular eukaryotes. Here 
we show that in the early branching eukaryote Trypanosoma brucei, the PKA signaling pathway has 
been retooled. The kinase is completely refractory to cAMP, and transcriptome profiling revealed a 
large number of kinetoplastid- or Trypanosoma-specific downstream substrates indicating 
involvement in regulation of an unusual subset of downstream processes. The observation that the 
kinase is indirectly activated by the adenosine antimetabolite dipyridamole provided evidence that T. 
brucei PKA is activated by an alternative, endogenous ligand. To define the chemical space of the 
alternative ligand(s), we conducted a small-scale chemical screen using several nucleoside and 
nucleotide derivatives combined with an in vivo PKA reporter assay and identified several 7-
deazapurine analogues as potent activators. The most potent compound was subsequently used as tool 
to successfully identify downstream components of PKA signaling in T. brucei. Sequence comparison 
revealed the presence of highly similar PKA orthologues in the related kinetoplastids Trypanosoma 
cruzi and Leishmania donovani indicating conservation of this unconventional pathway within 
kinetoplastids. The presence of a conserved PKA with unconventional properties in kinetoplastids 
combined with the essentiality of the kinase in T. brucei suggests it as an optimal drug target for 
kinetoplastid-caused diseases. 
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Introduction 
 
The cyclic AMP-dependent protein kinase PKA has been identified almost 50 years ago (Walsh et al., 
1968), ten years after the identification of its activator, the second messenger cyclic AMP (cAMP) 
(Rall and Sutherland, 1958), and is now one of the best studied protein kinases from a variety of 
eukaryotes. In most organisms, the inactive PKA holoenzyme is a heterotetramer composed of a dimer 
of regulatory subunits (PKAR) and two associated catalytic subunits (PKAC). However, in some 
unicellular eukaryotes such as Dictyostelium discoideum (Mutzel et al., 1987) or Paramecium 
tetraurelia (Hochstrasser and Nelson, 1989), heterodimeric holoenzymes have been described. PKAR 
shows a characteristic domain structure with an N-terminal dimerization/docking (DD) domain 
responsible for homodimerization and sub-cellular localization, an internal inhibitor site and two C-
terminal cNMP-binding domains (Scholten et al., 2008). The kinase is activated by the cooperative 
binding of two molecules of cAMP, produced by adenylyl cyclases (ACs) activated downstream of G 
protein-coupled receptors (GPCRs), to each PKAR subunit (Ogreid and Doskeland, 1981b, a; 
Ringheim et al., 1988; Herberg et al., 1996) resulting in a conformational change, which induces 
displacement of the internal inhibitor site and hence dissociation and activation of the catalytic kinase 
subunit. Whereas the mammalian genome encodes four different PKAR (RIα, RIβ, RIIα, RIIβ) and 
two to three different PKAC isoforms (Cα, Cβ, Cγ (only in primates)), which differ in their tissue-
specific expression pattern, sub-cellular localization and affinity to cAMP (Skalhegg and Tasken, 
2000), the genomes of most unicellular eukaryotes contain only one PKAR gene and a variable 
number of PKAC genes. PKA fulfills pleiotropic cellular functions by phosphorylation of a plethora of 
different substrates. Metabolism, differentiation, apoptosis, or cell cycle progression are among the 
manifold processes regulated by PKA in mammalian cells (Shabb, 2001). Several of these functions 
(such as regulation of metabolism of differentiation) are even conserved in unicellular eukaryotes 
(Primpke et al., 2000; Sonneborn et al., 2000; Bockmuhl and Ernst, 2001; Saran et al., 2002; Wilson et 
al., 2010; Tamanoi, 2011; Lastauskiene et al., 2014). PKA controls downstream processes either 
directly at the level of substrate phosphorylation or at the level of protein synthesis involving all steps 
from transcriptional (via phosphorylation of transcription factors) (Shabb, 2001), posttranscriptional 
(via phosphorylation of RNA-binding proteins with transcript stabilizing/destabilizing functions) 
(Huang et al., 1995; Mizunuma et al., 2013) or translational control (Vaidyanathan et al., 2014). 
The cAMP/PKA signaling pathway is highly conserved in most eukaryotes ranging from lower, 
unicellular organisms such as Dictyostelium discoideum or Saccharomyces cerevisiae to mammals. 
However, in Trypanosoma brucei, a unicellular protozoan parasite of the evolutionary early branching 
order of Kinetoplastida, this signaling pathway seems to be significantly different. Whereas several 
components of cAMP signaling such as ACs, which produce cAMP, or phosphodiesterases (PDEs), 
which degrade cAMP, have been identified and partially characterized in T. brucei, genes encoding 
GPCRs or heterotrimeric G proteins seem to be absent from trypanosomal genomes (Seebeck et al., 
2001; Seebeck et al., 2004). cAMP produced by the parasite has been shown to be involved in host-
parasite interaction by modulating the immune response of the host thereby enabling the establishment 
of an efficient infection (Salmon et al., 2012b). Furthermore, manipulation of the intracellular cAMP 
concentration results in cell cycle defects implying a role for the second messenger in cell division 
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control (Oberholzer et al., 2007; de Koning et al., 2012; Salmon et al., 2012a). Despite the presence of 
genes orthologous to regulatory and catalytic subunits of PKA of other organisms in the T. brucei 
genome (Shalaby et al., 2001; Kramer et al., 2007), there is no indication for a cAMP-dependent 
kinase activity. The recently identified alternative cAMP response protein CARP1 (Gould et al., 2013) 
might replace PKAR as cAMP receptor. Here we show that T. brucei PKA is the first example of a 
conserved PKA, which is completely uncoupled from the second messenger cAMP. Our results 
provide indications for the presence of an alternative endogenous purine nucleoside-related ligand. By 
a small-scale chemical screen we identified several 7-deazapurine derivatives as potent activators of T. 
brucei PKA, which were subsequently used as tools to identify downstream components of PKA 
signaling in T. brucei. Sequence comparison of T. brucei PKA with orthologues from the related 
kinetoplastids Trypanosoma cruzi and Leishmania donovani suggests conservation of the 
unconventional features of the kinase within kinetoplastids. Since several kinetoplastid species are the 
causative agents of severe, health threatening diseases (T. brucei: Human African Sleeping Sickness; 
T. cruzi: Chagas disease; Leishmania spp.: leishmaniasis) with the urgent need for the development of 
new therapeutics, identification of novel drug targets is highly important. We suggest the kinetoplastid 
PKA as ideal drug target due to its essentiality in T. brucei, the presence of ligand-binding sites 
deviating from orthologous proteins in the mammalian host, and the identification of a compound, 
which binds to and activates the parasite kinase in the lower nanomolar range. 
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Material and Methods 
 
Trypanosome strains and culture conditions. Bloodstream forms (BSFs) of the 
monomorphic strain Lister 427, variant MiTat 1.2 (Cross and Manning, 1973), of Trypanosoma brucei 
brucei were cultivated at 37°C in a 5% CO2 atmosphere in modified HMI-9 medium (Vassella et al., 
1997) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS). Expression of T7 
polymerase and Tet repressor in the cell lines 13-90 (Wirtz et al., 1999) or 1313-514 (Alibu et al., 
2005) was ensured by addition of 2.5 µg/ml G418 and 5 µg/ml hygromycin B or 0.2 µg/ml 
phleomycin and 2 µg/ml G418, respectively, to the culture medium. Cells were counted with a 
heamocytometer and diluted if required to keep the cell density below 1×106 cells/ml. 
Cloning and generation of transgenic trypanosomes. N-terminal in situ tagging of T. brucei 
PKAC1 (Tb427tmp.211.2410) and PKAC2 (Tb427tmp.211.2360) subunits was achieved by 
transfection with plasmids containing the full-length ORFs fused to a Ty1- or HA-epitope tag, 
respectively, in the pUC19 backbone. For transfection, the plasmids were linearized with HindIII and 
SdaI or ClaI and BstZ17I, respectively, and selection was performed in the presence of 2 µg/ml 
phleomycin or 2 µg/ml G418, respectively. A kinase-dead mutant of PKAC1 with an N-terminal Ty1-
tag was generated by replacement of N153 of PKAC1 by alanine using the type II restriction enzyme 
Eco31I. The correct mutation was confirmed by sequencing. For overexpression of PKAC3 
(Tb427.10.13010), the PKAC3 ORF was amplified from MiTat 1.2 genomic DNA with primers 
introducing a Ty1-tag at the N-terminus and cloned into pTSARib[HYG] (Xong et al., 1998). The 
plasmid was linearized with SphI for transfection, and cells were grown in the presence of 4 µg/ml 
hygromycin B. A T. brucei cell line with inducible overexpression of PKAR (Tb427tmp.02.2210) was 
generated by transfection with a plasmid based on plew82 (Wirtz et al., 1999) containing the PKAR 
ORF amplified from MiTat 1.2 genomic DNA using primers introducing a Ty1-tag at the C-terminus. 
The plasmid was linearized with NotI for transfection, and 1-5 µg/ml phleomycin and 1 µg/ml 
tetracycline were used for selection. A T. brucei cell line with in situ tagging of PKAR with a C-
terminal PTP tag (Protein A-TEV-Protein C) (Schimanski et al., 2005) was generated by replacement 
of the U170k coding sequence of pC-PTP-NEO (kindly provided by A. Bindereif, Giessen) with the 
PKAR ORF. Linearization for transfection was done using XcmI, and selection was performed by 
addition of 2 µg/ml G418 to the culture medium. PKAC1 deletion mutants were generated by 
replacing the PKAC1 ORF with a blasticidin or phleomycin resistance cassette flanked by actin UTRs. 
Antibiotic selection was performed using 1 µg/ml blasticidin or 1 µg/ml phleomycin, respectively. 
Similarly, PKAC2 alleles were deleted by replacement with neomycin and hygromycin resistance 
genes flanked by actin UTRs. PKAC2 knock out cells were grown in the presence of 2 µg/ml G418 
and 2 µg/ml hygromycin B. PKAR knock out cells were generated by exchanging the PKAR alleles 
with puromycin and hygromycin resistance cassettes flanked by actin or aldolase UTRs, respectively. 
Selection was done by addition of 0.05 µg/ml puromycin and 1 µg/ml hygromycin B to the culture 
medium. The PKAR knock out cell line was rescued by endogenous expression of a wild type copy of 
PKAR under phleomycin selection (2.5 µg/ml). Knockdown of PKAC1/2 was achieved by inducible 
RNAi targeting an N-terminal fragment of the PKAC1 and PKAC2 ORFs (pos. 30-648; difference 
between PKAC1 and PKAC2 within that region is only three nucleotides; no homology to PKAC3) 
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amplified from MiTat 1.2 genomic DNA and cloned into the RNAi vector p2t7TiTAblue (Alibu et al., 
2005). The plasmid was linearized with NotI and transfected into the MiTat 1.2 1313-514 cell line 
(Alibu et al., 2005), followed by selection with 2 µg/ml hygromycin B. PKAR was knocked down by 
inducible RNAi targeting an N-terminal fragment of the PKAR ORF (pos. 1-467). In order to confirm 
specificity of the RNAi phenotype, a non-overlapping region of the PKAR ORF including part of the 
3’UTR (PKAR ORF pos. 1106-end and PKAR 3’UTR pos. 1-34) was chosen for generation of a 
second PKAR RNAi cell line. Both fragments were amplified from MiTat 1.2 genomic DNA and 
independently cloned into the vector p2t7TiA (LaCount et al., 2002). The plasmids were linearized 
with NotI and transfected into the tetracycline-inducible 13-90 cell line (Wirtz et al., 1999). Selection 
was performed using 3 µg/ml phleomycin. RNAi-mediated repression of the T. brucei cAMP-specific 
phosphodiesterases PDEB1 and PDEB2 was carried out as published previously (Oberholzer et al., 
2007) with the exception that the Tet-inducible vector pHD615[PAC] (derivative of pHD615 
(Biebinger et al., 1997) with puromycin resistance gene) was used for hairpin RNAi in the present 
study. The 13-90 cell line (Wirtz et al., 1999) with or without expression of the PKA reporter substrate 
VASP was transfected with the PDEB1/2 RNAi construct linearized with NotI and grown in the 
presence of 0.1 µg/ml puromycin. T. brucei cell lines expressing VASP were generated by transgenic 
expression of the VASP ORF amplified from human cDNA (VASP p14/1 in pBSK-, Acc. No. Z46389; 
(Haffner et al., 1995) kindly provided by U. Walter, University of Würzburg Medical Clinic) and 
cloned into pTSARib[HYG] (Xong et al., 1998) and its derivatives pTSARib[BSD] and 
pTSARib[PAC] (exchange of hygromycin resistance cassette against blasticidin or puromycin). 
Linearization for transfection was done with SphI. Cells were grown in the presence of 4 µg/ml 
hygromycin B, 4 µg/ml blasticidin, or 0.1 µg/ml puromycin, respectively. An inducible version of 
VASP with a C-terminal Ty1 tag was cloned into the vector plew82 (Wirtz et al., 1999) and 
transfected into the 13-90 cell line (Wirtz et al., 1999). Antibiotic selection was performed in the 
presence of 1 µg/ml phleomycin. Details on primer sequences and cloning strategies are available 
upon request. All transfections were performed as described previously (Schumann Burkard et al., 
2011). 
Generation of polyclonal antibodies. Anti-PKAC1 and anti-PKAC3 antisera were produced 
in rabbits against GST fusion proteins (amino acids 277 to 334 for PKAC1 and 272 to 337 for 
PKAC3). Rabbits were immunized by Eurogentec with 500 µg GST fusion protein purified from E. 
coli BL21DE3 (Stratagene), followed by further boosts with 500 µg antigen. Full-length 
hexahistidine-fusion proteins expressed in E. coli M15 (Qiagen) and purified using Ni-NTA columns 
(Qiagen) were used for affinity purification of the antibodies according to the method of Olmsted 
(1981). 
Expression of PKA catalytic subunits in 293 cells. GST-fusion proteins of full-length 
PKAC1, PKAC2 and PKAC3 were expressed in human 293 cells. The ORFs were amplified by PCR 
from MiTat 1.2 genomic DNA and cloned into the eukaryotic expression vector pSCTEV3s (Matthias 
et al., 1989; Seipel et al., 1992). Cultivation and transfection of human 293 cells was performed as 
described in Vassella et al. (2001). For antibiotic selection, 300 µg/ml hygromycin B and 250 µg/ml 
G418 were added to the culture medium.  
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 (Co-) Immunoprecipitation. PTP purification was performed according to the protocol of 
Schimanski et al. (2005) with a few exceptions. Briefly, 2×108 BSF MiTat 1.2 cells with endogenous 
expression of PTP-tagged PKAR were lysed in PA-150 buffer (Schimanski et al., 2005; w/o DTT, 
supplemented with Complete Mini EDTA-free protease inhibitor cocktail and 25 µg/ml pepstatin A) 
by three sonication cycles à 30 seconds with the Bioruptor (Diagenode) at low power. After 
centrifugation (20 min, 20000×g, 4°C), the cleared supernatant was incubated with IgG beads (pre-
equilibrated with PA-150 buffer) for 4 hours to overnight by overhead rotation at low speed. After two 
washes with PA-150 buffer followed by a final wash with PBS, proteins bound to the IgG beads were 
eluted by incubation with 2× Laemmli sample buffer for 5 minutes at 95°C. 
Immunoprecipitation of Ty1- or HA-tagged PKA subunits was performed by incubation of 
trypanosome cells in lysis buffer (50 mM Tris pH 7.2, 2 mM EGTA, 150 mM NaCl, 0.2% NP-40; 
supplemented with 1 mM NaVO4, 0.5% aprotinin, 2 µg/ml leupeptin, 1 mM PMSF) for 10 min on ice 
with subsequent clearing of the supernatant by centrifugation (20 min, 20000×g, 4°C). The cleared 
lysate was incubated with the respective epitope-tag antibody coupled covalently (using the cross-
linker DMP (Thermo Scientific) according to the manufacturer’s instructions) or non-covalently to 
protein G sepharose beads (Amersham Pharmacia) for one hour to overnight. Bound proteins were 
either eluted by incubation with different concentrations of cNMPs or boiled in 2× Laemmli sample 
buffer for 5 minutes at 95°C. 
Southern blot. Total genomic DNA was isolated by phenol/chloroform extraction. Restriction 
enzyme digests of genomic DNA were analyzed by Southern blot with digoxigenine labeled probes 
(DIG DNA Labeling and Detection Kit, Roche). Details are available on request. 
Western Blot. Lysates of 1-5×106 trypanosome cells or 10 µg protein of human 293 cells 
were separated on 10% polyacrylamide gels and transferred to an Immobilon-FL PVDF membrane 
(Millipore) by semi-dry blotting. Primary antibodies used were anti-PKAR (1:500; Bachmaier et al., 
submitted manuscript; see chapter 5), anti-PKAC1/2 (1:500-1:1000), anti-PKAC3 (1:500), anti-Ty1 
(1:300-1:1000; Bastin et al., 1996), anti-HA (clone 12CA5; undiluted hybridoma), anti-HSP60 
(1:10000; Bringaud et al., 1995), anti-PFR-A/C (1:2000; Kohl et al., 1999), anti-VASP (1:5000; 
ImmunoGlobe, catalogue number IG-731), and anti-Phospho-(Ser/Thr) PKA substrate antibody 
(1:1000; Cell Signaling Technologies, catalogue number 9621). The immunological detection was 
either done with enhanced chemiluminescence (ECL) using horseradish peroxidase-conjugated 
secondary antibodies (Amersham Pharmacia, now GE Healthcare) according to the manufacturer’s 
instructions or with the OdysseyTM IR fluorescence scanning system (LI-COR) using fluorescently 
labeled secondary antibodies (Alexa Fluor® 680 goat anti-rabbit IgG (H+L) (1:5000; Life 
Technologies), IRDye 680LT goat anti-rabbit IgG (H+L) (1:50000; LI-COR), IRDye 800CW goat 
anti-mouse IgG (H+L) (1:5000; LI-COR)). Signals of T. brucei PKA subunit proteins or phospho-
RXXS/T-containing proteins were normalized to the PFR-A/C (Kohl et al., 1999) or Hsp60 (Bringaud 
et al., 1995) loading control after automatic subtraction of the background values (Median Left/Right 
method) using the Odyssey software (LI-COR). For the in vivo PKA reporter assay, the signals of the 
upper band (phosphorylated) and the lower band (non-phosphorylated) were quantified, and the extent 
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of phosphorylated VASP was calculated as follows: % phosphorylated VASP = (phosphorylated 
VASP / (phosphorylated + non-phosphorylated VASP)) × 100. 
In vivo PKA reporter assay (VASP assay). Trypanosomes were harvested (10 min, 1400×g, 
37°C) and resuspended in fresh HMI-9 medium (pre-heated to 37°C) at a density of 5×107 cells/ml. 
After a 5-10 minute recovery at 37°C while slightly shaking, test compounds were added to the cell 
suspension followed by careful mixing. Subsequently, cells were incubated at 37°C for a specified 
time period. Details on incubation time and compound concentration in each experiment are given in 
the results section. Cells were lysed with 6× Laemmli sample buffer preheated to 95°C and incubated 
for 5 minutes at 95°C. 
Phenotypic analysis. For microscopic analysis, 5×105 cells were spread on glass slides and 
fixed overnight in methanol at -20°C. Cellular DNA was visualized with 4′,6-diamidino-2-
phenylindole (DAPI; 1 µg/ml). Image acquisition was performed with a motorized Zeiss Axiophot2 
wide-field microscope equipped with a Zeiss 63×/1.4 NA Oil DIC objective, a 1.0×-2.5× optovar, and 
a Princeton Instruments Micromax cooled (-15°C) slow scan CCD camera (Kodak KAF-1400 CCD 
chip). 
Inhibitors and test compounds. PKI(5-24) and myr-PKI(14-22) were obtained from Biomol. 
CpdA was synthesized by Geert-Jan Sterk, Mercachem. Dipyridamole was obtained from Sigma-
Aldrich, toyocamycin and sangivamycin from Berry & Associates. All other compounds were 
synthesized by Biolog. 
Cyclic AMP measurement. Before lysis, all steps were performed identical to the in vivo 
PKA reporter assay. For lysis, 2×107 cells were pipetted into 5 ml of boiling water and incubated for 5 
minutes, followed by lyophilization. cAMP concentrations were determined using the Cyclic AMP 
XP® Assay Kit (NEB). Three independent experimental series were analyzed in duplicates. 
Cell viability assay. The viability of T. brucei BSF cells upon treatment with various 
compounds was assessed using the Alamar blue assay as published previously (Gould et al., 2013) 
with the exceptions that the initial seeding density was reduced from 1×105 to 5×103 trypanosomes/ml, 
the following growth period was extended from 48 h to 72 h, and the subsequent incubation with 0.5 
mM resazurin sodium salt was reduced from 24 h to 4 h. 
 Cultivation and transfection of Leishmania tarentolae, recombinant expression of PKA 
subunits and purification of the PKA holoenzyme. The L. tarentolae strain LEXSY T7-TR (Jena 
Biosciences) was cultivated at 26.5°C in BHI medium supplemented with 10 µg/ml hemin and 100 U/l 
streptomycin / 100 mg/l penicillin according to the conditions published by Jena Biosciences. For 
maintenance of T7 polymerase and Tet repressor, 10 µg/ml nourseothricin (NTC) and 10 µg/ml 
hygromycin B were added to the medium. For co-expression of T. brucei PKAR-10×His and Strep-
PKAC1, the full length ORFs were amplified from genomic DNA using primers introducing the 
respective epitope tag and cloned into pLEXSY_I-ble3 and pLEXSY_I-neo3 (Jena Biosciences), 
respectively. Cells transfected with both constructs were cultivated in the presence of 10 µg/ml 
phleomycin and 10 µg/ml neomycin. 200-500 ml of L. tarentolae cells at mid log phase (2-3×107 
cells/ml) were induced with 10 µg/ml tetracycline for 24 h. Cell lysis was performed using detergent 
(lysis buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 0.2% triton X-100, 1 mM β-mercaptoethanol) and 
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douncer homogenization. Purification of the holoenzyme complex was performed in a two-step 
procedure: His-tag purification using Ni-NTA beads (Thermo Fisher Scientific) was followed by 
Strep-tag purification using gravity flow chromatography and StrepTactin sepharose beads (IBA, 
Göttingen), according to the manufacturers’ instructions. The eluted fractions were pooled and 
dialyzed against the kinase storage buffer (20 mM MOPS, pH 7.0, 150 mM NaCl, 1 mM β-
mercaptoethanol). Details on primer sequences and cloning strategies are available upon request. 
 Recombinant expression and purification of the human PKARIα-PKACα holoenzyme 
complex. For co-expression of human PKARIα (with an N-terminal 6×His tag followed by a TEV 
cleavage site) and PKACα (with an N-terminal Strep-tag) in E. coli, the full length ORFs were 
amplified from cDNA (with primers introducing the respective epitope tag and protease cleavage site) 
and cloned into pETDuet-1 (Novagene). Purification of the holoenzyme complex was performed 
according to the protocol given for the T. brucei PKA holoenzyme. Details on primer sequences and 
cloning strategies are available upon request. 
In vitro kinase assay. A radioactive PKA kinase assay was performed according to Hastie et 
al. (2006), adapted from Witt and Roskoski (1975) using 100 µM Kemptide (LRRASLG; Kemp et al., 
1976; Kemp et al., 1977) as kinase substrate and 100 µM ATP spiked with [γ-32P] ATP to give 200-
400 cpm/pmol. Each compound was measured at least twice, in duplicates, including two controls, one 
lacking the substrate and the other one lacking the kinase.   
RNA isolation and transcriptome analysis. RNA extraction, library construction, and 
spliced leader trapping were performed as described in Nilsson et al. (2010). 
Bioinformatics. Read mapping and extraction was done as described previously (Nilsson et 
al., 2010). The read counts per gene were normalized using the DESeq2 package (Anders and Huber, 
2010). The statistical analysis was done using the R environment  (http://www.R-project.org/). A 
pairwise Z statistics was computed according to the description of Kal et al. (1999) dividing the 
normalized read counts by the predefined size factor. The analysis was based on four comparisons per 
gene in the wild type cell line: from time point 0 h to 0.5 h, from 0.5 h to 1 h, from 1 h to 4 h, and 
from 4 h to 8 h. The four resulting Z-scores were combined to one using Stouffer’s Z-score method 
(Stouffer, 1949) weighing them all equally. Bi-directional p-values were computed and FDR-corrected 
as adjustment for multiple testing (Benjamini and Hochberg, 1995). We extracted those genes that met 
the following criteria: 1) p-value in wild type < 0.05; 2) fold change in wild type > 1.75; 3) fold 
change in Rko < fold change in wild type; and 4) neither in the knock out nor in the wild type more 
than two changes in direction were allowed; a change in direction was defined as a fold change larger 
than 1.3 from one time point to the next, if previous changes showed different directions. This resulted 
in exclusion of transcripts showing many fluctuations. GO enrichment analysis has been performed 
using TriTrypDB (www.tritrypdb.org) and the bioinformatics database DAVID 
(http://david.abcc.ncifcrf.gov/) (Huang et al., 2009b, a). 
Quantitative RT-PCR. Total RNA was isolated in triplicates from T. brucei MiTat 1.2 BSF 
wild type cells or the homozygous PKAR deletion mutant incubated with or without 2 µM 
toyocamycin for 0 h and 8 h using the NucleoSpin RNA kit (Macherey-Nagel) followed by cDNA 
synthesis using the iScript cDNA Synthesis kit (Bio-Rad). Relative mRNA expression levels of 
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selected candidates (primer sequences available on request) were determined by quantitative real-time 
PCR according to the previously published protocol (Gould et al., 2013). TERT was used as reference 
gene (Brenndorfer and Boshart, 2010). 
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Results 
 
Sequence analysis of putative T. brucei PKA subunits. The T. brucei genome harbors three 
genes (PKAC1, PKAC2, PKAC3; TriTrypDB entries: Tb427tmp.211.2410, Tb427tmp.211.2360, 
Tb427.10.13010) with highest similarity to catalytic as well as one gene (PKAR; GenBank AF182823; 
TriTrypDB Tb427tmp.02.2210) with highest similarity to regulatory subunits of cAMP-dependent 
protein kinases from a range of organisms (Kramer et al., 2007; Bachmaier and Boshart, 2013). While 
PKAC1 and PKAC2 share 95% sequence identity with most differences at the very N- and C-terminal 
ends and are arranged in tandem in the trypanosomal genome, PKAC3 is more distant (60% and 59% 
sequence identity with PKAC1 and PKAC2, respectively) and is located on a different chromosome. 
These features are found in almost all kinetoplastid genomes sequenced to date. Many important 
characteristics of PKAs from other organisms are conserved in the T. brucei orthologues (Figure S1A) 
such as the 11 canonical kinase subdomains (Hanks et al., 1988), the essential threonine in the kinase 
activation loop or residues important for binding to a regulatory PKA subunit (Taylor et al., 2004). 
The most obvious difference between the T. brucei kinases and PKACs of higher organisms is found 
at the N-terminus. In higher eukaryotes, the PKAC N-terminus consists of a myristoylation motif 
followed by an alpha helix of 21 amino acids in length (A-helix) that is thought to stabilize the 
catalytically active C-subunit (Herberg et al., 1997). The corresponding N-terminal sequences of the T. 
brucei kinases are significantly shorter and, in addition, contain several helix breaking amino acids. 
Similar truncated N-termini have been reported from PKAs of other protozoa (Siman-Tov et al., 1996; 
Kiriyama et al., 1999). In addition, of the amino acids that carry post-translational modifications 
(PTMs) in catalytic PKA subunits from higher eukaryotes (Yonemoto et al., 1993; Gesellchen et al., 
2006), only Thr-197 located in the kinase activation loop is conserved in all T. brucei orthologues 
(Nett et al., 2009; Urbaniak et al., 2013). (Auto-)phosphorylation at this site is essential for kinase 
activity (Steinberg et al., 1993; Adams et al., 1995; Steichen et al., 2010). PTMs of the N- and C-
terminal tails of mammalian PKAC are known to confer specificity by influencing its activity, 
localization, and capacity to interact with other proteins. The divergence between the PTMs of the 
mammalian and the T. brucei orthologues might be an indication for differences in specificity. 
T. brucei PKAR shares characteristics with mammalian PKARI and PKARII isoforms (Figure S1B). 
The overall sequence shows higher similarity to the mammalian isoform PKARI, but the presence of a 
phosphorylatable residue in the inhibitor site (RRTTV) is a hallmark of PKARII isoforms. Despite a 
similar overall domain organization, the kinetoplastid orthologues display several unique features 
compared to other regulatory PKA subunits: they have an elongated N-terminus with leucine-rich 
repeats (LRR) lacking a dimerization/docking (DD) domain, and they show several substitutions of 
highly conserved amino acids in their cNMP-binding pockets. Due to the absence of a DD domain, T. 
brucei PKA is most likely a heterodimeric holoenzyme composed of one R and one C subunit. 
T. brucei PKAR interacts with all three PKA catalytic isoforms. In order to examine the 
composition of the T. brucei PKA holoenzyme, the interactions between the different 
subunits/isoforms were studied by co-immunoprecipitation. Specific antibodies were raised in rabbits 
against recombinant GST-tagged PKAC1 (anti-PKAC1/2) or PKAC3 (anti-PKAC3). Specificity and 
cross-reactivity of anti-PKAC1/2 and anti-PKAC3 were tested on a Western blot with lysates from 
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human 293 cells transiently transfected with DNA containing the sequence of the complete PKAC1, 
PKAC2 or PKAC3 ORFs (Figure S2). Anti-PKAC3 was specific for PKAC3 and did not recognize 
any of the other catalytic isoforms. Since PKAC1 and PKAC2 share 95% sequence identity, the 
antibody raised against PKAC1 detected both isoforms but did not detect PKAC3. In addition, no 
cross-reactivity with human PKACs was observed. Since PKAC1 and PKAC2 have the same 
molecular weight and are detected by the same antibody, they cannot be distinguished on a Western 
blot with lysate from T. brucei wild type cells. Therefore, a cell line was generated with deletion of 
one allele of PKAC1 and replacement of the other allele with Ty1-epitope tagged PKAC1 
(∆pkac1/Ty1-PKAC1) resulting in an electrophoretic mobility shift and thereby allowing the 
distinction between the two isoforms (Figure 1A). In addition, PKAR was fused to a C-terminal PTP-
tag in the cell line ∆pkac1/Ty1-PKAC1 (Figure 1B). Whereas PKAR and PKAC1/2 were almost 
exclusively found in the soluble fraction upon lysis, PKAC3 was equally distributed between soluble 
and insoluble fractions (Figure 1C). PKAR-PTP was able to pull down all three PKAC isoforms. In 
contrast, the same experiment in the parental ∆pkac1/Ty1-PKAC1 cell line without PTP-tagging of 
PKAR did not pull down any of the probed proteins indicating that PKACs do not unspecifically 
interact with the IgG beads. Furthermore, PKAR-PTP did not co-precipitate the endogenous, untagged 
PKAR, which indicates that the holoenzyme - at least in this cell line - is a heterodimer consisting of 
one regulatory and one of three different isoforms of a catalytic subunit. To exclude unspecific 
interactions of PKACs with the PTP-tag, independent co-immunoprecipitations were carried out in 
cell lines with Ty1-tagged PKAC1, PKAC3 or PKAR, or HA-tagged PKAC2, respectively, showing 
the same results as the PKAR-PTP pull-down (Figure S3A-C). Furthermore, this experiment showed 
that one specific PKAC isoform did not co-precipitate any of the other two isoforms supporting the 
idea of a heterodimeric holoenzyme. 
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Fig. 2: Developmental regulation of PKA subunit expression at the transcript (A) or protein 
level (B, C).
A. Northern Blots with total RNA (5 µg) isolated from AnTat1.1 parasites of different life 
cycle stages. PKAC1, PKAC2 and PKAC3 transcripts were detected by gene-specific probes. 
Actin and the anonymous cDNA P2 (provided by E. Pays) served as internal controls. Actin 
is equally expressed in LS and PCF cells but reduced in SS cells (Ben Amar et al., 1988). P2 
is equally expressed in LS and SS cells but reduced in PCF cells. 
B. Protein expression of PKA subunits in slender, stumpy and procyclic pleomorphic AnTat 
1.1 cells was analyzed by Western blotting using specific antibodies against PKAC1/2, 
PKAC3 and PKAR raised in rabbits. PFR-A/C detected by the monoclonal antibody L13D6 
(Kohl et al., 1999) was used for normalization.
C. Deletion of one allele of PKAC1 and fusion of the other one to a Ty1-tag induces an 
electrophoretic mobility shift of PKAC1 allowing discrimination between PKAC1 and 
PKAC2 on a Western blot. PFR-A/C detected by the monoclonal antibody L13D6 (Kohl et 
al., 1999) was used for normalization.
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Figure 1: T. brucei PKAR interacts with all three PKA catalytic isoforms. 
A. Western blot showing the discrimination between PKAC1 and PKAC2 in the cell line ∆pkac1/Ty1-
PKAC1. Deletion of one allele of PKAC1 and fusion of the other one to a Ty1-tag results in an 
electrophoretic mobility shift of PKAC1 allowing discrimination between PKAC1 and PKAC2 on a 
Western blot. Anti-PKAC1/2 and anti-Ty1 (Bastin et al., 1996) antibodies were used for detection. 
B. PKAR was fused to a C-terminal PTP-tag in the cell line ∆pkac1/Ty1-PKAC1. The Western blot 
shows two independent pools of the cell line ∆pkac1/Ty1-PKAC1 PKAR-PTP compared to wild type 
cells and was probed with anti-PKAR (Bachmaier et al., submitted manuscript; see chapter 5), anti-
PKAC1/2, anti-Ty1 (Bastin et al., 1996), and anti-PFR-A/C (Kohl et al., 1999) as loading control.  
C. Western blot analysis of PTP purification using the cell line ∆pkac1/Ty1-PKAC1 PKAR-PTP 
(upper panel) and the parental cell line ∆pkac1/Ty1-PKAC1, which does not express a PTP-tagged 
PKAR (lower panel). Western blots were probed with anti-PKAR (Bachmaier et al., submitted 
manuscript; see chapter 5), anti-PKAC1/2, anti-PKAC3, and anti-Ty1 (Bastin et al., 1996). Values of 
x indicate relative amounts of each fraction analyzed. 
 
T. brucei PKA orthologues are not activated by cAMP in vitro. Since all PKA orthologues 
analyzed to date are activated by the second messenger cAMP, we studied cAMP-dependence of the 
T. brucei orthologues. PKA holoenzymes were purified from trypanosomes by immunoprecipitation 
via PKAR-Ty1. The immunoprecipitate was able to phosphorylate the PKA-specific substrate 
kemptide (Figure 2A, upper panel), and kinase activity was inhibited by the PKA-specific inhibitor 
peptide PKI(5-24). PKI is the gold standard of a PKA-specific inhibitor (Walsh et al., 1971; Glass et 
al., 1989; Harris et al., 1997; Dalton and Dewey, 2006). Surprisingly, even though the T. brucei PKA 
orthologues exhibit all features of a classical PKA in terms of holoenzyme composition (R-C 
complex) as well as substrate and inhibitor specificity, no activation by cAMP was observed, not even 
when the second messenger was used in mM concentrations. In contrast, the presence of high 
concentrations of cGMP significantly increased the activity of the T. brucei PKA holoenzymes. These 
results were confirmed by in vitro kinase assays with holoenzymes purified via Ty1-PKAC1 or HA-
PKAC2, respectively, using antibodies against the respective epitope tag (Figure 2A, middle and 
lower panels). We can exclude that the measured kinase activities were due to contamination, since no 
substrate phosphorylation was detected with immunoprecipitate from wild type cells or with a 
catalytically inactive Ty1-PKAC1 mutant (dead mutant), in which the residue N153 in the kinase 
catalytic center was replaced by alanine (Cheek et al., 2002) (Figure S4A). In addition, the cNMPs 
cCMP (C = cytidine), cXMP (X = xanthosine), cIMP (I = inosine) and cUMP (U = uridine) did not 
show any influence on kinase activity (Figure S4B). It is unlikely that cGMP is the physiological 
activator since kinase activation was only detectable when cGMP was used in millimolar and thus 
unphysiologically high concentrations. In fact, for half maximal activation a concentration of 5-8 mM 
cGMP was required (Figure S4C), similar to previous observations (Shalaby et al., 2001). In addition, 
there are several lines of evidence arguing against the presence of cGMP or cGMP signaling in 
trypanosomatids (Laxman and Beavo, 2007). 
As expected from the results of the in vitro kinase assays, addition of cAMP did not dissociate the 
PKAR-PKAC1 holoenzyme purified by immunoprecipitation via Ty1-PKAC1, whereas high 
concentrations of cGMP (1 mM) induced some release of PKAR into the supernatant (Figure 2B). 
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Figure 2: T. brucei PKA is not activated by cAMP in vitro. 
A. In vitro kinase assays analyzing phosphorylation of the PKA-specific substrate kemptide by 
immunoprecipitated PKAR-Ty1 (upper panel), Ty1-PKAC1 (middle panel), or HA-PKAC2 (lower 
panel) in the presence or absence of cAMP or cGMP, respectively. Inhibition of kinase activity by 5 
µM PKI(5-24) was included as control. Each assay (except the ones with PKI) was performed in 
triplicate. Standard deviations are indicated by error bars. 
B. Dissociation of the PKAR-PKAC1 holoenzyme, purified via Ty1-PKAC1, in the presence of 
cGMP or cAMP was analyzed by Western blot. Ty1-PKAC1 and PKAR bound to the beads (B) and 
free PKAR released into the supernatant (SN) were detected by anti-PKAC1/2 and anti-PKAR 
(Bachmaier et al., submitted manuscript; see chapter 5). Note that the film was over-exposed on 
purpose to stress the absence of any PKAR in the supernatant without cGMP. 
 
T. brucei PKA orthologues are not activated by cAMP in vivo. The absence of PKA 
dissociation and activation by cAMP in vitro could have different reasons e.g. a lack of an intracellular 
factor or an interacting protein important for kinase regulation. To exclude this possibility, an in vivo 
PKA reporter assay was established in T. brucei. The human, platelet-derived PKA substrate VASP 
(vasodilator stimulated phosphoprotein) was transgenically expressed in trypanosomes. 
Phosphorylation of VASP at the PKA-specific site Ser-157 causes a mobility shift in SDS gel 
electrophoresis from 46 to 50 kDa (Halbrugge and Walter, 1989; Butt et al., 1994). VASP, involved in 
organizing the actin cytoskeleton (Sechi and Wehland, 2004), has no orthologous protein in T. brucei. 
This was determined by a HMM-based search (HMMER version 2.3.2, standard parameters as set by 
the software; Eddy, 1998) of the T. brucei GeneDB (www.genedb.org/genedb/tryp/index.jsp) using 
the SMART family alignment of the VASP specific WH1 domain (Smart Accession SM00461; 
Schultz et al., 1998; Letunic et al., 2004) as template. A Western blot with lysates of wild type and 
VASP expressing T. brucei cells as well as human platelet protein was probed with a VASP-specific 
antibody (Figure 3A). The PKA substrate is expressed in the transgenic T. brucei cell line, whereas 
wild type cells do not express an orthologous protein. Furthermore, two bands are detected with the 
anti-VASP antibody in T. brucei, the upper one with a MW of 50 kDa corresponding to the 
phosphorylated and the lower one with a MW of 46 kDa representing the non-phosphorylated version 
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of VASP. To prove that VASP is specifically phosphorylated by the parasite PKA orthologues, a 
myristoylated and hence membrane-permeable version of the PKA-specific inhibitor peptide PKI 
(myr-PKI(14-22)) was used to inhibit PKA activity. Upon treatment with 200 µM myr-PKI(14-22) for 
10 min, the intensity of the phosphorylated band decreased significantly (Figure 3B).  
 
 
Figure 3: T. brucei PKA phosphorylates the transgenically expressed PKA substrate VASP in 
vivo.  
A. Western blot showing the transgenic expression of the human PKA substrate VASP in T. brucei 
BSFs (VASP, lane 2). Human platelet protein (lane 1) and T. brucei wild type (wt) cells without 
expression of VASP (lane 3) were included as controls. PFR-A/C detected by the monoclonal 
antibody L13D6 (Kohl et al., 1999) was used as loading control.  
B. T. brucei PKA phosphorylates VASP in vivo. Treatment of VASP expressing trypanosomes with 
the membrane-permeable PKA-specific inhibitor peptide myr-PKI(14-22) (200 µM in TFA/H2O, 10 
min) causes repression of VASP phosphorylation. Results are derived from three independent 
experiments; error bars represent SD. The Western blot (inset) shows one representative experiment. 
 
To exclude any influence of the selectable marker on VASP phosphorylation, three independent cell 
lines expressing the reporter substrate with different markers were generated. VASP phosphorylation 
was analyzed in two of these cell lines (VASP[BSD] and VASP[PAC]) in the presence or absence of 
myr-PKI(14-22) showing efficient inhibitor-dependent reduction in reporter substrate phosphorylation 
in both cell lines (Figure S5). To examine the influence of cAMP on in vivo PKA activity, elevation of 
the intracellular cAMP concentration was induced by two independent approaches: pharmacological 
PDE inhibition using the recently published PDE inhibitor CpdA (de Koning et al., 2012) and RNAi 
against the cAMP-specific phosphodiesterases (PDEs) PDEB1 and PDEB2 (Oberholzer et al., 2007). 
A >600- or ~45-fold increase in intracellular [cAMP] compared to untreated wild type cells was 
observed upon treatment with 10 µM CpdA (p≤0.05) for 15 min or upon RNAi against PDEB1 and 
PDEB2 for 24h (p≤0.001), respectively (Figure 4A, C (upper panel)), corresponding to intracellular 
cAMP concentrations of ~200 µM or ~14 µM, respectively (assuming even intracellular distribution 
and no excretion of cAMP). Interestingly, even at these extremely high cAMP concentrations no 
increase in PKA activity was detected (Figure 4B, C (lower panel); Figure S6), supporting the 
observed lack of cAMP-dependent activation of the T. brucei PKA orthologues in vitro.  
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Figure 4: T. brucei PKA is not activated by cAMP in vivo. 
A. Analysis of cAMP levels of trypanosomes treated with 10 µM CpdA or with the solvent DMSO 
(1%) for 15 min. Untreated cells were included as control. Results are derived from three independent 
experiments; error bars represent SD. 
B. Analysis of in vivo PKA activity in the presence of 10 µM CpdA or 1% DMSO (solvent control) in 
a time course over 15 min. Untreated cells were included as control. Results are derived from three 
independent experiments; error bars represent SD. 
C. Determination of cAMP levels (upper panel) and in vivo PKA activity (lower panel) upon 
inducible RNAi against PDEB1 and PDEB2 in a time course over 24 h after induction with 1 µg/ml 
tetracycline (Tet). Since the PKA substrate VASP was expressed as Tet-inducible version, no VASP 
phosphorylation could be determined at time point zero. The parental cell line without RNAi against 
PDEB1 and PDEB2 was included as control. Results are derived from three independent experiments; 
error bars represent SD. 
 
The slight inhibition of VASP phosphorylation at very high cAMP concentrations (Figure 4C, lower 
panel; S6C) is most likely unphysiological and due to unhealthy and dying cells. Since cAMP levels 
were determined by boiling lysis, the sum of intracellular and extracellular cAMP was measured. In 
order to exclude that the >600-fold increase in [cAMP] measured after CpdA treatment was mainly 
extracellular, excreted or released cAMP, we determined the concentration of the second messenger in 
the supernatant. Even though in comparison to untreated cells a slight fraction of cAMP was in fact 
excreted/released, this did not significantly change the calculated intracellular cAMP concentration 
(data not shown).  
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T. brucei PKA is important for growth of bloodstream forms. Since the T. brucei PKA 
orthologues are not cAMP-responsive, we were interested whether they do have an essential function 
in the parasite. Hence, several cell lines with genetic manipulation of PKA subunits were generated 
and analyzed regarding growth and cell cycle phenotypes. Inducible RNAi targeting both, PKAC1 and 
PKAC2, resulted in a reduction in the PKAC1/2 protein level by 80-90% after 8h of induction with 1 
µg/ml tetracycline (Tet) accompanied by a decrease in PKAR protein (by 40-80%, depending on the 
clone analyzed) (Figure S7A, left). The cells stopped growing within 4 h of RNAi induction with 
subsequent cell death within 2 days (Figure 5A, left panel; additional clone: Figure S8A, left panel) 
indicating at least one of the two genes being essential. Western Blot analysis of the cell line ∆pkac1/ 
Ty1-PKAC1 showed that PKAC1 is expressed at a much higher level than PKAC2 in slender BSFs 
(Figure 1A), even in the presence of only one PKAC1 allele. In order to find out whether the two 
subunits are redundant or one or both of them are essential, deletion mutants were generated. Three 
independent attempts to generate a null mutant of PKAC1 failed indicating that PKAC1 is likely to be 
essential. The hemizygous PKAC1 deletion mutant (Figure S7B), however, only showed a very mild 
growth phenotype (PDT 6 h) compared to wild type cells (PDT 5.4 h) (Figure 5A, right panel). In 
contrast to PKAC1, it was possible to delete both PKAC2 alleles (Figure S7C). The PKAC2 deletion 
mutant initially showed reduced growth with a PDT of 8.5 h (data not shown), which decreased to   
6.8 h after prolonged cultivation (Figure 5A, right panel). Inducible RNAi against PKAR resulted in a 
growth arrest after 8 h of induction (Figure 5A, left panel; additional clone: Figure S8A, right panel). 
A decrease in PKAR protein by more than 90% with a concomitant decrease in PKAC1/2 levels (by 
>90%) and PKAC3 levels (by 60-80%) (Figure S7A, right) was observed. The growth phenotype of 
the PKAR RNAi cell line could be either caused by an initial increase in PKA activity due to free C 
subunits or it could result from a reduction in PKA activity by instability and degradation of free C 
subunits. The co-regulation of PKAR and PKACs observed in the RNAi cell lines indicates that these 
subunits interact in vivo by formation of a PKA holoenzyme. Co-regulation of PKA subunits has also 
been reported from mammalian cells, where loss, mutation, or overexpression of one PKA subunit can 
be partially compensated by co-regulation of the other at the level of protein stability (Amieux et al., 
1997; Burton et al., 1997; Duncan et al., 2006; Kirschner et al., 2009). In contrast to the PKAR-
PKAC1 co-regulation, which shows a correlation coefficient of r = 0.91 (R2 = 0.82) (Figure S7D) and 
hence represents a nearly perfect correlation, the correlation coefficient for PKAR-PKAC3 is only       
r = 0.59 (R2 = 0.35). This indicates that the amount of PKAC3 is not stoichiometrically co-regulated 
with the amount of PKAR. Possible explanations are that PKAC3 partially exists as free, inactive 
catalytic subunit, or that it is bound to an alternative intracellular inhibitor. For the following analyses 
we hence focused on PKAR and PKAC1/2. In contrast to the PKAR RNAi cell line, a homozygous 
deletion mutant of PKAR (Figure S7E) only showed a mild growth phenotype (PDT 7.5 h) (Figure 5A, 
right panel). The level of PKAC1/2 was reduced to 34% compared to wild type cells (Figure S7E) and 
hence does not show a perfect correlation with PKAR expression. The generation of a knock out cell 
line is always accompanied by selection of cells, which are able to survive under the altered 
conditions, which may be based on secondary adaptations when targeting an essential gene. The level 
of PKAC1/2 in the PKAR knock out cells may correspond to the minimal amount necessary for 
survival. This could explain why the PKAR knock out cells are able to survive in contrast to the PKAR 
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RNAi cell line, in which PKAC1/2 is reduced to a lower level. To exclude off-target effects of the 
RNAi fragment targeting PKAR, we generated a cell line with inducible RNAi against a non-
overlapping fragment covering the C-terminal part of the PKAR ORF and part of its 3’UTR. Both 
PKAR RNAi cell lines showed identical results regarding repression efficiency and growth phenotypes 
upon induction of RNAi (Figure 5A, Figure S7A right, Figure S8A right, Figure S9). The growth 
defects of PKAR and PKAC1/2 mutants shown in the present study are supported by data from a recent 
genome-wide RIT-seq screen, in which all three genes have scored essential after 6 days of RNAi 
induction in BSFs (Alsford et al., 2011). In addition, a recent kinome RNAi screen showed similar 
phenotypes when targeting PKAC1 and PKAC2 (Jones et al., 2014). 
Detailed cell cycle analysis revealed pronounced defects of most PKA mutants. By DAPI staining and 
subsequent determination of kinetoplast/nucleus (K/N) configurations we observed a decrease in the 
number of 1K1N cells and a concomitant increase in the number of 2K2N and aberrant, 
multinucleated cells for the PKAC1 and PKAC2 deletion mutants and the induced RNAi cell lines in a 
time course over 10 hours of induction (Figure 5B, Figure S8B). The strongest phenotype was 
observed for the PKAC1/2 RNAi cell line, which showed a significant increase in 2K2N and 
multinucleated cells already after 4h of Tet induction. After 8 hours, nearly 100% of the population 
consisted of 2K2N and multinucleated cells. The fraction of 2K1N cells decreased to zero. A very 
similar, but slightly delayed phenotype was observed for the PKAR RNAi cell line. As mentioned 
before, this may be caused by a reduction of total PKA activity, since RNAi against PKAR is 
accompanied by a reduction in PKAC1/2 levels. The hemizygous deletion mutant of PKAC1 and the 
PKAC2 null mutant showed phenotypes similar to PKAC1/2 RNAi, but less pronounced, with a 
doubling of the amount of 2K2N cells and a significant increase in the number of multinucleated cells. 
These results suggest a block in cytokinesis. In contrast, the PKAR null mutant does not show defects 
in cell division, again stressing the possibility of secondary adaptations in knock out cell lines. 
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Figure 5: Growth and cell cycle analysis of T. brucei PKA mutants.  
A. Growth analysis of cell lines with inducible RNAi against PKAC1/2 or PKAR  (left panel) grown in 
the presence (+Tet) or absence (-Tet) of 1 µg/ml tetracycline as well as of wild type (wt) cells and 
PKA deletion mutants (PKAR-/-, PKAC1-/+, PKAC2-/-) (right panel). Cells were counted at the 
indicated time points and diluted if necessary to keep the cell density below 1×106/ml. The y-axes 
represent the log10 of the cumulative cell densities.  
B. Cell cycle analysis by counting the number of kinetoplasts (K) and nuclei (N) per cell of wild type 
cells (wt), PKA deletion mutants (PKAR-/-, PKAC1-/+, PKAC2-/-) as well as of cell lines with 
inducible RNAi against PKAC1/2 or PKAR in a time course over 10 h after induction with 1 µg/ml 
tetracycline (+Tet). Non-induced cells (-Tet) were included as control. The K/N configurations of wild 
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type cells and the deletion mutants are represented by dashed lines, since they were analyzed only at 
one time point. A minimum of 100 cells of each cell line was analyzed at the indicated time points. 
Note that the y-axis of the 2K1N-analysis was stretched compared to the other analyses in order to be 
able to distinguish between the single graphs. 
 
 
T. brucei PKA is activated by the PDE inhibitor dipyridamole. Before CpdA became 
available, we had used dipyridamole for the experiments shown in Figure 4. Consistent with previous 
studies (Zoraghi et al., 2001; Laxman et al., 2006), the PDE inhibitor dipyridamole induced a slight 
increase (2.3-fold compared to treatment with the solvent DMSO in a 15 min assay, p≤0.001; 2.8-fold 
in a 90 min assay, p≤0.001) in the intracellular cAMP level (Figure 6A). Surprisingly, dose- and time-
dependent induction of in vivo PKA activity was observed upon treatment with dipyridamole (Figure 
6B; Figure S10A, B). This activation cannot be due to the slightly increased cAMP levels since no 
induction was observed upon treatment with the much more potent PDE inhibitor CpdA (Figure 4A, 
B). The specificity of the dipyridamole-induced PKA activation was proven by treatment with the 
PKA-specific inhibitor peptide myr-PKI(14-22), which prevented a dipyridamole-induced increase in 
VASP phosphorylation (Figure S10C). In addition, no activation by dipyridamole was observed in a 
PKAR null mutant (PKAR-/-) in comparison to wild type cells and an endogenous PKAR rescue cell 
line (PKAR-/+) (Figure S10D) indicating that dipyridamole induces VASP phosphorylation specifically 
via PKAR. 
 
 
 
 
Figure 6: T. brucei PKA is activated by dipyridamole in vivo. 
A. Analysis of cAMP levels upon treatment with 100 µM dipyridamole or the solvent DMSO (1%) 
for 15 min or 90 min, respectively. Untreated cells were included as control. Results are derived from 
three independent experiments; error bars represent SD. 
B. Determination of in vivo PKA activity upon treatment with 100 µM dipyridamole or the solvent 
DMSO (1%) in a time course over 15 min. Untreated cells were included as control. Results are 
derived from three independent experiments; error bars represent SD. 
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An in vivo small-scale screen identifies regulators of T. brucei PKA. The unexpected 
observation that T. brucei PKA is activated by dipyridamole in a cAMP-independent and PKAR-
dependent manner asked for definition of the chemical space of possible activators of the kinase. 
Among other side effects, dipyridamole is known to interfere with adenosine signaling (Pfleger et al., 
1969; Klabunde, 1983; Gibbs and Lip, 1998). Hence, we conducted a small-scale chemical screen 
with a major focus on testing the effect of several different membrane-permeable adenosine analogues 
on in vivo PKA activity as well as on cell proliferation (Table 1, Figure S11). In addition, six 
membrane-permeable cAMP or cGMP analogues were included in the screen to confirm the absence 
of cAMP-dependent activation of T. brucei PKA and to re-analyze the previously observed activation 
of the kinase by high concentrations of cGMP (Figure 2; Shalaby et al., 2001). The two adenosine 
analogues 8-pCPT-adenosine and 8-pCPT-2’O-me-adenosine were identified as inhibitors of in vivo 
PKA activity, although maximal inhibition was only modest (Table 1; Figure S11A). In contrast, 8-
pCPT-adenine, a possible intracellular degradation product of 8-pCPT-adenosine, did not show any 
effect on VASP phosphorylation (Table 1; Figure S11B), additionally serving as a control that the 
observed effects of 8-pCPT-(2’O-me-)adenosine are not caused by the chlorophenylthio (CPT) group. 
The nucleoside derivatives 8-pCPT-guanosine, 2-Cl-adenosine, 8-Br-adenosine and 6-Cl-
puroribonucleoside as well as six different cAMP or cGMP analogues did not significantly influence 
kinase activity at physiologically relevant concentrations (Table 1; Figure S11C, D), confirming the 
absence of cAMP-dependent activation of T. brucei PKA. Only at very high concentrations (>1 mM) 
inhibition by 8-pCPT-cAMP was observed, while high concentrations of 8-pCPT-cGMP caused 
activation of the kinase (Figure S11E), supporting previous observations (Shalaby et al., 2001). 
Interestingly, the 7-deaza-adenosine (tubercidin) analogues toyocamycin, 5-I-tubercidin, 5-Br-
tubercidin and sangivamycin were identified as in vivo activators of T. brucei PKA with EC50 values 
of 87.63 nM, 389.57 nM, 625.07 nM, and 39.26 µM, respectively (Table 1; Figure S11F). In order to 
prove specificity of PKA activation by toyocamycin, the most potent in vivo activator identified in the 
present study, VASP phosphorylation was analyzed in a null mutant of PKAR (Figure S11G) 
compared to wild type cells in a time course over 30 min. No increase in PKA activity was observed 
in the PKAR deletion mutant indicating that toyocamycin induces VASP phosphorylation specifically 
via PKAR. In contrast to the 5-substituted tubercidin derivatives, which activate T. brucei PKA, no 
effect was observed upon treatment with tubercidin or 6-Br-tubercidin (Table 1; Figure S11H). Since 
tubercidin cannot pass membranes by diffusion but has to be taken up via adenosine transporters (de 
Koning and Jarvis, 1999; Mäser et al., 2001; Geiser et al., 2005), its intracellular concentration may 
not be sufficient to activate PKA within 15 min. However, the lack of activation by 6-Br-tubercidin 
indicates that either the electronegative side group at C-5 of tubercidin is essential for activation or 
that the bromo group at C-6 of tubercidin prevents activation. 
Growth analysis by Alamar blue assay revealed that all compounds affecting in vivo PKA activity also 
showed anti-proliferative effects in BSFs (Table 1). 8-pCPT-2’O-me-adenosine, one of the two 
inhibitors of T. brucei PKA, was the most active compound with an IC50 of 122±16 nM. The other 
inhibitor, 8-pCPT-adenosine, was ~4-fold less potent. Analysis of the growth inhibitory effect in a 
PKAR null mutant showed a significant increase in resistance to 8-pCPT-2’O-me-adenosine and 8-
pCPT-adenosine of 2-fold (p≤0.001) and 4-fold (p≤0.001), respectively, indicating that the lethal 
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effects are at least in part mediated by inhibition of PKA. Similarly, the mutant showed increased 
resistance to the cAMP derivatives 8-pCPT-2’O-me-cAMP (1.6-fold (p≥0.05)) and 8-pCPT-cAMP (4-
fold (p≤0.05)), which are likely to be intracellularly degraded to the respective adenosine derivatives. 
The absence of an effect of these cAMP derivatives in the VASP assay can be easily explained by the 
short time course of the assay, which is most likely not sufficient for the degradation of the cAMP to 
the adenosine derivatives. A significant increase in resistance of the PKAR null mutant compared to 
wild type cells was also observed for dipyridamole (1.65-fold; p≤0.01) and sangivamycin (2.2-fold; 
p≤0.001), two of the in vivo activators of T. brucei PKA identified in the present study. The growth 
inhibitory effects of the other activators (toyocamycin, 5-I-tubercidin, 5-Br-tubercidin) did not differ 
between wild type and PKAR null mutant, indicating that lethal effects via other targets in the 
trypanosome cells are dominant. This is not surprising, since these 5-substituted tubercidin analogues 
are known to have various different intracellular targets in mammalian cells, e.g. inhibition of several 
kinases (Saffer and Glazer, 1981; Loomis and Bell, 1988; Osada et al., 1989; Palczewski et al., 1990; 
Bobek and Bloch, 1994) or general inhibition of DNA, RNA and protein synthesis (Cohen and Glazer, 
1985).  
T. brucei PKA is directly activated by 5-substituted tubercidin analogues in vitro. In order 
to investigate whether the identified in vivo regulators of T. brucei PKA act directly or indirectly, 
kinase assays were conducted in vitro with recombinantly expressed and purified holoenzyme using 
kemptide as substrate. Since PKAC1 is more abundant than PKAC2 in BSFs and is essential, it was 
chosen for inducible co-expression with T. brucei PKAR in the L. tarentolae expression system 
(LEXSY) (Figure S12A). Dipyridamole, the initially identified activator of in vivo PKA activity in T. 
brucei, did not show any effect on in vitro kinase activity indicating an indirect activation mechanism 
(Table 2, Figure S12B). In contrast, almost all tubercidin derivatives showed activation of the purified 
holoenzyme in vitro with the following order of potency: toyocamycin > 5-I-tubercidin > 5-Br-
tubercidin > tubercidin > sangivamycin (Table 2, Figure S12C). This order is almost identical to the in 
vivo observations with the exception that tubercidin did not regulate in vivo PKA activity. As 
mentioned above the most likely reason is that in contrast to all other tubercidin analogues tested in 
the screen it has to be taken up by adenosine transporters, which is most likely too slow for activation 
of the kinase within a short incubation time. 8-pCPT-2’O-me-adenosine, one of the two inhibitors of 
T. brucei PKA in vivo, did not inhibit PKA activation by toyocamycin in vitro suggesting an indirect 
mechanism (Table 2, Figure S12D). Differences in the EC50 values between in vivo and in vitro 
experiments can be based e.g. on uptake efficiency or intracellular accumulation.  
 Toyocamycin does not activate the human PKA holoenzyme. In order to analyze the 
specificity of activation by toyocamycin for the parasite PKA orthologue, in vitro kinase assays were 
conducted with recombinantly expressed human PKARIα-PKACα holoenzyme. Treatment with 
toyocamycin did not influence PKA activity up to a concentration of 50 µM (Figure S12E, left panel), 
whereas the kinase was activated by treatment with 10 µM cAMP. 
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Table 1: Influence of different nucleoside/nucleotide derivatives on in vivo PKA activity in T. brucei.  
compound EC50 growth wt  Alamar blue assay1,2 
EC50 growth PKAR-/- 
Alamar blue assay1,2 
EC50 VASP 
phosphorylation wt2,3 	  
8-pCPT-adenosine 475 ± 86 nM 1869 ± 292 nM (p ≤ 0.001)5 ! 369.2 ±120 nM 
PK
A
 
in
hi
bi
to
rs
 
8-pCPT-2'O-me-
adenosine 122 ± 16 nM 
234 ± 20 nM 
(p ≤ 0.001)5 ! 110.63 ± 23.5 nM 
8-pCPT-adenine no effect no effect no effect 	  
8-pCPT-guanosine 20 µM4 n.d. no effect 	  
8-Br-adenosine n.d. n.d. no effect 	  
2-Cl-adenosine 15.82 ± 2.5 µM 17.43 ± 2.3 µM no effect 	  
6-Cl-PuR n.d. n.d. no effect 	  
8-pCPT-cAMP 2.45 ± 0.7 µM 9.95 ± 2.2 µM (p ≤ 0.05)5 no effect 	  
8-pCPT-2'O-me-
cAMP 1.23 ± 0.3 µM 
1.98 ± 0.3 µM 
(p ≥ 0.05)5 no effect 	  
8-pCPT-cGMP n.d. n.d. no effect 	  
8-pCPT-2'O-me-
cGMP ∞
4 n.d. no effect 	  
cAMP-AM no effect4 n.d. no effect 	  
cGMP-AM no effect4 n.d. no effect 	  
dipyridamole 9.93 ± 1 µM 16.3 ± 1.8 µM (p ≤ 0.01)5 " 22.35 ± 4.2 µM 
PK
A
 a
ct
iv
at
or
s toyocamycin 739 ± 59 nM 690 ± 58 nM " 87.63 ± 9.6 nM 
5-I-tubercidin 330 ± 38 nM 346 ± 41 nM " 389.57 ± 20 nM 
5-Br-tubercidin 874 ± 122 nM 1009 ± 95 nM " 625.07 ± 65.5 nM 
sangivamycin 713 ± 40 nM 1548 ± 171 nM (p ≤ 0.001)5 " 39.26 ± 5.6 µM 
tubercidin n.d. n.d. no effect 	  
6-Br-tubercidin n.d. n.d. no effect 	  	  
1 average ± SEM determined from at least six independent replicates 
2 EC50 determined using GraphPad Prism 6.0 
3 average ± SD determined from three independent biological replicates 
4 determined by manual counting 
5 p-values indicate the significance of the change in the EC50 of PKAR-/- compared to wild type (wt); p-values were 
determined using the Excel Add-in QI Macros, 2014; F-test for identical or different variances followed by two-tailed T-test 
n.d. = not determined; " activation, ! inhibition 
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Table 2: Influence of the identified in vivo regulators on in vitro T. brucei PKA activity. 
compound 
 
EC50  in vitro kinase assay1, 2 
  
dipyridamole no effect  
8-pCPT-2'O-me-adenosine no effect 
toyocamycin 183 ± 70 nM 
PK
A
 a
ct
iv
at
or
s 
5-I-tubercidin 227 ± 92 nM 
5-Br-tubercidin 2.8 ± 0.9 µM 
sangivamycin ≥ 11 µM 
6-Br-tubercidin negligible  
   
1 average ± SEM determined from at least three independent replicates 
2 EC50 determined using GraphPad Prism 6.0 
 
 
Toyocamycin as tool to decipher downstream components of the PKA signaling pathway 
in T. brucei. The VASP assay is a useful tool to analyze regulation of PKA in vivo. However, nothing 
is known about endogenous PKA substrates in T. brucei. With the identification of toyocamycin as 
potent activator, the analysis of global changes in phosphorylations and transcript abundance could 
help identifying further components of this signaling pathway in T. brucei. Lysates of BSF wild type 
and PKAR null mutant cells treated or not with toyocamycin were analyzed by Western blot using a 
Phospho-(Ser/Thr) PKA substrate antibody (Figure 7). Whereas in the wild type sample a strong 
increase in the number and intensity of the bands recognized by the antibody was observed upon 
treatment with toyocamycin, no difference between treated and untreated samples was detected for the 
PKAR null mutant. The same result was obtained analyzing a wild type and a PKAR null mutant cell 
line with expression of the reporter substrate VASP (Figure S13). This indicates that toyocamycin can 
be used as tool to specifically detect proteins phosphorylated by T. brucei PKA, which can 
subsequently be identified by quantitative proteomics.  
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Figure 7: Toyocamycin induces phosphorylation of 
endogenous PKA substrates.  
Western blot analysis with lysates from T. brucei wild 
type or PKAR-/- cells treated or not with 2 µM 
toyocamycin for 10 min. Proteins phosphorylated at 
RXXS/T motifs were detected by a Phospho-PKA 
substrate antibody (anti-RXXS*/T*; * = 
phosphorylation). The monoclonal antibody L13D6 
(Kohl et al., 1999) was used for detection of PFR-A/C as 
loading control. 
 
 
 
 
 
 
In addition, combining activation of PKA by toyocamycin with transcriptome profiling using RNAseq 
allows the identification of components regulated by PKA at the transcript level. Wild type and PKAR 
null mutant cells were treated with toyocamycin, and RNA samples were taken after 0 h, 0.5 h, 1 h, 4 
h, and 8 h. Transcript abundance analyzed by RNAseq revealed significant regulation (p<0.05) of 225 
transcripts by toyocamycin in wild type cells without significant regulation in the PKAR deletion 
mutant (Table S1, Figure S14). GO (gene ontology) enrichment analysis using the TriTrypDB 
database (www.tritrypdb.org) as well as the DAVID bioinformatics database 
(http://david.abcc.ncifcrf.gov/) indicated a major involvement of T. brucei PKA in regulation of 
metabolic processes, translation, protein folding, (ribo-)nucleotide/nucleoside-binding, and transport 
(Table S2A, B), reminiscent of PKA downstream functions in other organisms (Tash and Means, 
1982; Brokaw, 1987; Leclerc et al., 1996; Robertson et al., 2000; Jones et al., 2003; Zhang et al., 
2003; Harcus et al., 2004; Hu et al., 2007; Baker, 2011; Wurtz et al., 2011). To validate the RNAseq 
analysis, the expression of four transcripts (phosphatidic acid phosphatase (Tb927.8.480), procyclin 
associated gene 1 (Tb927.10.10240), glycerol kinase (cluster of five nearly identical genes: 
Tb927.9.12550, Tb927.9.12570, Tb927.9.12590, Tb927.9.12610, Tb927.9.12630), and a hypothetical 
protein (Tb927.8.490)) showing significant toyocamycin-dependent regulation in the wild type but not 
in the deletion mutant was independently analyzed by qRT-PCR (Figure S15) in wild type and PKAR 
null mutant cells treated or not with toyocamycin for 8 h. The results of the qRT-PCR analysis are 
fairly in agreement with the RNAseq data. 
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Discussion 
 
The activation mechanism of Protein Kinase A by cAMP is highly conserved in most eukaryotes 
ranging from unicellular symbiotic pathogens such as plasmodia over yeast to mammals. Although 
there are exceptional cases of cAMP-independent regulation (Zhong et al., 1997; Wang et al., 1998; 
Dulin et al., 2001; Zieger et al., 2001; Yang et al., 2013), all these PKA orthologues can be activated 
by the cooperative binding of two cAMP molecules to each PKAR subunit. The PKA orthologue of T. 
brucei is the first PKA-related kinase identified, which is completely uncoupled from the second 
messenger cAMP. Residues mediating specific binding of cAMP to the cyclic nucleotide-binding 
domains (CNB domains) of PKAR subunits are located within the phosphate binding cassettes (PBCs) 
(Su et al., 1995; Diller et al., 2001; Berman et al., 2005). Figure 8 shows an alignment of the PBC core 
sequences of PKARs from the three kinetoplastids T. brucei, T. cruzi and L. donovani with 
orthologues from other unicellular eukaryotes as well as human PKARI alpha and PKARII alpha. The 
signature sequence of the PBC domain, which is shown below the alignment, has been determined by 
Canaves and Taylor (2002) and has been postulated to be characteristic of the PKAR family and 
sufficient to distinguish it from other cNMP-binding proteins. Although the PBC domains of the 
kinetoplastid PKAR orthologues show a high overall sequence conservation with PKARs of other 
organisms, there are a few amino acid deviations (Figure 8). Most importantly, the arginine 
highlighted in green in Figure 8, which forms specific hydrogen bonds with the O1P phosphate of 
cAMP (Su et al., 1995; Diller et al., 2001; Berman et al., 2005) and has been shown to be essential for 
phosphate binding (Bubis et al., 1988; Neitzel et al., 1991), is not conserved, indicating that 
kinetoplastid PKARs might not be able to specifically bind cNMPs. In contrast, the glutamate 
highlighted in blue, is responsible for interaction with the 2’OH group of the ribose ring and is 
conserved in kinetoplastid PKARs, suggesting that nucleoside binding is possible. These structural 
features are in agreement with the results obtained for T. brucei PKA in vitro as well as in vivo. Since 
the arginine critical for phosphate binding is not conserved in any of the three kinetoplastid PKARs 
analyzed (see Figure 8 and TriTrypDB), all orthologues of this ancient, early branching group of 
eukaryotes are likely to show a similar behavior in terms of cNMP responsiveness.  
Dipyridamole, a known inhibitor of mammalian PDEs (Ghosh et al., 2009), weakly inhibits T. brucei 
PDEB1 and PDEB2 (Rascon et al., 2002; Zoraghi and Seebeck, 2002) resulting in a ~2-fold increase 
in the intracellular cAMP concentration (Zoraghi et al., 2001; Laxman et al., 2006). Since T. brucei 
PKA is not responsive to cAMP, it came as a surprise that dipyridamole activated the kinase in vivo. 
The absence of activation in vitro suggests an indirect mechanism. As dipyridamole is known to 
interfere with adenosine signaling in mammalian cells (Pfleger et al., 1969; Klabunde, 1983; Gibbs 
and Lip, 1998), it might have similar effects in T. brucei. In fact, dipyridamole has been shown to 
inhibit adenosine uptake in BSFs (James and Born, 1980) and PCFs (Al-Salabi et al., 2007). Hence, 
perturbation of the parasite’s nucleoside metabolism might change the levels of an alternative second 
messenger-like molecule. This hypothesis is supported by the indirect inhibition of T. brucei PKA by 
the adenosine derivatives 8-pCPT-adenosine and 8-pCPT-2’O-me-adenosine. 
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Figure 8: Alignment of PBC core sequences from different PKAR orthologues. 
PBC core sequences of PKAR orthologues from Homo sapiens (Hs_PKAR alpha, accession P10644; 
Hs_PKARII alpha, accession P13861), Dictyostelium discoideum (Dd_PKAR, accession P05987), 
Plasmodium falciparum (Pf_PKAR, accession Q8T323), Toxoplasma gondii (Tg_PKAR, accession 
Q9BMY7), Candida albicans (Ca_PKAR, accession Q9HEW1), Trypanosoma brucei (Tb_PKAR, 
accession Tb427tmp.02.2210), Trypanosoma cruzi (Tc_PKAR, accession TcCLB.506227.150) and 
Leishmania donovani (Ld_PKAR, accession LdBPK_130160.1) were obtained from UniProt 
(www.uniprot.org) or TritrypDB (www.tritrypdb.org), respectively. Multiple sequence alignment was 
performed using clustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) with standard settings, and 
conservation is shown above the alignment according to the clustalW2 standard key. The numbering 
above the alignment refers to Hs_PKARIα. The signature sequence of PBC domains of the PKAR 
family determined by Canaves and Taylor (2002) is shown below the alignment. Amino acids of the 
kinetoplastid PKAR orthologues deviating from the signature motif are marked by red arrows. 
Residues mediating interaction with the 2’OH group of the ribose ring are highlighted in blue, the 
arginine important for specific phosphate binding is shown in green, and amino acids forming H-
bonds to additional sites are colored in yellow. 
 
In addition to the apparent absence of a cAMP-dependent protein kinase, none of the alternative 
cAMP effector proteins identified in other organisms like Epac or cyclic nucleotide gated ion channels 
are encoded by the T. brucei genome. However, just recently, an alternative cAMP signaling pathway 
has been discovered in the parasite: CARP1, a putative cAMP receptor protein, has been identified by 
a whole genome RNAi library screen selecting for cells resistant to elevated intracellular cAMP levels 
induced by treatment with CpdA (Gould et al., 2013). Interestingly, CARP1 is kinetoplastid-specific. 
This fits well into a model in which CARP1 has replaced PKA as primary cAMP acceptor and serves 
as entry point into a novel, kinetoplastid-specific cAMP-signaling pathway. In contrast to the 
unconventional upstream signaling pathway of T. brucei PKA, a strong overlap of downstream 
processes regulated by the kinase at the transcriptional level with processes regulated by PKAs of 
other organisms was observed. Transcriptional profiling revealed a predominant role of the parasite 
kinase in regulation of metabolic processes, translation, protein folding, and transport, reminiscent of 
its functions in many other eukaryotes ranging from protozoa over fungi to mammals (Tash and 
Means, 1982; Brokaw, 1987; Leclerc et al., 1996; Robertson et al., 2000; Jones et al., 2003; Zhang et 
al., 2003; Harcus et al., 2004; Hu et al., 2007; Baker, 2011; Wurtz et al., 2011).  
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The compounds 8-pCPT-cAMP as well as 8-pCPT-2’O-me-adenosine/cAMP have been shown to be 
effective inducers of in vitro stumpy formation in T. brucei (Vassella et al., 1997; Laxman et al., 
2006). In the present study, we could show that 8-pCPT-adenosine and 8-pCPT-2’O-me-adenosine are 
indirect inhibitors of in vivo PKA activity. In addition, their anti-proliferative effects are at least 
partially mediated by PKA, since the PKAR deletion mutant was ~2-fold and ~4-fold, respectively, 
more resistant compared to wild type cells. A similar increase in resistance was observed upon 
treatment with 8-pCPT-cAMP and 8-pCPT-2’O-me-cAMP, compounds intracellularly hydrolyzed by 
PDEs to the respective adenosine derivatives (Laxman et al., 2006). Consistent with this, a recent 
study has identified PKAR by a whole-genome RNAi library screen selecting for cells resistant to 8-
pCPT-cAMP (Mony et al., 2014). Whether T. brucei PKAR plays a role in slender to stumpy 
differentiation is yet an open question. 
Toyocamycin and sangivamycin, direct activators of T. brucei PKA identified by the current study, are 
natural antibiotics, produced by certain strains of Streptomyces. However, it is highly unlikely that 7-
deazapurines are endogenous, natural activators of T. brucei PKA since there is no indication for the 
presence of any enzyme involved in the pathway synthesizing the critical precursor preQ0 in the 
parasite (McCarty and Bandarian, 2008) (blastp using BLAST+ version 2.2.8 for ToyD, ToyB, ToyC 
and ToyM sequences from Streptomyces rimosus; HMMER search for the profile of ToyB using 
version 3.1b1; as a reference the proteome of T. brucei strain TREU927, release 8.0 was downloaded 
from TriTrypDB).  
Most importantly, toyocamycin is an excellent experimental tool for deciphering the PKA downstream 
signaling pathway in T. brucei at the transcriptional and translational level as well as at the level of 
substrate phosphorylation. 
7-deazapurine analogues are known to have pleiotropic targets in various cell types by interfering with 
cellular processes involving adenine nucleosides and nucleotides, such as inhibition of different 
kinases (Saffer and Glazer, 1981; Loomis and Bell, 1988; Osada et al., 1989; Palczewski et al., 1990; 
Bobek and Bloch, 1994) or inhibition of DNA, RNA and protein synthesis (Cohen and Glazer, 1985). 
Sangivamycin and its derivatives show cytotoxicity against cancer cells (Komi et al., 2007; Lee and 
Jung, 2007; Cappellini et al., 2009; Kang et al., 2010; Dolloff et al., 2012; Rayala et al., 2014; Wakao 
et al., 2014) as well as anti-viral activity (Bergstrom et al., 1984; Turk et al., 1987) but do not produce 
toxicity in humans at maximally tolerated doses (Cavins et al., 1967; Hardesty et al., 1974; Ohno et 
al., 2001; Komi et al., 2007; Lee and Jung, 2007). Since growth inhibition with EC50 values in the sub-
micromolar range was observed upon treatment of T. brucei BSF cells with the 7-deazapurine 
analogues toyocamycin, sangivamycin, 5-I-tubercidin and 5-Br-tubercidin, the potential of 7-
deazapurine derivatives for anti-trypanosomal therapy should be exploited in future studies. Yet, the 
major target of these compounds in T. brucei is not PKA, since their anti-proliferative effects were not 
mediated by the kinase. Only upon treatment with sangivamycin, a two-fold increase in the EC50 for 
growth inhibition was observed in the PKAR deletion mutant compared to wild type cells. 
Nevertheless, T. brucei PKA qualifies as good drug target due to the following aspects: 1) the enzyme 
is essential; 2) the kinase has ligand-binding domains, which can be exploited in designing specific 
activators or inhibitors, and which significantly differ from orthologous proteins of the mammalian 
host; and 3) a compound has been identified, which binds to and activates T. brucei PKA in the lower 
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nanomolar range. 7-deazapurine analogues might represent promising leads to design specific 
activators or inhibitors of T. brucei PKA with anti-trypanosomal activity. Due to the sequence 
conservation of the PBC domains of the kinetoplastid PKAR orthologues, compounds specifically 
targeting T. brucei PKAR are also likely to target the T. cruzi and L. donovani orthologues. Hence, a 
drug with the capability to be used against HAT by specifically targeting PKA could potentially also 
be used for treatment of Chagas disease and Leishmaniasis.  
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4.2 A cold-inducible protein kinase A regulates stage differentiation of 
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Abstract 
 
The cyclic AMP-dependent protein kinase PKA is one of the best-studied protein kinases. The enzyme 
is conserved in most eukaryotes and is responsible for regulation of a variety of cellular processes 
such as energy metabolism, differentiation, transcription, or transport. In Trypanosoma brucei, a 
unicellular, eukaryotic parasite with a complex life cycle involving a host switch between a mammal 
and an arthropod vector, the cAMP and PKA signal transduction pathways have been retooled. The 
conserved parasite PKA is not regulated by the second messenger cAMP but by a drop in temperature, 
an important trigger of life cycle stage differentiation. The kinase is activated by low temperature 
thereby sensitizing short stumpy bloodstream form trypanosomes to low, physiological concentrations 
of citrate/cis-aconitate, an essential stimulus for differentiation to insect stage procyclic trypanosomes. 
Identification of endogenous substrates of T. brucei PKA revealed partial conservation of processes 
regulated by PKA from trypanosomes over yeast to humans. However, one third of the identified 
proteins phosphorylated by the parasite kinase, are kinetoplastid- or Trypanosoma-specific with 
largely unknown function, supporting the unique role of this ubiquitous and in other organisms highly 
conserved signal transduction pathway in the evolutionary early branching eukaryote T. brucei. 
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Introduction 
 
The parasitic protozoan Trypanosoma brucei, the causative agent of human African sleeping sickness 
(HAT) and Nagana in cattle (Brun et al., 2010), has a complex life cycle with a host switch between 
an arthropod vector, the tsetse fly, and a mammalian host. Hence, the parasite faces highly variable 
environmental conditions, and the ability to quickly adapt to a new environment is crucial for survival 
and transmission efficiency. Changes in temperature, nutrient availability, pH or osmolarity, as well as 
attack by proteases or the immune system are conditions trypanosomes have to cope with. In both the 
mammalian host as well as the arthropod vector, dividing stages as well as cell cycle arrested stages 
exist with the latter being pre-adapted to the life in the next host (Fenn and Matthews, 2007). In the 
mammalian bloodstream, the dividing long slender (LS) and the cell cycle arrested short stumpy (SS) 
bloodstream forms (BSFs) live in an environment with plenty of glucose as energy source (Bringaud 
et al., 2006) and a constant temperature of 37°C. LS cells differentiate in a density-dependent, quorum 
sensing-like mechanism into SS cells (Reuner et al., 1997; MacGregor et al., 2011), which differ in 
characteristic features from LS cells: procyclin, the major surface protein of insect-stage, procyclic 
form (PCF) trypanosomes, is expressed and routed to the cell surface (Fenn and Matthews, 2007). 
Furthermore, enzymes crucial for utilization of alternative energy sources in the fly are expressed. 
Upon a blood meal on an infected mammal, tsetse flies take up LS and SS trypanosomes. The latter, 
pre-adapted to the life in the insect vector, differentiate within a few days into the dividing PCF form. 
LS cells, however, are attacked and killed by proteases in the fly midgut. In vitro, the differentiation 
process from SS to PCF can be induced by treatment with citrate/cis-aconitate (CCA) (Ziegelbauer et 
al., 1990), mild acid stress (Rolin et al., 1998) or proteases (Hunt et al., 1994; Sbicego et al., 1999; 
Szöőr et al., 2013). In addition, a temperature drop of >15°C (cold shock) sensitizes stumpy 
trypanosomes to low concentrations of CCA (Engstler and Boshart, 2004). The molecular mechanisms 
and signaling pathways underlying these differentiation processes are only partially uncovered. A 
family of putative citrate transporters, the PAD proteins, is required for perception of the CCA 
stimulus at the surface of SS cells (Dean et al., 2009). PAD proteins are encoded by an array of eight 
genes, and simultaneous knockdown of all members results in reduced ability to differentiate to the 
insect form and eliminates CCA hypersensitivity under cold shock conditions. Although all PAD 
genes encode closely related proteins, they might fulfill distinct functions: whereas PAD1 serves as 
molecular marker for defining the short stumpy stage (Dean et al., 2009; MacGregor et al., 2011), 
exposure of SS trypanosomes to cold shock induces expression and surface routing of PAD2, which 
might act as CCA receptor (Dean et al., 2009). Moreover, a phosphatase cascade involving the protein 
phosphatases PTP1 and PIP39 controls differentiation from SS to PCF (Szöör et al., 2006; Szöör et al., 
2010) with PTP1 being a negative and PIP39 a positive regulator. Phosphorylation of PIP39 at Y278 is 
a prerequisite for differentiation to the insect stage. As long as SS forms reside in the mammalian 
bloodstream, PTP1 inactivates PIP39 by dephosphorylation at Y278 and thereby prevents 
differentiation. PIP39 activates PTP1 and thereby promotes its own inhibition. Szöör et al. (2013) 
propose a model in which the feedback inhibition of PIP39 by PTP1 is blocked by a CCA-dependent 
mechanism upon uptake of SS cells by a tsetse fly: CCA entering the cells via transporters of the PAD 
family localized at the surface of SS cells promotes interaction between PIP39 and PTP1 and 
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independently blocks the ability of PIP39 to enhance PTP1 activity. In addition, expression of PIP39 
in SS is induced by cold shock (Szöör et al., 2010). These combined events eventually result in 
increased amounts of phosphorylated PIP39, which localizes to the glycosomes and consequently 
promotes efficient differentiation into PCFs. So far, the kinase responsible for phosphorylation of 
PIP39 at Y278 as well as the downstream pathway ultimately resulting in differentiation to the PCF 
stage is unknown. By a global kinome RNAi library screen, Jones et al. (2014) have recently 
discovered two kinases, RDK1 and RDK2, which negatively regulate SS to PCF differentiation. 
RDK1 has been shown to act in conjunction with the TbPTP1/TbPIP39 pathway blocking 
uncontrolled BSF to PCF differentiation, whereas RDK2 might act upstream of RDK1 and TbPTP1.  
In many organisms, the cAMP-PKA-signaling pathway is involved in sensing and/or response to 
environmental changes (Smith et al., 1998; Taminato et al., 2002; Hoffman, 2005; Busti et al., 2010; 
Fuller and Rhodes, 2012) and regulation of differentiation processes (Loomis, 1998; Yao et al., 1998; 
Blaschke et al., 2000; Busti et al., 2010; Fuller and Rhodes, 2012; Yamamizu et al., 2012). The T. 
brucei genome encodes one orthologue of a regulatory and three isoforms of catalytic subunits of a 
PKA-related kinase. In contrast to its orthologues from other organisms, the enzyme is not regulated 
by the second messenger cAMP but potentially by an alternative endogenous, purine nucleoside-
related ligand (Bachmaier et al., manuscript, see chapter 4.1). The present study extends the 
peculiarity of the T. brucei PKA signaling pathway upstream as well as downstream: instead of 
activation by cAMP, the kinase is specifically activated by a drop in temperature and is responsible for 
cold shock-mediated sensitization of stumpy trypanosomes to low CCA concentrations promoting 
efficient differentiation to the PCF stage. Putative substrates identified by a phosphoproteome 
approach reveal partial conservation of the PKA signaling pathway from the ancient eukaryote T. 
brucei over yeast to humans. One third of the identified substrates, however, represent kinetoplastid- 
or even Trypanosoma-specific proteins with largely unknown function, stressing the partial re-tooling 
of this ubiquitous and in other organisms highly conserved signaling pathway. 
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Material and Methods 
 
Trypanosome strains, culture conditions and in vitro differentiation. 
Bloodstream forms of the monomorphic strain Lister 427, variant MiTat 1.2 (Cross and Manning, 
1973), of Trypanosoma brucei brucei were cultivated at 37°C in a 5% CO2 atmosphere in modified 
HMI-9 medium (Vassella et al., 1997) supplemented with 10% (v/v) heat-inactivated fetal bovine 
serum (FBS). Slender bloodstream forms of the pleomorphic T. b. brucei strain AnTat 1.1 (Delauw et 
al., 1985) were harvested from immunosuppressed Wistar rats (Charles River Laboratories; 
intraperitoneal injection of 200 mg cyclophosphamide per kg body weight 16-24 h before infection) at 
a parasitemia below 8×107/ml blood three to five days after infection with 1×106 trypanosomes per 
animal. The blood was collected in 2 ml trypanosome dilution buffer (TDB; 5 mM KCl, 80 mM NaCl, 
1 mM MgSO4, 20 mM Na2HPO4, 2 mM NaH2PO4, 20 mM glucose [pH 7.4]) with 5000 i.U. heparin 
(Applichem). The parasites were separated from red blood cells by two centrifugation steps (10 min, 
300×g, RT; 10 min, 1400×g, RT) followed by a buffy coat preparation and frozen in HMI-9 medium 
supplemented with 20% FBS and 10% glycerol. Slender trypanosomes were thawed and plated on 
agarose plates (Vassella and Boshart, 1996) with cell numbers between 5×104 and 1.5×106 parasites 
per plate. After 3-6 days, pure populations of stumpy trypanosomes were harvested from the plates 
and transferred into modified DTM medium (Overath et al., 1986; modified by Vassella and Boshart 
(1996)) complemented with 15% (v/v) heat-inactivated FBS at a density of 2×106/ml. The cells were 
incubated for 16 h either at 20°C to induce sensitization to low cis-aconitate concentrations (Engstler 
and Boshart, 2004) or at 27°C. Differentiation to the procyclic stage was subsequently induced by 
addition of different concentrations of cis-aconitate (0, 0.06, 0.4, 6 mM; Sigma-Aldrich) and 
cultivation at 27°C. Procyclic forms of AnTat 1.1 were grown at 27°C in SDM-79 medium (Brun and 
Schonenberger, 1979) supplemented with 10% (v/v) heat-inactivated FBS.  
Cloning and generation of transgenic trypanosomes. A cell line with deletion of both 
alleles of PKAC3 (Tb427.10.13010) was generated by transfection of Lister 427, variant MiTat 1.2, 
with the plasmids pB∆PKAC3NEO and pB∆PKAC3HYGRO. These constructs contained the PKAC3 
UTRs and a neomycin or hygromycin resistance cassette flanked by actin UTRs. Linearization for 
transfection was done using DraIII and PvuI (pB∆PKAC3NEO) or HindIII (pB∆PKAC3HYGRO), 
respectively. Selection was performed with 2 µg/ml G418 and 2.5 µg/ml hygromycin B. 
Monomorphic and pleomorphic trypanosome cell lines expressing a double tetracycline repressor were 
generated by transfection of monomorphic MiTat 1.2 Lister 427 or pleomorphic AnTat 1.1 cells with 
the plasmid pHD1313 (Alibu et al., 2005). The plasmid was linearized with NotI before transfection, 
and cells were grown in the presence of 10 µg/ml phleomycin.  
PKAC1 and PKAC2 were simultaneously targeted by a hairpin RNAi construct based on pHD615 
(Biebinger et al., 1997). Sense (ORF pos. 136-469) and antisense (ORF pos. 28-520) fragments of 
PKAC1/2 were amplified by PCR from genomic DNA of MiTat 1.2 Lister 427. After digestion of the 
sense fragment with HindIII and XhoI and the antisense fragment with XhoI and BamHI, the hairpin 
RNAi vector pHD615[PAC]PKAC1/2 RNAi was generated by a three-component ligation with 
pHD615[PAC] (derivative of pHD615 with puromycin instead of hygromycin resistance cassette) 
digested with BamHI and HindIII. To exclusively target PKAC1 but not PKAC2 a hairpin RNAi 
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vector based on pHD615[PAC] was generated targeting part of the PKAC1 3’UTR (sense fragment 
pos. Tb427_09_v4 1700775-1701234, antisense fragment pos. Tb927_09_v4 1700692-1701234). The 
pHD615[PAC] plasmids were linearized with NotI for transfection, and antibiotic selection was 
performed in the presence of 0.1 µg/ml puromycin. Details on primer sequences and cloning strategies 
are available upon request. All transfections were performed as described previously (Schumann 
Burkard et al., 2011). 
Northern Blot. Total RNA (5 µg) was isolated from AnTat 1.1 parasites from infected 
irradiated rats (described in Reuner et al., 1997) 2.5 days post infection (long slender, LS), 5-6 days 
post infection (short stumpy, SS, 90% diaphorase-positiv), from culture two days after in vitro 
differentiation (procyclic form, PCF1), or from an established procyclic culture (PCF2). RNA 
separation and blotting was performed as previously described (Boshart et al., 1991). Antisense RNA 
probes were synthesized from nt position 923 to 1938 relative to the start codon of PKAC3, from nt 
position 26 to 1524 downstream of the stop codon for PKAC1, and from nt position 60 to 885 
downstream of the stop codon for PKAC2.  Random prime labeled DNA probes serving as loading 
controls were synthesized from the actin gene (SalI fragment; (Ben Amar et al., 1988)) or the 
anonymous cDNA P2 (EcoRI/KpnI fragment, provided by E. Pays). 
Western blot. Western blot analyses of PKA subunits, of proteins containing phospho-
RXXS*/T* sites and of the PKA reporter substrate VASP were done as described previously 
(Bachmaier et al., manuscript, see chapter 4.1). Detection of the stumpy marker PAD1 was performed 
according to Dean et al. (2009). 
2D gel electrophoresis. 2D gel electrophoresis was essentially carried out as described 
previously (van Deursen et al., 2003). Isoelectric focusing was done with lysates of 1×108 
trypanosomes using ReadyStripTM IPG strips pH 3-10NL (BioRad).  
Staining of proteins in polyacrylamide gels. Proteins separated in polyacrylamide gels were 
visualized by staining with Coomassie Brilliant Blue (Candiano et al., 2004) or by silver staining 
(Blum et al., 1987; Chevallet et al., 2006). 
VASP assay. Trypanosomes were harvested (10 min, 1400×g, 37°C (BSF) or 10 min, 900×g, 
27°C (PCF)) and resuspended in fresh HMI-9 (BSF) or SDM-79 (PCF) medium at a density of 5×107 
cells/ml. After a 5-10 minute recovery at 37°C (BSF) or 27°C (PCF) while slightly shaking, the cells 
were transferred to the indicated temperature (37°C, 27°C, 20°C, 4°C) for a fixed time period or over a 
defined time course. Care was taken that the temperature in each single experiment was constant and 
that cells were not cold shocked if not intended. All tubes, media and centrifuges were preheated to 
37°C (BSF) or 27°C (PCF) and the temperature of all heating blocks was constantly checked with a 
thermometer. Cells were lysed with 6× Laemmli sample buffer preheated to 95°C and incubated for 5 
minutes at 95°C. 
FACS analysis. 1-2×107 trypanosomes were fixed overnight in 2% paraformaldehyde in PBS 
at 4°C. The repeat portion of EP procyclin on the parasite surface was detected by a monoclonal 
mouse anti-EP antibody (1:500; Cedar Lane Laboratories). Alexa 488 donkey anti-mouse IgG (H+L) 
antibody (Molecular Probes; 1:2000) was used as secondary antibody. Quantitative analysis was 
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performed with a FACS-Calibur Flow Cytometer (Beckton Dickenson) using the software CellQuest 
(Becton Dickinson) and FlowJo (TreeStar). 
Immunoprecipitation. For immunoprecipitation of proteins with a phosphorylated 
RXXS*/T* motif, 5×107 trypanosomes were harvested (1400×g, 10 min, 4°C), resuspended in RIPA 
buffer (4°C) supplemented with protease and phosphatase inhibitors (complete EDTA-free, Roche; 25 
µg/ml pepstatin A; PhosSTOP, Roche) and incubated on ice for 15 min. After centrifugation 
(20000×g, 20 min, 4°C), the soluble fraction was incubated overnight with the Phospho-(Ser/Thr) 
PKA Substrate Antibody (Cell Signaling Technologies, catalogue number 9621) covalently coupled to 
magnetic protein A beads (Invitrogen) using DMP (Thermo Scientific) for crosslinking according to 
the manufacturer’s instructions. The beads were washed three times with RIPA buffer, followed by a 
final wash with PBS. Elution was performed by incubation with Laemmli sample buffer for 10 min at 
70°C. For identification of phospho-RXXS*/T* containing proteins by mass spectrometry, a lysate of 
4×108 trypanosomes was used for immunoprecipitation.  
Identification of phospho-RXXS/T proteins by mass spectrometry. The 
immunoprecipitated proteins were separated in an SDS gel and visualized by silver staining (Blum et 
al., 1987; Chevallet et al., 2006). The whole lane was cut into 27 slices, followed by reduction of the 
proteins by treatment with 1 mM dithiothreitol, alkylation with 5.5 mM iodoacetamide and digestion 
with an excess of endoproteinase Lys-C (1:100 w/w) and modified sequencing grade trypsin (1:100 
w/w) after 4-fold dilution in deionzied water, as described previously (Olsen et al., 2006). The 
resulting peptides were separated on a reversed-phase Sep-Pak C18 peptide purification cartridge via 
an acetonitrile gradient. Spectra were recorded on a QSTAR XL mass spectrometer (Applied 
Biosystems), followed by analysis of the resulting MS/MS data set using the Mascot search engine 
(Matrix Science Ltd.; Perkins et al., 1999) and the total proteome of T. brucei TREU927 (TriTrypDB 
release 3.3).  
Bioinformatics. Detailed analysis of mass spectrometry data was performed using the 
proteome software Scaffold 2 (Proteome Software, Inc.; Searle, 2010) with the following settings: a 
protein threshold of 90% and a minimum of three peptides with a peptide threshold of 95%. 
Bioinformatic data about the identified genes were retrieved from TriTrypDB (http://tritrypdb.org/), 
GeneDB (http://www.genedb.org), and OrthoMCL (http://www.orthomcl.org/). Putative PKA 
phosphorylation sites were predicted using NetPhosK 1.0 
(http://www.cbs.dtu.dk/services/NetPhosK/).  
 Immunofluorescence. For immunofluorescence analysis, 2×106 trypanosomes were fixed in 
2% formaldehyde. Phospho-RXXS*/T* containing proteins were detected by the Phospho-(Ser/Thr) 
PKA Substrate Antibody (1:2000; Cell Signaling Technologies, catalogue number 9621) and 
visualized using the Alexa Fluor 594-conjugated goat anti-rabbit IgG (H+L) secondary antibody 
(1:2000; Life Technologies, Thermo Fisher Scientifics). Cellular DNA was stained with 4′,6-
diamidino-2-phenylindole (DAPI; 1 µg/ml). Vertical stacks (0.2 µm steps) were captured using 
personal DV (Applied Precision) deconvolution (softWoRx Software) microscopy. The average Z-
projection of nine images is shown. 
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Results 
 
Developmental regulation of PKA subunit expression and phosphorylation. Expression 
analysis of T. brucei PKA subunits in fully differentiation competent, pleomorphic AnTat 1.1 cells 
revealed inverse regulation of PKAC1 and PKAC2 mRNAs in the different life cycle stages with 
PKAC1 being predominantly expressed in BSF and PKAC2 in PCF stages (Figure 1A). In contrast, the 
PKAC3 transcript was detectable at approximately equal amounts in all stages with a slight decrease in 
PCFs. The PKAC3 protein followed a similar expression pattern (Figure 1B). Due to their high 
sequence similarity and nearly identical molecular weight the isoforms PKAC1 and PKAC2 are not 
distinguishable by the PKAC1/2 antibody on a Western blot (Bachmaier et al., manuscript, see chapter 
4.1). PKAC1/2 expression is not significantly regulated between slender and stumpy BSFs but is 
down-regulated in the procyclic stage (Figure 1B). Analysis of PKA subunit expression in slender and 
stumpy-like stages of the monomorphic strain MiTat 1.2 Lister 427 (Figure S1) showed comparable 
results to expression in pleomorphic cells. To be able to discriminate between PKAC1 and PKAC2, 
the monomorphic cell line ∆pkac1/PKAC1-Ty1 (Bachmaier et al., manuscript, see chapter 4.1) was 
used for expression analysis. In this cell line, one allele of PKAC1 has been deleted and the other 
allele has been tagged with a Ty1-epitope resulting in an electrophoretic mobility shift thereby 
allowing the distinction between the two isoforms. A Western blot with lysates of the different 
developmental stages of this cell line showed that PKAC1 is almost exclusively expressed in BSFs, 
while PKAC2 is more abundant in PCFs (Figure 1C), which is fairly in agreement with their transcript 
levels in the different stages. As one PKAC1 allele has been deleted in this cell line, the actual 
expression of PKAC1 in wild type cells might be higher. In addition, PKAC1 shows two bands with 
the upper one being more prominent in the stumpy-like stage. Although PKAC1 and PKAC2 share 
94% sequence identity, this modification is absent from PKAC2. Since the few amino acid 
differences, which are located at the very N- and C-terminal ends of these two isoforms, encompass 
several phosphorylation sites (Nett et al., 2009; Urbaniak et al., 2013), a PKAC1-specific 
phosphorylation might be responsible for the observed mobility shift. The PKAR transcript was 
expressed at approximately equal amounts in LS and SS and lowered in PCF cells (data not shown), 
which is in agreement with the data from Shalaby et al. (2001). This regulation is as well reflected at 
the protein level (Figure 1B). The expression of PKA subunits in T. brucei is therefore most likely 
regulated at the level of mRNA stability. 
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Figure 1: Developmental regulation of PKA subunit expression at the transcript (A) or protein 
level (B, C). 
A. Northern blot analysis of total RNA (5 µg) isolated from AnTat 1.1 parasites at different life cycle 
stages. PKAC1, PKAC2 and PKAC3 transcripts were detected by gene-specific probes. Actin and the 
anonymous cDNA P2 (provided by E. Pays) served as internal controls. Actin is equally expressed in 
slender (LS) and procyclic (PCF) cells but reduced in stumpy (SS) cells (Ben Amar et al., 1988). P2 is 
equally expressed in LS and SS cells but reduced in PCF cells. PCF1: procyclic cells after 2 days of in 
vitro differentiation; PCF2: established procyclic cells. 
B. Protein expression of PKA subunits in slender (LS), stumpy (SS) and established procyclic (PCF) 
pleomorphic AnTat 1.1 cells was analyzed by Western blotting using specific antibodies against 
PKAC1/2, PKAC3 (Bachmaier et al., manuscript, see chapter 4.1) and PKAR (Bachmaier et al., 2015, 
submitted manuscript, see chapter 5). PFR-A/C detected by the monoclonal antibody L13D6 (Kohl et 
al., 1999) was used for normalization. The diagram shows the percentage of PKAR, PKAC1/2 and 
PKAC3 in the different life cycle stages (LS was set to 100%). 
C. Western blot analysis of PKAC1 and PKAC2 expression in slender (LS), stumpy-like (SS*) and 
established procyclic (PCF) stages of the monomorphic cell line MiTat 1.2 ∆pkac1/Ty1-PKAC1, 
which allows discrimination between PKAC1 and PKAC2 due to deletion of one PKAC1 allele and 
fusion of the other one to Ty1-tag. PFR-A/C detected by the monoclonal antibody L13D6 (Kohl et al., 
1999) was used for normalization. The diagram shows the percentage of PKAC1 and PKAC2 on the 
total amount of PKAC1/2 (set to 100%) in the different life cycle stages. 
A
  LS   SS  PCF1 PCF2         LS   SS PCF1 PCF2        LS   SS  PCF1 PCF2
7.5
4.4
7.5
4.4
kb kb
4.4
2.4
kb
actin
P2
actin
P2 P2
actin
PKAC1 PKAC2 PKAC3
   LS          SS         PCF
    LS         SS*      PCF
PKAC3
PFR-A/C
B
PFR-A/C
PKAR
PKAC1/2
C
anti-
PKAC1/2
anti-
PFR-A/C
anti-Ty1
overlay
0 
40 
80 
%
 e
xp
re
ss
io
n 
PKAC1 
PKAC2 
  LS            SS*         PCF
0 
40 
80 
120 
%
 e
xp
re
ss
io
n 
  LS            SS           PCF
PKAR
PKAC1/2 
PKAC3 
	  	   94 
4. Activation of T. brucei PKA 
T. brucei PKAR-C1 is rapidly and reversibly activated by temperatures below 37°C in 
BSFs. The developmental regulation of PKA subunit expression prompted us to examine the effect of 
developmental triggers on in vivo PKA activity. We have recently established an in vivo PKA reporter 
assay in T. brucei that is based on phosphorylation of the transgenically expressed PKA reporter 
substrate VASP and can be used as a specific measure for endogenous PKA activity (Bachmaier et al., 
manuscript, see chapter 4.1). Reporter substrate phosphorylation in a monomorphic BSF cell line was 
not dependent on cell density or treatment with cis-aconitate (Figure S2A, B), both of which are 
important triggers for life cycle stage differentiation of the parasite. However, exposure to low 
temperature, an important trigger for BSF to PCF differentiation in vitro (Engstler and Boshart, 2004), 
caused rapid and reversible increase in VASP phosphorylation (Figure 2A). Temperatures below 37°C 
induced a rapid phosphorylation of the reporter substrate with a maximum after 5-10 minutes, which 
was completely reversible when transferred back to 37°C. Lower temperatures resulted in stronger 
phosphorylation. Cold shock is known to act as an inducer of life cycle stage differentiation in T. 
brucei in vitro by sensitizing stumpy cells to low citrate/cis-aconitate concentrations inducing 
differentiation to the procyclic stage (Engstler and Boshart, 2004). Investigation of temperature-
dependent PKA activation in different developmental stages revealed that cold activation is specific 
for the bloodstream stage (Figure 2B; Figure S2C). Since the regulatory subunit of T. brucei PKA can 
form a heterodimeric holoenzyme with any of the three different catalytic subunits (Bachmaier et al., 
manuscript, see chapter 4.1), cold inducibility was analyzed in a number of PKA mutants. Upon 
deletion of both alleles of PKAR, cold shock activation of PKA was lost, but was restored by add-back 
of a PKAR wild type copy (Figure 2C) in the endogenous locus. Inhibition of cold shock-induced 
VASP phosphorylation was also obtained by knock down of PKAC1/2 by RNAi or by specifically 
targeting PKAC1 by RNAi against its 3’UTR (Figure 2C; Figure S3B, C). In contrast, homozygous 
deletion mutants of PKAC2 (Bachmaier et al., manuscript, see chapter 4.1) or PKAC3 (Figure S3A) 
showed induction by cold shock comparable to wild type cells (Figure 2C). We conclude that the 
PKAR-PKAC1 holoenzyme is specifically activated by cold shock, although cold-dependent 
activation of PKAR-PKAC2 cannot be completely ruled out due to the low expression of PKAC2 in 
BSF cells. All attempts to knock out both alleles of PKAC1 or to replace them by PKAC2 were 
unsuccessful indicating that PKAC1 might be essential. All deletion mutants and RNAi cell lines were 
viable with several cell lines showing slight growth phenotypes (PDT wild type: 5.6h; PDT PKAR-/-: 
7.5h; PDT PKAC2-/-: 6.8h; PDT PKAC3-/-: 9.2h; PDT PKAC1/2 RNAi +/- Tet: 5.9/6.1h; PDT PKAC1 
UTR RNAi +/- Tet: 5.7/5.8h). Note that we have previously published a PKAC1/2 RNAi cell line with 
a severe growth and cytokinesis phenotype upon induction of RNAi, which eventually resulted in cell 
death (Bachmaier et al., 2014, manuscript, see chapter 4.1). While in the cell line of the previous study 
the RNAi strategy was based on a p2t7 plasmid (Wickstead et al., 2002; RNAi driven by T7 
polymerase from two opposing T7 promoters), in the present study we used a hairpin-based RNAi 
strategy (using the vector pHD615 (Biebinger et al., 1997), RNAi regulated by Tet operator only). The 
efficiency of the RNAi-mediated repression of PKAC1/2 was identical between the two cell lines. The 
different phenotypes might depend on the kinetics of the RNAi. 
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Figure 2: Specific activation of T. brucei PKA by cold shock. 
A. Rapid and reversible increase in VASP phosphorylation by temperatures below 37°C. VASP 
phosphorylation was analyzed over 20 min at 37°C, 27°C, 20°C, 12°C or 4°C. After 20 min 
incubation at the respective temperature, the trypanosomes were transferred to 37°C, and VASP 
phosphorylation was analyzed over 10 min. Data points represent means of triplicate determinations; 
error bars indicate SD. 
B. Cold shock-induced VASP phosphorylation is specific for BSFs. VASP phosphorylation was 
analyzed in wild type BSF slender and stumpy-like trypanosomes and in early (2 days after induction 
of differentiation) and established procyclic cells after 10 min incubation at 37°C (BSFs) or 27°C 
(PCFs), respectively, and at 4°C. Data points represent means of triplicate determinations; error bars 
indicate SD. 
C. Cold shock induced VASP phosphorylation is mediated by PKAR-C1. VASP phosphorylation was 
analyzed in different mutants of PKA subunits and isoforms and in wild type (wt) cells expressing 
VASP after 10 min incubation at 37°C or 4°C, respectively. Data points represent means of triplicate 
determinations; error bars indicate SD. 
PKAR-/-: homozygous deletion mutant of PKAR; PKAR-/+: endogenous PKAR rescue; PKAC3-/-: 
homozygous deletion mutant of PKAC3; PKAC2-/-: homozygous deletion mutant of PKAC2; PKAC1/2 
RNAi: cell line with inducible RNAi against PKAC1/2; PKAC1 UTR RNAi: cell line with inducible 
RNAi against the PKAC1 UTR. 
 
 
 
 
 
time [min] 
A B
0 
20 
40 
60 
80 
100 37/27°C 
4°C 
sle
nd
er 
stu
mp
y-
lik
e
est
ab
lis
he
d
PC
F
ea
rly
PC
F
%
 p
ho
sp
ho
ry
la
te
d 
VA
SP
 
%
 p
ho
sp
ho
ry
la
te
d 
VA
SP
 
0 
20 
40 
60 
80 
100 
%
 p
ho
sp
ho
ry
la
te
d 
VA
SP
 
37°C 
4°C 
wt
PK
AR
-/-
PK
AR
-/+
PK
AC
3-
/-
PK
AC
2-
/-
PK
AC
1/2
 R
NA
i
PK
AC
1 U
TR
 R
NA
i
C
0 10 20 30
0
20
40
60
80
100 4°C
12°C
20°C
27°C
30°C
37°C
	  	   96 
4. Activation of T. brucei PKA 
T. brucei PKA mediates cold shock-induced sensitization to low CCA concentrations in 
SS cells promoting differentiation to the PCF stage. Since cold shock is a known differentiation 
trigger in the T. brucei life cycle by sensitizing SS trypanosomes to low CCA concentrations and 
thereby promoting differentiation to the PCF stage (Engstler and Boshart, 2004), the observed stage-
specific activation of the parasite PKA by low temperatures suggested a putative role of the kinase in 
this differentiation process. To analyze this hypothesis, a pleomorphic and hence fully differentiation-
competent cell line with inducible RNAi against PKAC1/2 was generated. Expression analysis of the 
stumpy marker PAD1 in pleomorphic AnTat 1.1 wild type cells grown on agarose plates showed that 
maximal expression was observed after three days of cultivation (Figure S4A). Stumpy stage AnTat 
1.1 wild type as well as PKAC1/2 RNAi cells grown in the presence or absence of 10 µg/ml 
tetracycline were harvested from agarose plates followed by expression analysis of PKAC1/2 and 
PAD1 (Figure 3A). While PAD1 expression was at the same level in all cell lines, PKAC1/2 was 
efficiently repressed in the PKAC1/2 RNAi cell line induced with tetracycline. Another marker for a 
population with a high proportion of stumpy cells is surface expression of EP procyclin after exposure 
to 6 mM cis-aconitate. EP surface expression was analyzed by flow cytometry in AnTat 1.1 wild type 
and PKAC1/2 RNAi cells induced or not with 10 µg/ml tetracycline (Figure S4B). Stumpy cells 
harvested from agarose plates were transferred into DTM, and samples for flow cytometry were taken 
after exposure to the following conditions: immediately after transfer into DTM (0 h), after 16 h 
cultivation at 27°C, or after 16 h cultivation at 27°C in the presence of 6 mM cis-aconitate. All cell 
lines showed efficient induction of EP surface expression upon incubation with 6 mM cis-aconitate, 
characteristic for populations with a high proportion of stumpy cells. To analyze whether PKAC1/2 
plays a role in cold shock-mediated sensitization to low cis-aconitate concentrations, SS cells were 
transferred into DTM medium and subjected to a cold shock at 20°C for 16 h. To induce 
differentiation to the PCF stage, different concentrations of cis-aconitate were added (0, 0.06, 0.4 or 6 
mM, respectively), and differentiation efficiency was analyzed by outgrowth of procyclic cells (Figure 
3B). Whereas all cell lines showed efficient differentiation at 6 mM cis-aconitate, at 0.4 mM or 0.06 
mM cis-aconitate only the wild type and the non-induced PKAC1/2 RNAi cells differentiated.  
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Figure 3: Role of T. brucei PKA for in vitro differentiation of pleomorphic trypanosomes. 
A. Western blot analysis of PKAC1/2 (left) or PAD1 (right) expression in pleomorphic AnTat 1.1 
cells (wt) and derived AnTat 1.1 1313 PKAC1/2 RNAi cells in the presence (+Tet) or absence (-Tet) 
of 10 µg/ml tetracycline. Slender cells derived from infected rats were plated on agarose plates and 
grown for 4 days until the population showed a clear stumpy morphology. Required selection 
antibiotics as well as tetracycline were included in the plates. PFR-A/C detected by the monoclonal 
antibody L13D6 (Kohl et al., 1999) was used for normalization. The normalized signal for PKAC1/2 
or PAD1, respectively, in the parental AnTat 1.1 cell line was set to 100%. 
B. Differentiation of pleomorphic AnTat 1.1 and derived AnTat 1.1 1313 PKAC1/2 RNAi cells to the 
procyclic stage in the presence (+Tet) or absence (-Tet) of 10 µg/ml tetracycline. Stumpy cells 
harvested from agarose plates were subjected to differentiation by transfer into differentiation medium 
(DTM) and incubation at 20°C for 16 h, followed by addition of the indicated concentrations of cis-
aconitate and subsequent incubation at 27°C. Cell growth was determined daily using a Casy® 
automated cell counter, and cells were diluted if required to keep the cell density between 2×106 and 
1×107 cells/ml. 
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Upon differentiation from SS to PCF, the cells re-enter the cell cycle accompanied by a change in the 
distances between nucleus, kinetoplast and posterior end of the cell (Matthews et al., 1995). Upon 
treatment with 6 mM cis-aconitate for 24 h, all cell lines showed a high fraction of cells with a 
subterminal kinetoplast, characteristic for PCF cells, indicating that differentiation is complete (Figure 
S4C, D). However, the time course analysis of kinetoplast repositioning revealed a differentiation 
delay in the induced PKAC1/2 RNAi cell line. In contrast, upon treatment with 0.4 mM cis-aconitate, 
only the wild type and non-induced PKAC1/2 RNAi cell lines showed a significant increase in the 
fraction of cells with subterminal kinetoplast, while the majority of the induced PKAC1/2 RNAi cells 
had a kinetoplast, which was positioned at the very posterior end of the cell, a typical feature of SS 
cells. Hence, we conclude that repression of PKAC1/2 prevents cold shock-induced sensitization to 
low cis-aconitate concentrations, suggesting that the kinase is involved in transduction of the cold 
shock stimulus to the CCA sensing pathway.  
 Specific phosphorylation of endogenous PKA substrates upon cold shock. We have 
previously shown that T. brucei PKA substrates can be effectively and specifically detected by a 
phospho-PKA substrate antibody (Bachmaier et al., manuscript, see chapter 4.1). Western blot 
analysis of lysates from MiTat 1.2 wild type cells incubated for 10 min at 37°C or 4°C, respectively, 
showed a strong increase in the number and intensity of bands detected by the Phospho-(Ser/Thr) PKA 
Substrate antibody upon cold shock (Figure 4A). As control, lysates from VASP expressing MiTat 1.2 
cells were analyzed, and phosphorylation of the band corresponding to the size of the reporter 
substrate increased significantly upon cold shock. Consistent with the results of the PKA reporter 
assay (Figure 2), no increase in PKA-specific phosphorylations was observed in PCFs or in the 
homozygous PKAR deletion mutant (Figure 4A). Moreover, upon treatment with the myristoylated 
peptide myr-PKI(14-22) derived from the PKA-specific inhibitor PKI (Walsh et al., 1971; Glass et al., 
1989; Harris et al., 1997; Dalton and Dewey, 2006), no bands could be detected with the phospho-
PKA substrate antibody in VASP expressing wild type or PKAR knock out cells at 37°C or 4°C, 
respectively, further supporting the high specificity of the antibody for detection of PKA-dependent 
phosphorylations in T. brucei. The motif RXXS/T is also a well-known consensus phosphorylation 
sequence for a few other kinases, e.g. calmodulin-dependent kinase II (CaMKII) or ribosomal S6 
kinase (RSK) (Ubersax and Ferrell Jr, 2007; Salazar and Hofer, 2009; Pearce et al., 2010), both of 
which are present in the T. brucei kinome (Parsons et al., 2005). However, the disappearance of all 
bands detected by the anti-RXXS*/T* antibody after treatment with the PKA-specific inhibitor myr-
PKI(14-22) suggests a higher abundance of RXXS/T sites phosphorylated by PKA than by any other 
kinase in T. brucei. Alternatively, the other parasite kinases might show different substrate 
specificities.  
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Figure 4: Detection of Phospho-PKA substrates in T. brucei. The antibodies used for all Western 
blots are Phospho-(Ser/Thr) PKA Substrate antibody (anti-RXXS*/T*) and anti-PFR-A/C (Kohl et al., 
1999). 
A. Western blot analysis of proteins phosphorylated at the motif RXXS*/T* in T. brucei BSF wild 
type cells (BSF wt) or VASP expressing BSF (BSF VASP) or procyclic trypanosomes (PCF VASP) 
incubated for 10 min at 4°C compared to incubation at 37°C (BSF) or 27°C (PCF), respectively.  
B. Western blot analysis of proteins phosphorylated at the motif RXXS*/T* in a VASP expressing T. 
brucei BSF cell line (BSF VASP) compared to a VASP expressing BSF cell line with deletion of both 
alleles of PKAR (BSF PKAR-/- VASP) in the presence (+PKI) or absence (-PKI) of the membrane-
permeable, PKA-specific inhibitor peptide myr-PKI(14-22) combined with cold shock (4°C) or 
normal temperature (37°C). 
 
 
Identification of T. brucei PKA substrates by a phosphoproteomics approach. 
Phosphorylation of the transgenically expressed reporter substrate VASP serves as useful assay for 
analysis of regulation of in vivo PKA activity. However, the endogenous substrates of the kinase are 
completely unknown so far. In a first approach, lysates of VASP expressing MiTat 1.2 cells incubated 
for 10 min at 4°C or 37°C, respectively, were separated by 2D gel electrophoresis (Figure S5) and 
analyzed by Western blotting using the Phospho-(Ser/Thr) PKA Substrate antibody. Consistent with 
the results of the 1D Western blot analysis (Figure 4), the number and intensity of the spots detected 
by the antibody increased significantly upon cold shock (Figure S5). In order to validate the usefulness 
of the Phospho-(Ser/Thr) PKA Substrate antibody in detecting and identifying PKA substrates from T. 
brucei lysates, two of the spots, which showed a significant cold-dependent increase in signal intensity 
for PKA-dependent phosphorylation and correspond to the molecular weight of phosphorylated 
VASP, were cut from the corresponding Coomassie-stained gel and confirmed by MS/MS analysis. 
However, in other spots cut from the gel a complex mixture of proteins was detected by MS, 
indicating the requirement for reduction in sample complexity. Hence, in a second approach, proteins 
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containing phosphorylated RXXS*/T* sites were enriched by immunoprecipitation using the Phospho-
(Ser/Thr) PKA Substrate antibody. Although phosphorylation of RXXS/T sites seems to be 
predominantly mediated by PKA in T. brucei (Figure 4), we cannot exclude that our approach 
identifies substrates of other kinases, like CaMKII or RSK, with an overlapping consensus 
phosphorylation motif (Ubersax and Ferrell Jr, 2007; Salazar and Hofer, 2009; Pearce et al., 2010). 
The elution fraction was separated by SDS PAGE and the whole lane was cut into slices and analyzed 
by MS/MS (Figure 5). 178 proteins were identified (Table S1), out of which 171 proteins contain 
RXXS/T motifs within their primary amino acid sequence (Figure 6A). The seven proteins without 
RXXS/T motif might either be false positives or co-immunoprecipitated proteins, with five of these 
seven proteins being putative ribosomal proteins. Phosphorylated RXXS*/T* sites were identified for 
twelve of the 171 proteins, with eight of these proteins having an unknown function. Since the IP with 
the phospho-PKA substrate antibody pulls down phospho-RXXS*/T*-containing proteins, which are 
subsequently digested into peptides before they are analyzed by MS/MS, the probability of identifying 
a phosphorylated RXXS*/T* by MS/MS is very low. Functional analysis by bioinformatics revealed a 
high abundance of proteins involved regulation of processes like ribosome biogenesis/translation, 
metabolism, RNA association, protein folding or motility (Figure 6B) as putative substrates of T. 
brucei PKA, which is reminiscent of the situation in other organisms (Skalhegg and Tasken, 2000; 
Shabb, 2001; Santangelo, 2006; Livas et al., 2011; Vaidyanathan et al., 2014). Evolutionary analysis 
via OrthoMCL showed that 112 out of the 171 identified putative PKA substrates are conserved 
beyond kinetoplastids, whereas one third is kinetoplastid- (41 proteins) or Trypanosoma-specific (14 
proteins), (Figure 6C; Table S1) with largely unknown functions, supporting a partially unique role of 
the kinase in T. brucei. According to available proteome data (Broadhead et al., 2006; Bridges et al., 
2008; Zhou et al., 2010; Oberholzer et al., 2011; Subota et al., 2014), T. brucei PKA substrates are 
strongly enriched in the plasma membrane, cytoskeleton and flagellar fractions (Figure 6D; Table S1), 
which was confirmed by immunofluorescence analysis using the Phospho-(Ser/Thr) PKA Substrate 
antibody in BSF and PCF trypanosomes (Figure 6E). 
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Figure 5: Identification of T. brucei PKA substrates by a phosphoproteome approach. 
Upon cold shock, the number and intensity of bands detected by the Phospho-(Ser/Thr) PKA Substrate antibody (anti-RXXS*/T*) increases significantly (Western 
blot A). The cold shocked sample was centrifuged to separate soluble from insoluble proteins (Western blot B). Pull down of proteins with a phosphorylated 
RXXS*/T* motif from the soluble fraction of the cold shocked sample was achieved by immunoprecipitation using the Phospho-(Ser/Thr) PKA Substrate antibody 
(anti-RXXS*/T*) (Western blots C; two independent biological replicates). I = input fraction; FT = flow through; W1, W4 = wash fractions; E = elution. Enriched 
proteins from the elution fraction were cut from a silver-stained polyacrylamide gel (D) and identified by MS/MS. 
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Figure 6: Bioinformatics analyses of T. brucei PKA substrates. 
A. Sequence analysis of the 178 identified putative T. brucei PKA substrates regarding the presence of RXXS/T 
motifs. The proteins fall into three categories: 1) RXXS*/T* phosphopeptide identified: phosphorylated 
RXXS*/T* motifs were identified in 12 proteins; 2) no RXXS/T in primary amino acid sequence: 7 identified 
proteins do not contain an RXXS/T motif; 3) RXXS/T motif in primary amino acid sequence but RXXS*/T* 
phosphopeptide not identified. 159 proteins contain an RXXS/T motif in their amino acid sequence but 
phosphorylated RXXS*/T* peptides were not identified. 
B. Functional analysis of the identified, putative T. brucei PKA substrates by bioinformatics. The proteins were 
classified into ten categories (carbohydrate and non-carbohydrate metabolism, microtubule-based movement, 
other, protein folding, protein transport and maturation, ribosome biogenesis/translation, RNA associated, 
signaling, transport) according to their GO term annotation. 
C. Conservation analysis of the identified, putative T. brucei PKA substrates using the OrthoMCL database. 
Whereas 66% (112 out of 171) of the identified proteins with RXXS/T motif are conserved beyond 
kinetoplastids, 26% (41 out of 171) are conserved within kinetoplastids and 8% (14 out of 171) are 
Trypanosoma-specific. 
D. Subcellular localization of the identified putative T. brucei PKA substrates compared to the total proteome. 
Comparison of identified PKA substrates with the published plasma membrane, cytoskeleton and flagellar 
proteomes (Bridges et al., 2008; Broahdead et al., 2006; Zhou et al., 2010; Oberholzer et al., 2011; Subota et al., 
2014) shows a strong enrichment in these fractions. 
E. Immunofluorescence analysis of T. brucei PKA substrates with the anti-RXXS*/T* antibody in BSF and PCF 
trypanosomes. Red = phospho-PKA substrates; blue = DAPI. The scale bar represents 3 µm. 
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Discussion 
 
Role of T. brucei PKA in cold shock-induced SS to PCF differentiation. A signaling 
cascade including the phosphatases TbPTP1 (Szöör et al., 2006) and TbPIP39 (Szöör et al., 2010) as 
well as CCA transporters of the PAD family (Dean et al., 2009) has been shown to be involved in 
regulation of SS to PCF differentiation. Phosphorylation of the serine/threonine phosphatase TbPIP39 
at Y278 by a so far unknown kinase is a prerequisite for this differentiation process. Depletion of 
PKAC1/2 by RNAi prevents cold shock-induced sensitization to low CCA concentrations, resembling 
the phenotype observed upon depletion of TbPIP39 (Szöör et al., 2010). In LS cells, PKA and 
TbPTP1 are expressed (Figure 7A). Since TbPIP39 is not expressed in LS, the cells cannot 
differentiate to the PCF stage. In SS cells, all known components of the differentiation pathway are 
expressed: PAD, PKA, TbPTP1, TbPIP39. However, differentiation is prevented by TbPTP1, which 
negatively regulates TbPIP39 by dephosphorylation. TbPIP39 positively regulates TbPTP1 thereby 
enhancing its own inhibition. In the tsetse environment, CCA (or an alternative, as yet unknown 
signal) is taken up by a carboxylate transporter of the PAD family expressed at the surface of stumpy 
cells and inhibits the feedback activation of TbPTP1 by TbPIP39 (Szöör et al., 2010). In turn, 
phosphorylated TbPIP39 promotes differentiation by a so far unknown downstream pathway. Yet, for 
sufficient inhibition of TbPTP1 unphysiologically high concentrations of CCA are required. Here we 
observe that activation of the parasite PKA by cold shock sensitizes the cells to physiological CCA 
concentrations. There are several models of how PKA could be involved in regulation of temperature-
dependent differentiation (Figure 7B). One possible scenario is that upon cold shock PKA directly 
inhibits TbPTP1 by phosphorylation at Thr238 (model 1, Figure 7B), a site with an RXXT PKA 
consensus phosphorylation motif, which according to NetPhosK is predicted to be a PKA 
phosphorylation site with a probability of 0.58. PKA-dependent inhibition of human tyrosine 
phosphatases, including PTP1B, has been reported by several studies (Garton and Tonks, 1994; Tao et 
al., 2001; Howe, 2004). However, TbPTP1 has not been identified as PKA substrate in T. brucei by 
our phosphoproteome screen, rather supporting an indirect mechanism of regulation. Human PTP1B 
can be phosphorylated and thereby activated by kinases of the cdc2-like kinase (CLK) family 
(Moeslein et al., 1999). Since a CLK family kinase (Tb11.01.4230) has been identified as putative 
substrate of T. brucei PKA (Table S1, S2), the following pathway would be possible (model 2, Figure 
7B): TbPTP1 is phosphorylated and activated by the CLK kinase in BSF cells in the mammalian 
bloodstream and keeps TbPIP39 in an inactive state. Upon uptake of SS cells by a tsetse fly, PKA is 
activated by cold shock and phosphorylates the CLK kinase thereby inactivating it. Inactive CLK 
kinase can no longer phosphorylate and activate TbPTP1 resulting in increased amounts of 
phosphorylated TbPIP39 that promotes differentiation. Apart from phosphorylation, human PTP1B 
can be regulated by oxidation, sumoylation or proteolysis (Bourdeau et al., 2005; Dadke et al., 2007; 
Yip et al., 2010). Several studies report activation of human PTP1B by cleavage mediated by the 
protease calpain (Frangioni et al., 1993; Franco and Huttenlocher, 2005; Cortesio et al., 2008; Yip et 
al., 2010). Calpain, which has been suggested by several studies to be negatively regulated by direct 
phosphorylation by PKA in humans (Jay et al., 2000; Shiraha et al., 2002; Smith et al., 2003; Franco 
and Huttenlocher, 2005), has been identified as PKA substrate in T. brucei by our phosphoproteome 
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study with a mapped PKA consensus phosphorylation site at S261 (Tb927.8.8330; NetPhosK 0.81), 
determined by mass spectrometry (Table S1). Assuming that cold shock-activated PKA 
phosphorylates and thereby inhibits calpain in SS cells, cleavage and hence activation of TbPTP1 
would be prevented (model 3, Figure 7B). In turn, phosphorylated, active TbPIP39 would promote 
differentiation. According to recent SILAC proteome data, calpain expression is strongly 
downregulated in PCFs (Urbaniak et al., 2012; Butter et al., 2013), supporting a BSF-specific 
function. Regulation of PTP1 activity by sumoylation could also be dependent on phosphorylation by 
PKA. Just recently, it has been shown that human PKA is able to promote protein sumoylation by 
phosphorylation (Su et al., 2012; Lee et al., 2014). Combined inhibition of TbPTP1 by CCA and cold 
shock-activated PKA (either directly or indirectly) upon uptake of SS trypanosomes by a tsetse fly 
could result in a larger amount of phosphorylated TbPIP39 eventually causing efficient differentiation 
to the PCF stage. However, if PKA would directly or indirectly inhibit TbPTP1, cold shock alone 
should be sufficient to induce differentiation at least to some extent. Yet, it has been shown that CCA 
but not cold shock alone can induce differentiation (Engstler and Boshart, 2004). An alternative model 
of action for the parasite PKA in the differentiation process would be regulation of the kinase, which 
is responsible for phosphorylation of TbPIP39 at Y278 (model 4, Figure 7B). Since phosphorylation 
of TbPIP39 is essential to promote SS to PCF differentiation, activation of the upstream kinase by a 
cold shock-induced pathway e.g. upon phosphorylation by cold-induced PKA would be a conceivable 
scenario. Cold shock alone would not be sufficient to induce differentiation, since active TbPTP1 
would immediately dephosphorylate TbPIP39 thereby inactivating it. Only in the tsetse midgut or 
upon addition of CCA for in vitro differentiation, TbPTP1 gets inactivated and SS cells differentiate 
into PCFs. Due to the absence of conventional tyrosine kinases in most protozoans including T. 
brucei, tyrosine residues are phosphorylated by dual specificity kinases, which are able to 
phosphorylate substrates at serine, threonine and tyrosine residues (Parsons et al., 2005; Nett et al., 
2009). Our phosphoproteome analysis revealed seven protein kinases as putative PKA substrates with 
mapped, phosphorylated RXXS*/T* sites for two of the kinases, determined by mass spectrometry 
(Table S2): mitogen-activated protein kinase 2 (MAPK2, Tb927.10.5140), casein kinase I isoform 2 
(CK1.2, Tb927.5.800, mapped phosphorylation site S186(p)), glycogen synthase kinase 3 (GSK3, 
Tb927.10.13780), a protein kinase belonging CLK family of CMGC kinases (Tb11.01.4230), a kinase 
of the PEK (pancreatic eIF-2α kinase) kinase family (Tb11.02.5050), and two unique, kinetoplastid-
specific kinases (Tb11.01.1050; Tb927.2.2720, phosphorylation sites S492(p), S1427(p)). Dual 
specificity of orthologous kinases in other organisms has been reported for CLK (Ben-David et al., 
1991; Howell et al., 1991; Myers et al., 1994; Lee et al., 1996), CK1 (Ali et al., 1994; Hoekstra et al., 
1994; Klimczak et al., 1995; Pulgar et al., 1996; Kametani et al., 2009) and GSK3 (Wang et al., 1994), 
albeit most of these studies showed only intramolecular autophosphorylation at tyrosine residues 
and/or were conducted in vitro with recombinantly expressed and purified kinase and/or synthetic 
substrate(s). Dual specificity regarding phosphorylation of downstream substrates is only known from 
a small group of kinases, e.g. MAPKKs (Dhanasekaran and Premkumar Reddy, 1998) or casein kinase 
2 (CK2) (Litchfield, 2003). Although genes encoding these kinases are found in the T. brucei genome 
(Parsons et al., 2005), none of these kinases has been identified as putative PKA substrate. 
Phosphorylation of tyrosine residues can also be accomplished by atypical tyrosine kinases like Wee1 
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(Squire et al., 2005). Interestingly, although Wee1 is functionally a tyrosine kinase, it most closely 
resembles serine/threonine kinases such as Chk1 or PKA in structure and sequence. Hence, the large 
number of unique, kinetoplastid-specific kinases in the T. brucei kinome, which cannot be placed into 
typical groups or families of eukaryotic protein kinases (Parsons et al., 2005), could represent a 
reservoir of atypical tyrosine or dual specificity kinases. Domain analysis using Pfam 27.0 predicted 
that the kinetoplastid-specific kinase Tb11.01.1050, which has been identified as putative substrate of 
T. brucei PKA, contains an N-terminal protein tyrosine kinase domain (pos. 32-199) with an E-value 
of 6.3e-08. Whether this kinase is able to phosphorylate Y278 of TbPIP39 or tyrosine residues of other 
trypanosomal proteins is yet an open question. Although highly unlikely, T. brucei PKAC1/2 itself 
could show dual specificity and directly phosphorylate TbPIP39 upon activation by cold shock.  
 
	  
Figure 7: Possible roles of T. brucei PKA in SS to PCF differentiation. 
A. Expression and regulation of known components of the BSF to PCF differentiation pathway in 
slender (LS) and stumpy (SS) trypanosomes. In LS cells, PKA and PTP1 are expressed, whereas 
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PIP39 and PAD proteins are not. Since the presence of phosphorylated PIP39 is a prerequisite of 
differentiation to the PCF stage, LS cells are unable to differentiate. In the SS stage, all known 
components of the BSF to PCF differentiation pathway are expressed. However, PTP1 
dephosphorylates and inactivates PIP39, thereby preventing differentiation of SS cells in the 
mammalian bloodstream. PIP39 activates PTP1 and thus enhances its own inhibition. In the tsetse 
midgut, CCA is taken up by transporters of the PAD family expressed at the surface of SS cells and 
inhibits the feedback activation of PTP1 by PIP39. For efficient differentiation, additional stimulation 
by cold shock is required. Cold shock activates the parasite PKA thereby sensitizing the cells to low, 
physiological concentrations of CCA. 
B. Possible modes of action of PKA in BSF to PCF differentiation. The presence of phosphorylated 
PIP39 is a prerequisite of this differentiation step. In the mammalian bloodstream, PTP1 inhibits 
PIP39 by dephosphorylation. Upon uptake by a tsetse fly, the trypanosome encounters a cold shock 
resulting in activation of the parasite PKA, which in turn: 
Model 1: directly inhibits PTP1 by phosphorylation at T238. 
Model 2: inhibits PTP1 by an inhibitory phosphorylation of its upstream activating CLK kinase 
Tb11.01.4230. 
Model 3: inhibits PTP1 by an inhibitory phosphorylation of its upstream activating protease calpain. 
Model 4: activates the kinase, which phosphorylates and thereby activates PIP39. 
Model 5: directly phosphorylates and activates PIP39. 
 
 
Activation of T. brucei PKA by low temperature. Usually, the rate of an enzyme-catalyzed 
reaction increases as the temperature is raised. In addition, each enzyme has a specific temperature 
optimum. Hence, the observation that low temperature induces the activity of the T. brucei PKA 
orthologue raised the question about the mechanism of activation. In several freeze-tolerant or 
hibernating animals, purified PKA catalytic subunit showed a higher activity at low temperatures in 
vitro, most likely induced by a temperature-dependent conformational change (Holden and Storey, 
1998; MacDonald and Storey, 1998; Holden and Storey, 2000). However, in T. brucei, analysis of in 
vivo PKA activity by a specific reporter assay revealed that cold shock activation is dependent on 
PKAR. If both alleles of PKAR were deleted, no temperature-dependent increase in PKA activity was 
observed excluding a role of the catalytic subunit alone in the activation mechanism. Changes in PKA 
subunit expression upon a temperature drop as observed in S. cerevisiae and human hepatoblastoma 
cells (Ohsaka et al., 2001; Sahara et al., 2002) cannot account for the increased kinase activity in T. 
brucei, since maximal activation was observed within minutes. Direct or indirect activation 
mechanisms of T. brucei PKA are conceivable. Direct activation by low temperature could be an 
intrinsic property of the parasite PKA holoenzyme, resulting in a conformational change of PKAR 
with subsequent release of an active catalytic subunit. We have previously reported that T. brucei PKA 
is indirectly activated in vivo by dipyridamole, an adenosine antimetabolite, suggesting the presence of 
an endogenous ligand (Bachmaier et al., manuscript, see chapter 4.1). In addition, the kinase can be 
activated by direct binding of 5-substituted tubercidin analogues to the cryptic cNMP-binding sites of 
PKAR resulting in holoenzyme dissociation and release of an active catalytic subunit. Hence, it is 
possible that the cold shock-induced conformational change does not alone induce dissociation of the 
holoenzyme but sensitizes it to the local concentration of a putative endogenous ligand. Chaperones 
like the heat shock protein Hsp90, whose expression is up-regulated in response to temperature 
changes or other cellular stresses in pro- and eukaryotes (Liu et al., 1994; Martinez et al., 2002; 
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Sonoda et al., 2006) thereby assisting the folding of a specific subset of proteins (Young et al., 2001; 
Delogu et al., 2002; Li et al., 2012), could support a conformational change of PKAR upon a 
temperature shift. Alternatively, cold shock could induce the production of a putative endogenous 
ligand, which binds to PKAR resulting in a conformational change and eventually in release of an 
active catalytic subunit. Reduction in membrane fluidity, inefficient folding of some proteins, or 
changes in DNA and RNA secondary structure impairing transcriptional and translational efficiency 
are among the immediate general cellular consequences of a temperature drop (Phadtare, 2004; 
Phadtare and Severinov, 2010). In bacteria, membranes have been shown to be able to sense 
temperature changes by alterations in their membrane phase state and microdomain organization, 
resulting in activation of a two-component signal transduction pathway involving a sensor kinase and 
a response regulator (Weber and Marahiel, 2003). Interestingly, major changes in the T. brucei BSF 
plasma membrane upon a temperature drop below 26°C have been reported (Ter Kuile et al., 1992). 
Although several kinases have been described in plants, which are activated in the early response to 
cold shock (Jonak et al., 1996; Li and Komatsu, 2000; Sangwan et al., 2002), nothing is known about 
the underlying activation mechanism. 
Evolutionary conservation of the PKA downstream signaling pathway? By a 
phosphoproteomics approach using an anti-Phospho-(SerThr) PKA Substrate antibody, which 
recognizes the phosphorylated motif RXXS*/T*, for immunoprecipitation, we identified 171 putative 
substrates of T. brucei PKA. Although other kinases like Akt/PKB, RSK or CaMKII are known to 
have highly similar consensus phosphorylation motifs, treatment with the myristoylated peptide myr-
PKI(14-22) derived from the PKA-specific inhibitor PKI (Walsh et al., 1971; Glass et al., 1989; Harris 
et al., 1997; Dalton and Dewey, 2006) resulted in disappearance of all visible bands detected by the 
anti-RXXS*/T* antibody, suggesting that the majority of proteins with phosphorylated RXXS*/T* 
sites were substrates of the parasite PKA. Bioinformatics analysis revealed a role of the kinase in 
regulation of diverse cellular processes with a high abundance of substrates involved in metabolism 
and ribosome biogenesis/translation as well as in RNA-binding. This strongly resembles PKA 
functions known from many other organisms, in which the kinase has pleiotropic functions including 
regulation of energy metabolism and transcription (Skalhegg and Tasken, 2000; Shabb, 2001; Ptacek 
et al., 2005; Santangelo, 2006; Livas et al., 2011; http://www.phosphosite.org (Hornbeck et al., 2012), 
www.phospho.elm.eu.org/ (Dinkel et al., 2011)). Interestingly, one third of the identified proteins, 
comprise kinetoplastid- or Trypanosoma-specific proteins with largely unknown function, highlighting 
the partially unique role of PKA in the evolutionary early branching eukaryote T. brucei. The special 
features of trypanosomal transcription, i.e. transcription in polycistronic units, co-transcriptional trans-
splicing and the absence of transcription factors prevent regulation of transcription by PKA at the level 
of transcription factors. Posttranscriptional regulation in trypanosomes is mainly based on RNA 
stability and translational efficiency. RNA-associated proteins phosphorylated by T. brucei PKA 
might be important regulators of downstream processes regulated by the kinase. This is consistent with 
our recent transcriptome study, which showed that PKA regulates processes like translation, transport 
or metabolism at the posttranscriptional level (Bachmaier et al., manuscript, see chapter 4.1).  	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Abstract 
 
Parasitic protozoa of the genus Leishmania are obligatory intracellular parasites that cycle between the 
phagolysosome of mammalian macrophages, where they grow as intracellular amastigotes, and the 
midgut of female sand flies, where they proliferate as extracellular promastigotes. Shifting between 
the two environments induces signaling pathway-mediated developmental processes that enable 
adaptation to both host and vector. Developmentally regulated expression and phosphorylation of 
protein kinase A (PKA) subunits in Leishmania and in T. brucei point to an involvement of PKA in 
parasite development. To assess this hypothesis in L. donovani, we determined proteome-wide 
changes in phosphorylation of PKA substrates. Using a phospho-specific antibody for detection of the 
conserved PKA phosphorylation motifs RXXS and RXXT, rapid dephosphorylation of PKA 
substrates was observed upon initiation of promastigote to amastigote differentiation in culture. No 
phosphorylated substrates were detected in axenic amastigotes. To analyze the kinetics of substrate 
(re)phosphorylation during axenic reverse differentiation from L. donovani amastigotes to 
promastigotes, we first established a map of this process with morphological and molecular markers. 
Upon initiation, the parasites rest for 6-12 hours before proliferation of an asynchronous population 
resumes. After early changes in cell shape, the major changes in molecular marker expression and 
flagella biogenesis occurred between 24 and 33 hours after initiation. PKA substrate re-
phosphorylation and expression of the regulatory subunit PKAR1 correlated with promastigote 
maturation, indicating a promastigote-specific function of PKA signaling. This is supported by the 
localization of PKAR1 to the flagellum, an organelle absent from amastigote forms. A significant 
increase in PKA-mediated phosphorylation is part of the ordered changes that characterize the 
amastigote to promastigote differentiation. 
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Introduction 
 
Leishmania donovani are intracellular parasitic protozoa that cause kala azar, a fatal form of visceral 
leishmaniasis in humans. During their life cycle, the parasites shuttle between the midgut of female 
sand flies, where they proliferate as extracellular flagellated promastigotes, and the phagolysosomes of 
human macrophages, where they live as aflagellated amastigotes (Herwaldt, 1999). Upon a blood meal 
of an infected sand fly, virulent metacyclic promastigotes are transmitted to the host and phagocytosed 
by resident macrophages near the bite (Chang and Dwyer, 1976). Following infection, the parasites 
encounter a temperature increase of >10°C (from 26 to 37°C) followed by a significant pH shift, from 
pH 7 in the vector to around pH 5 in the phagolysosome (Zilberstein, 2008).  
Development of host-free systems using axenic culture conditions has enabled a better understanding 
of the molecular mechanism of Leishmania intracellular differentiation. L. donovani differentiation 
can be induced by exposing promastigotes to the high temperature and acidity (37°C, pH5.5, 5% CO2) 
typically found in the phagolysosome (Saar et al., 1998; Burchmore and Barrett, 2001; Zilberstein, 
2008). The axenic amastigotes of both old and new world species have been shown to resemble real 
animal-derived amastigotes using biochemical and molecular markers (Bates, 1994; Saar et al., 1998; 
Goyard et al., 2003; Debrabant et al., 2004). Based on morphological criteria, axenic L. donovani 
differentiation consists of four phases (Barak et al., 2005): signal perception with no morphological 
change (phase I, 0-5 hours); movement cessation and aggregation (phase II, 5-10 hours); 
morphological transformation to amastigote-shaped cells (phase III, 10-25 hours); and amastigote 
maturation (phase IV, 25-144 hours). Analyses using high-coverage transcriptomic and proteomic 
approaches showed that L. donovani differentiation is well-regulated with ordered and coordinated 
changes in mRNA and protein abundance (Saxena et al., 2007; Rosenzweig et al., 2008b) that result in 
the parasites retooling their metabolic pathways for life in the new host environment. We recently 
described stage-specific protein phosphorylation patterns (Tsigankov et al., 2013) and have now 
completed an extensive examination of phosphorylation changes during promastigote-to-amastigote 
differentiation (Tsigankov et al., 2014). 
When amastigote parasites residing in host macrophages are ingested by the vector during a blood 
meal, sensing of a colder and more alkaline environment in the fly gut induces development into the 
promastigote insect stage. Temperature and pH are also well-known triggers of life cycle stage 
differentiation in the related kinetoplastid parasite Trypanosoma brucei, the causative agent of Human 
African sleeping sickness (Czichos et al., 1986; Overath et al., 1986; Rolin et al., 1998; Engstler and 
Boshart, 2004; Szöör et al., 2013). In T. brucei, the regulatory pathway that controls differentiation 
from the mammalian to the fly stage in a culture model of differentiation involves a cascade of the 
protein phosphatases PTP1B and PIP39 (Szöör et al., 2006; Szöör et al., 2010) and protein kinases 
RDK1 and RDK2 (Jones et al., 2014), indicating the dominant role of protein phosphorylation in the 
process. The high phosphorylation dynamics during promastigote to amastigote differentiation 
(Tsigankov et al., 2014) also suggests that protein phosphorylation cascades are involved in the 
developmental regulation of Leishmania parasites. 
Several observations suggest an involvement of PKA signaling in regulation of the differentiation 
process in Leishmania: (1) a catalytic subunit of PKA termed c-Lpk2 (the orthologue of T. brucei 
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PKAC3 (Bachmaier and Boshart, 2013)) is differentially expressed in the promastigote and the 
amastigote stage at the mRNA level and undergoes temperature-dependent regulation at the level of 
mRNA stability (Siman-Tov et al., 1996); (2) an orthologue of the regulatory subunit of PKA is 
regulated during promastigote to amastigote differentiation and has been suggested to be important for 
metacyclogenesis based on reverse genetic analysis (Bhattacharya et al., 2012); (3) the abundance of 
consensus PKA phosphorylation motifs (RRXS, RXXS) shows stage-specific regulation (Tsigankov et 
al., 2013) and (4) a Leishmania-specific protein with similarity to the PKA regulatory subunit contains 
12 sites that are differentially phosphorylated during promastigote to amastigote differentiation 
(Tsigankov et al., 2014). These observations prompted us to study the kinetics of PKA-specific 
phosphorylation during differentiation in more detail. 
Using antibodies recognizing the PKA-specific substrate phosphorylation motif RXXS*/T* (* 
phosphorylation), we investigated changes in PKA phosphorylation activity during the complete life 
cycle of L. donovani, i.e. during bidirectional axenic differentiation from promastigote to amastigote 
as well as from amastigote to promastigote forms. Interestingly, we observed that PKA-mediated 
phosphorylation faded completely and rapidly at the end of phase I of promastigote differentiation to 
amastigotes. During the reverse differentiation process from the amastigote to the promastigote stage, 
PKA-dependent phosphorylations reappeared more gradually and peaked during terminal 
promastigote maturation. This study provides direct evidence that PKA substrate phosphorylation is 
correlated with stage differentiation and is particularly important for promastigote-specific functions.  
	  	   121	  
5. Leishmania donovani PKA 
Materials and Methods 
 
Cell culture and differentiation of L. donovani. A cloned line of L. donovani 1SR cells was 
used in all experiments (Saar et al., 1998). Promastigotes were grown at 26°C in medium 199 (Sigma, 
St. Louis, MO, USA) supplemented with 10% fetal calf serum (FCS). Differentiation of promastigotes 
to amastigotes in axenic culture was carried out as in	  Barak et al. (2005). To initiate differentiation of 
axenic amastigotes to promastigotes, log phase axenic amastigotes (0.5-1×107 cells/ml) were 
centrifuged using a table swing out centrifuge at 1244×g for 10 minutes at room temperature (22-
25°C). Subsequently, the cell pellet was resuspended in promastigote medium (M199 at pH 7 + 10% 
FCS) to a density of 0.5×106 cells/ml and incubated at 26°C. Aliquots were taken after 3, 6, 10, 16, 20, 
24, 30, 33, 48 and 96 hours. At each time point, parasites were collected, washed in phosphate 
buffered saline (PBS) and used for microscopy and lysate sampling. 
Cultivation of Trypanosoma b. brucei and generation of transgenic lines. Bloodstream 
forms of the monomorphic strain Lister 427, variant MiTat1.2 (Cross and Manning, 1973) were 
cultivated at 37°C in a 5% CO2 atmosphere in modified HMI-9 medium (Vassella et al., 1997) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum. A homozygous deletion mutant of 
the regulatory subunit of protein kinase A (PKAR) (Tb427tmp.02.2210) was generated by transfection 
of MiTat1.2 with the plasmids pBSK.PKARko.puro and pBSK.PKARko.hygro. These constructs 
contained a puromycin or hygromycin resistance cassette, respectively, flanked by actin UTRs and the 
PKAR UTRs. The constructs were digested with KpnI and XmnI for transfection, and PKAR knock out 
cells were grown in the presence of 0.05 µg/ml puromycin and 1 µg/ml hygromycin B. The L. 
donovani PKAR ORF (LdBPK_130160.1) was amplified from genomic DNA of L. donovani strain 
Lo8 and cloned into the pBSK.phleo backbone containing the phleomycin resistance cassette flanked 
by actin UTRs and T. brucei PKAR UTRs. The construct was digested with KpnI and XmnI for 
transfection, and antibiotic selection was performed by addition of 2.5 µg/ml phleomycin to the 
culture medium. 
Antibodies. The gene encoding the L. donovani 2,3-trans-enoyl CoA isomerase precursor 
(LdteCi1, LdBPK_312400.1) was cloned into pGEX4T-1 and expressed in E.coli-E151. Bacteria 
formed inclusion bodies of expressed LdteCi1 were extracted according to Sambrook and Russell 
(2001), and 0.5 mg of recombinant LdteCi1 protein was injected into rabbits with five consecutive 
boosts. Injections and bleedings were carried out as a contracted service by Sigma-Aldrich. Antiserum 
was used at a dilution of 1:1000. For production of a polyclonal antibody against T. brucei PKAR, the 
full-length protein was expressed as C-terminal hexahistidine fusion protein in E. coli M15 and 
purified under denaturing conditions using Ni-NTA columns (Qiagen). After separation of the 
concentrated protein fractions on a 10% SDS gel, rabbits were immunized with Coomassie-stained 
PKAR containing gel slices according to a standard immunization protocol (BioScience, Göttingen). 
Affinity purification of the antibody was performed according to the method of	  Olmsted (1981). A 
dilution of 1:250-1:500 was used for Western blot analysis. Other antibodies used were: anti-Hsp90 
and anti-Hsp100 (Hubel et al., 1997; kindly provided by Dr. Joachim Clos, Bernhart Nocht Institute, 
Hamburg), L13D6 monoclonal antibodies against Leishmania paraflagellar rod 2C (LinJ.16.1510 and 
LinJ.16.1520) and T. brucei PFR-A/C (Kohl et al., 1999; kindly provided by Dr. Philippe Bastin, 
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Institute Pasteur, Paris) and Phospho-(Ser/Thr) PKA substrate antibody (1:1000; Cell Signaling 
Technologies, catalog number 9621). 
Western blot analyses. Western blot analyses of L. donovani and T. brucei lysates were 
performed as previously reported (Barak et al., 2005; Salmon et al., 2012) using either luminol reagent 
for detection of peroxidase-conjugated secondary antibodies, or fluorescently labeled secondary 
antibodies (IRDye 680LT goat anti-rabbit IgG (H+L), 1:50000; IRDye 800CW goat anti-mouse IgG 
(H+L), 1:5000; IRDye 800 donkey anti-chicken; 1:5000; all from LI-COR) and the OdysseyTM IR 
fluorescence scanning system (LI-COR). For quantification, signals were normalized to the Hsp90 
internal control after automatic subtraction of the background values (median left/right method) using 
the Odyssey software (LI-COR). 
Growth and cell cycle analyses. Radiolabeled thymidine (3H-thymidine, Perkin-Elmer Inc.) 
incorporation into differentiating axenic L. donovani was used to determine the rate of cell 
proliferation as previously described (Shaked-Mishan et al., 2001). At different time points of 
amastigote to promastigote differentiation, cell aliquots were collected and subjected to flow 
cytometry as described previously (Barak et al., 2005). For each assay, 5 ml of cell culture (0.5–1×107 
cells/ml) were collected, washed twice with PBS and suspended in 70% ice-cold methanol for 
fixation. These cells were kept at -20°C for further use. Prior to analysis, the cells were treated with 20 
mg/ml RNase A for one hour at 37°C. Subsequently, DNA was stained using propidium iodide and 
20,000 cells were analyzed for DNA content using the BD LSR-II flow cytometer (Becton Dickinson). 
The distribution of G1, S and G2/M phases was calculated from each histogram using FCS Express 4 
flow cytometry (Denovo Software Inc.). 
Scanning electron microscopy. At each time point, 1×108 cells were washed once (1244×g, 
10 min, room temperature) in PBS and subsequently settled on poly-L-lysine coated silicon discs. Cell 
were fixed using 2.5% glutaraldehyde, washed three times in PBS and dehydrated in increasing 
concentrations of ethanol, from 30 to 100%, followed by critical point drying (CPD, Baltek Inc.). 
Finally, cells were viewed in a FEI E-SEM Quanta-200 scanning electron microscope. 
Fluorescence microscopy. For immunofluorescence, mid-log L. donovani axenic 
promastigotes and amastigotes (1×108 cells) were fixed in 1% formaldehyde/PBS on a slide for 10 
min, followed by permeabilization with 0.2% Triton X-100/PBS for 10 min. Blocking in 10% (v/v) 
non-fat dried skimmed milk powder/PBST for 30 minutes was followed by incubation with anti-
TbPKAR antiserum (1:50 dilution) for 1 h (all at room temperature). Polyclonal goat anti-rabbit IgG 
conjugated to Cy3 (1:500 dilution; Jackson Inc.) was used as secondary antibody. For counterstaining, 
rabbit anti L. donovani membranes IgG (1:2000 dilution; Saar et al., 1998) and polyclonal goat anti-
rabbit IgG conjugated to Alexa 488 (1:500 dilution; Jackson Inc.) were used. Cellular DNA was 
stained with DAPI (4',6-diamidino-2-phenylindole; Fluka; 0.25 µg/ml), and cells were imaged with a 
Zeiss LSM 700 Inverted confocal laser scanning microscope. 
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Results 
 
Protein kinase A (PKA)-mediated signaling was investigated as candidate pathway implicated in stage 
differentiation in Leishmania, mainly motivated by the observed stage-specific expression and 
phosphorylation of PKA subunits (Siman-Tov et al., 1996; Rosenzweig et al., 2008a; Bhattacharya et 
al., 2012; Tsigankov et al., 2013; Tsigankov et al., 2014). Global patterns of PKA substrate 
phosphorylation can be probed by phospho-specific antibodies specifically detecting the RXXS*/T* 
peptide motif that characterizes a large fraction of all known PKA phosphorylation sites in a broad 
range of organisms and substrates (Shabb, 2001). We have used this tool to probe the degree of 
proteome-wide PKA substrate phosphorylation during axenic promastigote to amastigote 
differentiation using the established differentiation protocol of Barak et al. (2005). In promastigotes 
(Fig. 1A, t=0), many proteins, most prominently visible as a cluster of bands in the 50-60 kDa range, 
were detected by the phospho-specific antibody. Interestingly, the abundance of these RXXS*/T* 
phospho-sites decreased ~5-fold within 6 h of differentiation, i.e. the end of phase I (Barak et al., 
2005). This lower level of phosphorylation remained unchanged through subsequent phases of 
differentiation and in mature amastigotes. Remarkably, exposure of promastigotes to amastigote 
growth conditions for only 10 minutes resulted in complete loss of PKA-dependent phosphorylations 
(Fig. 1B), excluding the possibility that changes in the expression level of PKA substrates account for 
the altered phosphorylation pattern. Furthermore, we show that the RXXS*/T*-specific antibody 
detects PKA-specific phosphorylation. In the related organism T. brucei, RXXS/T phosphorylation is 
completely abolished upon incubation with the cell-permeable, myristoylated derivative of the PKI 
(14-22) peptide inhibitor (Supplementary Fig. S1). PKI is the gold standard PKA-specific inhibitor 
(Walsh et al., 1971; Glass et al., 1989; Harris et al., 1997; Dalton and Dewey, 2006). Moreover, in a 
mutant cell line with homozygous deletion of the T. brucei gene encoding the regulatory subunit of 
PKA (lane ∆pkar/∆pkar in Supplementary Fig. S1 and Fig. S2), RXXS/T phosphorylation is strongly 
reduced. Since PKA is a complex of catalytic and regulatory subunits, the ∆pkar/∆pkar mutant still 
expresses low amounts of catalytic subunits (data not shown) and therefore is not expected to abolish 
substrate phosphorylation completely (Supplementary Fig. S1, lane ∆pkar/∆pkar). 
We then asked whether PKA substrates or PKA substrate phosphorylation reappeared upon 
differentiation of amastigotes back to promastigotes in culture. To initiate differentiation, logarithmic 
phase axenic amastigotes grown in amastigote medium were shifted to promastigote growth 
conditions (see Materials and Methods, section 2.1). Subsequently, parasite aliquots were collected at 
the indicated time points after initiation of differentiation and probed for RXXS/T phospho-sites (Fig. 
1C). Phosphorylated RXXS/T sites became detectable 24 hours after initiation of differentiation and 
reached the maximum level at 48 hours. 
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Figure 1: Regulation of phosphorylated PKA substrates during differentiation of L. donovani. Lysates 
were prepared at the indicated time points after initiation of differentiation. Western blot analysis 
during promastigote to amastigote (A) or amastigote to promastigote (C) differentiation was 
performed using antibodies specifically detecting Phospho-(Ser/Thr) RXXS/T sites, mainly 
representing phosphorylated PKA substrates. The abundance of these phospho-sites was quantified by 
fluorescence imaging and normalized to Hsp90 as loading control (graphs adjacent to the Western 
blots; y-axes represent normalized intensity counts). A minor and transient upregulation of Hsp90 in 
amastigotes has been reported (Krobitsch et al., 1998), which may lead to maximally 1.5-fold 
overestimation of regulation at some time points. (B) Regulation of PKA substrate phosphorylation 
upon exposure of L. donovani promastigotes to differentiation conditions for 10 min.  
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The quantification shows the mean of six independent biological replicates; error bars represent SEM; 
significance was determined using the Excel Add-in QI Macros, 2014, with a two-tailed T-test 
assuming equal variances (determined by F-test). Note that in (B) less material has been loaded 
compared to (A) and (C). 
 
As the time course of axenic amastigote to promastigote differentiation has not been described in 
detail, we were unable to correlate the reappearance of phosphorylated PKA sites (Fig. 1C) with a 
particular process during differentiation. Therefore, the morphology was recorded in a time course of 
L. donovani amastigote to promastigote differentiation (Fig. 2). Samples were collected at 0, 3, 6, 8, 
16, 24, 33, 40, 48 and 96 hours after shift to promastigote growth conditions for morphologic analysis 
using scanning electron microscopy. No change in amastigote morphology was observed during the 
first 3 hours (Fig. 2A-B). At 6 hours, one third of the parasite population started to elongate, but with 
no sign of flagella biogenesis (C). The proportion of elongated cells increased to 44% at 8 hours, and 
at 16 hours two thirds were elongated almost to the length of mature promastigotes but still had no 
visible flagella (D-E). First signs of flagellar emergence were observed at 24 hours after initiation of 
differentiation. At this time point, all cells in culture were elongated, 19% of them had developed short 
flagella (F). At 33 hours, most cells had visible flagella (G), and at 40 hours, the culture contained 
predominantly mature promastigotes as judged by morphology and motility (H-J). Thus, as displayed 
in Fig. 1C, the PKA-specific phospho-sites first became visible at 24 hours, when flagella emerged. 
 
Figure 2: Time course of axenic amastigote morphogenesis to promastigotes during differentiation in 
vector-free culture. Axenic amastigotes were subjected to promastigote growth medium as described 
in Materials and Methods (section 2.1), and aliquots were collected at the indicated time points after 
initiation of differentiation for scanning electron microscopy (see Materials and Methods, section 2.6). 
Cell body elongation is detected as early as 6 hours after medium change. Flagellated promastigote-
like cells first appeared at 24 hours after differentiation was initiated. Bars represent 2 µm. 
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The growth curve of a representative differentiation experiment (Fig. 3A) suggests that upon initiation 
of differentiation, amastigotes rest for about 12 h before they reinitiate proliferation as elongated cells 
and show signs of flagellar outgrowth. This is reminiscent of promastigote to amastigote 
differentiation, which is initiated by growth arrest and synchronization of cells in the G1 phase of the 
cell cycle (Barak et al., 2005). We therefore determined thymidine incorporation in a time course of 
differentiation. As shown in Fig. 3B (grey squares), the rate of thymidine incorporation dropped 
within the first 6 hours after transferring amastigotes to promastigote growth conditions and then 
steeply increased 8-fold within the following 27 hours. At later time points, the rate of thymidine 
incorporation returned to the level of promastigotes (about 2.5 times higher than that of amastigotes). 
The fraction of cells in S-phase was also determined by DNA content analysis using flow cytometry 
(Fig. 3B, black diamonds). The S-phase fraction initially dropped to a minimum value during the first 
6 hours of differentiation and then peaked at ~16 hours and ~32 hours. As the population doubling 
time of the differentiating population is around 16 hours (Fig. 3A), the double peak might reflect 
transient synchronization when cells reenter the cell cycle. Thymidine incorporation does not show 
this double peak, probably due to the length of the labeling pulse. The consistent results of both 
thymidine incorporation and flow cytometry confirmed an initial cell cycle arrest prior to 
differentiation of amastigotes to promastigotes. After the lag, a constant growth rate (population 
doubling time of 16 h) indicates that differentiation in culture is an efficient process (Fig. 3A). The 
possible transient synchronization is not maintained (not shown). 
 
 
Figure 3: Growth arrest during L. donovani amastigote to promastigote differentiation. Aliquots of 
amastigote cells inoculated in promastigote culture medium were collected at the indicated time 
points. (A) Growth curve. From the linear regression of values between 10 and 50 hours after 
initiation of differentiation, a population doubling time of 16 hours is estimated. (B) Cell cycle 
analysis: aliquots of cells were pulse labeled for 1 hour with [3H]-thymidine, nuclei were purified, and 
radioactivity was determined by scintillation counting (■). Values represent the average of two 
independent biological replicates. Additional aliquots were subjected to RNAse A treatment followed 
by propidium iodide staining and flow cytometry to quantify DNA content and determine the relative 
number of S phase cells (♦). Data points represent the average of three biological replicates. 
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We also have used protein markers to relate the abundance of PKA-specific phospho-sites to the 
kinetics of amastigote to promastigote differentiation. The first marker is a putative 2,3-trans-enoyl 
CoA isomerase precursor (LdteCi1, LdBPK_312400.1) whose protein abundance increases 7-fold at 
late stages of promastigote to amastigote differentiation (Saxena et al., 2007; Rosenzweig et al., 
2008a). The L. donovani genome contains encodes a second isoforms of this protein: LdteCi2 
(LdBPK_312320.1) is 89% identical to LdteCi1, but lacks 7 amino acids near its N-terminus and has a 
divergent C-terminal region. Antibodies raised against LdteCi1 detect both isoforms with LdteCi1 
showing a slightly higher molecular weight (data not shown). As shown in Fig. 4A, axenic 
amastigotes express predominantly LdteCi1. This level of expression remains unchanged during the 
first 24 hours of amastigote to promastigote differentiation, when the parasites complete elongation 
but still lack flagella. Later the level decreases. LdteCi2 is expressed in amastigotes at a low level, and 
its abundance increases from 24 hours on. The second marker is the paraflagellar rod 2C protein 
(PFR2C; LdBPK_161520.1). Previous proteomic analysis indicated that this protein is hardly 
expressed in amastigotes (Rosenzweig et al., 2008a). This was further confirmed using monoclonal 
antibodies against PFR2C (Fig. 4A, middle row). Amastigotes also do not express PFR2C mRNA 
(Lahav et al., 2011). The PFR2C protein appeared on the Western blot at 33 hours after differentiation 
initiation. This perfectly corresponds to the time when flagella have emerged in most differentiating 
cells (33 h in Fig. 2G), as expected for a protein that has been associated with flagellar motility in 
promastigotes (Santrich et al., 1997). The third marker is Hsp100, whose expression is induced by 
elevated temperature and thus is expressed at higher level in amastigotes (Hubel et al., 1997; 
Krobitsch et al., 1998). As shown in the lower row of Fig. 4A and in agreement with Rosenzweig et al. 
(2008a), Hsp100 abundance dropped 24 hours after differentiation initiation. Important changes in 
marker protein expression thus occur between 24 and 33 h after initiation of differentiation, i.e. at least 
12 h after the onset of proliferation. Comparing the differentiation marker kinetics with the kinetics in 
Fig. 1C, we conclude that the change of PKA phospho-site abundance is not an early event in 
amastigote to promastigote differentiation, but correlated with promastigote maturation. This suggests 
stage-specific roles of PKA signaling. Expression of the regulatory subunit of PKA (LdPKAR1) was 
also quantified during differentiation. The antibody used was raised against T. brucei PKAR and 
cross-reacts sensitively and specifically with the transgenically expressed L. donovani protein 
(Supplementary Fig. S2). Fig. 4B shows stage-specific regulation of LdPKAR1 expression. A low 
level in amastigotes contrasts with a 3- and 5-fold increase after 24 and 48 hours, respectively, post 
initiation of differentiation. The regulatory subunit binds and inhibits the catalytic subunit, and its 
amount correlates with maximally stimulatable PKA activity, as PKA R and C subunits are co-
regulated due to instability of free catalytic subunits in most cells including T. brucei (see 
Supplementary Fig. S1, lane ∆pkar/∆pkar). Interestingly, LdPKAR1 was predominantly localized to 
the flagellum of promastigotes as seen by immunofluorescence microscopy (Fig. 4C), but was 
undetectable in amastigotes that do not have a flagellum. This is in agreement with stage-specific 
expression of LdPKAR1 shown in Fig. 4B. In summary, PKA-specific phosphorylation of many 
substrates increases during amastigote to promastigote differentiation, implicating this kinase in a 
regulatory process important for promastigote maturation, function or promastigote adaptation to 
environmental conditions. 
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    Figure 4: Expression of marker 
proteins and PKAR during axenic 
differentiation of amastigotes into 
promastigotes. (A) Lysates were 
prepared from parasites at the 
indicated time points after 
differentiation was initiated. Western 
blot analysis was performed with: 
rabbit anti-2,3-trans-enoyl CoA 
isomerase precursor (LdteCi1, 
LdBPK_312400.1), mouse anti-
paraflagellar rod protein 2C (PFR2C), 
and chicken anti-Hsp100. Secondary 
antibodies coupled to horseradish 
peroxidase were used for 
chemiluminescence detection. Equal 
cell numbers were loaded. (B) Lysates 
were prepared from parasites at the 
indicated time points after 
differentiation was initiated. 
LdPKAR1 was quantified by 
fluorescence detection on Western 
blots with a cross-reacting anti-
TbPKAR antiserum and anti-Hsp90 as 
internal reference for normalization. 
Anti-PKAR antibody specificity is 
documented in Supplementary Fig. 
S2. The graph gives the mean and the 
range of LdPKAR1 abundance from 
two independent biological replicates, 
one of which is shown as Western 
blot. The y-axis represents normalized 
intensity counts. (C) Subcellular 
localization of LdPKAR1 by confocal 
fluorescence microscopy of 
promastigotes and amastigotes stained 
with the PKAR-specific antibody (red 
channel). The cell surface is 
counterstained with anti L. donovani 
membranes IgG (green channel), and 
DNA is stained with DAPI. The size 
bar corresponds to 2 µm. 
Fluorescence was monitored using a 
Zeiss LSM 700 Inverted 
confocal laser scanning microscope. 
 
 
A
30 166 10 3320 24 6904 84
LdteCi1
LdteCi2
Hsp100
43 kDa
70 kDa
95 kDa
Time in differentiation [h]
PFR2C
B
kDa
80
46
Time in differentiation [h]
 0        6          24       48
0 
40 
80 
120 
160 
PK
A
R
 e
xp
re
ss
io
n
PKAR
Hsp90
C
anti-PKAR anti-membrane merge
promastigote
amastigote
(AMA)
(AMA)
	  	   129	  
5. Leishmania donovani PKA 
Discussion 
 
This study uses an established protocol for axenic differentiation of Leishmania promastigotes to 
amastigotes (Barak et al., 2005) and axenic reverse differentiation of amastigotes to promastigotes to 
generate a complete life cycle profile of PKA substrate phosphorylation.  
In vitro systems that simulate parasite development are essential tools for the discovery of host and 
vector signals that enable parasites to identify their host environment and subsequently activate the 
signaling pathways that stimulate their transformation from one developmental stage to the other. 
The axenic reverse amastigote to promastigote differentiation has been reported previously (Duncan et 
al., 2001) but has not been correlated to defined morphological events. Analyzing the kinetics of this 
developmental process, we detected a transient growth and cell cycle arrest that precedes the changes 
in marker expression and morphology. This arrest may be important for reprograming of gene 
expression. Resetting the cell cycle may also be required to enable cytoskeletal changes associated 
with morphogenesis and flagellar biogenesis. A transient cell cycle arrest is a defining feature of 
kinetoplastid differentiation, as described in detail for promastigote to amastigote differentiation in 
Leishmania (Barak et al., 2005) and bloodstream to procyclic differentiation in T. brucei where a well-
defined arrested life cycle stage, the stumpy bloodstream form, exists (Vickerman, 1985; Vassella et 
al., 1997; MacGregor et al., 2011; MacGregor et al., 2012).  
In T. brucei, bloodstream to procyclic stage differentiation is co-stimulated by a temperature shift of > 
10°C, termed cold shock (Engstler and Boshart, 2004; Dean et al., 2009; Szöör et al., 2010). Similarly, 
shifting L. donovani amastigotes from body temperature (37°C) to insect temperature (26°C) together 
with a change in pH was sufficient to induce differentiation of axenic amastigotes into promastigotes 
within 24-30 hours.  
The global detection of PKA substrate phosphorylation in L. donovani showed strong developmental 
regulation. The rapid and almost complete loss of phosphorylated PKA substrates upon initiation of 
promastigote to amastigote differentiation within minutes can only be explained by a change in the 
balance between the kinase and counteracting protein phosphatases. A very fast proteolysis of all of 
these substrates with a similar time course is highly unlikely. Inactivation of the kinase is the most 
likely event initially triggered. In fact, this is followed by a second phase of down-regulation of the 
mRNA encoding a catalytic subunit of PKA (c-Lpk2; Siman-Tov et al., 1996; Duncan et al., 2001) 
and of the regulatory subunit LdPKAR1 (LdBPK_130160.1) (Fig. 4B). During the reverse 
differentiation of amastigotes to promastigotes, phosphorylated PKA substrates and, by inference, 
PKA activity rose only later and gradually after the initial growth arrest phase and reached high levels 
during maturation of promastigotes. This again corresponds perfectly to the profile of c-lpk2 mRNA 
expression during amastigote to promastigote differentiation (Duncan et al., 2001). The rapid loss of 
PKA substrate phosphorylation upon promastigote to amastigote differentiation suggests that PKA 
activity and signaling are dispensable in amastigotes but required for promastigote-specific functions. 
In agreement with this argument, LdPKAR1 is specifically localized in the flagellum, a structure 
essentially absent from amastigotes. A flagellar localization has also been observed for the T. brucei 
PKAR orthologue (Krumbholz C. and Boshart M., unpublished), consistent with its identification in 
the soluble flagellar proteome (Oberholzer et al., 2011; Subota et al., 2014). Reverse genetic depletion 
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in T. brucei has furthermore established a role for PKAR in flagellar motility (Oberholzer et al., 2011; 
Krumbholz and Boshart, unpublished). Yet, the role of PKA seems not to be limited to flagellar 
motility as overexpression of LdPKAR1 in L. donovani accelerates autophagy, a starvation-induced 
cytological event necessary for metacyclogenesis (Bhattacharya et al., 2012). Surprisingly, the protein 
detected by the anti-PKAR1 antibody used in Bhattacharya et al. (2012) is distributed evenly in the 
cell body but excluded from the flagellum. Moreover, the developmental expression profile of 
LdPKAR1 deviates significantly from the profile shown here (Fig. 4B). Since the specificity of our 
anti-PKAR antibody has been proven by a gene knock out and a genetic rescue (Supplementary Fig. 
S2), it remains possible that Bhattacharya et al. (2012) do not detect the same protein 
(LdBPK_130160.1) in L. donovani cells. The phosphorylation kinetics suggests that in vivo PKA 
activity is regulated at multiple levels, including kinase inactivation/activation and expression of PKA 
subunits, during bidirectional axenic differentiation. We cannot separate the obvious promastigote-
specific functions suggested by differential activity and localization of PKA subunits from a possible 
direct involvement of this kinase in signaling environmental conditions that trigger differentiation. 
However, the bidirectional differentiation system will be very valuable in addressing these questions 
directly by genetic analysis.	  
  
	  	   131	  
5. Leishmania donovani PKA 
References 
 
Bachmaier, S., Boshart, M., 2013. Kinetoplastid AGC Kinases, Protein Phosphorylation in Parasites. 
Wiley-VCH Verlag GmbH & Co. KGaA, pp. 99-122. 
Barak, E., Amin-Spector, S., Gerliak, E., Goyard, S., Holland, N., Zilberstein, D., 2005. 
Differentiation of Leishmania donovani in host-free system: analysis of signal perception and 
response. Molecular and biochemical parasitology 141, 99-108. 
Bates, P.A., 1994. The developmental biology of Leishmania promastigotes. Experimental 
parasitology 79, 215-218. 
Bhattacharya, A., Biswas, A., Das, P.K., 2012. Identification of a protein kinase A regulatory subunit 
from Leishmania having importance in metacyclogenesis through induction of autophagy. 
Molecular microbiology 83, 548-564. 
Burchmore, R.J., Barrett, M.P., 2001. Life in vacuoles--nutrient acquisition by Leishmania 
amastigotes. International journal for parasitology 31, 1311-1320. 
Chang, K.P., Dwyer, D.M., 1976. Multiplication of a human parasite (Leishmania donovani) in 
phagolysosomes of hamster macrophages in vitro. Science 193, 678-680. 
Cross, G.A., Manning, J.C., 1973. Cultivation of Trypanosoma brucei sspp. in semi-defined and 
defined media. Parasitology 67, 315-331. 
Czichos, J., Nonnengaesser, C., Overath, P., 1986. Trypanosoma brucei: cis-aconitate and temperature 
reduction as triggers of synchronous transformation of bloodstream to procyclic 
trypomastigotes in vitro. Experimental parasitology 62, 283-291. 
Dalton, G.D., Dewey, W.L., 2006. Protein kinase inhibitor peptide (PKI): a family of endogenous 
neuropeptides that modulate neuronal cAMP-dependent protein kinase function. 
Neuropeptides 40, 23-34. 
Dean, S., Marchetti, R., Kirk, K., Matthews, K.R., 2009. A surface transporter family conveys the 
trypanosome differentiation signal. Nature 459, 213-217. 
Debrabant, A., Joshi, M.B., Pimenta, P.F., Dwyer, D.M., 2004. Generation of Leishmania donovani 
axenic amastigotes: their growth and biological characteristics. International journal for 
parasitology 34, 205-217. 
Duncan, R., Alvarez, R., Jaffe, C.L., Wiese, M., Klutch, M., Shakarian, A., Dwyer, D., Nakhasi, H.L., 
2001. Early response gene expression during differentiation of cultured Leishmania donovani. 
Parasitology research 87, 897-906. 
Engstler, M., Boshart, M., 2004. Cold shock and regulation of surface protein trafficking convey 
sensitization to inducers of stage differentiation in Trypanosoma brucei. Genes & 
development 18, 2798-2811. 
Glass, D.B., Cheng, H.C., Mende-Mueller, L., Reed, J., Walsh, D.A., 1989. Primary structural 
determinants essential for potent inhibition of cAMP-dependent protein kinase by inhibitory 
peptides corresponding to the active portion of the heat-stable inhibitor protein. The Journal of 
biological chemistry 264, 8802-8810. 
	  	   132 
5. Leishmania donovani PKA 
Goyard, S., Segawa, H., Gordon, J., Showalter, M., Duncan, R., Turco, S.J., Beverley, S.M., 2003. An 
in vitro system for developmental and genetic studies of Leishmania donovani 
phosphoglycans. Molecular and biochemical parasitology 130, 31-42. 
Harris, T.E., Persaud, S.J., Jones, P.M., 1997. Pseudosubstrate inhibition of cyclic AMP-dependent 
protein kinase in intact pancreatic islets: effects on cyclic AMP-dependent and glucose-
dependent insulin secretion. Biochemical and biophysical research communications 232, 648-
651. 
Herwaldt, B.L., 1999. Leishmaniasis. Lancet 354, 1191-1199. 
Hubel, A., Krobitsch, S., Horauf, A., Clos, J., 1997. Leishmania major Hsp100 is required chiefly in 
the mammalian stage of the parasite. Molecular and cellular biology 17, 5987-5995. 
Jones, N.G., Thomas, E.B., Brown, E., Dickens, N.J., Hammarton, T.C., Mottram, J.C., 2014. 
Regulators of Trypanosoma brucei cell cycle progression and differentiation identified using a 
kinome-wide RNAi screen. PLoS pathogens 10, e1003886. 
Kohl, L., Sherwin, T., Gull, K., 1999. Assembly of the paraflagellar rod and the flagellum attachment 
zone complex during the Trypanosoma brucei cell cycle. The Journal of eukaryotic 
microbiology 46, 105-109. 
Krobitsch, S., Brandau, S., Hoyer, C., Schmetz, C., Hubel, A., Clos, J., 1998. Leishmania donovani 
heat shock protein 100. Characterization and function in amastigote stage differentiation. The 
Journal of biological chemistry 273, 6488-6494. 
Lahav, T., Sivam, D., Volpin, H., Ronen, M., Tsigankov, P., Green, A., Holland, N., Kuzyk, M., 
Borchers, C., Zilberstein, D., Myler, P.J., 2011. Multiple levels of gene regulation mediate 
differentiation of the intracellular pathogen Leishmania. FASEB journal : official publication 
of the Federation of American Societies for Experimental Biology 25, 515-525. 
MacGregor, P., Savill, N.J., Hall, D., Matthews, K.R., 2011. Transmission stages dominate 
trypanosome within-host dynamics during chronic infections. Cell host & microbe 9, 310-318. 
MacGregor, P., Szoor, B., Savill, N.J., Matthews, K.R., 2012. Trypanosomal immune evasion, 
chronicity and transmission: an elegant balancing act. Nature reviews. Microbiology 10, 431-
438. 
Oberholzer, M., Langousis, G., Nguyen, H.T., Saada, E.A., Shimogawa, M.M., Jonsson, Z.O., 
Nguyen, S.M., Wohlschlegel, J.A., Hill, K.L., 2011. Independent analysis of the flagellum 
surface and matrix proteomes provides insight into flagellum signaling in mammalian-
infectious Trypanosoma brucei. Molecular & cellular proteomics : MCP 10, M111 010538. 
Olmsted, J.B., 1981. Affinity purification of antibodies from diazotized paper blots of heterogeneous 
protein samples. The Journal of biological chemistry 256, 11955-11957. 
Overath, P., Czichos, J., Haas, C., 1986. The effect of citrate/cis-aconitate on oxidative metabolism 
during transformation of Trypanosoma brucei. European journal of biochemistry / FEBS 160, 
175-182. 
Rolin, S., Hancocq-Quertier, J., Paturiaux-Hanocq, F., Nolan, D.P., Pays, E., 1998. Mild acid stress as 
a differentiation trigger in Trypanosoma brucei. Molecular and biochemical parasitology 93, 
251-262. 
	  	   133	  
5. Leishmania donovani PKA 
Rosenzweig, D., Smith, D., Myler, P.J., Olafson, R.W., Zilberstein, D., 2008a. Post-translational 
modification of cellular proteins during Leishmania donovani differentiation. Proteomics 8, 
1843-1850. 
Rosenzweig, D., Smith, D., Opperdoes, F., Stern, S., Olafson, R.W., Zilberstein, D., 2008b. Retooling 
Leishmania metabolism: from sand fly gut to human macrophage. FASEB journal : official 
publication of the Federation of American Societies for Experimental Biology 22, 590-602. 
Saar, Y., Ransford, A., Waldman, E., Mazareb, S., Amin-Spector, S., Plumblee, J., Turco, S.J., 
Zilberstein, D., 1998. Characterization of developmentally-regulated activities in axenic 
amastigotes of Leishmania donovani. Molecular and biochemical parasitology 95, 9-20. 
Salmon, D., Bachmaier, S., Krumbholz, C., Kador, M., Gossmann, J.A., Uzureau, P., Pays, E., 
Boshart, M., 2012. Cytokinesis of Trypanosoma brucei bloodstream forms depends on 
expression of adenylyl cyclases of the ESAG4 or ESAG4-like subfamily. Molecular 
microbiology 84, 225-242. 
Sambrook, J., Russell, D.W., 2001. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor 
Laboratory Press. 
Santrich, C., Moore, L., Sherwin, T., Bastin, P., Brokaw, C., Gull, K., LeBowitz, J.H., 1997. A 
motility function for the paraflagellar rod of Leishmania parasites revealed by PFR-2 gene 
knockouts. Molecular and biochemical parasitology 90, 95-109. 
Saxena, A., Lahav, T., Holland, N., Aggarwal, G., Anupama, A., Huang, Y., Volpin, H., Myler, P.J., 
Zilberstein, D., 2007. Analysis of the Leishmania donovani transcriptome reveals an ordered 
progression of transient and permanent changes in gene expression during differentiation. 
Molecular and biochemical parasitology 152, 53-65. 
Shabb, J.B., 2001. Physiological substrates of cAMP-dependent protein kinase. Chemical reviews 101, 
2381-2411. 
Shaked-Mishan, P., Ulrich, N., Ephros, M., Zilberstein, D., 2001. Novel Intracellular SbV reducing 
activity correlates with antimony susceptibility in Leishmania donovani. The Journal of 
biological chemistry 276, 3971-3976. 
Siman-Tov, M.M., Aly, R., Shapira, M., Jaffe, C.L., 1996. Cloning from Leishmania major of a 
developmentally regulated gene, c-lpk2, for the catalytic subunit of the cAMP-dependent 
protein kinase. Molecular and biochemical parasitology 77, 201-215. 
Subota, I., Julkowska, D., Vincensini, L., Reeg, N., Buisson, J., Blisnick, T., Huet, D., Perrot, S., 
Santi-Rocca, J., Duchateau, M., Hourdel, V., Rousselle, J.C., Cayet, N., Namane, A., Chamot-
Rooke, J., Bastin, P., 2014. Proteomic analysis of intact flagella of procyclic Trypanosoma 
brucei cells identifies novel flagellar proteins with unique sub-localization and dynamics. 
Molecular & cellular proteomics : MCP 13, 1769-1786. 
Szöör, B., Dyer, N.A., Ruberto, I., Acosta-Serrano, A., Matthews, K.R., 2013. Independent pathways 
can transduce the life-cycle differentiation signal in Trypanosoma brucei. PLoS pathogens 9, 
e1003689. 
Szöör, B., Ruberto, I., Burchmore, R., Matthews, K.R., 2010. A novel phosphatase cascade regulates 
differentiation in Trypanosoma brucei via a glycosomal signaling pathway. Genes & 
development 24, 1306-1316. 
	  	   134 
5. Leishmania donovani PKA 
Szöör, B., Wilson, J., McElhinney, H., Tabernero, L., Matthews, K.R., 2006. Protein tyrosine 
phosphatase TbPTP1: A molecular switch controlling life cycle differentiation in 
trypanosomes. The Journal of cell biology 175, 293-303. 
Tsigankov, P., Gherardini, P.F., Helmer-Citterich, M., Spath, G.F., Myler, P.J., Zilberstein, D., 2014. 
Regulation dynamics of Leishmania differentiation: deconvoluting signals and identifying 
phosphorylation trends. Molecular & cellular proteomics : MCP 13, 1787-1799. 
Tsigankov, P., Gherardini, P.F., Helmer-Citterich, M., Spath, G.F., Zilberstein, D., 2013. 
Phosphoproteomic analysis of differentiating Leishmania parasites reveals a unique stage-
specific phosphorylation motif. Journal of proteome research 12, 3405-3412. 
Vassella, E., Reuner, B., Yutzy, B., Boshart, M., 1997. Differentiation of African trypanosomes is 
controlled by a density sensing mechanism which signals cell cycle arrest via the cAMP 
pathway. J Cell Sci 110 ( Pt 21), 2661-2671. 
Vickerman, K., 1985. Developmental cycles and biology of pathogenic trypanosomes. British Medical 
Bulletin 41, 105-114. 
Walsh, D.A., Ashby, C.D., Gonzalez, C., Calkins, D., Fischer, E.H., 1971. Krebs EG: Purification and 
characterization of a protein inhibitor of adenosine 3',5'-monophosphate-dependent protein 
kinases. The Journal of biological chemistry 246, 1977-1985. 
Zilberstein, D., 2008. Physiological and biochemical aspects of Leishmania develpment., in: Myler, 
P.J., Fasel, N. (Eds.), Leishmania after the genome: biology and control. Horizon Scientific 
Press and Caiser Academic Press, New York, pp. 107-122 
 
 
 
 
 
	  	   135	  
5. Leishmania donovani PKA 
Acknowledgements 
 
We are grateful to Joachim Clos, Hamburg and Philippe Bastin, Paris for providing antibody reagents. 
We thank Prof. Moshe Ephros and Dr. Gerald Spaeth for critical comments on some experiments. This 
work was supported by grant number 1065-86.13/2008 from the German-Israeli Foundation for 
Scientific Research and Development (GIF) to M. B. and D. Z. 
	  	   136 
6. Discussion 
6. Concluding Discussion 
 
The cAMP/PKA signaling pathway, which is highly conserved in most eukaryotes, is significantly 
different in the evolutionary early branching protozoan parasite T. brucei (Figure 6.1): A large family 
of receptor-type adenylate cyclases with atypical sequence and structural features (Figure 1.2 
(Introduction)) may replace the receptor function of GPCRs, which are apparently absent from 
trypanosomal genomes. Cyclic AMP produced by ACs does not activate the parasite PKA orthologue, 
nor does the trypanosomal genome encode any proteins with similarity to known alternative cAMP 
effectors from other organisms (such as CRP, Epac or cyclic nucleotide regulated ion channels). 
Instead, CARP1, a protein exclusively found in kinetoplastids, acts as putative cAMP acceptor and 
might represent the entry point into a novel, kinetoplastid-specific cAMP signaling pathway. Apart 
from its involvement in regulation of cell division, cAMP plays an important extracellular role by 
modulation of the host innate immune response thereby ensuring high parasite transmission. The PKA 
orthologue of T. brucei is the first example of a PKA not regulated by cAMP. In T. brucei, we 
discovered regulation by low temperature and presumably by an alternative endogenous ligand. The 
kinase is involved in regulation of parasite differentiation, motility, carbohydrate metabolism, 
ribosome biogenesis, translation, transport, and protein folding, reminiscent of PKA downstream 
functions in other organisms (Skalhegg and Tasken, 2000; Shabb, 2001; Ptacek et al., 2005; 
Vaidyanathan et al., 2014). One third of the putative substrates of T. brucei PKA, however, are 
kinetoplastid- or even Trypanosoma-specific proteins with mostly unknown function and hence might 
indicate partially unique PKA downstream signaling.  
 
 
 
Figure 6.1: T. brucei cAMP (left) and PKA signaling (right) pathways. 
 
cAMP signaling PKA signaling
AC
cAMPATP
PDE
PDE
?
CARP1
CARP2
CARP3
CARP4
CARP5
CARP6
?
release
modulation of
host immune
response
cell division control
R C
nucleoside-
related
compound(s)?
PKA
cold shock
?
ATP
ADP
metabolism
signaling
motility
transport
substrate
P
	  	   137	  
6. Discussion 
6.1 Why is there such a diversity of ACs in T. brucei? 
 
The surprisingly high number of AC isoforms encoded by the T. brucei genome (>80 isoforms; 
www.tritrypdb.org; Salmon et al., 2012a; Salmon et al., 2012b) compared to the human genome (9 
isoforms; Ludwig and Seuwen, 2002) raises the question: why do trypanosomes need such a high 
number of diverse ACs? To be able to answer this question, a better understanding of the function of 
the variable extracellular domain will be required. This domain is discussed to serve as receptor 
domain for extracellular ligands replacing the receptor function of GPCRs (Gould and de Koning, 
2011). The architectural similarity of trypanosomal ACs to receptor-type GCs (Seebeck et al., 2004), 
their localization at the flagellar surface (Paindavoine et al., 1992; Salmon et al., 2012b; Saada et al., 
2014) as well as the reported enrichment of sites of positive selection in the variable, extracellular 
region compared to the catalytic domain (Emes and Yang, 2008) are facts supporting the receptor 
hypothesis. Moreover, the extracellular domain displays homology to the superfamily of ‘Periplasmic 
binding protein-like I’ domains (analyzed by http://supfam.cs.bris.ac.uk/SUPERFAMILY/index.html). 
Interestingly, periplasmic binding proteins (PBP) function as primary receptors for a variety of ligands 
implicated in regulation of signal transduction, chemotaxis and metabolite transport systems in 
archaea, bacteria and eukaryotes (Munshi et al., 2013). Yet, no ligand binding to kinetoplastid ACs 
has been identified to date. The remarkable expansion of the AC family in extracellular African 
trypanosomes (T. brucei, T. congolense, T. vivax) in contrast to intracellularly developing related 
kinetoplastids (T. cruzi, Leishmania major) (Salmon et al., 2012b) indicates a link between AC 
diversity and exposure to the host immune system and hence points to a role for ACs in host-parasite 
interaction. Moreover, the large variety of ACs at the trypanosomal surface could be important for 
binding of diverse ligands in the different life cycle stages and host environments. This idea is 
supported by life cycle stage specific expression of several AC isoforms: whereas some ACs are 
predominantly expressed in BSFs, a recent study identified AC isoforms strongly up-regulated in 
PCFs (Saada et al., 2014). Interestingly, isoform-specific localization to distinct flagellar subdomains 
(along the flagellum or at the distal tip of the flagellum) has been observed for insect stage-specific 
ACs, thus enabling compartmentalization of cAMP signaling by initiation of independent downstream 
pathways. Since the flagellum and particularly the flagellar tip play an important role in the 
differentiation from epimastigote to infectious, metacyclic forms in the fly (Vickerman et al., 1988), 
microdomains of cAMP signaling involving specific AC isoforms might play a role in these 
differentiation processes. A putative role for specific AC isoforms in interaction of the parasite with 
defined tsetse fly environments is furthermore supported by the observed variation of the AC family 
expansion among tsetse-transmitted parasites: the complexity of development as well as the tissue 
distribution in the insect vector correlate with the size of the AC gene family, with T. vivax 
(developing in the fly mouthparts and foregut) showing the lowest, T. congolense (developing in the 
fly mouthparts, foregut and midgut) an intermediate and T. brucei (developing in the fly mouthparts, 
foregut, midgut and salivary glands) showing the largest number of AC genes (Saada et al., 2014).  
Perception of an extracellular ligand is also important for the density-dependent differentiation from 
the LS to the SS stage within the mammalian bloodstream (Reuner et al., 1997; Vassella et al., 1997) 
(see Introduction, chapter 1.2.3.1). Increase in the extracellular concentration of SIF, a molecule 
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thought to be excreted by the trypanosomes, is perceived by a quorum sensing-like mechanism 
(Reuner et al., 1997; MacGregor et al., 2011). Interestingly, a PBP domain is also found in the quorum 
sensing signal binding protein LuxP of Vibrio harveyi (Pappas et al., 2004). Could specific AC 
isoforms act as SIF receptors at the surface of T. brucei LS cells? The observed transient increase in 
the intracellular cAMP concentration by treatment of LS trypanosomes with conditioned medium 
containing SIF (Vassella et al., 1997) would support this hypothesis. Whether specific AC isoforms 
could indeed act as SIF receptors and whether trypanosomal ACs are able to bind ligands at all is yet 
an open question and should be subject of extensive future studies. 
Activation of trypanosomal ACs has so far only been observed upon membrane stress e.g. by acid 
treatment, osmotic lysis or attack by the host immune system (Voorheis and Martin, 1980; Rolin et al., 
1996; Nolan et al., 2000; Salmon et al., 2012b). Hence, trypanosomal ACs might act as sensors of 
general disturbances within the cell surface membrane, maybe via sensing the density of the VSG 
coat. This hypothesis fits well to the proposed involvement of ACs in regulation of cytokinesis 
(Salmon et al., 2012a). 
 
6.2 Unconventional upstream activation mechanism(s) of T. brucei PKA 
 
The activation mechanism of PKA by the second messenger cAMP is highly conserved in organisms 
ranging from primitive protozoa to humans. Hence, the discovery of a PKA orthologue in T. brucei 
with strong sequence conservation but complete insensitivity to cAMP came as an unexpected 
surprise. Intriguingly, there is evidence for the presence of an endogenous, nucleoside-related ligand, 
which may activate the parasite kinase via a mechanism similar to the conserved cAMP-dependent 
activation of other PKA orthologues. Moreover, in vivo kinase activity is induced upon exposure to 
low temperature by an as yet unknown mechanism. In this chapter, potential mechanisms of T. brucei 
PKA activation as well as a possible connection between cold shock and ligand-mediated activation 
will be discussed. 
 
6.2.1 No activation by cAMP – predictable from the primary amino acid sequence of 
T. brucei PKAR? 
 
All cAMP-binding proteins are characterized by the presence of a highly conserved cyclic nucleotide-
binding domain (CNB) harboring the phosphate-binding cassette (PBC), a module providing the key 
residues for cAMP interaction. Based on sequence comparison of PKAR orthologues from a large and 
evolutionary divergent set of eukaryotes ranging from protozoa such as Paramecium tetraurelia to 
humans, Canaves and Taylor (2002) derived a signature sequence capable of unequivocally 
identifying members of the PKAR family (F-G-E-[LIV]-A-L-[LIMV]-x(3)-[PV]-R-[ANQV]-A; x 
represents any amino acid) and distinguishing them from other cAMP-binding proteins. However, 
although the strong overall sequence conservation undoubtedly classifies the T. brucei PKAR 
orthologue as a member of the PKAR family, there are deviations from the proposed signature 
sequence of the PBC (G. Githure PhD thesis, 2014; chapter 4.1; T. brucei PBC-A: V-G-E-L-E-L-M-
Y-Q-T-P-T-V-A; PBC-B: V-G-E-L-E-F-L-N-N-H-A-N-V-A; residues shown in red deviate from the 
consensus signature sequence shown above). Most importantly, these deviations include an arginine, 
	  	   139	  
6. Discussion 
suggested to be invariant and required for interaction with the phosphate moiety of cAMP. Was the 
cAMP-insensitivity of T. brucei PKA predictable? Mutation of the conserved arginine in human 
PKAR or in the cyclic nucleotide regulated channels MlotiK1 (bacterial) and HCN2 (mammalian) 
results in significant reduction in cAMP affinity (Bubis et al., 1988; Tibbs et al., 1998; Kannan et al., 
2007; Zhou and Siegelbaum, 2007; Altieri et al., 2008). Thus, at most it could have been predicted that 
T. brucei PKAR might have a somewhat lower affinity to cAMP compared to PKAR orthologues from 
other organisms. Moreover, activation by cAMP is the identifying feature of a cAMP-dependent 
protein kinase. Proving the existence of a conserved PKA devoid of cAMP sensitivity necessitated 
several complementary, independent approaches. Strikingly, rendering the PBCs of T. brucei PKAR 
more similar to the proposed signature sequence by introducing only three mutations within each 
cassette (PBC-A: E311A, T318R, V319A; PBC-B: E435A, N442R, V443A) guided by structural 
modeling was sufficient to restore some cAMP sensitivity of the parasite PKA (G. Githure PhD thesis, 
2014). This mutated PKAR was not only recombinantly expressed for in vitro kinase assays but was 
also endogenously expressed in T. brucei. Several characteristics of this cell line (designated PKAR 
PBCmut) will be of great importance for the discussion of putative activation mechanisms of T. brucei 
PKA. 
 
6.2.2 Possible mechanisms of cold shock-induced PKA activation 
 
According to the Arrhenius equation, there is a positive correlation between the rate of an enzymatic 
reaction and the reaction temperature within a certain temperature range. In addition, each enzyme has 
a specific temperature optimum. Unexpectedly, in contrast to any other PKA orthologue characterized 
to date, T. brucei PKA is activated upon exposure to low temperature (see chapter 4.2), an important 
trigger in the parasite’s life cycle. In the absence of experimental data regarding the mechanism of 
cold shock activation of T. brucei PKA, only speculations can be drawn, mainly deduced from known 
mechanisms of cold shock perception and transduction in other organisms. The temperature-dependent 
activation of T. brucei PKA can either be based on the intrinsic property of the enzyme, i.e. 
temperature-dependent structural rearrangements influencing enzymatic activity, or on temperature-
dependent changes of upstream components of PKA signaling in T. brucei. In other words: is T. brucei 
PKA itself a temperature sensor? Or are there alternative temperature sensors, which mediate kinase 
activation upon exposure to low temperature? Most examples of cold-activated enzymes are found in 
plants, hibernating animals and cold-adapted psychrophilic and psychrotolerant (micro-)organisms. 
The higher enzymatic activity under cold conditions is an intrinsic property of many of these enzymes 
and is based on temperature-dependent structural rearrangements. Cold-induced conformational 
changes in T. brucei PKAC resulting in increased enzymatic activity, as observed for purified PKAC 
orthologues from several hibernating animals (Holden and Storey, 1998; MacDonald and Storey, 
1998; Holden and Storey, 2000), can be excluded, since in the absence of PKAR, no cold shock 
activation was observed in vivo (see chapter 4.2). However, structural changes in PKAR or the PKA 
holoenzyme upon exposure to cold conditions resulting in increased enzymatic activity would be a 
possible scenario. Biophysical methods for studying the thermal stability of proteins such as circular 
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dichroism, fluorescence spectroscopy or differential scanning calorimetry (He et al., 2013) will be 
used in future experiments to address this question.  
Assuming that T. brucei PKA itself is not a temperature sensor, a temperature-dependent upstream 
mechanism must be responsible for regulation of kinase activity. In plants, an increase in the 
cytoplasmic calcium concentration has been reported as an immediate (<1 minute) consequence of a 
temperature drop, presumably via cold-induced changes in membrane fluidity resulting in activation of 
calcium channels (Knight et al., 1991; Knight et al., 1996; Plieth et al., 1999; Martin and Busconi, 
2001). This observation has led to the hypothesis that calcium might act as second messenger in 
response to chilling and cold acclimation. The manifold, well-known examples of crosstalk between 
calcium and cAMP/PKA signaling (Bugrim, 1999; Bruce et al., 2003; Borodinsky and Spitzer, 2006; 
Howe, 2011) might also provide a link between cold shock, calcium and PKA activation in T. brucei. 
The high abundance of putative components of cAMP/PKA (e.g. ACs, PDEs, PKAR, PKAC and other 
putative cAMP-binding proteins) and calcium signaling (e.g. calflagins, calmodiluns, Ca2+-binding 
proteins, calpains, calcium channels) inside the trypanosomal flagellum (Broadhead et al., 2006; 
Oberholzer et al., 2007; Saada et al., 2014; Subota et al., 2014) suggests close proximity of at least 
parts of these signaling pathways. Moreover, the identification of several proteins with possible 
involvement in calcium signaling as putative substrates of T. brucei PKA (see Supplemental Material - 
Chapter 4.2, Table S1) supports the idea of crosstalk between these signaling pathways in 
trypanosomes. Adenylate cyclases are considered to be centers of highly organized microdomains of 
cAMP and calcium and hence represent a major interface for these two signaling pathways (Cooper 
and Tabbasum, 2014). As observed for many AC isoforms from a variety of organisms, T. brucei AC 
activity is induced by calcium (Voorheis and Martin, 1980, 1981). However, given the uncoupling of 
the parasite PKA from cAMP, an increase in the concentration of the second messenger will not result 
in direct PKA activation. Moreover, treatment of BSF trypanosomes with 300 µM CaCl2 did not affect 
in vivo PKA activity over a time course of 20 minutes at 37°C or 4°C (data not shown). Nevertheless, 
there could be alternative ways of crosstalk between calcium and PKA signaling. An approach 
involving measurement of intracellular calcium levels and simultaneous analysis of in vivo PKA 
activity upon exposure to low temperature will be appropriate to answer this open question. 
A temperature-dependent increase in the intracellular concentration of certain cations is also known to 
be mediated by receptors of the TRP (transient receptor potential) superfamily of cation channels, 
which are responsible for sensing a huge variety of environmental signals such as temperature or 
osmolarity in many evolutionary divergent organisms ranging from bacteria over unicellular 
eukaryotes such as Euglena gracilis or Chlamydomonas reinhardtii to mammals (Huang et al., 2007; 
Venkatachalam and Montell, 2007; Häder et al., 2009; Fujiu et al., 2011; Nilius and Owsianik, 2011). 
TRPs are characterized by six transmembrane domains (TMDs), which connect the intracellular N- 
and C-termini and form a pore between TMD5 and TMD6. In mammals, six different temperature-
activated TRP channels have been identified four of which are activated by heat (TRPV1-4) and two 
by cold (TRPM8 and TRPA1) (Dhaka et al., 2006). While their intrinsic thermodynamic properties are 
discussed to be directly responsible for gating, channel activity after the initial stimulation can be 
regulated by several other mechanisms e.g. by phosphorylation, as observed for the cold-stimulated 
mammalian TRPM8 receptor, which is regulated by PKA-mediated phosphorylation (De Petrocellis et 
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al., 2007; Bavencoffe et al., 2010). While two putative TRP homologues have recently been identified 
in kinetoplastids (Chenik et al., 2005) with one of them having a putative role in iron transport from 
the lysosome to the cytosol in T. brucei (Taylor et al., 2013), genes with significant similarity to the 
known mammalian temperature-activated TRP receptors are apparently absent from kinetoplastid 
genomes. However, due to the diversity between subfamilies of the large TRP superfamily as well as 
the diversity between TRP receptors of evolutionary divergent species, the presence of cold-activated 
TRP-like channels in trypanosomes is not excluded. 
Proteins bearing cold shock domains (CSDs) constitute a protein family involved in temperature 
sensing of many organisms. CSD-containing proteins, also called cold shock proteins (CSPs), have 
first been identified in bacteria (Horn et al., 2007) and are now being discovered in a growing number 
of eukaryotes ranging from yeast to humans (Mihailovich et al., 2010). The CSD represents a highly 
conserved nucleic acid-binding domain capable of interaction with DNA and RNA thereby enabling 
CSPs to regulate transcription, translation and RNA turnover. A BLAST search for sequences with 
homology to the CSD domain (Pfam PF00313) revealed four proteins encoded by the T. brucei 
TREU927 genome (www.tritrypdb.org) (TriTrypDB entries: Tb927.11.7900, Tb927.8.7820, 
Tb927.4.4520, Tb927.7.3810). However, an increase in PKA activity due to temperature-dependent 
transcriptional changes as shown for yeast and human PKA in hepatoblastoma cells (Ohsaka et al., 
2001; Sahara et al., 2002) can be excluded since maximal activation of T. brucei PKA is observed 
within minutes.  	  	  
6.2.3 Ligand-dependent activation of T. brucei PKA. 	  
6.2.3.1 Activation by a/several purine nucleoside-related endogenous ligand/s? 
 
The observation that T. brucei PKA was activated by dipyridamole in vivo via an indirect mechanism 
provided strong evidence for the presence of an endogenous, nucleoside-related ligand. Dipyridamole, 
a potent inhibitor of mammalian PDEs (Ghosh et al., 2009) with poor activity against trypanosomal 
PDEs (Rascon et al., 2002; Zoraghi and Seebeck, 2002), is known to significantly interfere with 
mammalian adenosine metabolism via several independent mechanisms (Pfleger et al., 1969; 
Klabunde, 1983; Gibbs and Lip, 1998) and has been shown to similarly block adenosine uptake in 
trypanosomes (James and Born, 1980; Al-Salabi et al., 2007). This raises that question whether purine 
nucleosides could be endogenous regulators of the parasite kinase. Trypanosomes, as most other 
protozoan parasites, are devoid of de novo purine synthesis and hence rely on salvage of purines from 
the mammalian host (Hammond and Gutteridge, 1984; de Koning et al., 2005). Notably, proteins with 
putative functions in nucleoside metabolism are significantly enriched in the proteome of the T. brucei 
flagellum (Broadhead et al., 2006; Zhou et al., 2010; Oberholzer et al., 2011; Subota et al., 2014), the 
predominant localization of the parasite PKA (C. Krumbholz PhD thesis, 2006; Oberholzer et al., 
2011; Subota et al., 2014). Moreover, we have identified adenosine derivatives (8-pCPT-adenosine, 8-
pCPT-2’O-me-adenosine), which block PKA activation via an as yet unknown, indirect mechanism 
(this study, data not shown; J. Pepperl Diploma thesis, 2007; G. Githure PhD thesis, 2014), possibly 
having an impact on nucleoside metabolism, thereby supporting the idea of an endogenous, 
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nucleoside-related ligand. Another interesting finding in this context is provided by the PBC mutant of 
T. brucei PKAR, which bears mutations in the PBC domains (see chapter 6.2.1): while the 
recombinantly expressed protein has gained some cAMP sensitivity in vitro (Ec50 20 µM) (G. Githure 
PhD thesis, 2014), the corresponding T. brucei cell line has lost activation by toyocamycin or 
dipyridamole in vivo (G. Githure PhD thesis, 2014 and data not shown). A small-scale chemical screen 
aiming to define the chemical space of putative ligands resulted in identification of several activating 
7-substituted adenosine derivatives with toyocamycin (7-cyano-7-deaza-adenosine) being the most 
potent compound in vivo (EC50 78 nM) (see chapter 4.1) and in vitro (EC50 183 nM) (G. Githure PhD 
thesis, 2014). A possible effect of the common nucleosides adenosine, guanosine and inosine on PKA 
activity was tested in vitro due to the poor membrane permeability of these molecules. The in vitro 
kinase assay showed that all three nucleosides directly activate the T. brucei R-C1 holoenzyme with 
different affinities (G. Githure PhD thesis, 2014). Taken together, these results indicate regulation of 
T. brucei PKA via binding of an intracellular purine nucleoside-related compound to PKAR. The very 
few amino acid deviations within the PBCs of T. brucei PKAR from orthologues of other organisms 
account for the replacement of cAMP as upstream activator by a purine nucleoside-related ligand. 
 
6.2.3.2 What could be the physiological relevance of the proposed nucleoside-dependent 
regulation of T. brucei PKA? 	  
The essential uptake of nucleosides and nucleobases from the environment is mediated by 
nucleoside/nucleobase transporters of the ENT (equilibrative nucleoside transporter) family some of 
which show life cycle stage-specific expression (de Koning et al., 2005; Jensen et al., 2009; Kabani et 
al., 2009; Ortiz et al., 2009; Queiroz et al., 2009; Urbaniak et al., 2012; Butter et al., 2013; Capewell et 
al., 2013; Jensen et al., 2014; Telleria et al., 2014; Vasquez et al., 2014). This may indicate stage-
specific availability of nucleosides/nucleobases and/or stage-specific requirements. Assuming that the 
parasite PKA, according to the in vitro observations, can also be regulated in vivo by several purine 
nucleosides (inosine, adenosine and guanosine) with different affinities, regulation of kinase activity 
dependent on nucleoside availability would be possible. Interestingly, as shown in Table 6.1, despite a 
comparable level of basal kinase activity in BSF and PCF trypanosomes, activation by cold shock, 
toyocamycin or dipyridamole is restricted to BSFs. This might be dependent on the presence of 
different R-C holoenzymes with distinct affinities to putative ligands in the specific life cycle stages.  
 
Table 6.1: Stage-specific characteristics of T. brucei PKA activity in vivo 
  BSF PCF 
basal activity 20-30% 20-30% 
activation by 
cold shock ✔ ✖ 
activation by 7-
deazapurines ✔ ✖ 
activation by 
dipyridamole ✔ ✖ 
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C1 expression 
level high 
no 
expression 
C2 expression 
level low high 
 
 
R-C1 is exclusively present in BSFs and is regulated by the aforementioned stimuli in vivo and in 
vitro. Lack of detectable kinase activation in PCFs, which show a high relative expression level of 
PKAC2, as well as in a BSF cell line with RNAi-mediated depletion of PKAC1, indicates that the R-
C2 holoenzyme might be refractory to the identified activators. These findings may indicate that R-C1 
and R-C2 indeed exhibit distinct characteristics not only in terms of expression during the parasite’s 
life cycle but also regarding their response to putative upstream regulators. Yet, the high sequence 
identity between C1 and C2 (94% at the protein level) with only few amino acid differences at the 
very N- and C-terminal ends (Bachmaier and Boshart, 2013) rather argues against an activation 
mechanism specific for R-C1. The low abundance of R-C2 holoenzymes in BSFs could well explain 
the lack of a visible increase in cold-induced substrate phosphorylation in PKAC1-depleted cells in 
vivo. Moreover, other putative life cycle stage-specific differences such as a stage-specific 
posttranslational modification of the regulatory and/or catalytic subunits could influence kinase 
inducibility. In fact, a recent study has shown that PKA subunit phosphorylation is strongly regulated 
between BSFs and PCFs (Urbaniak et al., 2013). Moreover, C1 but not C2 undergoes stumpy-specific 
phosphorylation (see chapter 4.2; S. Kramer PhD thesis, 2004) (albeit no functional role of this 
modification could be established yet). The question whether the observed differences in sensitivity to 
the identified regulators reflect distinct intrinsic properties of the R-C1 and R-C2 holoenzymes can be 
addressed by two complementary genetic approaches:  
1) generation of a T. brucei BSF cell line expressing C2 instead of C1; 
2) expression of C1 in procyclic stage trypanosomes. 
Several attempts to replace C1 by C2 in BSFs (in the C1 locus with C1 UTRs) have failed either 
indicating an essential C1-specific function or toxicity of higher levels of C2 in this life cycle stage, 
most likely dependent on the few amino acid differences between these two isoforms. Inducible 
expression of C1 in PCFs followed by analysis of sensitivity to the identified regulators of in vivo 
PKA activity will be the next step in this project. In vitro kinase assays with recombinantly expressed 
PKAR-C2 holoenzyme will complement the in vivo studies. 
It is well possible that sensitivity to the identified regulators might be dependent on both, holoenzyme 
composition and life cycle stage. In any case, the stage-specific properties of T. brucei PKA point 
towards distinct functions of the enzyme presumably at various stages of the parasite’s life cycle. The 
strong upregulation of C2 expression in PCFs combined with the significantly increased 
phosphorylation at four sites (which are unique to C2, i.e. not present in C1) compared to BSFs 
(Urbaniak et al., 2013) suggests an insect stage-specific, as yet unknown function of C2. Interestingly, 
two independent studies have recently identified C2 in the glycosomal proteome of PCFs (Güther et 
al., 2014; F. Bringaud, Bordeaux, personal communication). Glycosomes are peroxisome-like 
organelles mainly occupying metabolic enzymes and detoxification pathways. An additional role of 
this organelle in signal transduction is displayed by the presence of putative signaling proteins 
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including the protein serine/threonine phosphatase PIP39. Glycosomal localization of PIP39 has been 
shown to be essential for BSF to PCF differentiation (Szöör et al., 2010). 
 
6.2.3.3 Does T. brucei PKAR play a role in LS to SS differentiation? 	  
An interesting observation that supports the idea of a nucleoside-dependent regulation of T. brucei 
PKA is the putative involvement of PKAR in slender to stumpy differentiation. The hydrolysable 
cAMP derivatives 8-pCPT-(2’O-me-)cAMP as well as degradation products thereof, namely the 
respective 5’AMP and adenosine derivatives, can mimic the effect of SIF by inducing LS to SS 
differentiation (Vassella et al., 1997; Laxman et al., 2006) (see Introduction, chapter 1.2.3.1). 
Interestingly, a cell line with deletion of both alleles of PKAR showed increased resistance to 8-pCPT-
cAMP and 8-pCPT-(2’O-me-)adenosine compared to wild type cells (see chapter 4.1). Consistent with 
this, a recent whole-genome RNAi library screen selecting for cells resistant to these compounds and 
hence defective in stumpy formation, identified PKAR among several other proteins (Mony et al., 
2014). Although proof for a role of PKAR in this differentiation process is still missing, preliminary 
experiments showed that LS to SS differentiation was strongly impaired in a pleomorphic PKAR 
knock out mutant compared to wild type cells (data not shown). Even at high cell densities, several 
independent clones of the mutant cell line showed slender morphology and were devoid of PAD1 
expression (marker for stumpy stage; Dean et al., 2009). These experiments were however 
complicated by the reversion of this phenotype after a prolonged cultivation period, most likely due to 
secondary adaptations. Follow-up experiments to confirm the putative role of PKAR in LS to SS 
differentiation will be conducted with freshly transfected PKAR knock out cells as well as with PKAR 
RNAi cells. The putative involvement of PKA in LS to SS differentiation cannot (yet) be 
unambiguously assigned to one specific R-C holoenzyme. However, the low abundance of R-C2 in 
BSFs and the insensitivity of R-C3 to the stumpy-inducing compound 8-pCPT-adenosine (data not 
shown) render a role of these holoenzymes in LS to SS differentiation rather unlikely. Moreover, a 
pleomorphic cell line with inducible RNAi against C1/2 shows normal LS to SS differentiation at 
maximal C1/2 repression (no difference in the expression level of the stumpy marker PAD1 between 
wild type, uninduced and induced RNAi cell line; see chapter 4.2). These findings rather point to a C-
independent function of R in the signaling mechanism involved in regulation of LS to SS 
differentiation. Identification of putative PKAR-interacting proteins might be very useful for the 
discovery of other signaling components putatively involved in regulation of this differentiation step. 
 
6.2.4 Is there a physiological connection between cold shock- and purine nucleoside-
dependent PKA activation? 
 
T. brucei PKA activity is regulated by temperature and by purine nucleoside derivatives in vivo. 
Although there might be independent upstream signaling pathways eventually resulting in kinase 
induction, the perfect correlation between the results obtained from the in vivo PKA assays upon 
exposure to cold shock with the ones involving toyocamycin as regulator point to a connection 
between cold shock- and nucleoside-dependent activation (Table 6.2). 
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Table 6.2 Regulation of in vivo PKA activity in different T. brucei cell lines 
 activation by: 
  cold shock toyocamycin dipyridamole 
BSF wt ✔ ✔ ✔ 
BSF Rko ✖ ✖ ✖ 
BSF PKAR_PBCmut ✖ ✖ ✖ 
BSF C1/2 RNAi -Tet ✔ ✔ n.d. 
BSF C1/2 RNAi +Tet ✖ ✖ n.d. 
BSF C1_UTR_RNAi -Tet ✔ ✔ n.d. 
BSF C1_UTR_RNAi +Tet ✖ ✖ n.d. 
BSF C2ko ✔ ✔ n.d. 
BSF C3ko ✔ ✔ n.d. 
PCF wt ✖ ✖ ✖ 
 
 
One possibility for interconnection between the two upstream activating pathways would be 
temperature-dependent availability of the putative endogenous, nucleoside-related ligand(s), e.g. via a 
cold-sensitive enzyme producing the ligand(s) or via a cold-sensitive transporter responsible for 
uptake of a precursor of the ligand(s). Alternatively, cold shock might induce conformational changes 
in PKAR or the PKA holoenzyme resulting in altered affinity to the local concentration of the 
nucleoside-related ligand(s). The kinetics of PKA activation by cold shock with maximal activation 
after only two minutes rather argues for the latter hypothesis. Moreover, a preliminary experiment 
showed temperature-dependent changes in the affinity of recombinantly expressed and purified R-C1 
holoenzyme to adenosine in vitro (G. Githure PhD thesis, 2014).  
 
6.3 The special properties of the catalytic PKA isoform C3 
 
The catalytic isoform C3 differs in several aspects from C1 and C2: while C1 and C2 share 94% 
sequence identity and show inversely regulated expression during the trypanosomal life cycle, C3 is 
more divergent (only 59% and 58% identity to C1 and C2, respectively) and is expressed at 
comparable levels between slender, stumpy and procyclic trypanosomes. Moreover, the R-C3 
holoenzyme is refractory to any of the identified in vivo regulators (inducers as well as inhibitors!) of 
PKA activity (see chapter 4.2, figure 2; and unpublished observations). C3 accounts for ~75% of the 
basal in vivo PKA activity in BSFs (see chapter 4.2, figure 2), suggesting the presence of ‘free’ C3 
(i.e. not interacting with R). It is well known from several mammalian cell types as well as from other 
eukaryotes that free catalytic (as well as free regulatory) PKA subunits are more susceptible to 
proteolytic degradation than PKA subunits in the holoenzyme complex, consequently resulting in a 
rather tight co-regulation of R and C protein levels e.g. upon genetic perturbations (Amieux et al., 
1997; Burton et al., 1997; Park et al., 2000; Duncan et al., 2006; Kirschner et al., 2009). Consistent 
with the suggested occurrence of ‘free’ C3 in T. brucei, we observed co-regulation between R and 
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C1/2 but not between R and C3 in RNAi and knock out cell lines (see Supplemental Material - 
Chapter 4.1, figure S7D). Two additional observations point to the association of a fraction of C3 with 
an alternative binding partner (hereinafter referred to as ‘X’): knock out of PKAR resulted in complete 
loss of flagellar localization of C1/2, whereas a fraction of C3 remained localized to the flagellum. 
Moreover, detergent treatment resulted in complete solubilization of R and C1/2, but only in partial 
solubilization of C3 (C. Krumbholz, unpublished). Although it is completely open, whether the 
suggested alternative interaction partner of C3 exhibits PKAR-like properties regarding structure and 
function (i.e. regulator of C3), the putative X-C3 complex is certainly not responsive to cAMP nor to 
any of the identified regulators of in vivo PKA activity in T. brucei. Unfortunately, protein-protein-
interaction analysis based on tandem affinity purification (TAP) followed by mass spectrometry has so 
far only identified PKAR as interaction partner of C3 (G. Githure PhD thesis, 2014), possibly due to 
the apparent detergent resistance of X. BioID (proximity-dependent biotin identification), a recently 
established method for identification of proximal and interacting proteins (Roux et al., 2012), might be 
a particularly promising approach to identify rather insoluble interacting partners. This technique is 
based on inducible expression of a targeting protein fused to a promiscuous E. coli biotin protein 
ligase, which biotinylates proteins that are in close proximity to the fusion protein. Biotinylated 
proteins are affinity purified using a streptavidin matrix and subsequently analyzed by MS. Since 
biotinylation of nearby proteins occurs before solubilization, this method is equally well applicable for 
soluble and insoluble proteins. Detergents such as SDS and Triton-X100 can be added to the lysis 
buffer to ensure high solubilization efficiency. This method has already successfully been used for 
identification of novel protein-protein-interactions in T. brucei (Morriswood et al., 2013) and is 
currently being optimized and expanded in our laboratory with the aim to identify interacting partners 
of T. brucei cAMP response proteins (CARPs) (see discussion chapter 6.5). 
 
6.4 Downstream signaling of T. brucei PKA 
 
In mammalian cells, PKA regulates a number of different cellular processes such as metabolism, 
transcription, differentiation, and motility (Shabb, 2001). An involvement of PKA in control of 
differentiation (BSF to PCF, see chapter 4.2) and motility (C. Krumbholz PhD thesis, 2006; 
(Oberholzer et al., 2011)) was as well observed in T. brucei, yet the downstream components of the 
pathway involved in regulation of these processes are unknown. In order to identify downstream 
targets of PKA signaling in T. brucei as well as to determine additional physiological functions of the 
kinase, we applied transcriptome profiling (see chapter 4.1) and MS-based phosphoproteomics (see 
chapter 4.2). These studies revealed putative involvement in regulation of a number of cellular 
processes with a major focus on carbohydrate metabolism, transport, ribosome biogenesis and 
translation, and motility. Moreover, RNA-binding proteins were highly represented within the putative 
substrates directly phosphorylated by PKA. RNA-binding proteins play a major role in trypanosomal 
gene expression control (recent review: (Clayton, 2013)), which occurs exclusively at the 
posttranscriptional level (i.e. transcript stability, transcript processing and transport, and translational 
efficiency) owing to the virtual absence of regulation at the transcriptional level (Clayton, 2002; Haile 
and Papadopoulou, 2007). Phosphorylation of RNA-binding proteins by T. brucei PKA might also 
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account for the changes observed by RNAseq analysis upon activation of the kinase. Several of the 
putative physiological functions of T. brucei PKA are conserved in S. cerevisiae and humans such as 
regulation of carbohydrate metabolism, transport, or differentiation (Tash and Means, 1982; Brokaw, 
1987; Leclerc et al., 1996; Robertson et al., 2000; Shabb, 2001; Jones et al., 2003; Ptacek et al., 2005). 
However, a considerable number of putative downstream targets are kinetoplastid- or Trypanosoma-
specific with mostly unknown function and largely devoid of conserved functional domains, likely 
representing partially unique functions of the kinase in the evolutionary early branching kinetoplastid 
parasite.  
 
Candidate substrates acting as possible PKA downstream effectors in regulation of cold shock-induced 
BSF to PCF differentiation have already been discussed in chapter 4.2. The present chapter will focus 
on PKA substrates with a possible link to regulation of flagellar motility. A role of the parasite PKA in 
regulation of BSF motility has been first discovered in a PKAR knock out cell line (C. Krumbholz 
PhD thesis, 2006) and subsequently described in a cell line with down-regulation of PKAR by RNAi 
(Oberholzer et al., 2011). Since the same motility phenotype is found upon RNAi-mediated down-
regulation of PKAC1/2 (targeting both catalytic subunits simultaneously) or PKAC1 (targeting 
specifically the PKAC1 3’UTR) in BSFs and is absent from BSF PKAC2 or PKAC3 deletion mutants 
and from procyclic PKAR knock out cells (personal observations, not shown), the R-C1 holoenzyme is 
likely to be involved in motility control. An essential role of PKA in motility has also been observed 
in several other ciliated or flagellated eukaryotes: in addition to the well-established role of human 
PKA in regulation of sperm motility (Tash and Means, 1982; Brokaw, 1987; Leclerc et al., 1996), the 
kinase has been implicated in controlling locomotion of several protozoa including the slime mold 
Dictyostelium discoideum (Zhang et al., 2003) and the malaria parasite Plasmodium falciparum 
(Lasonder et al., 2012a; Lasonder et al., 2012b). T. brucei PKA substrate candidates with a putative or 
experimentally verified role in parasite motility are listed in Table S1 (Supplemental Material – 
Discussion, Table S1), and several interesting candidates are discussed in detail in the following. 
 
The axoneme, a bundle of microtubules (MTs) with nine outer doublet MTs surrounding a central pair 
of singlet MTs, represents a conserved structure of nearly all eukaryotic motile cilia and flagella. ATP-
dependent axonemal dynein heavy chains trigger flagellar bending by driving the sliding of the outer 
doublet MTs against one another eventually resulting in generation of the flagellar beat (Satir, 1995; 
Cosson, 1996). Mutation or deregulation of axonemal dyneins is linked to ciliary disease in humans, 
and consistently, a number of previous studies in T. brucei revealed motility defects upon down-
regulation or mutation of dyneins in BSFs and PCFs (Branche et al., 2006; Baron et al., 2007a; Baron 
et al., 2007b; Monnerat et al., 2009; Ralston et al., 2011; Springer et al., 2011; Zukas et al., 2012; 
Kisalu et al., 2014; Rotureau et al., 2014). The three dyneins (Tb11.02.0760; Tb927.3.930; 
Tb11.02.0030) identified as putative PKA substrates (Table S1) hence represent promising 
downstream candidates for regulation of motility. Interestingly, PKA-dependent regulation of 
axonemal dyneins has also been proposed in Paramecium (Walczak and Nelson, 1993) and in 
Chlamydomonas (Howard et al., 1994). The transport of components into and out of the flagellum is 
mainly accomplished by specific kinesins and dyneins, responsible for anterograde and retrograde 
transport, respectively, and intraflagellar transport proteins (IFTs). Since impairment of the transport 
	  	   148 
6. Discussion 
of proteins essential for flagellar motility is likely to result in motility defects, the three kinesins 
(Tb927.10.890; Tb927.10.12490; Tb927.10.14890) and the three IFTs (IFT172 (Tb927.10.1170); 
IFT88 (Tb11.55.0006); PIFTF6 (Tb11.03.0880)) identified as putative PKA substrates (Table S1) are 
candidates to be tested for a role in PKA-mediated motility control. Recently, members of the kinesin 
9 family have been shown to be important for proper motility in T. brucei BSFs (Demonchy et al., 
2009) and in Chlamydomonas (Yokoyama et al., 2004). 
Flagella of kinetoplastids, euglenoids and dinoflagellates differ from other eukaryotic flagella and cilia 
by the presence of the so-called paraflagellar rod (PFR), a lattice-like structure proximal to the 
axoneme (Cachon et al., 1988). The PFR is mainly composed of the two proteins PFR1 and PFR2 and 
is essential for parasite motility (Bastin et al., 1998; Bastin et al., 1999; Durand-Dubief et al., 2003). 
Moreover, several other proteins, designated paraflagellar rod components (PFCs) localize to this 
structure in T. brucei. PKA-dependent phosphorylation of PFR components represents a possible way 
of motility control. PFR1 and PFC1 have been identified as putative PKA substrates (Table S1), and 
future experiments will aim to analyze a role of these proteins in PKA-dependent motility control. 
The kinetoplastid-specific protein TbLRRP, whose depletion causes severe motility defects in PCFs, is 
putatively phosphorylated by PKA at three sites (Table S1), all of them predicted to be PKA 
phosphorylation sites (PTM prediction software NetPhosK; 
http://www.cbs.dtu.dk/services/NetPhosK/). TbLRRP has recently been shown to form a complex 
with Ran and RanBP (Brasseur et al., 2014) thereby possibly acting as RanGAP (Ran GTPase 
activating protein). Interestingly, Ran is known to be involved in regulation of ciliary protein targeting 
in various eukaryotes (Dishinger et al., 2010; Fan et al., 2011; Ludington et al., 2013). Intriguingly, 
the only Ran homologue of T. brucei (Tb927.3.1120) has also been identified by the PKA 
phosphoproteome screen (see Supplemental Material - Chapter 4.2, Table S1). It could either be 
directly phosphorylated by PKA (two RXXT sites in the primary amino acid sequence) or it could be 
co-precipitated with TbLRRP by the phospho-PKA substrate antibody. Co-precipitation is also one 
possible explanation for identification of proteins lacking RXXS/T sites in their primary amino acid 
sequence by immunoprecipitation with the anti-RXXS*/T* antibody. An alternative explanation may 
be provided by the findings of a recent study (Duarte et al., 2014), which revealed that 
phosphorylation motifs could also be formed by the secondary structure of a protein, hence adding 
even more complexity to the nature of signal transduction pathways. 
Further interesting candidate substrates of T. brucei PKA are homologues of calpain, casein kinase 1 
(CK1) and 14-3-3 protein, all of which are well-known substrates of human PKA (Table S1). Human 
calpain homologues function as MT-stabilizing proteins (calpain-6) (Tonami et al., 2007; Tonami et 
al., 2011) and are suggested to control cell motility (Wells et al., 2005). Casein kinase 1 (CK1) 
homologues are important for proper motility in the flagellated eukaryotes C. reinhardtii and 
Paramecium (Walczak and Nelson, 1993; Gokhale et al., 2009; Boesger et al., 2012). Down-
regulation of T. brucei 14-3-3 homologues results in motility defects of procyclic trypanosomes, and 
mammalian homologues play as well a role in regulation of cell motility.  
All these PKA substrate candidates with putative or experimentally verified functions in regulation of 
trypanosomal motility will be analyzed by reverse genetic approaches, i.e. RNAi-mediated down-
regulation and generation of phosphomutants, followed by detailed motility analyses. 
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6.5 A kinetoplastid-specific cAMP downstream pathway 
 
Initially, the discovery of a PKA completely uncoupled from cAMP came as an unexpected surprise, 
especially in the absence of any other known alternative cAMP downstream effectors in T. brucei. The 
identification of the putative, kinetoplastid-specific cAMP receptor protein CARP1 provided the 
missing piece in the puzzle (see chapter 3). Recent pull-down experiments with BSF lysates have 
indeed confirmed that CARP1 is able to bind cAMP coupled to agarose beads (Radoslaw 
Omelianczyk, Master thesis, 2014). CARP1 might represent a promising drug target due to the 
following aspects: 1) CARP1 is a kinetoplastid-specific protein without orthologues in any other 
known clade; 2) all attempts to generate homozygous deletion mutants of CARP1 failed indicating that 
it is essential for T. brucei (note that upon RNAi-mediated repression of CARP1, the expression level 
was reduced by only two-fold (see chapter 3) and hence might correlate with the amount required for 
parasite survival); 3) CARP1 bears known ligand-binding domains, the cNMP-binding domains, 
which differ significantly from mammalian cNMP-binding domain-containing proteins and hence 
provide an excellent target structure for designing and developing specific inhibitors. Since genes 
encoding CARP1 orthologues are found in all kinetoplastid genomes sequenced to date, a drug with 
the potential of curing HAT by specifically interfering with T. brucei CARP1 might also be effective 
against Chagas disease and Leishmaniasis caused by T. cruzi and Leishmania spp., respectively.  
Interaction studies by yeast two-hybrid (Y2H) analysis revealed direct interaction of CARP2 with 
CARP4 and CARP5, as well as interaction of CARP4 with CARP2 and CARP6 in a complex 
(unpublished observations, Ana Brennand, this lab). (Note that CARP5 (Tb927.10.12390) and CARP6 
(Tb927.10.1740) are not published yet; these proteins were identified by RITseq analysis of the cell 
line resistant to elevated levels of CpdA (see chapter 3) after publication of CARP1-4 in Gould et al., 
2013). Interestingly, no significant interaction of the primary cAMP receptor CARP1 with CARP2-6 
has been detected by the Y2H analysis. However, technical limitations of Y2H assays resulting in 
false-negative results cannot be excluded. Since the whole genome RNAi library screen conducted to 
identify T. brucei CARPs is limited to identification of proteins, which are non-essential at the level of 
induced RNAi-mediated repression, the existence of additional primary cAMP receptor proteins in T. 
brucei is well possible. CARP1-6 have been identified as putative cAMP downstream signaling 
components in BSFs, but with the recent discovery of PCF-specific adenylate cyclases (Saada et al., 
2014) and the essential role of a subset of these ACs for social motility (Lopez et al., 2014) additional, 
insect stage-specific cAMP receptors become possible. It will be highly interesting to find out whether 
CARP1 also functions as cAMP receptor protein in insect stages and whether it might be required for 
development within the tsetse vector. This hypothesis will be addressed by generation of procyclic 
cAMP-binding site mutants of CARP1 and CARP1 RNAi cell lines, which will be fed to tsetse flies 
followed by analysis of their ability to differentiate into subsequent life cycle stages. In parallel, 
cAMP binding of CARP1 will be analyzed by pull-down assays with cAMP coupled to agarose beads. 
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6.6 Evolutionary conservation of the unconventional cAMP and PKA signal 
transduction pathways within kinetoplastids? 
 
Most of the discovered peculiarities of the cAMP and PKA signal transduction pathways in T. brucei 
seem to be conserved in other kinetoplastids. The existence of unconventional ACs and the absence of 
GPCRs and heterotrimeric G-proteins are common kinetoplastid characteristics. The sequence 
deviations of the CNB domains of T. brucei PKAR from the highly conserved signature sequence are 
also found in PKAR orthologues of T. cruzi and L. donovani (see chapter 4.1) indicating that 
uncoupling of PKA from cAMP might be conserved within kinetoplastids. This fits perfectly into a 
model in which the kinetoplastid-specific protein CARP1 has replaced the cAMP receptor function of 
PKA within the evolutionary early branching kinetoplastid order. Like CARP1, PKA represents an 
ideal drug target due to its essentiality and its cNMP-binding domains that significantly differ from 
mammalian cNMP-binding domain-containing proteins. Moreover, the discovery of toyocamycin as 
high-affinity ligand that activates the kinase in the lower nanomolar range in vivo offers a good 
starting point for anti-trypanosomal drug development. 
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Figure S1A: Sequence comparison of PKAC orthologues. Homo sapiens (Hs_PKACalpha, accession P17612), Plasmodium falciparum 
(Pf_PKAC, accession Q7K6A0), Toxoplasma gondii (Tg_PKAC, accession S7UXF9) and Trypanosoma brucei (Tb_PKAC1, accession 
Tb427tmp.211.2410; Tb_PKAC2, accession Tb427tmp.211.2360; Tb_PKAC3, accession Tb427.10.13010) PKAC sequences were obtained 
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from Uniprot (www.uniprot.org) or TriTrypDB (www.tritrypdb.org), respectively. Multiple sequence alignment was performed using 
clustalW (www.ebi.ac.uk/Tools/msa/clustalW2/) with standard settings. Important domains are boxed by different colors. The A-helix, which 
is conserved in PKAs of higher eukaryotes, is boxed in green. The 11 canonical kinase subdomains are boxed in red. The highly conserved 
(auto-)phosphorylation site in the kinase activation loop is indicated by a blue arrow. Phosphorylation sites identified by mass spectrometry 
(Seidler et al., 2009 for the mammalian Cα; Nett et al., 2009 and Urbaniak et al., 2013 for TbPKACs) are highlighted in light blue, the N-
terminal myristoylation site of human PKACalpha is shown in orange. Residues important for R-C interaction (Kim et al., 2005; Kim et al., 
2007) are marked by red asterisks. 
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Figure S1B: Sequence comparison of PKAR orthologues. Homo sapiens (Hs_PKARI alpha, accession P10644; Hs_PKARII alpha, accession P13861), 
Dictyostelium discoideum (Dd_PKAR, accession P05987), Plasmodium falciparum (Pf_PKAR, accession Q8T323), Toxoplasma gondii (Tg_PKAR, 
accession Q9BMY7), Candida albicans (Ca_PKAR, accession Q9HEW1), Trypanosoma brucei (Tb_PKAR, accession Tb427tmp.02.2210), Trypanosoma 
cruzi (Tc_PKAR, accession TcCLB.506227.150) and Leishmania donovani (Ld_PKAR, accession LdBPK_130160.1) PKAR sequences were obtained from 
UniProt (www.uniprot.org) or TriTrypDB (www.tritrypdb.org), respectively. Multiple sequence alignment was performed using clustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2/) with standard settings. Important domains are highlighted by different colors. The elongated N-terminus of 
kinetoplastid PKAR proteins is highlighted in blue, the leucin-rich repeat (LRR) region in yellow. The dimerization / docking (DD) domain of PKAR 
proteins of higher eukaryotes, which is responsible for PKAR dimerization and for interaction with anchoring proteins, is colored in orange. The inhibitor 
site, which enables discrimination between type I and type II PKAR proteins in mammalian cells, is shown in green. The cyclic nucleotide binding (CNB) 
domains A and B including their phosphate binding cassettes (PBC) are highlighted in red. 
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Figure S2: Specificity of the T. brucei anti-PKAC antibodies. 
The anti-PKAC1/2 and anti-PKAC3 antibodies specifically recognize the respective T. brucei PKA 
catalytic subunits. T. brucei PKAC1, PKAC2 or PKAC3 were transiently expressed in human 293 cells as 
GST-tagged fusion proteins. 10 µg of soluble protein was separated by SDS PAGE, transferred to a 
nitrocellulose membrane and detected with the anti-PKAC1/2 (left) or anti-PKAC3 antibodies (right). Cells 
transfected with the empty vector (PSCTEV3s) were included as control. 
 
 
 
 
 
 
 
 
 
 
 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mo
ck
PSC
Tα
PSC
Tβ
PSC
Tγ
45
31
21.5
kDa m
ockPSC
Tα
PSC
Tβ
PSC
Tγ
anti-PKAC1/2
anti-PKAC3
	  	   165	  
Supplemental Material – Chapter 4.1 
 
 
 
A
B
Ty1-PKAC1*
Ty1-PKAC1
PKAC1*
PKAC1/
HA-PKAC2
PKAC1*
PKAC1
PKAC2
Ty1-PKAC3
PKAC3
PKAR-Ty1
PKAR
Ty
1-
PK
A
C
1
H
A
-P
K
A
C
2
Ty
1-
PK
A
C
3
PK
A
R
-T
y1
 cell line
anti-PKAR
anti-Ty1
anti-PKAC3
anti-Ty1
anti-PKAC1/2
anti-HA
anti-PKAC1/2
anti-Ty1
PKAC2
C
anti-PKAC1/2
anti-Ty1
anti-PKAR
anti-Ty1
anti-PKAC1/2
anti-HA
goat anti-rabbit
goat anti-mouse
 cell line and immunoprecipitate
goat anti-rabbit goat anti-mouse
64
50
36
[kDa]
anti-PKAC3
anti-Ty1
64
50
36
64
50
36
64
50
36
Ty
1-
PK
A
C
1
H
A
-P
K
A
C
2
Ty
1-
PK
A
C
3
PK
A
R
-T
y1
wt Ty1
-PK
AC
3
anti-PKAC3
anti-Hsp60
wt PK
AR
-Ty
1
anti-PKAR
anti-Hsp60
10x 2.6x
	  	   166	  
Supplemental Material – Chapter 4.1 
	  
Figure S3: T. brucei PKAR interacts with all three different catalytic isoforms in cell lines with 
independently tagged PKA subunits. 
A. Western blot analysis of T. brucei cell lines with expression of epitope-tagged PKA subunits. PKAC1 
and PKAC2 were in situ tagged with a Ty1- or HA-epitope tag, respectively, whereas PKAC3 and PKAR 
were ectopically overexpressed as Ty1-tag fusions. The Western blots were probed with the respective 
PKA subunit antibody (anti-PKAR: Bachmaier et al., submitted manuscript; see chapter 5) as well as with 
anti-Ty1 (Ty1-PKAC1, Ty1-PKAC3, PKAR-Ty1) or anti-HA (HA-PKAC2), respectively. Epitope tagged 
PKA subunits appear yellow in the merged image due to color blending. Note that the band shift due to the 
Ty1-epitope tag merges with the upper band of PKAC1, which is marked by an asterisk (*).  
B. Western blot analysis of T. brucei cell lines with overexpression of Ty1-PKAC3 or PKAR-Ty1, 
respectively. Immunodetection was performed with anti-PKAC3 or anti-PKAR (Bachmaier et al., 
submitted manuscript; see chapter 5), respectively, as well as with anti-HSP60 (Bringaud et al., 1995) for 
normalization. The quantification after normalization is given as fold increase compared to wild type cells 
(wt) (set to 1). 
C. Ty1-PKAC1, HA-PKAC2, Ty1-PKAC3 and PKAR-Ty1 were immunoprecipitated with the epitope tag 
antibodies anti-Ty1 or anti-HA. The precipitates were analyzed on four parallel blots, and each blot was 
probed with a different PKA antibody together with the respective epitope tag antibody, as indicated. Each 
Western blot is shown three times, with both secondary antibodies (left), with Alexa Fluor® 680 goat anti-
rabbit (red, center), and with IRDye 800CW goat anti-mouse (green, right). Note that the latter antibody 
also recognizes the heavy chain of anti-HA IgG (white dashed square), since anti-HA was not cross-linked 
to the sepharose beads.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   167	  
Supplemental Material – Chapter 4.1 
 
 
 
Figure S4: Kinase activity in response to cyclic nucleotides. 
A. In vitro kinase assays analyzing phosphorylation of the PKA-specific substrate kemptide by 
immunoprecipitated Ty1-PKAC1 (two independent clones (#1, #2)) or a kinase dead mutant (Ty1-PKAC1-
dead; N165->A; three independent clones (#11, #12, #14)) in the presence or absence of 5 µM PKI(5-24). 
Immunoprecipitate from wild type cells was included as negative control (control). Each assay (except the 
ones with PKI) was performed in triplicate. Standard deviations are indicated by error bars. The Western 
blot shows the precipitated amount of PKAR and PKAC1 of the clones analyzed in the kinase assay. It was 
probed with anti-PKAR (Bachmaier et al., submitted manuscript; see chapter 5), anti-PKAC1/2 and anti-
Ty1 (Bastin et al., 1996).  
B. In vitro kinase assays analyzing kemptide phosphorylation by the PKA holoenzyme immunoprecipitated 
via Ty1-PKAC1 in the presence or absence of different cyclic nucleotides (1 mM). Each assay (except the 
ones with PKI) was performed in triplicate. Standard deviations are indicated by error bars. (cXMP: 
xanthosine-3’,5’-cyclic monophosphate; cIMP: inosine-3’,5’-cyclic monophosphate; cCMP: cytidine-3’,5’-
cyclic monophosphate; cUMP: uridine -3’,5’-cyclic monophosphate). 
C. In vitro kinase assay analyzing the EC50 of cGMP for kemptide phosphorylation by immunoprecipitated 
PKA. Immunoprecipitation was done via PKAR-Ty1 using the anti-Ty1 antibody coupled to sepharose 
beads. Each assay was performed in triplicate. Standard deviations are indicated by error bars. 
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Figure S5: VASP phosphorylation is independent of the selectable marker. 
VASP phosphorylation was analyzed in the cell lines VASP[BSD] and VASP[PAC] in the presence or 
absence of myr-PKI(14-22). In the cell line VASP[BSD], reporter substrate phosphorylation was analyzed 
in a time course over 20 min after addition of 100 µM myr-PKI(14-22), whereas in the cell line 
VASP[PAC], substrate phosphorylation was only analyzed at time points zero and 25 min after addition of 
200 µM myr-PKI(14-22). The values of VASP phosphorylation given in percentage indicate the mean of 
three independent biological replicates represented by the Western blots. 
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Figure S6: T. brucei PKA is not activated by cAMP in vivo. 
A. Western blots corresponding to the quantification shown in Figure 4B. VASP phosphorylation was 
analyzed in the presence of 10 µM CpdA or the solvent DMSO (1%) over 15 min. Untreated cells were 
included as control. The three Western blots (blot 1-3) represent three independent biological replicates. 
B. Western blots corresponding to the quantification shown in Figure 4C, lower panel. VASP 
phosphorylation was investigated in a cell line with inducible RNAi targeting PDEB1 and PDEB2 in a time 
course over 24 h. Since the reporter substrate was expressed as Tet-inducible version, no signal was 
detected at time point zero. The parental cell line without RNAi against PDEB1 and PDEB2 was included 
as control. The three Western blots (blot 1-3) represent three independent biological replicates. 
C. Dose-response analysis of VASP phosphorylation upon incubation with the PDE inhibitor CpdA for 15 
min. The three Western blots (blot 1-3) represent three independent biological replicates and were used for 
the quantification shown in the chart; error bars represent SD. 
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Figure S7: Western and Southern blot analyses of PKA mutants. 
A. Expression of PKAR and PKAC1/2 in cell lines with inducible RNAi against PKAC1/2 (left) or PKAR 
(right). Two clones of each RNAi cell line were analyzed. Samples were taken at time points 0, 4, 8, 12 and 
24 h from the non-induced control (-Tet) or after induction of RNAi by addition of 1 µg/ml tetracycline 
(+Tet). Detection of Hsp60 served as normalization control. 
B. Southern blot confirming the replacement of one PKAC1 allele by a blasticidin resistance cassette. 
Genomic DNA of wild type cells (wt) or a hemizygous deletion mutant of PKAC1 (PKAC1-/+) was 
digested with SmaI, separated on an agarose gel, transferred to a nylon membrane and probed with a 
digoxigenine labeled probe against the C-terminus of PRP8, the gene upstream of PKAC1. The expected 
DNA fragment sizes are: 3347 bp for wt and 3766 bp for PKAC1-/+. Restriction maps are shown for the wt 
and the ∆PKAC1BSD locus. The two lanes marked with an asterisk (*) correspond to samples not related 
to this work. 
C. Southern blot analyses of hemizygous and homozygous deletion mutants of PKAC2. Genomic DNA of 
wild type cells (wt) and PKAC2 deletion mutants (C2-/+, C2-/-) was digested with the indicated enzymes, 
separated on agarose gels and blotted to nylon membranes. The blots were probed with digoxigenine 
labeled MCP3 (upper blot) or PKAC1/2 (lower blot) probes. MCP3 is the gene upstream of PKAC2. It was 
used to enable the detection of the PKAC2 replacement fragments. The PKAC1/2 probe detects both 
PKAC1 and PKAC2 but not the deleted PKAC2 allele. It was used to prove absence of additional PKAC2 
alleles. Restriction maps are shown for the wt, ∆PKAC2HYG and ∆PKAC2NEO locus. Sizes of the 
expected DNA fragments are indicated. 
D. Co-regulation of PKA subunit expression. Signals corresponding to PKAR, PKAC1/2 and PKAC3 were 
quantified from Western blots of PKAR RNAi clones (Western blots shown in S7A and Western blots from 
additional clones not shown) and the PKAR deletion mutant (Western blot shown in S7C and additional 
Western blots not shown). The correlation between PKAR expression (x-axis; given in percentage) and 
PKAC1/2 or PKAC3 expression (y-axis; given in percentage), respectively, is depicted in the diagram. The 
correlation coefficient (r) and the coefficient of determination (R2) are given for each graph. 
E. Western blot showing the expression of PKAR and PKAC1/2 in a homozygous deletion mutant of 
PKAR (PKAR-/-) compared to wild type cells (wt). Expression levels normalized on PFR-A/C detected by 
the monoclonal antibody L13D6 (Kohl et al., 1999) are given as percentage of wild type (wt) levels. 
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Figure S8: Growth and cell cycle analysis of additional clones of the cell lines PKAC1/2 RNAi and 
PKAR RNAi. 
A. Growth analysis of cell lines with inducible RNAi against PKAC1/2 or PKAR in the presence or absence 
of 1 µg/ml tetracycline (Tet). Cells were counted at the indicated time points and diluted if necessary to 
keep the cell density below 1×106/ml. The y-axes represent the log10 of the cumulative cell densities.  
B. Cell cycle analysis by counting the number of kinetoplasts (K) and nuclei (N) per cell in wild type cells 
(wt) and cell lines with inducible RNAi against PKAC1/2 or PKAR in a time course of 10 hours after 
induction with 1 µg/ml tetracycline (Tet). The K/N configurations of wild type cells are represented by 
dashed lines, since they were analyzed only at one time point. A minimum of 100 cells of each cell line was 
analyzed at the indicated time points.  
C. Representative microscopic images showing typical 1K1N, 2K1N, and 2K2N configurations in wild 
type cells as well as typical 2K2N and multinucleated cells of the cell lines PKAC1/2 RNAi and PKAR 
RNAi after induction with 1 µg/ml tetracycline for 8 h. 
 
 
 
 
 
 
 
 
Figure S9: Non-overlapping RNAi against T. brucei PKAR targeting a C-terminal fragment of the 
ORF and part of the 3’UTR. 
A. Western blot analysis of a cell line with inducible RNAi against PKAR revealed efficient repression of 
the PKAR protein (given in percentage) after 24 h of induction with 1 µg/ml tetracycline (+Tet) compared 
to non-induced cells (-Tet). Four independent clones (clones 1-4) were analyzed, and detection of PFR-A/C 
by the monoclonal antibody L13D6 (Kohl et al., 1999) served as normalization control. 
B. Growth of four independent clones (#1, #2, #3, #4) of a cell line with inducible RNAi against PKAR was 
analyzed over a time course of 120 h in the presence (+Tet) or absence (-Tet) of 1 µg/ml tetracycline. The 
y-axis represents the log10 of the cumulative cell density. 
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Figure S10: Specific activation of T. brucei PKA by dipyridamole in vivo. 
A. Western blots corresponding to the quantification shown in Figure 6B. VASP phosphorylation was analyzed over 15 min in the presence of 100 µM dipyridamole or 
1% DMSO (solvent control). Untreated cells were included as control. The three Western blots (blot 1-3) represent three independent biological replicates.  
B. Dose-Response analysis of VASP phosphorylation upon incubation with dipyridamole for 15 min. The three Western blots (blot 1-3) represent three independent 
biological replicates and were used for the quantification shown in the chart; error bars represent SD. 
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C. Inhibition of dipyridamole-induced PKA activation by treatment with 100 µM myr-PKI(14-22). VASP phosphorylation was determined upon incubation with or 
without 100 µM myr-PKI(14-22) for 10 min followed by addition of 100 µM dipyridamole. Samples were taken at the indicated time points. The three Western blots 
(blot 1-3) shown below the graph represent three independent biological replicates of cells treated with myr-PKI(14-22) and dipyridamole. The Western blots with the 
samples of the cells treated with dipyridamole only are shown in (A) (the samples taken after 2 min are not shown). Error bars represent SD.  
D. Dipyridamole-induced PKA activation is dependent on PKAR. VASP phosphorylation was investigated in wild type, PKAR-/- and PKAR-/+ (endogenous rescue) cells 
in the presence of 100 µM dipyridamole or 1% DMSO (solvent control) or without treatment (negative control). Samples were taken after 10 min of incubation. Error 
bars represent SD of three independent biological replicates corresponding to the three Western blots shown. 
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Figure S11: An in vivo small-scale screen identifies regulators of PKA activity in T. brucei.  
The incubation time in all dose-response experiments was 15 min. Error bars represent SD of three 
independent biological replicates corresponding to the three Western blots shown for each experiment. For 
all compounds dissolved in DMSO, the untreated control is shown in the graphs as red dot. 
A. Dose-response analysis of VASP phosphorylation upon incubation with 8-pCPT-adenosine or 8-pCPT-
2’O-me-adenosine.  
B. Dose-response analysis of VASP phosphorylation upon incubation with 8-pCPT-adenine.  
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Figure S11: An in vivo small-scale screen identifies regulators of PKA activity in T. brucei. 
C. Dose-response analysis of VASP phosphorylation upon incubation with the nucleoside derivatives 8-
pCPT-guanosine, 2-Cl-adenosine, 8-Br-adenosine, or 6-Cl-purine riboside (6-Cl-PuR).  
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Figure S11: An in vivo small-scale screen identifies regulators of PKA activity in T. brucei. 
D. Dose-response analysis of VASP phosphorylation upon incubation with the cAMP or cGMP derivatives 
8-pCPT-cAMP, 8-pCPT-2’O-me-cAMP, 8-pCPT-cGMP, 8-pCPT-2’O-me-cGMP, cAMP-AM, or cGMP-
GM. 
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Figure S11: An in vivo small-scale screen identifies regulators of PKA activity in T. brucei. 
E. Dose-response analysis of VASP phosphorylation upon incubation with high concentrations of 8-pCPT-
cAMP or 8-pCPT-cGMP.  
F. Dose-response analysis of VASP phosphorylation upon incubation with the 7-deazapurine derivatives 
toyocamycin, 5-I-tubercidin, 5-Br-tubercidin, or sangivamycin.  
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Figure S11: An in vivo small-scale screen identifies regulators of PKA activity in T. brucei. 
G. Analysis of VASP phosphorylation in wild type cells or a homozygous deletion mutant of PKAR 
(PKAR-/-) in the presence of 250 nM toyocamycin or 1% DMSO (solvent control) over 30 min.  
H. Dose-response analysis of VASP phosphorylation upon incubation with tubercidin or 6-Br-tubercidin. 
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Figure S12: In vitro kinase assays with the identified in vivo regulators of T. brucei PKA. 
A. T. brucei PKAR-10xHis and Strep-PKAC1 were recombinantly co-expressed using the L. tarentolae expression system (LEXSY). The holoenzyme was purified 
via His- and Strep-tag purification and subsequently used for in vitro kinase assays using kemptide as substrate.  
B. Kemptide phosphorylation in the presence of dipyridamole (at the indicated concentrations) or 5 µM toyocamycin (positive control). Data points represent the 
average of two determinations, and error bars represent the range. 
C. Kemptide phosphorylation was analyzed in dose-response experiments upon incubation with toyocamycin, 5-I-tubercidin, 5-Br-tubercidin, sangivamycin, 
tubercidin or 6-Br-tubercidin. Data points are the average of two determinations, and error bars represent the range. This is a representative data set of at least two 
independent assays. The calculated EC50 values (Graphpad Prism 6.0) are shown in Table 2.  
D. Kemptide phosphorylation in the presence of 200 µM toyocamycin (corresponds to the EC50 concentration) and increasing concentrations of 8-pCPT-2’O-me-
adenosine as indicated. The activity of the holoenzyme without compound treatment (nt) was included as control. Data points represent the average of two 
determinations, and error bars represent the range. 
E. The human PKARIα holoenzyme complex (6xHis-PKAR and Strep-PKACα) was co−expressed in E. coli and co-purified similarly to T. brucei PKA in A. In 
vitro kinase assays were performed in the presence of the indicated concentrations of toyocamycin. The activity of the holoenzyme upon treatment with 10 µM 
cAMP or without compound treatment (nt), respectively, was included as control. Data points represent the average of two determinations, and error bars represent 
the range. 
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Figure S13: Increase in PKA-specific phosphorylations upon treatment with toyocamycin. 
Western blot analysis of lysates from VASP expressing T. brucei wild type (VASP) or PKAR-/- cells 
(PKAR-/- VASP) treated or not with 2 µM toyocamycin for 10 min. Proteins phosphorylated at RXXS/T 
motifs were detected by a Phospho-PKA substrate antibody (anti-RXXS*/T*; * = phosphorylation). The 
band corresponding to the size of the transgenically expressed PKA reporter substrate VASP is marked by 
a blue arrowhead. The monoclonal antibody L13D6 (Kohl et al., 1999) was used for detection of PFR-A/C 
as loading control. 
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Figure S14: Scatter plot representing the RNAseq analysis of toyocamycin-treated wild type and 
PKAR knock out cells. 
The logarithmic ratio of the fold change of transcripts detected in wild type (wt) cells versus the fold 
change in the PKAR deletion mutant was plotted against the p-value in wild type cells. The following 
selection criteria were applied: p-value wt < 0.05; fold change wt > 1.75; fold change wt / fold change 
PKAR-/- >1; < 2 changes in direction in both cell lines over the time course from 0 h to 8 h. Grey dots 
represent transcripts not matching these criteria, while transcripts matching these criteria are shown by 
black dots. Transcripts chosen for independent expression analysis by qRT-PCR are depicted by black 
dots encircled in red. The gene IDs (as TriTrypDB entries; www.tritrypdb.org) or annotated/predicted 
gene products are given for a selection of the transcripts matching the selectivity criteria. 
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Figure S15: Validation of the RNAseq analysis by qRT-PCR. 
A. Four transcripts (phosphatidic acid phosphatase (PAP; Tb927.8.480), procyclin associated gene 1 
(PAG1; Tb927.10.10240), glycerol kinase 1 (GLK1; cluster of five nearly identical genes: 
Tb927.9.12550, Tb927.9.12570, Tb927.9.12590, Tb927.9.12610, Tb927.9.12630), and a hypothetical 
protein (HYP; Tb927.8.490)) matching the arbitrary defined selectivity criteria were chosen for 
independent expression analysis by qRT-PCR (highlighted in red in the scatter plot in Figure S14). RNA 
was extracted from wild type cells (wt) and the PKAR deletion mutant (PKAR-/-) treated or not with 
toyocamycin for 8 h. Relative expression normalized to TERT as reference gene (Brenndoerfer et al., 
2010) and the wild type cell line is given with standard error (SEM) of three biological replicates.  
B. Relative expression of the four transcripts chosen for the analysis shown in (A) revealed by the 
RNAseq study. Transcripts were normalized to the level in untreated wild type cells. 
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Table S1: Results of the RNAseq analysis: genes significantly regulated in wild type (wt) cells but not in the PKAR deletion mutant (PKAR-/-) upon toyocamycin 
treatment in a time course over 8 h. 
 
gene product wt 0 h wt 0.5 h wt 1 h wt 4 h wt 8 h 
PKAR-
/- 
0 h 
PKAR-
/- 
0.5 h 
PKAR-
/- 
1 h 
PKAR-
/- 
4 h 
PKAR-
/- 
8 h 
p-value 
wt 
fold 
change 
wt 
fold 
change 
PKAR-
/- 
fold 
change 
wt/ fold 
change 
PKAR-/- 
Tb927.1.2480 hypothetical protein, unlikely 27 8 1 15 24 44 33 26 30 47 0,0110 27,21 1,77 15,34 
Tb927.1.2460 hypothetical protein, unlikely 22 1 4 21 33 20 24 32 31 61 0,0089 33,45 3,05 10,95 
Tb927.2.1350 
retrotransposon hot spot protein 
(RHS, pseudogene), 
putative,retrotransposon hot spot 
protein 1 (RHS1), interrupted 
5 26 56 150 77 8 8 20 33 29 0,0000 31,22 4,14 7,53 
Tb7.NT.91   14 5 1 20 22 10 10 5 12 15 0,0000 21,64 3,14 6,90 
Tb927.8.480 phosphatidic acid phosphatase protein, putative 364 565 636 1460 3030 2712 3540 2889 2962 2919 0,0000 8,32 1,31 6,38 
Tb8.NT.2   25 66 66 147 205 100 120 123 126 189 0,0000 8,25 1,89 4,36 
Tb927.1.3200 SGT1-like protein, putative 14 54 116 164 110 30 35 61 84 60 0,0000 12,09 2,80 4,32 
Tb2.NT.37   17 79 116 51 44 28 34 45 41 37 0,0012 6,87 1,62 4,23 
Tb927.11.17820_1 expression site-associated gene 3 (ESAG3), degenerate 2 29 36 49 50 4 12 10 22 30 0,0000 31,35 7,43 4,22 
Tb3.NT.41   20 64 149 280 152 24 40 51 81 72 0,0000 14,01 3,36 4,17 
Tb927.8.490 hypothetical protein 73 47 35 130 202 166 164 153 119 142 0,0000 5,73 1,39 4,12 
Tb927.9.12590 glycerol kinase, glycosomal (glk1) 17 93 171 149 101 38 57 83 110 82 0,0000 10,15 2,91 3,49 
Tb927.10.10240 procyclin-associated gene 1 (PAG1) protein (PAG1) 50 33 48 128 153 178 156 161 150 203 0,0000 4,64 1,35 3,43 
Tb927.1.3770 hypothetical protein, unlikely 28 50 83 222 122 28 26 33 61 58 0,0000 7,93 2,35 3,37 
Tb927.1.4630 cyclin-like F-box protein (CFB1E) 6 77 71 57 59 12 23 43 47 44 0,0000 11,97 3,96 3,02 
Tb927.9.7300 hypothetical protein, unlikely 1 10 20 8 7 2 1 4 7 7 0,0309 19,85 6,62 3,00 
Tb927.9.17800 hypothetical protein, unlikely 3 11 28 64 63 6 12 20 35 40 0,0000 20,00 6,74 2,97 
Tb1.NT.33   145 71 54 142 213 146 152 165 195 210 0,0122 3,94 1,44 2,73 
Tb927.1.4600 cyclin-like F-box protein (CFB1D) 12 61 90 78 60 18 26 42 50 43 0,0000 7,52 2,76 2,72 
Tb927.8.510 hypothetical protein 64 42 50 100 173 176 179 150 115 163 0,0002 4,16 1,56 2,66 
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Tb927.7.4060 
calpain-like cysteine peptidase, 
putative,cysteine peptidase, Clan 
CA, family C2, putative 
16 75 119 160 137 22 26 54 77 84 0,0000 10,02 3,83 2,62 
Tb927.10.9500 
expression site-associated gene 
(ESAG) protein, 
putative,expression site-
associated gene 3 (ESAG3) 
protein, putative 
141 54 67 119 203 188 135 126 183 171 0,0463 3,76 1,49 2,52 
Tb927.7.1290 hypothetical protein, conserved 33 120 143 105 96 52 61 79 88 91 0,0003 4,35 1,75 2,49 
Tb927.11.10340 phosphoglycerate mutase family member 5, putative 639 427 463 1133 2027 996 790 699 1213 1391 0,0000 4,74 1,99 2,38 
Tb927.7.6500 variant surface glycoprotein (VSG), putative 53 192 191 91 93 62 72 86 96 79 0,0023 3,64 1,55 2,34 
Tb927.7.6880 hypothetical protein, conserved 51 29 23 73 97 44 43 43 77 66 0,0293 4,15 1,78 2,33 
Tb927.2.3340 hypothetical protein 325 142 91 298 372 335 280 247 294 436 0,0015 4,08 1,77 2,31 
Tb927.10.9360 hypothetical protein, conserved 162 54 69 203 201 224 168 181 246 278 0,0149 3,77 1,65 2,28 
Tb927.9.6760 hypothetical protein, conserved 129 595 634 186 95 104 201 305 120 107 0,0000 6,65 2,94 2,26 
Tb927.10.10610 protein tyrosine phosphatase, putative 638 204 227 512 658 509 432 353 424 507 0,0133 3,22 1,44 2,23 
Tb927.9.12570 glycerol kinase, glycosomal (glk1) 18 101 156 160 112 22 43 81 89 82 0,0000 9,07 4,07 2,23 
Tb7.NT.112   150 270 472 546 313 186 199 257 307 236 0,0000 3,65 1,65 2,21 
Tb927.11.2690 
succinyl-coA:3-ketoacid-
coenzyme A transferase, 
mitochondrial precursor, 
putative 
899 1649 1291 689 496 495 607 749 602 494 0,0074 3,33 1,51 2,20 
Tb5.NT.25   64 37 42 116 124 52 60 73 77 82 0,0143 3,36 1,59 2,12 
Tb8.NT.1   39 81 99 194 202 54 58 75 99 131 0,0000 5,14 2,43 2,12 
Tb927.9.12610 glycerol kinase, glycosomal (glk1) 25 99 186 139 96 28 55 88 100 76 0,0000 7,49 3,59 2,09 
Tb927.10.15020 protein kinase, putative 48 39 31 69 108 38 54 47 66 54 0,0288 3,53 1,74 2,02 
Tb6.NT.31_homologue   82 113 139 185 279 154 171 184 126 212 0,0000 3,39 1,68 2,01 
Tb927.11.9070 palmitoyl acyltransferase 4, putative 159 96 119 227 270 240 176 175 222 243 0,0106 2,79 1,39 2,01 
Tb6.NT.31   247 407 399 527 825 481 498 553 416 690 0,0000 3,34 1,66 2,01 
Tb927.1.470 hypothetical protein, conserved 193 82 91 245 301 182 151 140 228 255 0,0003 3,66 1,83 2,00 
Tb927.3.2600 ATP-dependent DEAD/H RNA helicase, putative 332 393 375 228 143 341 273 325 336 245 0,0010 2,75 1,39 1,97 
Tb927.11.14190 hypothetical protein, conserved 516 681 501 393 278 529 613 564 485 586 0,0015 2,45 1,26 1,94 
Tb927.1.2330 beta tubulin 555 1369 2328 2581 1935 683 1050 1195 1653 1380 0,0000 4,65 2,42 1,92 
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Tb927.9.7230 ADP-ribosylation factor-like protein, putative (ARL1B) 35 108 108 91 100 54 50 41 65 61 0,0028 3,08 1,60 1,92 
Tb927.2.1452 18S ribosomal RNA 22 28 61 98 62 28 28 27 65 40 0,0458 4,54 2,37 1,91 
Tb927.11.7710 Gp63-1 surface protease homolog, putative 5 16 27 33 44 8 17 20 30 39 0,0036 9,22 4,85 1,90 
Tb927.10.8520 glucose transporter, putative 16 86 124 87 104 24 46 41 92 99 0,0000 7,73 4,13 1,87 
Tb927.10.10520 histone H2B, putative 27 103 188 257 221 26 69 87 131 117 0,0000 9,44 5,06 1,87 
Tb7.NT.82   338 187 201 370 472 351 273 269 344 367 0,0111 2,52 1,36 1,85 
Tb2.NT.20   127 125 173 339 219 114 130 138 169 164 0,0106 2,72 1,48 1,83 
Tb927.6.2330 RGG protein (RGG1) 908 545 384 881 1137 758 749 643 1044 867 0,0000 2,96 1,62 1,82 
Tb927.5.970 class I transcription factor A, subunit 6 (CITFA-6) 398 224 212 446 493 425 398 334 411 431 0,0439 2,32 1,29 1,80 
Tb927.11.3150 hypothetical protein, conserved 61 41 43 68 141 58 56 41 64 78 0,0061 3,46 1,93 1,80 
Tb927.1.270 hypothetical protein 410 227 210 598 796 311 283 288 578 601 0,0000 3,78 2,13 1,78 
Tb927.9.12630 glycerol kinase, glycosomal (glk1) 19 113 190 139 100 20 53 76 111 94 0,0000 9,92 5,58 1,78 
Tb927.11.13800 hypothetical protein, conserved 345 225 317 459 485 345 361 355 324 399 0,0448 2,15 1,23 1,75 
Tb11.NT.105_1   78 46 59 84 181 124 90 111 158 200 0,0006 3,91 2,23 1,75 
Tb927.6.2270 hypothetical protein, conserved 969 611 390 864 1071 796 769 670 1059 842 0,0074 2,75 1,58 1,74 
Tb927.11.6440 hypothetical protein, conserved 320 317 300 193 110 317 355 372 278 222 0,0000 2,91 1,67 1,74 
Tb7.NT.116   184 151 128 237 312 210 188 167 185 239 0,0098 2,43 1,43 1,70 
Tb927.9.12550 glycerol kinase, glycosomal (glk1) 26 111 173 123 116 24 61 89 93 87 0,0000 6,56 3,87 1,70 
Tb927.10.2470 hypothetical protein, conserved 743 364 388 843 824 854 643 622 821 759 0,0159 2,32 1,37 1,69 
Tb927.11.12850 
oligopeptidase b,serine 
peptidase, clan SC, family S9A-
like protein (OPB) 
1789 977 1410 1613 1251 1445 1476 1560 1543 1435 0,0091 1,83 1,09 1,68 
Tb9.NT.99   286 226 195 385 563 345 301 301 405 517 0,0000 2,89 1,72 1,68 
Tb927.11.9640 glycyl-tRNA synthetase, putative 438 563 539 339 271 423 413 387 366 337 0,0422 2,08 1,26 1,66 
Tb927.7.2170 hypothetical protein, conserved 289 393 333 211 142 200 236 226 196 140 0,0188 2,78 1,69 1,65 
Tb927.8.4820 eukaryotic translation initation factor 4 gamma, putative 446 591 442 331 206 349 368 397 267 227 0,0003 2,88 1,75 1,65 
Tb927.11.13870 hypothetical protein, conserved 326 260 220 463 478 397 321 315 416 418 0,0047 2,17 1,33 1,64 
Tb927.9.15460 calcium motive p-type ATPase, putative 824 492 400 563 446 729 699 660 681 577 0,0001 2,06 1,26 1,63 
Tb927.10.6630 
ATP-dependent DEAD/H RNA 
helicase HEL64, putative 
(HEL64) 
308 384 322 256 176 220 290 295 239 248 0,0477 2,18 1,34 1,62 
Supplem
ental M
aterial - C
hapter 4.1
	  	  
	  190	  	  
Tb927.8.6390 
lysophospholipase, 
putative,alpha/beta hydrolase, 
putative (TbLysoPLA) 
531 203 203 540 547 579 520 558 546 864 0,0151 2,69 1,66 1,62 
Tb927.10.9570 paraflagellar rod component, putative (PFC14) 1435 1666 1253 900 1003 1243 1263 1308 1217 1137 0,0005 1,85 1,15 1,61 
Tb927.8.6760 IgE-dependent histamine-releasing factor, putative 1520 713 881 1012 1002 1483 1603 1518 1309 1211 0,0025 2,13 1,32 1,61 
Tb927.6.1240 hypothetical protein, conserved 290 178 118 354 422 230 291 244 341 510 0,0000 3,57 2,22 1,61 
Tb927.2.650 hypothetical protein 154 90 96 220 260 114 117 142 205 195 0,0041 2,89 1,80 1,60 
Tb927.9.5320 nucleolar RNA binding protein, putative 581 689 766 446 291 395 468 496 398 301 0,0002 2,63 1,65 1,59 
Tb927.8.6520 hypothetical protein, conserved 222 184 136 311 309 249 201 224 291 288 0,0442 2,28 1,45 1,58 
Tb927.10.7410 succinyl-CoA ligase [GDP-forming] beta-chain, putative 1929 2211 3055 1698 1221 1627 1561 1899 1509 1193 0,0000 2,50 1,59 1,57 
Tb3.NT.52   115 80 67 218 277 110 102 157 193 270 0,0000 4,15 2,65 1,57 
Tb10.NT.107   210 136 127 248 316 170 158 170 250 242 0,0275 2,48 1,59 1,56 
Tb927.10.6890 hypothetical protein 214 153 106 206 337 224 179 194 226 367 0,0038 3,20 2,05 1,56 
Tb927.4.4730 amino acid transporter, putative (AATP11) 467 366 298 235 287 297 324 306 271 253 0,0230 1,99 1,28 1,55 
Tb927.2.1810 transcription silencer (ISWI) 520 799 602 461 214 299 395 411 265 171 0,0001 3,73 2,40 1,55 
Tb10.NT.74   1235 973 977 2165 2235 1271 1156 1062 1580 1384 0,0000 2,30 1,49 1,54 
Tb927.4.1910 hypothetical protein, conserved 450 480 356 328 246 353 306 279 286 299 0,0022 1,95 1,27 1,54 
Tb10.NT.193_1   272 196 135 314 366 234 259 273 323 409 0,0242 2,70 1,75 1,54 
Tb927.3.1380 
ATP synthase beta chain, 
mitochondrial precursor,ATP 
synthase F1, beta subunit 
1528 1418 1667 1174 841 1066 1073 1240 967 958 0,0000 1,98 1,29 1,53 
Tb927.9.3550 hypothetical protein, conserved 469 327 416 668 735 693 531 583 697 779 0,0002 2,25 1,47 1,53 
Tb927.10.1630 unspecified product (RLI) 510 562 387 339 241 365 432 534 349 396 0,0000 2,33 1,53 1,52 
Tb927.9.13820 kinetoplastid membrane protein KMP-11 43 181 335 408 409 58 121 135 292 361 0,0000 9,47 6,23 1,52 
Tb927.10.3650 NADH-dependent fumarate reductase, putative 746 610 621 853 1081 822 716 777 705 810 0,0007 1,77 1,17 1,52 
Tb927.10.8400 legume-like lectin, putative 462 320 256 496 630 537 400 338 523 546 0,0054 2,46 1,62 1,52 
Tb927.7.6860 
expression site-associated gene 
(ESAG) protein, 
putative,expression site-
associated gene 5 (ESAG5) 
protein, putative 
2865 1648 2140 3426 3842 3822 3744 3188 3661 4902 0,0000 2,33 1,54 1,52 
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Tb927.10.540 
ATP-dependent DEAD/H RNA 
helicase, putative,DEAD box 
RNA helicase, putative 
1512 1900 1530 1154 1018 1485 1582 1408 1318 1284 0,0000 1,87 1,23 1,51 
Tb8.NT.73   62 77 92 69 131 96 78 68 86 86 0,0465 2,12 1,41 1,51 
Tb3.NT.53   266 219 182 373 463 244 273 258 377 410 0,0001 2,54 1,68 1,51 
Tb927.4.120 hypothetical protein 132 60 79 168 201 100 81 102 175 182 0,0370 3,37 2,23 1,51 
Tb927.2.5980 
ATP-dependent Clp protease 
subunit, heat shock protein 104 
(HSP104), putative,atp-
dependent chaperone (HSP104) 
126 226 411 360 260 158 175 228 341 305 0,0003 3,25 2,16 1,50 
Tb927.10.14710 40S ribosomal protein S2, putative (RPS2) 11337 14647 11370 14469 6976 10602 13453 11340 14868 12971 0,0000 2,10 1,40 1,50 
Tb927.3.1630 casein kinase 1, putative (CK1) 3 33 37 19 17 2 8 6 15 12 0,0001 11,56 7,74 1,49 
Tb927.11.11520 glycosomal membrane protein (PEX11) 3645 3875 2779 2048 2324 2720 2759 2962 2333 2591 0,0000 1,89 1,27 1,49 
Tb7.NT.102   62 31 34 95 129 66 67 46 98 129 0,0056 4,13 2,77 1,49 
Tb927.2.900 hypothetical protein 365 220 218 564 751 281 297 324 619 651 0,0000 3,44 2,31 1,49 
Tb927.11.9850 hypothetical protein, conserved 370 394 304 437 601 327 335 329 436 375 0,0012 1,98 1,33 1,48 
Tb927.9.10310 mitochondrial carrier protein (MCP11) 1115 1221 1144 817 694 982 913 1044 942 879 0,0000 1,76 1,19 1,48 
Tb10.NT.193_3   659 526 467 929 1008 772 765 815 825 1115 0,0000 2,16 1,46 1,48 
Tb927.9.6470 hypothetical protein, conserved 10 34 41 38 42 10 14 27 20 26 0,0491 4,07 2,75 1,48 
Tb927.11.9610 
eukaryotic translation initiation 
factor 3 subunit 2, putative (eIF-
3 beta) 
1130 1698 1659 931 662 858 946 1078 664 622 0,0002 2,56 1,73 1,48 
Tb9.NT.106   71 48 77 102 153 134 78 95 120 170 0,0211 3,18 2,16 1,47 
Tb1.NT.41   32 40 29 57 93 38 42 34 71 75 0,0147 3,24 2,20 1,47 
Tb9.NT.1   110 47 65 166 175 150 85 102 181 213 0,0122 3,70 2,52 1,47 
Tb927.11.11830 40S ribosomal protein S17, putative 15195 19012 18227 21302 27569 15574 18030 15521 19211 18980 0,0000 1,81 1,24 1,47 
Tb927.7.6770 hypothetical protein, conserved 22 51 64 80 81 28 21 33 51 47 0,0144 3,60 2,46 1,46 
Tb927.6.480 
EP3-2 procyclin,PARP A-
beta,surface protein EP3-
2,surface protein EP3-2 
procyclin precursor,procyclic 
form specific polypeptide A-
beta precursor 
378 528 445 554 709 515 624 573 487 611 0,0000 1,87 1,28 1,46 
Tb927.8.6750 translationally controlled tumor protein (TCTP), putative 1555 790 920 1062 1102 1607 1691 1603 1399 1246 0,0133 1,97 1,36 1,45 
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Tb10.NT.111   1105 832 666 1440 1204 996 826 1234 992 1010 0,0241 2,16 1,49 1,45 
Tb927.11.7380 
glycerol-3-phosphate 
dehydrogenase (FAD-
dependent), mitochondrial 
1889 2293 1973 1525 1283 1958 2091 2142 1739 1735 0,0000 1,79 1,23 1,45 
Tb927.11.7930 RNA polymerase B subunit RPB8, putative (RPB8) 532 349 361 646 699 613 527 442 576 588 0,0174 2,00 1,39 1,44 
Tb927.8.3760 hypothetical protein 806 924 1097 800 542 788 664 789 673 563 0,0132 2,02 1,40 1,44 
Tb927.8.7230 hypothetical protein, conserved 274 201 152 351 392 299 216 207 372 358 0,0072 2,59 1,80 1,44 
Tb927.3.4530 hypothetical protein, conserved 282 258 187 365 416 222 280 239 307 344 0,0159 2,23 1,55 1,43 
Tb8.NT.98   566 538 438 740 817 419 468 500 550 454 0,0021 1,87 1,31 1,42 
Tb10.NT.193_2   254 179 158 338 366 236 241 254 257 384 0,0190 2,32 1,63 1,42 
Tb927.7.1110 asparagine synthetase a, putative 2328 2749 2237 2001 1348 1659 1631 1867 1620 1301 0,0000 2,04 1,44 1,42 
Tb927.3.3030 hypothetical protein, conserved 326 401 435 331 147 208 233 368 204 175 0,0065 2,97 2,10 1,42 
Tb927.11.16760 T-complex protein 1, alpha subunit, putative (TCP-1-alpha) 2398 2852 2780 1807 1182 1828 1723 2330 1754 1361 0,0000 2,41 1,71 1,41 
Tb927.4.4380 
vacuolar-type proton 
translocating pyrophosphatase 1, 
putative (PPase1) 
1115 1439 1533 936 800 1150 1299 1425 1046 1118  1,92 1,36 1,41 
Tb927.11.17440 variant surface glycoprotein (VSG), degenerate 43 39 71 149 162 86 55 96 158 163 0,0000 4,19 2,98 1,40 
Tb927.11.3250 dynein heavy chain, putative 2448 1768 1634 1363 1035 2058 2162 2321 1860 1368 0,0000 2,37 1,70 1,39 
Tb927.9.6850 hypothetical protein, unlikely 101 47 65 143 176 80 58 53 122 142 0,0142 3,72 2,68 1,39 
Tb11.NT.125   430 281 253 512 566 445 378 313 503 505 0,0158 2,24 1,61 1,39 
Tb927.5.4420 
nucleolar RNA helicase II, 
putative,nucleolar RNA helicase 
Gu, putative 
853 1301 1145 757 557 774 669 725 699 459 0,0149 2,34 1,69 1,39 
Tb927.10.14820 
mitochondrial carrier 
protein,ADP/ATP translocase 1, 
putative (MCP5c) 
769 922 752 547 512 565 629 639 486 594 0,0058 1,80 1,31 1,37 
Tb927.10.14840 mitochondrial carrier protein (MCP5a) 763 876 800 530 473 493 633 630 467 553 0,0009 1,85 1,36 1,36 
Tb927.10.1060 T-complex protein 1, delta subunit, putative (TCP-1-delta) 1884 2389 2402 1404 1089 1607 1570 2013 1543 1244 0,0000 2,21 1,62 1,36 
Tb927.6.520 
EP3-2 procyclin,PARP A-
beta,surface protein EP3-3 
procyclin precursor,procyclic 
form specific polypeptide A-
beta precursor 
373 520 511 539 682 473 634 549 499 607 0,0000 1,83 1,34 1,36 
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Tb927.6.510 
GPEET2 procyclin 
precursor,PARP A-
alpha,procyclin A-
alpha,procyclic form specific 
polypeptide A-alpha precursor 
371 532 467 528 664 457 601 592 482 592 0,0001 1,79 1,32 1,36 
Tb927.8.4330 small GTP-binding protein Rab11 (RAB11) 961 1043 945 730 563 892 824 1013 741 792 0,0000 1,85 1,37 1,36 
Tb927.11.1870 histone H1, putative 2160 1432 1988 2405 2648 2241 2251 1795 2447 2368 0,0005 1,85 1,36 1,36 
Tb10.NT.182   202 140 124 198 321 204 188 213 251 359 0,0159 2,59 1,91 1,36 
Tb927.1.275 
expression site-associated gene 
(ESAG, pseudogene), 
putative,expression site-
associated gene 4 (ESAG4), 
pseudogene 
330 233 238 502 498 287 321 286 360 456 0,0012 2,16 1,60 1,35 
Tb927.5.150 hypothetical protein, conserved 533 445 381 358 299 313 362 357 414 335 0,0008 1,78 1,32 1,35 
Tb927.4.3600 hypothetical protein, conserved 333 233 199 336 475 405 292 229 289 330 0,0194 2,38 1,77 1,35 
Tb927.11.6880 hypothetical protein 456 333 354 393 224 443 514 412 415 339 0,0010 2,03 1,51 1,34 
Tb927.6.3590 hypothetical protein, conserved 202 223 246 285 388 206 210 193 276 265 0,0024 1,91 1,43 1,34 
Tb927.10.16190 
expression site-associated gene 
4 (ESAG4) protein, 
putative,expression site-
associated gene (ESAG) protein, 
putative,receptor-type adenylate 
cyclase 
1930 3092 2555 1715 1299 1900 2619 2304 1901 1462 0,0002 2,38 1,79 1,33 
Tb927.11.2430 
Cytoplasmic dynein 2 heavy 
chain (DYNC2H1), 
putative,Cytoplasmic dynein 2 
heavy chain (DYNC2H2), 
putative (DHC1b) 
226 171 157 138 118 251 189 209 225 174 0,0458 1,92 1,45 1,33 
Tb927.9.10650 hypothetical protein 339 464 410 501 628 393 335 468 424 447 0,0001 1,85 1,40 1,33 
Tb10.NT.193   242 153 152 338 369 218 227 280 287 401 0,0037 2,43 1,84 1,32 
Tb927.2.160 hypothetical protein, conserved 150 76 72 197 208 134 94 101 205 203 0,0298 2,88 2,19 1,32 
Tb927.11.1530 
expression site-associated gene 
(ESAG) protein, 
putative,expression site-
associated gene 3 (ESAG3) 
protein, putative 
274 203 191 258 462 347 257 297 350 475 0,0005 2,42 1,85 1,31 
Tb927.6.4580 hypothetical protein, conserved 432 502 505 505 764 599 616 454 564 582 0,0000 1,77 1,36 1,30 
Tb927.5.3810 
orotidine-5-phosphate 
decarboxylase/orotate 
phosphoribosyltransferase, 
putative,OMPDCase-OPRTase, 
putative 
791 1009 1101 637 473 854 865 892 632 499 0,0016 2,33 1,79 1,30 
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Tb1.NT.4   541 438 474 571 790 651 578 494 545 470 0,0060 1,80 1,39 1,30 
Tb11.NT.105   114 86 87 151 225 160 143 187 203 288 0,0066 2,62 2,01 1,30 
Tb8.NT.11   315 279 219 223 162 303 330 273 278 221 0,0084 1,94 1,49 1,30 
Tb927.11.8270 hypothetical protein, conserved 206 241 229 161 97 136 161 187 125 98 0,0394 2,48 1,91 1,30 
Tb927.10.4640 eukaryotic translation initiation factor 3 subunit L, putative 1038 1260 1097 866 667 796 985 1027 776 704 0,0002 1,89 1,46 1,30 
Tb927.8.1730 hypothetical protein, conserved 374 361 310 484 564 339 302 366 424 380 0,0145 1,82 1,40 1,30 
Tb927.10.4750 hypothetical protein, conserved 339 347 307 300 178 202 201 303 242 217 0,0096 1,95 1,51 1,29 
Tb927.10.8110 hypothetical protein, conserved 518 590 474 507 331 341 333 459 384 331 0,0284 1,79 1,38 1,29 
Tb927.10.10140 paraflagellar rod component, putative (PFC19) 2294 2890 2119 1955 1564 2297 1987 2253 2859 2041 0,0000 1,85 1,44 1,28 
Tb11.NT.95   456 397 371 579 716 555 585 431 529 652 0,0008 1,93 1,51 1,28 
Tb927.10.14830 mitochondrial carrier protein (MCP5b) 807 855 762 545 476 539 665 665 472 585 0,0001 1,80 1,41 1,27 
Tb927.10.2370 RNA-binding protein, putative (LA) 579 718 630 398 322 581 598 531 429 341 0,0009 2,23 1,75 1,27 
Tb927.10.14600 40S ribosomal protein S2, putative (RPS2) 10829 15508 12736 15637 8713 9227 12181 11769 13080 12209 0,0003 1,79 1,42 1,27 
Tb927.10.5840 translation elongation factor 1-beta, putative 4700 5249 4683 3526 2830 3738 4948 5004 3953 3412 0,0000 1,85 1,47 1,26 
Tb4.NT.1   1128 688 567 1164 1386 752 653 836 980 1267 0,0001 2,45 1,94 1,26 
Tb927.6.4540 3-hydroxy-3-methylglutaryl-CoA reductase, putative 350 310 265 441 498 247 270 250 361 369 0,0498 1,88 1,49 1,26 
Tb927.6.4480 valyl-tRNA synthetase, putative (ValRS) 462 459 446 403 243 429 412 464 304 320 0,0010 1,90 1,52 1,25 
Tb927.4.1930 RNA-binding protein, putative (EIF3D) 1025 1420 1550 1000 693 862 849 1202 727 670 0,0112 2,24 1,79 1,25 
Tb927.4.2000 
ruvB-like DNA helicase, 
putative,ATP-dependent DNA 
helicase, putative 
728 807 568 555 440 513 692 627 580 470 0,0006 1,83 1,47 1,24 
Tb927.11.14840 chromosomal passenger protein (CTC2) 643 478 611 469 314 615 519 698 489 423 0,0000 2,05 1,65 1,24 
Tb927.6.4370 eukaryotic translation initiation factor 3 subunit 7-like protein 687 635 726 488 392 631 657 677 583 455 0,0003 1,85 1,49 1,24 
Tb927.10.12700 pyruvate dehydrogenase E1 alpha subunit, putative 73 196 232 186 153 62 90 116 159 107 0,0038 3,19 2,57 1,24 
Tb927.10.2880 calcium channel protein, putative 486 351 336 287 262 411 449 492 335 328 0,0009 1,86 1,50 1,24 
Tb927.8.4870 DIGIT 473 408 403 357 261 327 415 430 378 293 0,0015 1,81 1,47 1,24 
Tb927.11.14090 hypothetical protein, conserved 636 587 578 324 321 531 586 511 419 365 0,0000 1,98 1,61 1,24 
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Tb927.10.7300 hypothetical protein, conserved 368 284 310 267 206 457 414 338 314 334 0,0128 1,79 1,45 1,23 
Tb927.6.4590 glutamyl-tRNA synthetase, putative 1090 1111 962 804 611 912 884 1043 813 705 0,0000 1,82 1,48 1,23 
Tb927.10.11340 hypothetical protein, conserved 334 264 224 259 175 295 293 286 299 192 0,0122 1,91 1,56 1,22 
Tb927.2.1250 hypothetical protein 190 128 106 238 272 158 140 134 214 283 0,0477 2,57 2,11 1,22 
Tb927.10.6070 
universal minicircle sequence 
binding protein (UMSBP), 
putative,predicted zinc finger 
protein 
14830 16947 18461 10279 8264 9561 13777 16420 8991 8915 0, 0000 2,23 1,84 1,21 
Tb927.8.1600 lysyl-tRNA synthetase, putative 913 1120 961 869 593 882 807 1085 835 695 0,0010 1,89 1,56 1,21 
Tb927.10.16100 
FK506-binding protein (FKBP)-
type peptidyl-prolyl isomerase, 
putative 
831 884 1564 2694 1973 1435 1351 1824 3632 2992 0,0000 3,24 2,69 1,21 
Tb927.11.590 hypothetical protein, conserved 243 177 183 365 379 246 233 167 298 290 0,0082 2,14 1,78 1,20 
Tb927.8.760 nucleolar RNA-binding protein (Nopp44/46) 2097 3227 3482 1698 1517 1962 1941 2543 1330 1397 0,0452 2,30 1,91 1,20 
Tb927.9.11270 
T-complex protein 1, eta 
subunit, putative,t- complex 
protein 1 (eta subunit), putative 
(TCP-1-eta) 
2816 3291 3419 2263 1408 2146 2268 3392 1665 1761 0,0000 2,43 2,04 1,19 
Tb927.11.14000 NRBD1 (NRBD1) 4040 5412 5467 3177 2567 2942 3050 4424 2572 2474 0,0000 2,13 1,79 1,19 
Tb927.7.1060 hypothetical protein, conserved 545 484 585 527 263 363 432 553 403 296 0,0002 2,23 1,87 1,19 
Tb5.NT.81   148 138 143 237 262 188 157 183 200 250 0,0340 1,89 1,59 1,19 
Tb927.10.8510 glucose transporter, putative 14 85 98 94 92 18 50 66 110 104 0,0000 7,23 6,14 1,18 
Tb927.8.4890 
endoplasmic reticulum 
oxidoreductin, putative,pol-
associated gene 1 
995 1320 976 805 718 1265 1283 1175 831 821 0,0190 1,84 1,56 1,18 
Tb927.7.4900 
5'-3' exonuclease XRNA, 
putative,exoribonuclease 1, 
putative (XRNA) 
282 278 297 236 151 168 217 281 213 185 0,0309 1,96 1,67 1,17 
Tb927.10.4560 elongation factor 2 12871 15238 19557 10019 6530 9846 13320 17629 8014 6845 0,0000 3,00 2,58 1,16 
Tb927.10.3560 arginine N-methyltransferase, putative 587 689 690 395 385 455 454 560 362 378 0,0368 1,79 1,55 1,16 
Tb927.1.3190 hypothetical protein, unlikely 612 569 856 1261 1052 766 619 960 1166 1181 0,0000 2,21 1,91 1,16 
Tb927.11.11080 Nucleoporin (TbNup149) 484 494 556 384 283 413 373 524 385 309 0,0074 1,96 1,70 1,16 
Tb927.4.2310 asparaginyl-tRNA synthetase, putative 647 943 798 504 385 908 890 726 554 428 0,0063 2,45 2,12 1,15 
Tb927.11.15370 hypothetical protein, conserved (TbKap123) 1115 984 1269 817 562 916 1077 1101 726 563 0,0000 2,26 1,96 1,15 
Tb927.1.3390 hypothetical protein, conserved 353 516 596 632 621 471 437 542 662 679 0,0005 1,79 1,55 1,15 
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Tb927.8.3540 hypothetical protein, conserved 307 225 209 160 103 204 251 297 194 115 0,0000 2,97 2,59 1,15 
Tb927.11.1990 arginyl-tRNA synthetase, putative 815 823 767 551 451 740 675 652 652 464 0,0000 1,83 1,60 1,14 
Tb927.10.4570 elongation factor 2 13061 15137 19626 10068 6533 9978 13044 17536 8112 6660 0,0000 3,00 2,63 1,14 
Tb927.7.3550 hypothetical protein, conserved 1648 1627 1734 1375 910 1762 1556 2105 1533 1259 0,0000 1,91 1,67 1,14 
Tb927.6.3740 
heat shock 70 kDa protein, 
mitochondrial precursor, 
putative 
1121 1394 1413 712 754 1186 1293 1029 739 859 0,0074 1,98 1,75 1,13 
Tb927.10.2090 elongation factor 1-alpha,EF-1-alpha (TEF1) 3214 4803 6380 6385 5289 3152 4274 4953 5532 3833 0,0000 1,99 1,76 1,13 
Tb927.10.7190 D-tyrosyl-tRNA deacylase, putative 321 232 227 413 464 369 310 268 487 353 0,0201 2,05 1,82 1,13 
Tb927.11.3240 T-complex protein 1, zeta subunit, putative (TCP-1-zeta) 1922 1842 1697 1177 934 1214 1373 1917 1046 1073 0,0000 2,06 1,83 1,12 
Tb927.11.17040 
expression site-associated gene 
(ESAG) protein, 
putative,expression site-
associated gene 4 (ESAG4) 
protein, putative,receptor-type 
adenylate cyclase, putative 
1830 2350 2492 1704 1352 1677 2283 2285 1753 1389 0,0013 1,84 1,65 1,12 
Tb927.5.2570 translation initiation factor, putative (EIF3B) 1273 1511 1630 927 691 974 950 1286 868 610 0,0000 2,36 2,11 1,12 
Tb927.11.1980 zinc finger protein family member, putative (ZC3H41) 3010 2738 3324 2477 1844 2411 2495 3205 2300 1990 0,0000 1,80 1,61 1,12 
Tb927.1.4580 cyclin-like F-box protein (CFB1C) 8 69 107 66 43 4 28 48 44 33 0,0000 13,42 12,08 1,11 
Tb927.7.4070 
calpain-like cysteine peptidase, 
putative,cysteine peptidase, Clan 
CA, family C2, putative 
3342 2292 2628 4366 4822 3589 3536 3299 4531 6255 0,0000 2,10 1,90 1,11 
Tb7.NT.19   191 220 254 174 335 220 170 231 222 296 0,0024 1,93 1,74 1,11 
Tb927.4.3590 translation elongation factor 1-beta, putative 4462 5463 5416 4104 3079 3457 3948 5440 3537 3390 0,0000 1,77 1,60 1,11 
Tb927.8.750 nucleolar RNA-binding protein, putative 2024 2859 2985 1487 1402 1832 1848 2286 1330 1181 0,0016 2,13 1,94 1,10 
Tb927.8.1510 ATP-dependent DEAD/H RNA helicase, putative 464 460 421 293 249 447 325 418 363 263 0,0010 1,86 1,70 1,10 
Tb927.11.2290 hypothetical protein, conserved 417 409 394 362 236 283 347 377 337 232 0,0073 1,77 1,63 1,08 
Tb927.10.14750 fibrillarin, putative 1986 3242 2738 1779 1319 1475 1478 2313 1470 1020 0,0002 2,46 2,27 1,08 
Tb927.1.5280 
expression site-associated gene 
(ESAG, pseudogene), 
putative,expression site-
associated gene 3 (ESAG3), 
pseudogene 
342 402 441 601 531 503 395 375 591 615 0,0217 1,76 1,64 1,07 
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Tb927.5.3800 
glutamine hydrolysing (not 
ammonia-dependent) carbomoyl 
phosphate synthase, putative 
586 710 674 459 338 547 548 657 431 335 0,0016 2,10 1,96 1,07 
Tb927.8.3150 
T-complex protein 1, gamma 
subunit, putative (TCP-1-
gamma) 
3668 3502 4334 2647 1750 2782 2997 4135 2611 1777 0,0000 2,48 2,33 1,06 
Tb927.6.3490 zinc finger protein (ZFP1) 1119 1277 1531 871 782 1116 1047 1402 752 1109 0,0122 1,96 1,86 1,05 
Tb927.11.4910 predicted ankyrin repeat family protein 1871 2104 1875 1487 1067 1108 1303 1929 1231 1027 0,0000 1,97 1,88 1,05 
Tb927.10.13280 hypothetical protein, conserved 242 215 188 160 122 212 179 225 158 119 0,0208 1,99 1,90 1,05 
Tb927.8.4370 hypothetical protein, conserved 350 364 414 339 199 238 214 328 243 165 0,0330 2,08 1,99 1,05 
Tb927.10.2240 hypothetical protein, conserved 734 757 930 531 429 597 587 959 544 460 0,0011 2,17 2,09 1,04 
Tb927.10.6060 
universal minicircle sequence 
binding protein (UMSBP), 
putative,DNA-binding protein 
HEXBP, putative,zinc finger 
protein 
3698 4372 3632 1950 1777 3184 4270 4545 2087 1917 0,0000 2,46 2,37 1,04 
Tb927.1.5020 hypothetical protein, unlikely 68 49 54 98 145 44 59 55 111 124 0,0270 2,94 2,83 1,04 
Tb927.9.13860   8166 5928 6623 8538 10915 8185 7543 7011 9862 12520 0,0000 1,84 1,79 1,03 
Tb927.11.3730 leucyl-tRNA synthetase, putative (LeuRS) 710 646 797 581 449 599 627 777 517 449 0,0039 1,78 1,73 1,03 
Tb927.9.13920 kinetoplastid membrane protein KMP-11 (KMP-11) 7986 5943 6475 8542 10811 8054 7487 7026 9980 12665 0,0000 1,82 1,80 1,01 
Tb927.10.10480 histone H2B, putative 38 126 201 219 227 26 48 80 156 134 0,0000 6,04 5,99 1,01 
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Table S2A: GO enrichment analysis of PKA downstream targets using DAVID. 
 
Annotation cluster 1 Enrichment score: 3.731590820350524           
Category Term Count % P-value List total 
Pop 
hits 
Pop 
total 
Fold 
enrichment Bonferroni Benjamini FDR 
GOTERM_BP_FAT GO:0006072~glycerol-3-phosphate metabolic process 6 3,09 8,46E-07 72 8 2497 26,01 2,14E-04 2,14E-04 1,10E-03 
INTERPRO IPR018485: Carbohydrate kinase, FGGY, C-terminal 5 2,58 4,69E-06 85 5 2636 31,01 8,53E-04 8,53E-04 5,79E-03 
INTERPRO IPR018484: Carbohydrate kinase, FGGY, N-terminal 5 2,58 4,69E-06 85 5 2636 31,01 8,53E-04 8,53E-04 5,79E-03 
INTERPRO IPR000577: Carbohydrate kinase, FGGY 5 2,58 4,69E-06 85 5 2636 31,01 8,53E-04 8,53E-04 5,79E-03 
INTERPRO IPR018483: Carbohydrate kinase, FGGY, conserved site 5 2,58 4,69E-06 85 5 2636 31,01 8,53E-04 8,53E-04 5,79E-03 
INTERPRO IPR005999: Glycerol kinase 5 2,58 4,69E-06 85 5 2636 31,01 8,53E-04 8,53E-04 5,79E-03 
GOTERM_MF_FAT GO:0004370~glycerol kinase activity 5 2,58 4,92E-06 89 5 2730 30,67 7,93E-04 7,93E-04 5,95E-03 
GOTERM_BP_FAT GO:0006071~glycerol metabolic process 6 3,09 6,53E-06 72 11 2497 18,92 1,65E-03 8,26E-04 8,50E-03 
GOTERM_BP_FAT GO:0019400~alditol metabolic process 6 3,09 6,53E-06 72 11 2497 18,92 1,65E-03 8,26E-04 8,50E-03 
GOTERM_BP_FAT GO:0019751~polyol metabolic process 6 3,09 1,09E-05 72 12 2497 17,34 2,77E-03 5,54E-04 1,42E-02 
PIR_SUPERFAMILY PIRSF000538: xylulokinase 5 2,58 3,03E-05 36 5 670 18,61 9,08E-04 9,08E-04 2,58E-02 
KEGG_PATHWAY tbr00561: Glycerolipid metabolism 5 2,58 0,001442921 34 14 849 8,92 3,41E-02 1,72E-02 1,15E+00 
GOTERM_BP_FAT GO:0019637~organophosphate metabolic process 7 3,61 0,010082906 72 66 2497 3,68 9,23E-01 2,26E-01 1,24E+01 
GOTERM_BP_FAT GO:0006793~phosphorus metabolic process 9 4,64 0,551566733 72 280 2497 1,11 1,00E+00 1,00E+00 1,00E+02 
GOTERM_BP_FAT GO:0006796~phosphate metabolic process 9 4,64 0,551566733 72 280 2497 1,11 1,00E+00 1,00E+00 1,00E+02 
SP_PIR_KEYWORDS kinase 6 3,09 0,70941219 55 139 1291 1,01 1,00E+00 9,83E-01 1,00E+02 
SP_PIR_KEYWORDS transferase 7 3,61 0,870556298 55 201 1291 0,82 1,00E+00 9,96E-01 1,00E+02 
 
 
 
 
 
 
           
Annotation cluster 2 Enrichment score: 3.6829780458417662           
Category Term Count % P-value List total 
Pop 
hits 
Pop 
total 
Fold 
enrichment Bonferroni Benjamini FDR 
GOTERM_BP_FAT GO:0006418~tRNA aminoacylation for protein translation 8 4,12 8,20E-06 72 28 2497 9,91 2,07E-03 6,91E-04 1,07E-02 
GOTERM_BP_FAT GO:0043038~amino acid activation 8 4,12 1,06E-05 72 29 2497 9,57 2,67E-03 6,68E-04 1,38E-02 
GOTERM_BP_FAT GO:0043039~tRNA aminoacylation 8 4,12 1,06E-05 72 29 2497 9,57 2,67E-03 6,68E-04 1,38E-02 
GOTERM_MF_FAT GO:0004812~aminoacyl-tRNA ligase activity 8 4,12 1,14E-05 89 26 2730 9,44 1,83E-03 9,15E-04 1,38E-02 
GOTERM_MF_FAT GO:0016876~ligase activity, forming aminoacyl-tRNA and related compounds 8 4,12 1,14E-05 89 26 2730 9,44 1,83E-03 9,15E-04 1,38E-02 
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GOTERM_MF_FAT GO:0016875~ligase activity, forming carbon-oxygen bonds 8 4,12 1,14E-05 89 26 2730 9,44 1,83E-03 9,15E-04 1,38E-02 
KEGG_PATHWAY tbr00970: Aminoacyl-tRNA biosynthesis 7 3,61 2,26E-04 34 25 849 6,99 5,40E-03 5,40E-03 1,81E-01 
GOTERM_BP_FAT GO:0006399~tRNA metabolic process 8 4,12 4,76E-04 72 51 2497 5,44 1,13E-01 1,99E-02 6,17E-01 
GOTERM_BP_FAT GO:0034660~ncRNA metabolic process 9 4,64 0,001149395 72 76 2497 4,11 2,52E-01 4,07E-02 1,49E+00 
GOTERM_BP_FAT GO:0006412~translation 17 8,76 0,001935562 72 260 2497 2,27 3,87E-01 5,30E-02 2,49E+00 
SP_PIR_KEYWORDS Aminoacyl-tRNA synthetase 3 1,55 0,074170061 55 11 1291 6,40 9,64E-01 6,69E-01 5,12E+01 
SP_PIR_KEYWORDS ligase 4 2,06 0,266636354 55 43 1291 2,18 1,00E+00 7,36E-01 9,44E+01 
 
            
Annotation cluster 3 Enrichment score: 2.366736896928375           
Category Term Count % P-value List total 
Pop 
hits 
Pop 
total 
Fold 
enrichment Bonferroni Benjamini FDR 
GOTERM_MF_FAT GO:0032553~ribonucleotide binding 37 19,07 5,45E-04 89 678 2730 1,67 8,41E-02 2,89E-02 6,57E-01 
GOTERM_MF_FAT GO:0032555~purine ribonucleotide binding 37 19,07 5,45E-04 89 678 2730 1,67 8,41E-02 2,89E-02 6,57E-01 
GOTERM_MF_FAT GO:0000166~nucleotide binding 40 20,62 7,29E-04 89 769 2730 1,60 1,11E-01 2,89E-02  
GOTERM_MF_FAT GO:0017076~purine nucleotide binding 37 19,07 9,55E-04 89 697 2730 1,63 1,43E-01 3,03E-02 1,15E+00 
GOTERM_MF_FAT GO:0005524~ATP binding 31 15,98 0,002991737 89 578 2730 1,65 3,83E-01 7,73E-02 3,56E+00 
GOTERM_MF_FAT GO:0032559~adenyl ribonucleotide binding 31 15,98 0,002991737 89 578 2730 1,65 3,83E-01 7,73E-02 3,56E+00 
GOTERM_MF_FAT GO:0030554~adenyl nucleotide binding 31 15,98 0,004858666 89 596 2730 1,60 5,43E-01 1,06E-01 5,72E+00 
GOTERM_MF_FAT GO:0001883~purine nucleoside binding 31 15,98 0,004858666 89 596 2730 1,60 5,43E-01 1,06E-01 5,72E+00 
GOTERM_MF_FAT GO:0001882~nucleoside binding 31 15,98 0,005251308 89 599 2730 1,59 5,72E-01 1,01E-01 6,17E+00 
SP_PIR_KEYWORDS nucleotide-binding 16 8,25 0,124678578 55 266 1291 1,41 9,97E-01 6,15E-01 7,10E+01 
SP_PIR_KEYWORDS ATP-binding 12 6,19 0,322508566 55 223 1291 1,26 1,00E+00 7,52E-01 9,73E+01 
 
 
            
Annotation cluster 4 Enrichment score: 2.048626865000886           
Category Term Count % P-value List total 
Pop 
hits 
Pop 
total 
Fold 
enrichment Bonferroni Benjamini FDR 
GOTERM_CC_FAT GO:0005832~chaperonin-containing T-complex 5 2,58 8,48E-05 54 8 1513 17,51 5,67E-03 5,67E-03 8,70E-02 
INTERPRO IPR002194: Chaperonin TCP-1, conserved site 4 2,06 9,96E-04 85 7 2636 17,72 1,66E-01 8,67E-02 1,22E+00 
INTERPRO IPR017998: Chaperone, tailless complex polypeptide 1 4 2,06 9,96E-04 85 7 2636 17,72 1,66E-01 8,67E-02 1,22E+00 
GOTERM_BP_FAT GO:0051726~regulation of cell cycle 5 2,58 0,001684566 72 19 2497 9,13 3,47E-01 5,19E-02 2,17E+00 
INTERPRO IPR002423: Chaperonin Cpn60/TCP-1 4 2,06 0,004281377 85 11 2636 11,28 5,42E-01 1,77E-01 5,16E+00 
GOTERM_CC_FAT GO:0044445~cytosolic part 7 3,61 0,007415818 54 51 1513 3,85 3,93E-01 2,21E-01 7,35E+00 
GOTERM_CC_FAT GO:0005829~cytosol 8 4,12 0,018979082 54 80 1513 2,80 7,23E-01 3,48E-01 1,78E+01 
PIR_SUPERFAMILY PIRSF002584: molecular chaperone t-complex-type 3 1,55 0,024018991 36 5 670 11,17 5,18E-01 3,06E-01 1,87E+01 
SP_PIR_KEYWORDS Chaperone 5 2,58 0,033380787 55 30 1291 3,91 7,68E-01 5,18E-01 271E+01 
SP_PIR_KEYWORDS cytoplasm 4 2,06 0,07524734 55 24 1291 3,91 9,65E-01 5,69E-01 5,17E+01 
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GOTERM_MF_FAT GO:0051082~unfolded protein binding 5 2,58 0,187307953 89 70 2730 2,19 1,00E+00 8,92E-01 9,18E+01 
GOTERM_BP_FAT GO:0006457~protein folding 6 3,09 0,2700358 72 123 2497 1,69 1,00E+00 9,95E-01 9,83E+01 
 
            
Annotation cluster 5 Enrichment score: 1.2601629776770822           
Category Term Count % P-value List total 
Pop 
hits 
Pop 
total 
Fold 
enrichment Bonferroni Benjamini FDR 
INTERPRO IPR002113: Adenine nucleotide translocator 1 3 1,55 0,005775476 85 4 2636 23,26 6,52E-01 1,90E-01 6,90E+00 
INTERPRO IPR002067: Mitochondrial carrier protein 3 1,55 0,013849072 85 6 2636 15,51 9,21E-01 3,45E-01 1,58E+01 
INTERPRO IPR001993: Mitochondrial substrate carrier 4 2,06 0,018024939 85 18 2636 6,89 9,64E-01 3,77E-01 2,01E+01 
INTERPRO IPR018108: Mitochondrial substrate/solute carrier 4 2,06 0,02092073 85 19 2636 6,53 9,79E-01 3,82E-01 2,30E+01 
GOTERM_CC_FAT GO:0005743~mitochondrial inner membrane 5 2,58 0,025861844 54 33 1513 4,25 8,27E-01 3,55E-01 2,36E+01 
GOTERM_CC_FAT GO:0031966~mitochondrial membrane 5 2,58 0,025861844 54 33 1513 4,25 8,27E-01 3,55E-01 2,36E+01 
GOTERM_CC_FAT GO:0019866~organelle inner membrane 5 2,58 0,028564009 54 34 1513 4,12 8,57E-01 3,22E-01 2,57E+01 
GOTERM_CC_FAT GO:0005740~mitochondrial envelope 5 2,58 0,034459697 54 36 1513 3,89 9,05E-01 3,24E-01 3,02E+01 
SP_PIR_KEYWORDS transport 5 2,58 0,075990421 55 39 1291 3,01 9,67E-01 4,93E-01 5,21E+01 
GOTERM_CC_FAT GO:0031967~organelle envelope 5 2,58 0,078739793 54 47 1513 2,98 9,96E-01 4,97E-01 5,69E+01 
GOTERM_CC_FAT GO:0031975~envelope 5 2,58 0,094202564 54 50 1513 2,80 9,99E-01 4,85E-01 6,38E+01 
GOTERM_CC_FAT GO:0044429~mitochondrial part 5 2,58 0,1229241 54 55 1513 2,55 1,00E+00 5,50E-01 7,40E+01 
SP_PIR_KEYWORDS transmembrane 6 3,09 0,163754372 55 70 1291 2,01 1,00E+00 6,18E-01 8,11E+01 
SP_PIR_KEYWORDS membrane 5 2,58 0,277119958 55 64 1291 1,83 1,00E+00 7,19E-01 9,51E+01 
GOTERM_CC_FAT GO:0005739~mitochondrion 9 4,64 0,317264479 54 185 1513 1,36 1,00E+00 8,18E-01 9,80E+01 
GOTERM_CC_FAT GO:0031090~organelle membrane 5 2,58 0,34717512 54 85 1513 1,65 1,00E+00 8,32E-01 9,87E+01 
 
            
Annotation cluster 6 Enrichment score: 1.1918165215059067           
Category Term Count % P-value List total 
Pop 
hits 
Pop 
total 
Fold 
enrichment Bonferroni Benjamini FDR 
GOTERM_MF_FAT GO:0003746~translation elongation factor activity 5 2,58 0,006537976 89 24 2730 6,39 6,52E-01 1,11E-01 7,62E+00 
SP_PIR_KEYWORDS elongation factor 4 2,06 0,026329228 55 16 1291 5,87 6,83E-01 6,83E-01 2,20E+01 
GOTERM_MF_FAT GO:0008135~translation factor activity, nucleic acid binding 6 3,09 0,028360472 89 54 2730 3,41 9,90E-01 3,71E-01 2,94E+01 
GOTERM_BP_FAT GO:0006414~translational elongation 4 2,06 0,043409712 72 28 2497 4,95 1,00E+00 6,40E-01 4,39E+01 
INTERPRO IPR004161: Translation elongation factor EFTu/EF1A, domain 2 3 1,55 0,045794652 85 11 2636 8,46 1,00E+00 5,74E-01 4,39E+01 
GOTERM_MF_FAT GO:0003924~GTPase activity 5 2,58 0,089299775 89 53 2730 2,89 1,00E+00 7,15E-01 6,77E+01 
INTERPRO IPR000795:Protein synthesis factor, GTP-binding 3 1,55 0,090224913 85 16 2636 5,81 1,00E+00 7,91E-01 6,89E+01 
GOTERM_MF_FAT GO:0005525~GTP binding 7 3,61 0,108329092 89 102 2730 2,11 1,00E+00 7,58E-01 7,50E+01 
GOTERM_MF_FAT GO:0032561~guanyl ribonucleotide binding 7 3,61 0,108329092 89 102 2730 2,11 1,00E+00 7,58E-01 7,50E+01 
 
GOTERM_MF_FAT GO:0019001~guanyl nucleotide binding 7 3,61 0,108329092 89 102 2730 2,11 1,00E+00 7,58E-01 7,50E+01 
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SP_PIR_KEYWORDS GTP-binding 5 2,58 0,177087445 55 53 1291 2,21 1,00E+00 6,06E-01 8,37E+01 
INTERPRO IPR005225: Small GTP-binding protein 3 1,55 0,28353409 85 33 2636 2,82 1,00E+00 9,91E-01 9,84E+01 
 
List total: number of genes in the gene list (transcripts regulated by PKA) mapped to any term in this ontology. 
Pop hits (population hits): number of genes with this GO term on the background list (all transcripts identified by the RNAseq analysis). 
Pop total (population total): number of genes on the background list mapped to any term in this ontology. 
 
 
 
Table S2B: GO enrichment analysis of PKA downstream targets using TriTrypDB (www.tritrypdb.org). 
 
Biological process 
         
ID Name Background count 
Result 
count 
% of 
background 
Fold 
enrichment Odds ratio P-value Benjamini Bonferroni 
GO:0006072 glycerol-3-phosphate metabolic process 10 6 60 25,56 26,7 8,64E+04 3,63E+06 5,96E+06 
GO:0006418 tRNA aminoacylation for protein translation 30 8 26,7 11,36 12,01 1,71E+05 3,63E+06 1,18E-04 
GO:0043039 tRNA aminoacylation 31 8 25,8 10,99 11,62 2,10E+05 3,63E+06 1,45E-04 
GO:0043038 amino acid activation 31 8 25,8 10,99 11,62 2,10E+05 3,63E+06 1,45E-4 
GO:0006412 translation 327 21 6,4 2,74 3,05 3,65E+06 4,84E-04 2,52E-03 
GO:0006399 tRNA metabolic process 65 9 13,8 5,9 6,25 4,21E+05 4,84E-04 2,90E-03 
GO:0006520 cellular amino acid metabolic process 88 10 11,4 4,84 5,15 7,27E+06 7,16E-04 5,02E-03 
GO:0051726 regulation of cell cycle 35 6 17,1 7,3 7,59 3,03E-04 2,61E-03 2,09E-02 
GO:0044281 small molecule metabolic process 436 22 5 2,15 2,37 6,53E-04 5,01E-03 4,51E-02 
GO:0044237 cellular metabolic process 2109 68 3,2 1,37 1,75 9,26E-04 6,39E-03 6,39E-02 
GO:0034660 ncRNA metabolic process 105 9 8,6 3,65 3,84 1,14E-03 6,97E-03 7,85E-02 
GO:0044238 primary metabolic process 2173 69 3,2 1,35 1,72 1,29E-03 6,97E-03 8,88E-02 
GO:0034645 cellular macromolecule biosynthetic process 499 23 4,6 1,96 2,16 1,59E-03 6,97E-03 1,10E-01 
GO:0043436 oxoacid metabolic process 134 10 7,5 3,18 3,35 1,63E-03 6,97E-03 1,12E-01 
GO:0019752 carboxylic acid metabolic process 134 10 7,5 3,18 3,35 1,63E-03 6,97E-03 1,12E-01 
GO:0006082 organic acid metabolic process 135 10 7,4 3,16 3,33 1,72E-03 6,97E-03 1,18E-01 
GO:0009059 macromolecule biosynthetic process 502 23 4,6 1,95 2,15 1,72E-03 6,97E-03 1,18E-01 
GO:0044282 small molecule catabolic process 20 4 20 8,52 8,75 1,97E-03 7,21E-03 1,36E-01 
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GO:0010467 gene expression 637 27 4,2 1,81 2,01 1,99E-03 7,21E-03 1,37E-01 
GO:0044249 cellular biosynthetic process 810 32 4 1,68 1,89 2,19E-03 7,26E-03 1,51E-01 
GO:0042180 cellular ketone metabolic process 140 10 7,1 3,04 3,21 2,21E-03 7,26E-03 1,52E-01 
GO:0008284 positive regulation of cell proliferation 2 2 100 42,6 43,22 3,04E-03 9,27E-03 2,10E-01 
GO:0009987 cellular process 2785 82 2,9 1,25 1,64 3,09E-03 9,27E-03 2,13E-01 
GO:0009058 biosynthetic process 843 32 3,8 1,62 1,81 4,04E-03 1,15E-02 2,79E-01 
GO:0008152 metabolic process 2513 75 3 1,27 1,61 4,18E-03 1,15E-02 2,88E-01 
GO:0016070 RNA metabolic process 419 19 4,5 1,93 2,08 4,96E-03 1,32E-02 3,42E-01 
GO:0034641 cellular nitrogen compound metabolic process 981 35 3,6 1,52 1,7 6,79E-03 1,74E-02 4,69E-01 
GO:0019932 second-messenger-mediated signaling 4 2 50 21,3 21,6 7,37E-03 1,74E-02 5,09E-01 
GO:0042127 regulation of cell proliferation 4 2 50 21,3 21,6 7,37E-03 1,74E-02 5,09E-01 
GO:0006807 nitrogen compound metabolic process 988 35 3,5 1,51 1,69 7,57E-03 1,74E-02 5,22E-01 
GO:0044267 cellular protein metabolic process 927 33 3,6 1,52 1,68 9,04E-03 2,01E-02 6,24E-01 
GO:0019637 organophosphate metabolic process 98 7 7,1 3,04 3,15 1,01E-02 2,13E-02 6,95E-01 
GO:0006402 mRNA catabolic process 5 2 40 17,04 17,28 1,02E-02 2,13E-02 7,02E-01 
GO:0006139 nucleobase-containing compound metabolic process 944 33 3,5 1,49 1,65 1,17E-02 2,32E-02 8,07E-01 
GO:0050789 regulation of biological process 457 19 4,2 1,77 1,9 1,18E-02 2,32E-02 8,14E-01 
GO:0019538 protein metabolic process 1065 36 3,4 1,44 1,6 1,36E-02 2,61E-02 9,39E-01 
GO:0050794 regulation of cellular process 368 16 4,3 1,85 1,97 1,41E-02 2,63E-02 9,74E-01 
GO:0065007 biological regulation 485 19 3,9 1,67 1,78 2,06E-02 3,68E-02 1,00E+00 
GO:0006401 RNA catabolic process 8 2 25 10,65 10,79 2,08E-02 3,68E-02 1,00E+00 
GO:0006457 protein folding 142 8 5,6 2,4 2,49 2,14E-02 3,70E-02 1,00E+00 
GO:0008150 biological_process 3816 101 2,6 1,13 1,5 2,35E-02 3,96E-02 1,00E+00 
GO:0006414 translational elongation 25 3 12 5,11 5,21 2,54E-02 4,18E-02 1,00E+00 
GO:0007051 spindle organization 10 2 20 8,52 8,63 2,96E-02 4,67E-02 1,00E+00 
GO:0006413 translational initiation 29 3 10,3 4,41 4,48 3,61E-02 4,67E-02 1,00E+00 
GO:0033043 regulation of organelle organization 13 2 15,4 6,55 6,64 4,51E-02 4,67E-02 1,00E+00 
GO:0006438 valyl-tRNA aminoacylation 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0019563 glycerol catabolic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0044275 cellular carbohydrate catabolic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
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GO:0019405 alditol catabolic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0070408 carbamoyl phosphate metabolic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0033044 regulation of chromosome organization 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0006467 protein thiol-disulfide exchange 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0033047 regulation of mitotic sister chromatid segregation 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0006420 arginyl-tRNA aminoacylation 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0046164 alcohol catabolic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0046174 polyol catabolic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0006424 glutamyl-tRNA aminoacylation 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0070409 carbamoyl phosphate biosynthetic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0006543 glutamine catabolic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0006426 glycyl-tRNA aminoacylation 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0019933 cAMP-mediated signaling 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0006429 leucyl-tRNA aminoacylation 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0033045 regulation of sister chromatid segregation 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0019935 cyclic-nucleotide-mediated signaling 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0000291 nuclear-transcribed mRNA catabolic process, exonucleolytic 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0043044 ATP-dependent chromatin remodeling 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0046952 ketone body catabolic process 1 1 100 42,6 42,91 4,53E-02 4,67E-02 1,00E+00 
GO:0044260 cellular macromolecule metabolic process 1520 45 3 1,26 1,39 4,74E-02 4,81E-02 1,00E+00 
GO:0000226 microtubule cytoskeleton organization 33 3 9,1 3,87 3,94 4,86E-02 4,86E-02 1,00E+00 
 
 
Molecular function 
	  
	   	   	   	   	   	   	   	  
ID Name Background count 
Result 
count 
% of 
background 
Fold 
enrichment Odds ratio P-value Benjamini Bonferroni 
GO:0035639 purine ribonucleoside triphosphate binding 815 42 5,2 2,2 2,73 5,88E+04 8,58E+05 3,35E+06 
GO:0032555 purine ribonucleotide binding 816 42 5,1 2,19 2,73 6,07E+04 8,58E+05 3,46E+06 
GO:0032553 ribonucleotide binding 816 42 5,1 2,19 2,73 6,07E+04 8,58E+05 3,46E+06 
GO:0017076 purine nucleotide binding 818 42 5,1 2,19 2,72 6,48E+04 8,58E+05 3,69E+06 
GO:0016876 ligase activity, forming aminoacyl-tRNA and related compounds 28 8 28,6 12,17 12,87 1,10E+05 8,58E+05 6,25E+06 
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GO:0016875 ligase activity, forming carbon-oxygen bonds 28 8 28,6 12,17 12,87 1,10E+05 8,58E+05 6,25E+06 
GO:0004812 aminoacyl-tRNA ligase activity 28 8 28,6 12,17 12,87 1,10E+05 8,58E+05 6,25E+06 
GO:0000166 nucleotide binding 870 43 4,9 2,11 2,62 1,24E+05 8,58E+05 7,04E+05 
GO:0004370 glycerol kinase activity 5 5 100 42,6 44,19 1,35E+04 8,58E+05 7,72E+06 
GO:0036094 small molecule binding 907 43 4,7 2,02 2,49 3,64E+05 1,92E+06 2,08E-04 
GO:0005524 ATP binding 692 36 5,2 2,22 2,65 4,11E+05 1,92E+06 2,34E-04 
GO:0032559 adenyl ribonucleotide binding 693 36 5,2 2,21 2,65 4,24E+05 1,92E+06 2,42E-04 
GO:0030554 adenyl nucleotide binding 694 36 5,2 2,21 2,65 4,38E+05 1,92E+06 2,50E-04 
GO:0008135 translation factor activity, nucleic acid binding 53 7 13,2 5,63 5,88 4,01E-04 1,63E-03 2,28E-02 
GO:0005488 binding 2862 87 3 1,3 1,82 4,99E-04 1,90E-03 2,84E-02 
GO:0003723 RNA binding 384 20 5,2 2,22 2,43 8,09E-04 2,88E-03 4,61E-02 
GO:0016462 pyrophosphatase activity 418 21 5 2,14 2,35 9,26E-04 3,02E-03 5,28E-02 
GO:0016818 hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 419 21 5 2,14 2,34 9,53E-04 3,02E-03 5,43E-02 
GO:0003676 nucleic acid binding 807 33 4,1 1,74 1,98 1,04E-03 3,05E-03 5,91E-02 
GO:0016817 hydrolase activity, acting on acid anhydrides 423 21 5 2,12 2,32 1,07E-03 3,05E-03 6,10E-02 
GO:0004386 helicase activity 106 9 8,5 3,62 3,8 1,21E-03 3,28E-03 6,90E-02 
GO:0017111 nucleoside-triphosphatase activity 410 20 4,9 2,08 2,26 1,74E-03 4,51E-03 9,93E-02 
GO:0016874 ligase activity 113 9 8 3,39 3,56 1,83E-03 4,54E-03 1,04E-01 
GO:0003674 molecular_function 4258 114 2,7 1,14 1,87 3,29E-03 7,81E-03 1,88E-01 
GO:0016887 ATPase activity 202 12 5,9 2,53 2,68 3,52E-03 8,03E-03 2,01E-01 
GO:0002161 aminoacyl-tRNA editing activity 3 2 66,7 28,4 28,81 4,99E-03 1,09E-02 2,84E-01 
GO:0003746 translation elongation factor activity 16 3 18,8 7,99 8,15 8,74E-03 1,80E-02 4,98E-01 
GO:0003743 translation initiation factor activity 32 4 12,5 5,33 5,46 8,83E-03 1,80E-02 5,03E-01 
GO:0016787 hydrolase activity 898 32 3,6 1,52 1,68 1,01E-02 1,98E-02 5,75E-01 
GO:0003824 catalytic activity 2232 66 3 1,26 1,5 1,20E-02 2,27E-02 6,82E-01 
GO:0008026 ATP-dependent helicase activity 83 6 7,2 3,08 3,18 1,60E-02 2,85E-02 9,11E-01 
GO:0070035 purine NTP-dependent helicase activity 83 6 7,2 3,08 3,18 1,60E-02 2,85E-02 9,11E-01 
GO:0052689 carboxylic ester hydrolase activity 23 3 13 5,56 5,66 2,09E-02 3,60E-02 1,00E+00 
GO:0051082 unfolded protein binding 92 6 6,5 2,78 2,86 2,45E-02 4,11E-02 1,00E+00 
GO:0003924 GTPase activity 68 5 7,4 3,13 3,21 2,55E-02 4,15E-02 1,00E+00 
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GO:0032561 guanyl ribonucleotide binding 124 7 5,6 2,41 2,48 3,03E-02 4,53E-02 1,00E+00 
GO:0005525 GTP binding 124 7 5,6 2,41 2,48 3,03E-02 4,53E-02 1,00E+00 
GO:0019001 guanyl nucleotide binding 124 7 5,6 2,41 2,48 3,03E-02 4,53E-02 1,00E+00 
GO:0030246 carbohydrate binding 11 2 18,2 7,75 7,85 3,45E-02 4,53E-02 1,00E+00 
GO:0042623 ATPase activity, coupled 158 8 5,1 2,16 2,23 3,63E-02 4,53E-02 1,00E+00 
GO:0030295 protein kinase activator activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004832 valine-tRNA ligase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0031491 nucleosome binding 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004420 hydroxymethylglutaryl-CoA reductase (NADPH) activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0019209 kinase activator activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004814 arginine-tRNA ligase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004590 orotidine-5'-phosphate decarboxylase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004071 aspartate-ammonia ligase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004588 orotate phosphoribosyltransferase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0032574 5'-3' RNA helicase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0032575 ATP-dependent 5'-3' RNA helicase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004823 leucine-tRNA ligase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004055 argininosuccinate synthase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0043539 protein serine/threonine kinase activator activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004820 glycine-tRNA ligase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0008410 CoA-transferase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0004818 glutamate-tRNA ligase activity 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
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Cellular compartment 
        ID Name Background count Result count 
% of 
background Fold enrichment Odds ratio P-value Benjamini Bonferroni 
GO:0005832 chaperonin-containing T-complex 8 5 62,5 26,63 27,6 6,55E+05 2,23E-04 2,23E-04 
GO:0020015 glycosome 46 7 15,2 6,48 6,78 1,83E-04 1,75E-03 6,21E-03 
GO:0044445 cytosolic part 22 5 22,7 9,68 10,01 3,17E-04 1,75E-03 1,08E-02 
GO:0005623 cell 2707 84 3,1 1,32 1,84 3,48E-04 1,75E-03 1,18E-02 
GO:0044464 cell part 2707 84 3,1 1,32 1,84 3,48E-04 1,75E-03 1,18E-02 
GO:0005777 peroxisome 52 7 13,5 5,74 5,99 3,61E-04 1,75E-03 1,23E-02 
GO:0042579 microbody 52 7 13,5 5,74 5,99 3,61E-04 1,75E-03 1,23E-02 
GO:0005575 cellular_component 3314 96 2,9 1,23 1,8 1,01E-03 3,93E-03 3,44E-02 
GO:0044424 intracellular part 2446 76 3,1 1,32 1,73 1,04E-03 3,93E-03 3,53E-02 
GO:0005622 intracellular 2624 79 3 1,28 1,67 2,05E-03 6,98E-03 6,98E-02 
GO:0005743 mitochondrial inner membrane 83 7 8,4 3,59 3,73 4,39E-03 1,24E-02 1,49E-01 
GO:0019866 organelle inner membrane 83 7 8,4 3,59 3,73 4,39E-03 1,24E-02 1,49E-01 
GO:0043234 protein complex 489 21 4,3 1,83 1,98 5,74E-03 1,50E-02 1,95E-01 
GO:0005737 cytoplasm 1820 57 3,1 1,33 1,58 6,91E-03 1,68E-02 2,35E-01 
GO:0005852 eukaryotic translation initiation factor 3 complex 6 2 33,3 14,2 14,4 1,34E-02 2,63E-02 4,54E-01 
GO:0005853 eukaryotic translation elongation factor 1 complex 6 2 33,3 14,2 14,4 1,34E-02 2,63E-02 4,54E-01 
GO:0032991 macromolecular complex 776 28 3,6 1,54 1,68 1,41E-02 2,63E-02 4,79E-01 
GO:0044446 intracellular organelle part 637 24 3,8 1,61 1,73 1,45E-02 2,63E-02 4,93E-01 
GO:0031966 mitochondrial membrane 106 7 6,6 2,81 2,91 1,47E-02 2,63E-02 5,00E-01 
GO:0031090 organelle membrane 191 10 5,2 2,23 2,33 1,67E-02 2,83E-02 5,66E-01 
GO:0044422 organelle part 650 24 3,7 1,57 1,7 1,81E-02 2,93E-02 6,14E-01 
GO:0031967 organelle envelope 139 8 5,8 2,45 2,54 1,92E-02 2,93E-02 6,54E-01 
GO:0031975 envelope 140 8 5,7 2,43 2,52 2,00E-02 2,93E-02 6,78E-01 
GO:0005740 mitochondrial envelope 114 7 6,1 2,62 2,7 2,07E-02 2,93E-02 7,04E-01 
GO:0005829 cytosol 92 6 6,5 2,78 2,86 2,45E-02 3,34E-02 8,34E-01 
GO:0009986 cell surface 30 3 10 4,26 4,33 3,90E-02 4,53E-02 1,00E+00 
GO:0005730 nucleolus 30 3 10 4,26 4,33 3,90E-02 4,53E-02 1,00E+00 
GO:0000331 contractile vacuole 12 2 16,7 7,1 7,19 3,97E-02 4,53E-02 1,00E+00 
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GO:0031981 nuclear lumen 54 4 7,4 3,16 3,22 4,33E-02 4,53E-02 1,00E+00 
GO:0005876 spindle microtubule 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0009345 glycine-tRNA ligase complex 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0031332 RNAi effector complex 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0035097 histone methyltransferase complex 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
GO:0016442 RNA-induced silencing complex 1 1 100 42,6 42,91 4,53E-02 4,53E-02 1,00E+00 
 
Background count: number of genes in the background (all transcripts identified by the RNAseq analysis) with this term. 
Result count: number of genes in the gene list (transcripts regulated by PKA) with this term. 
% of background: of the genes in the background with this term, the percent that are present in the gene list.
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Figure S1: Developmental regulation of PKA subunit expression in monomorphic T. brucei cells. 
Protein expression of PKA subunits in slender and stumpy-like (stumpy*) MiTat 1.2 cells was 
analyzed by Western blotting using specific antibodies against PKAC1/2, PKAC3 and PKAR 
(Bachmaier et al., submitted manuscript, see chapter 5; Bachmaier et al, manuscript, see chapter 4.1). 
PFR-A/C detected by the monoclonal antibody L13D6 (Kohl et al., 1999) was used for normalization. 
The diagram shows the percentage of PKAR, PKAC1/2 and PKAC3 in the two different life cycle 
stages (slender was set to 100%). 
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Figure S2: Activation of T. brucei PKA by cold shock. 
A. VASP phosphorylation is independent of the cell density. Phosphorylation of the transgenically 
expressed PKA reporter substrate VASP was analyzed at the indicated cell densities and incubation 
times (2 min, 10 min, 30 min). Error bars represent SD of three independent biological replicates. 
B. PKA activity is not regulated by cis-aconitate in vivo. VASP phosphorylation was analyzed upon 
incubation with the indicated concentrations of cis-aconitate for 10 minutes. The diagram shows the 
average and range of two independent biological replicates. 
C. Analysis of VASP phosphorylation in slender versus stumpy-like monomorphic BSF trypanosomes 
at 37°C, 27°C, 20°C or 4°C, respectively. VASP expressing cells were incubated at the indicated 
temperatures for 10 minutes, followed by quantitative Western blotting to determine the percentage of 
phosphorylated VASP and the extent of the ‘stumpy-specific’ phosphorylation of PKAC1/2. Error 
bars represent SD of three independent biological replicates. The Western blot below the graph shows 
one representative experiment. 
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Figure S3: PKA subunit 
expression and VASP 
phosphorylation in PKA mutants. 
A. Western blot analysis of MiTat 
1.2 wild type (wt) and hemi- 
(PKAC3-/+, clones 1 and 2) and 
homozygous (PKAC3-/-, clones 1, 2 
and 3) deletion mutants of PKAC3. 
PKAC3 expression was analyzed 
using an anti-PKAC3 antibody 
(Bachmaier et al., manuscript; see 
chapter 4.1). The monoclonal 
antibody L13D6 detecting PFR-
A/C (Kohl et al., 1999) was used as 
loading control. 
B. Western blot analysis of the cell 
lines PKAC1/2 RNAi (clones 5 and 
7) and PKAC1 UTR RNAi (pool 
and clone 3) in the presence (+Tet) 
or absence (-Tet) of 10 µg/ml 
tetracycline (induced 24 h). The 
parental cell line MiTat 1.2 1313 
was included as control. The 
following antibodies were used: 
anti-PKAC1/2 (Bachmaier et al., 
manuscript; see chapter 4.1), anti-
PKAR (Bachmaier et al., submitted 
manuscript; see chapter 5) and anti-
PFR-A/C (loading control; Kohl et 
al., 1999). The normalized 
PKAC1/2 signal of the parental 
cells was set to 100%. 
Quantification of the PKAC1/2 
signal is indicated (in %) below the 
Western blots. 
C. Analysis of VASP 
phosphorylation in cell lines with 
inducible RNAi against PKAC1/2 
(clones 5 and 7; upper panel) or 
PKAC1 (pool and clone 3; lower 
panel), respectively. 
Phosphorylation of the PKA 
reporter substrate was analyzed in 
cells with (+Tet) or without (-Tet) 
induction of RNAi with 10 µg/ml 
tetracycline for 24 h followed by 
incubation at 37°C or 4°C, respectively, for 10 min. Error bars represent SD of three independent biological 
replicates. 
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Figure S4: Analysis of differentiation markers in cells with depleted PKAC1/2. 
A. Western blot analysis of PAD1 expression in pleomorphic AnTat 1.1 p cells grown on agarose 
plates. Slender cells derived from infected rats were plated on agarose plates. In a time course over 
four days cells were harvested from one plate each day, and PAD1 expression was analyzed by 
Western blot. PFR-A/C detected by the monoclonal antibody L13D6 (Kohl et al., 1999) was used as 
loading control. 
B. Surface expression of EP procyclin was analyzed by flow cytometry of AnTat 1.1 p wild type (wt) 
and PKAC1/2 RNAi cells induced (+Tet) or not (-Tet) with 10 µg/ml tetracycline. Samples for flow 
cytometry were taken from stumpy cells harvested from agarose plates followed by cultivation in 
DTM for 0 h or for 16 h at 27°C with or without addition of 6 mM cis-aconitate. 
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C. Kinetoplast repositioning during SS to PCF differentiation was analyzed in pleomorphic AnTat 1.1 
p wild type cells as well as in the derived PKAC1/2 RNAi cell line in the presence (+ Tet) or absence 
(- Tet) of 10 µg/ml tetracycline. The distance between kinetoplast and posterior end of the cell was 
determined at the indicated time points after initiation of differentiation by addition of 0.4 mM or 6 
mM cis-aconitate, respectively, using the software ImageJ. 
D. Representative microscopic images showing the kinetoplast repositioning during SS to PCF 
differentiation of AnTat 1.1 wild type cells and the derived PKAC1/2 RNAi cell line (RNAi induced: 
+Tet; RNAi non-induced: -Tet). 
 
 
 
 
 
Figure S5: Detection of RXXS*/T*-phosphorylated proteins in T. brucei BSF cells expressing the 
PKA reporter substrate VASP by 2D gel electrophoresis followed by Western blotting. 
BSF trypanosomes expressing the PKA reporter substrate VASP were incubated for 10 min at 37°C or 
4°C, respectively, followed by lysis and separation of the proteins by isoelectric focusing (IEF) and 
SDS PAGE. Each sample was run in duplicates. While one gel was stained with Colloidal Coomassie 
(bottom), the other one was blotted to a PVDF membrane (top). Detection of phosphorylated 
RXXS*/T* proteins was carried out using the anti-RXXS*/T* antibody. The spots encircled in the 
Western blot and in the Coomassie-stained gel with the cold shocked sample represent spots, which 
were cut and subjected to MS/MS. They represent the transgenically expressed PKA reporter substrate 
VASP. 
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Table S1: Identified candidate substrates of T. brucei PKA.  	  
# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
136 Tb927.7.3550 hypothetical protein, conserved null null 
unknown 
function c 
P-peptide 
identified 
(RELS* 
(S587)) 
not predicted 
to be a PKA 
site 
PM, CS x   
x 
(C2 
domain) 
65 Tb927.1.4310 hypothetical protein, conserved 
protein 
binding null 
unknown 
function k     PM, CS x     
63 Tb927.8.6660 
paraflagellar rod 
component, putative 
(PFC1) 
null null unknown function k 
P-peptide 
identified 
(RRQT 
(T477)) 
0,71 PM, CS x x x (EF hand) 
53 Tb11.01.0680 leucine rich repeat (TbLRRP1) null null motility c 
P-peptide 
identified 
(RPPS 
(S559); 
RSAS 
(S608); 
RRRS 
(S620)) 
0.74; 0.65; 
0.89 PM CS x     
51 Tb927.4.2920 hypothetical protein, conserved null null 
unknown 
function t 
P-peptide 
identified 
(RRLS 
(S395)) 
0,85 PM x     
41 Tb09.160.1160 nucleolar protein (NOP86) null null other k     PM, CS x     
39 Tb927.8.8330 
calpain, putative, 
cysteine peptidase, 
putative 
calcium-
dependent 
cysteine-
type 
endopepti-
dase 
activity 
proteolysis 
protein 
transport 
and 
maturation 
k 
P-peptide 
identified 
(RRPS 
(S261)) 
0,81 PM, CS x   
x 
(calcium-
dep. cystein 
peptidase) 
38 Tb927.10.840 hypothetical protein, conserved null null other k 
P-peptide 
identified 
(RLHS 
(S1112 or 
S1240)) 
0.54; 0.66 PM, CS x	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
33 Tb927.1.2330 beta tubulin 
GTP 
binding, 
GTPase 
activity, 
structural 
molecule 
activity 
microtubule-
based 
movement, 
microtubule-
based 
process, 
protein 
polymeriza-
tion 
motility c     PM, CS x x   
31 Tb927.10.10980 
heat shock protein 
83,heat shock 
protein 
ATP 
binding, 
unfolded 
protein 
binding 
protein 
folding, 
response to 
stress 
protein 
folding c 
P-peptide 
identified 
(RFHS 
(S442)) 
0,51 PM x	       
31 Tb927.1.2340 alpha tubulin 
GTP 
binding, 
GTPase 
activity, 
structural 
molecule 
activity 
microtubule-
based 
movement, 
microtubule-
based 
process, 
protein 
polymeriza-
tion 
motility c     PM, CS 	  	   x   
30 Tb927.10.5620 
fructose-
bisphosphate 
aldolase, glycosomal 
(ALD) 
84 glycolysis 
carbohy-
drate 
metabolism 
c     PM, CS x x   
29 Tb11.02.1085 40S ribosomal protein S4, putative 
RNA 
binding, 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     PM, CS 	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
27 Tb927.2.2720 protein kinase, putative 
ATP 
binding, 
protein 
kinase 
activity, 
protein 
serine/threo
nine kinase 
activity, 
protein 
tyrosine 
kinase 
activity 
protein 
phosphorylati
on 
signaling k 
P-peptide 
identified 
(RPHS 
(S492); 
RRTS 
(S1427)) 
not predicted 
to be a PKA 
site; 0.88 
  	  	       
24 Tb927.4.2080 
C2 domain 
containing protein 
(CC2D) 
null null other k 
P-peptide 
identified 
(RNNS 
(S488)) 
0,76 PM, CS x   
x 
(C2 
domain) 
24 Tb927.6.4280 
glyceraldehyde 3-
phosphate 
dehydrogenase, 
glycosomal 
(GAPDH) 
NAD or 
NADH 
binding, 
binding, 
catalytic 
activity, 
glyceralde-
hyde-3-
phosphate 
dehydroge-
nase 
activity 
glucose 
metabolic 
process, 
metabolic 
process 
carbohy-
drate 
metabolism 
c     PM, CS x x   
22 Tb927.10.2110 elongation factor 1-alpha (TEF1) 
GTP 
binding, 
GTPase 
activity, 
translation 
elongation 
factor 
activity 
translational 
elongation 
ribosome 
biogenesis / 
translation 
c     PM, CS x x   
22 Tb11.02.5450 
glucose-regulated 
protein 78, 
putative,luminal 
binding protein 1 
(BiP), putative 
ATP 
binding null 
protein 
folding c     PM 	  	   x   
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
20 Tb927.3.3270 
ATP-dependent 
phosphofructokinase 
(TbPFK) 
6-phospho-
fructokina-
se activity, 
ATP 
binding 
glycolysis 
carbohy-
drate 
metabolism 
c     PM, CS x x   
20 Tb09.160.5250 
adenosine 
monophosphate 
deaminase, 
putative,AMP 
deaminase, putative 
deaminase 
activity 
purine 
ribonucleo-
side 
monophos-
phate 
biosynthetic 
process 
other 
metabolism c     PM, CS x     
20 Tb927.4.1800 
ribosomal protein 
L3, mitochondrial, 
putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c       	  	       
19 Tb927.10.6050 clathrin heavy chain (CHC) 
binding, 
protein 
binding, 
structural 
molecule 
activity 
intracellular 
protein 
transport, 
vesicle-
mediated 
transport 
protein 
transport 
and 
maturation 
c     PM x     
18 Tb09.211.0620 actin A protein binding null other c     PM, CS 	  	       
18 Tb927.10.4560 elongation factor 2 
GTP 
binding, 
GTPase 
activity 
null 
ribosome 
biogenesis / 
translation 
c     PM, CS 	  	       
17 Tb927.1.1100 hypothetical protein, conserved null null motility k       	  	       
16 Tb09.211.3550 glycerol kinase, glycosomal (glk1) 
glycerol 
kinase 
activity 
carbohydrate 
metabolic 
process, 
glycerol-3-
phosphate 
metabolic 
process 
carbohy-
drate 
metabolism 
c     PM, CS x x   
16 Tb927.10.5910 hypothetical protein, conserved null null 
unknown 
function k       	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
14 Tb11.02.2210 
protein kinase A 
regulatory subunit 
(PKA-R) 
cAMP-
dependent 
protein 
kinase 
regulator 
activity 
regulation of 
protein 
phosphorylati
on 
signaling c     PM, CS x     
14 Tb927.10.8940 hypothetical protein, conserved null null 
protein 
transport 
and 
maturation 
k     PM, CS x     
14 Tb11.02.4190 MRB1-associated protein 
protein 
binding null 
unknown 
function k       	  	       
13 Tb11.02.0170 hypothetical protein, conserved null null 
unknown 
function t 
P-peptide 
identified 
(RTLS 
(S357)) 
0,74 PM, CS x	       
13 Tb11.55.0006 
intraflagellar 
transport protein 
IFT88 (IFT88) 
null null 
protein 
transport 
and 
maturation 
c       	  	       
13 Tb11.01.5570 NRBD1 (NRBD1) nucleic acid binding null 
RNA 
associated k     CS 	  	       
12 Tb927.10.2890 enolase 
phospho-
pyruvate 
hydratase 
activity 
glycolysis 
carbohy-
drate 
metabolism 
c       x     
12 Tb09.244.2630 40S ribosomal protein S6, putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     PM, CS x     
12 Tb927.3.5050 60S ribosomal protein L4 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     PM, CS x     
12 Tb927.3.3300 hypothetical protein, conserved null null 
unknown 
function t     PM, CS x     
12 Tb09.211.1620 hypothetical protein, conserved null null 
unknown 
function c       	  	       
Supplem
ental M
aterial - C
hapter 4.2
	  	  
219	  	  
# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
12 Tb927.3.1010 hypothetical protein, conserved null null 
unknown 
function t     PM, CS 	  	       
11 Tb927.10.11390 60S ribosomal protein L6, putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     CS x     
11 Tb927.3.3310 
60S ribosomal 
protein L13, 
putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     CS x     
11 Tb927.2.4710 
RNA-binding 
protein, putative 
(TRRM1) 
nucleic acid 
binding, 
zinc ion 
binding 
null RNA associated c     PM x     
11 Tb927.7.2450 hypothetical protein, conserved null null 
unknown 
function k       	  	       
11 Tb927.10.1510 NOT1 (NOT1) null null unknown function c     PM 	  	       
11 Tb927.10.8830 hypothetical protein, conserved 
heat shock 
protein 
binding 
null protein folding k     PM 	  	       
10 Tb927.10.2010 hexokinase (HK1) ATP binding 
carbohydrate 
metabolic 
process 
carbohy-
drate 
metabolism 
c     PM x x   
10 Tb927.10.890 kinesin, putative 
ATP 
binding, 
microtubule 
motor 
activity, 
nucleotide 
binding 
microtubule-
based 
movement 
motility t       x     
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
10 Tb11.02.0760 dynein heavy chain, putative 
ATP 
binding, 
ATPase 
activity, 
microtubule 
motor 
activity, 
nucleoside-
triphospha-
tase 
activity, 
nucleotide 
binding 
biolumines-
cence, 
microtubule-
based 
movement, 
protein-
chromophore 
linkage 
motility c     PM,  CS x     
10 Tb927.6.3740 
heat shock 70 kDa 
protein, 
mitochondrial 
precursor, putative 
ATP 
binding, 
unfolded 
protein 
binding 
protein 
folding 
protein 
folding c     PM x x   
10 Tb927.10.450 hypothetical protein, conserved null null motility c       x     
10 Tb11.01.4940 AAA ATPase, putative 
ATP 
binding, 
nucleoside-
triphospha-
tase 
activity, 
nucleotide 
binding 
null metabolism c       	  	       
10 Tb927.8.1330 60S ribosomal protein L7a, putative null null 
ribosome 
biogenesis / 
translation 
c     PM, CS 	  	       
Supplem
ental M
aterial - C
hapter 4.2
	  	  
221	  	  
# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
10 Tb927.10.13720 
RNA-binding 
protein, putative 
(RBP29) 
nucleic acid 
binding null 
RNA 
associated k       	  	       
10 Tb927.10.5140 
protein kinase, 
putative, mitogen-
activated protein 
kinase 2, putative 
ATP 
binding, 
protein 
kinase 
activity, 
protein 
serine/ 
threonine 
kinase 
activity, 
protein 
tyrosine 
kinase 
activity 
protein 
phosphory-
lation 
signaling c     PM 	  	       
10 Tb11.02.1540 hypothetical protein, conserved null null 
unknown 
function k       	  	       
9 Tb927.1.700 phosphoglycerate kinase (PGKC) 
phospho-
glycerate 
kinase 
activity 
glycolysis 
carbohy-
drate 
metabolism 
c       x x   
9 Tb11.01.3110 heat shock protein 70 
ATP 
binding null 
protein 
folding c     PM, CS x x   
9 Tb927.2.5160 chaperone protein DNAj, putative 
heat shock 
protein 
binding, 
unfolded 
protein 
binding 
protein 
folding 
protein 
folding c       x     
9 Tb927.7.5000 
60S ribosomal 
protein L19, 
putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     CS x     
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
9 Tb09.211.2150 
Polyadenylate-
binding protein 2 
(Poly(A)-binding 
protein 2) (Poly(A)-
binding protein II) 
(PABII) 
(Polyadenylate-
binding nuclear 
protein 1) (Nuclear 
poly(A)-binding 
protein 1) (PABP2), 
putative (PABP2) 
RNA 
binding, 
nucleic acid 
binding 
null RNA associated c     PM, CS x     
9 Tb927.8.900 splicing factor TSR1 (TSR1) 
nucleic acid 
binding null 
RNA 
associated c       x     
9 Tb11.02.0810 hypothetical protein, conserved null null 
unknown 
function c     PM, CS x     
9 Tb927.10.3930 
40S ribosomal 
protein S3A, 
putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c no RXXS/T   CS 	  	       
9 Tb927.7.1730 60S ribosomal protein L7, putative 
structural 
constituent 
of 
ribosome, 
transcrip-
tion 
regulator 
activity 
translation 
ribosome 
biogenesis / 
translation 
c     CS 	  	       
9 Tb927.10.14550 
ATP-dependent 
DEAD/H RNA 
helicase, putative 
ATP 
binding, 
ATP-
dependent 
helicase 
activity, 
helicase 
activity, 
nucleic acid 
binding 
null RNA associated c       	  	       
9 Tb927.7.6730 hypothetical protein, conserved null null 
unknown 
function k       	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
9 Tb927.8.5710 
recombination 
initiation protein 
NBS1, putative 
null null unknown function k     PM 	  	       
8 Tb927.3.930 dynein heavy chain, putative 
ATP 
binding, 
ATPase 
activity, 
microtubule 
motor 
activity, 
nucleoside-
triphospha-
tase 
activity, 
nucleotide 
binding 
microtubule-
based 
movement 
motility c     PM, CS x     
8 Tb927.10.8190 
T-complex protein 
1, theta subunit, 
putative, CCT-theta, 
putative (TCP-1-
theta) 
ATP 
binding, 
protein 
binding, 
unfolded 
protein 
binding 
cellular 
protein 
metabolic 
process, 
protein 
folding 
protein 
folding c       x     
8 Tb11.01.7960 
60S ribosomal 
protein L2, 
putative,60S 
ribosomal protein 
L8, putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c no RXXS/T   CS x	       
8 Tb927.8.6150 40S ribosomal protein S8, putative null null 
ribosome 
biogenesis / 
translation 
c     CS x     
8 Tb927.10.2880 calcium channel protein, putative 
ion channel 
activity ion transport transport c     PM x   
x 
(calcium 
channel) 
8 Tb09.160.0650 hypothetical protein, conserved null null 
unknown 
function k     PM, CS x	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
8 Tb927.4.4570 hypothetical protein, conserved 
sequence-
specific 
DNA 
binding 
transcriptio
n factor 
activity 
regulation of 
transcription other k       	  	       
8 Tb09.244.2730 unspecified product 
5S rRNA 
binding, 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     CS 	  	       
8 Tb11.01.3420 
eukaryotic 
translation initiation 
factor, putative 
null null 
ribosome 
biogenesis / 
translation 
c       	  	       
8 Tb927.10.2240 hypothetical protein, conserved null transport transport k       	  	       
8 Tb09.160.5060 hypothetical protein, conserved null null 
unknown 
function k     PM, CS 	  	       
8 Tb927.7.7190 hypothetical protein, conserved null null 
unknown 
function t       	  	       
7 Tb927.3.4720 
dynamin, 
putative,vacuolar 
sortin protein 1, 
putative 
GTP 
binding, 
GTPase 
activity 
null other c     PM x     
7 Tb11.02.4700 14-3-3 protein 
protein 
domain 
specific 
binding 
null other c       x     
7 Tb11.01.5860 
T-complex protein 
1, epsilon subunit, 
putative (TCP-1-
epsilon) 
ATP 
binding, 
protein 
binding, 
unfolded 
protein 
binding 
cellular 
protein 
metabolic 
process, 
protein 
folding 
protein 
folding c     PM x     
7 Tb927.7.710 
heat shock 70 kDa 
protein, putative 
(HSP70) 
ATP 
binding null 
protein 
folding c     PM x     
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
7 Tb09.211.3610 
ubiquitin-activating 
enzyme E1, putative 
(UBA2) 
ATP 
binding, 
catalytic 
activity, 
small 
protein 
activating 
enzyme 
activity 
protein 
modification 
process 
protein 
transport 
and 
maturation 
k       x     
7 Tb927.10.1170 
intraflagellar 
transport protein 
IFT172, putative 
(IFT172) 
null null 
protein 
transport 
and 
maturation 
c       x x   
7 Tb927.3.2600 
ATP-dependent 
DEAD/H RNA 
helicase, putative 
ATP 
binding, 
ATP-
dependent 
helicase 
activity, 
helicase 
activity, 
nucleic acid 
binding 
null RNA associated c       x     
7 Tb927.4.2180 
60S ribosomal 
protein L35a, 
putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     CS x     
7 Tb11.01.8770 
leucine-rich repeat 
protein (LRRP), 
putative 
carbohy-
drate 
binding, 
protein 
binding 
null motility c     PM, CS x     
7 Tb927.10.14710 
40S ribosomal 
protein S2, putative 
(RPS2) 
RNA 
binding, 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     PM, CS x     
7 Tb927.10.12680 
60S ribosomal 
protein L34, 
putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c no RXXS/T     x	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
7 Tb927.2.5870 hypothetical protein, conserved null null 
unknown 
function k 
P-peptide 
identified 
(RRAS 
(S1678)) 
0,8 CS 	  	       
7 Tb11.02.5050 protein kinase, putative 
ATP 
binding, 
protein 
kinase 
activity, 
protein 
serine/ 
threonine 
kinase 
activity, 
protein 
tyrosine 
kinase 
activity 
protein 
phosphory-
lation 
signaling c       	  	       
7 Tb09.160.4610 unspecified product null null unknown function t       	  	       
7 Tb927.5.3240 hypothetical protein, conserved null null 
unknown 
function k       	  	       
7 Tb927.6.2210 hypothetical protein, conserved binding null 
unknown 
function c       	  	       
7 Tb11.01.2560 40S ribosomal protein SA, putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     PM, CS 	  	       
7 Tb927.1.4280 hypothetical protein, conserved 
protein 
binding null 
unknown 
function t     PM, CS 	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
6 Tb927.5.800 casein kinase I, isoform 2 (CK1.2) 
ATP 
binding, 
protein 
kinase 
activity, 
protein 
serine/threo
nine kinase 
activity, 
protein 
tyrosine 
kinase 
activity 
protein 
phosphory-
lation 
signaling c 
P-peptide 
identified 
(RYCS 
(S186)) 
0,7 PM, CS x     
6 Tb09.211.3180 
6-phosphogluconate 
dehydrogenase, 
decarboxylating 
(gnD) 
NADP or 
NADPH 
binding, 
binding, 
catalytic 
activity, 
oxidoreduc-
tase activity 
metabolic 
process, 
oxidation-
reduction 
process, 
pentose-
phosphate 
shunt 
metabolism c       x x   
6 Tb927.10.540 
ATP-dependent 
DEAD/H RNA 
helicase, putative, 
DEAD box RNA 
helicase, putative 
ATP 
binding, 
ATP-
dependent 
helicase 
activity, 
helicase 
activity, 
nucleic acid 
binding 
null RNA associated c       x     
6 Tb09.211.3510 
ATP-dependent 
DEAD/H RNA 
helicase, putative 
(DED1) 
ATP 
binding, 
ATP-
dependent 
helicase 
activity, 
helicase 
activity, 
nucleic acid 
binding 
null RNA associated c       x     
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
6 Tb927.8.2390 hypothetical protein, conserved null null 
unknown 
function k       x     
6 Tb927.10.14890 
C-terminal motor 
kinesin, putative 
(TBKIFC1) 
ATP 
binding, 
microtubule 
motor 
activity 
intracellular 
protein 
transport, 
microtubule-
based 
movement 
motility c     PM x     
6 Tb11.02.0250 heat shock protein 84, putative 
ATP 
binding, 
unfolded 
protein 
binding 
protein 
folding, 
response to 
stress 
protein 
folding c     PM x x   
6 Tb09.160.3270 
ATP-dependent 
DEAD box helicase, 
putative 
ATP 
binding, 
ATP-
dependent 
helicase 
activity, 
helicase 
activity, 
nucleic acid 
binding 
null RNA associated c     PM x     
6 Tb11.02.0030 
Cytoplasmic dynein 
2 heavy chain 
(DYNC2H1), 
putative, 
Cytoplasmic dynein 
2 heavy chain 
(DYNC2H2), 
putative (DHC1b) 
ATP 
binding, 
ATPase 
activity, 
microtubule 
motor 
activity, 
nucleotide 
binding 
microtubule-
based 
movement 
motility c     PM x     
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
6 Tb927.8.3530 
glycerol-3-
phosphate 
dehydrogenase 
[NAD ], glycosomal 
NAD or 
NADH 
binding, 
binding, 
catalytic 
activity, 
oxidoreduct
ase activity, 
protein 
homodimer
ization 
activity 
carbohydrate 
metabolic 
process, 
glycerol-3-
phosphate 
catabolic 
process, 
glycerol-3-
phosphate 
metabolic 
process, 
metabolic 
process, 
oxidation-
reduction 
process 
carbohy-
drate 
metabolism 
c     PM, CS x x   
6 Tb927.2.340 
retrotransposon hot 
spot protein 4 
(RHS4), putative 
null null unknown function t     PM, CS x     
6 Tb927.10.6510 
chaperonin HSP60, 
mitochondrial 
precursor (HSP60) 
ATP 
binding, 
protein 
binding 
cellular 
protein 
metabolic 
process 
protein 
folding c     PM, CS x x   
6 Tb09.211.0110 
60S ribosomal 
protein L10, 
putative, QM-like 
protein (QM) 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c       x	       
6 Tb11.46.0001 
60S acidic 
ribosomal subunit 
protein, putative 
structural 
constituent 
of ribosome 
ribosome 
biogenesis, 
translational 
elongation 
ribosome 
biogenesis / 
translation 
c no RXXS/T   CS 	  	   x   
6 Tb927.10.13180 hypothetical protein, conserved null null 
RNA 
associated c     CS 	  	       
6 Tb927.3.4750 
aminopeptidase, 
putative, metallo-
peptidase, Clan 
MA(E) Family M1 
metallopep-
tidase 
activity, 
zinc ion 
binding 
null 
protein 
transport 
and 
maturation 
c       X	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
6 Tb09.211.3270 unspecified product 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c       	  	       
6 Tb927.8.4450 
RNA-binding 
protein, putative 
(RBP11) 
nucleic acid 
binding null 
RNA 
associated c       	  	       
6 Tb927.5.1560 
ATP-dependent 
DEAD/H RNA 
helicase, putative 
ATP 
binding, 
ATP-
dependent 
helicase 
activity, 
helicase 
activity, 
nucleic acid 
binding 
null RNA associated c       	  	       
6 Tb11.01.4230 protein kinase, putative 
ATP 
binding, 
protein 
kinase 
activity, 
protein 
serine/threo
nine kinase 
activity, 
protein 
tyrosine 
kinase 
activity 
protein 
phosphory-
lation 
signaling c       	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
6 Tb927.10.13780 glycogen synthase kinase 3 (GSK3) 
ATP 
binding, 
protein 
kinase 
activity, 
protein 
serine/threo
nine kinase 
activity, 
protein 
tyrosine 
kinase 
activity 
protein 
phosphory-
lation 
signaling c       	  	       
6 Tb09.160.5670 
predicted 
tetratricopeptide 
repeat protein 
null null 
protein 
transport 
and 
maturation 
c       	  	       
6 Tb927.8.3840 hypothetical protein, conserved null null 
unknown 
function k       	  	       
5 Tb927.8.3150 
T-complex protein 
1, gamma subunit, 
putative (TCP-1-
gamma) 
ATP 
binding, 
protein 
binding, 
unfolded 
protein 
binding 
cellular 
protein 
metabolic 
process, 
protein 
folding 
protein 
folding c       x     
5 Tb927.7.900 hypothetical protein, conserved null null 
unknown 
function k     PM x x   
5 Tb927.3.4290 PFR1 (PFR1) calmodulin binding null motility k     PM, CS x x 
 x 
(calmodulin 
binding) 
5 Tb927.8.3060 
cytosolic leucyl 
aminopeptidase, 
putative, metallo-
peptidase, Clan MF, 
Family M17 
aminopep-
tidase 
activity 
proteolysis 
protein 
transport 
and 
maturation 
c     PM, CS x     
5 Tb927.10.13500 60S ribosomal protein L10a 
RNA 
binding 
RNA 
processing 
ribosome 
biogenesis / 
translation 
c no RXXS/T   PM, CS x     
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
5 Tb927.8.1590 
ubiquitin-protein 
ligase, putative 
(upl3) 
acid-amino 
acid ligase 
activity, 
zinc ion 
binding 
protein 
modification 
process 
protein 
transport 
and 
maturation 
c     CS 	  	       
5 Tb927.10.12490 kinesin, putative 
ATP 
binding, 
microtubule 
motor 
activity, 
sequence-
specific 
DNA 
binding 
microtubule-
based 
movement 
motility k       	  	       
5 Tb11.03.0880 
predicted WD40 
repeat protein 
(PIFTF6) 
null null 
protein 
transport 
and 
maturation 
c       	  	       
5 Tb927.7.3180 
Mu-adaptin 1, 
putative,adaptor 
complex AP-1 
medium subunit, 
putative 
protein 
binding 
intracellular 
protein 
transport, 
transport, 
vesicle-
mediated 
transport 
protein 
transport 
and 
maturation 
c       	  	       
5 Tb927.10.14680 ribosome biogenesis protein, putative null null 
ribosome 
biogenesis / 
translation 
c       	  	       
5 Tb927.3.2470 
pumilio RNA 
binding protein, 
putative (PUF8) 
RNA 
binding, 
binding 
null RNA associated c       	  	       
5 Tb927.3.4600 hypothetical protein, conserved binding null 
protein 
transport 
and 
maturation 
k       	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
5 Tb927.10.180 
ATP synthase F1 
subunit gamma 
protein, putative 
null 
ATP 
synthesis 
coupled 
proton 
transport 
metabolism c     PM 	  	       
5 Tb927.3.4070 hypothetical protein, conserved null null transport k     PM 	  	       
5 Tb11.47.0011 hypothetical protein, conserved null null 
unknown 
function c     PM 	  	       
5 Tb927.10.15660 hypothetical protein, conserved null null 
unknown 
function t     PM 	  	       
5 Tb09.211.4511 
kinetoplastid 
membrane protein 
KMP-11 
null 
defense 
response, 
positive 
regulation of 
cell 
proliferation 
other k     PM, CS 	  	   x   
5 Tb09.211.1800 hypothetical protein, conserved null null other c     PM, CS 	  	       
5 Tb11.01.6790 hypothetical protein, conserved null null 
unknown 
function t     PM, CS 	  	       
4 Tb927.10.12710 heat shock protein 110, putative 
ATP 
binding null 
protein 
folding c       x     
4 Tb927.10.3660 aspartate aminotransferase 
pyridoxal 
phosphate 
binding, 
transaminas
e activity 
biosynthetic 
process, 
cellular 
amino acid 
metabolic 
process 
other 
metabolism c       x     
4 Tb927.7.5610 hypothetical protein, conserved null null 
unknown 
function k       x     
4 Tb11.02.1420 hypothetical protein, conserved null null 
unknown 
function k       x     
4 Tb11.02.5280 
glycerol-3-
phosphate 
dehydrogenase 
(FAD-dependent), 
mitochondrial 
glycerol-3-
phosphate 
dehydrogen
ase activity, 
oxidoreduc-
tase activity 
glycerol-3-
phosphate 
metabolic 
process 
carbohy-
drate 
metabolism 
c     PM x x   
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
4 Tb927.10.14140 pyruvate kinase 1 (PYK1) 
catalytic 
activity, 
magnesium 
ion binding, 
potassium 
ion binding, 
pyruvate 
kinase 
activity 
glycolysis 
carbohy-
drate 
metabolism 
c     PM, CS x x   
4 Tb927.3.2310 PACRGA binding null motility c no RXXS/T   PM, CS x x   
4 Tb11.01.1960 hypothetical protein, conserved null null 
unknown 
function k     PM, CS x     
4 Tb927.7.2390 hypothetical protein, conserved null null 
unknown 
function k     PM, CS x     
4 Tb10.v4.0052 
microtubule-
associated protein 
2,chrX additional, 
unordered contigs 
null null unknown function c       x	       
4 Tb09.211.0180 hypothetical protein, conserved null 
cell 
proliferation 
ribosome 
biogenesis / 
translation 
c     CS 	  	       
4 Tb927.7.2170 hypothetical protein, conserved 
protein 
binding, 
telomeric 
DNA 
binding 
telomere 
maintenance 
via 
telomerase 
other k     CS 	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
4 Tb11.02.3360 
replication factor C, 
subunit 1, putative, 
replication factor C 
large subunit, 
putative 
ATP 
binding, 
ATP-
dependent 
peptidase 
activity, 
DNA 
binding, 
DNA 
clamp 
loader 
activity, 
nucleoside-
triphospha-
tase 
activity, 
nucleotide 
binding, 
serine-type 
endopepti-
dase 
activity 
DNA 
replication, 
proteolysis 
other c       	  	       
4 Tb927.10.15520 
signal recognition 
particle protein, 
putative 
7S RNA 
binding 
SRP-
dependent 
cotranslatio-
nal protein 
targeting to 
membrane 
protein 
transport 
and 
maturation 
c       	  	       
4 Tb09.160.5580 
60S ribosomal 
protein L11, 
putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c       	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
4 Tb11.01.1050 hypothetical protein, conserved 
ATP 
binding, 
protein 
kinase 
activity, 
protein 
serine/threo
nine kinase 
activity, 
protein 
tyrosine 
kinase 
activity 
protein 
phosphory-
lation 
signaling k       	  	       
4 Tb09.160.1790 hypothetical protein, conserved null null 
RNA 
associated k       	  	       
4 Tb11.02.5580 hypothetical protein, conserved null null 
unknown 
function t       	  	       
4 Tb927.10.12430 hypothetical protein, conserved binding null 
unknown 
function c       	  	       
4 Tb927.10.850 hypothetical protein, conserved null null 
unknown 
function c       	  	       
4 Tb927.5.2770 hypothetical protein, conserved null null 
unknown 
function k       	  	       
4 Tb927.7.4410 hypothetical protein, conserved null null 
unknown 
function t       	  	       
4 Tb927.10.14840 
mitochondrial 
carrier protein 
(MCP5a) 
binding, 
transporter 
activity 
transport transport c     PM, CS 	  	       
4 Tb927.3.2050 hypothetical protein, conserved null null 
unknown 
function k     PM, CS 	  	       
4 Tb927.3.5370 hypothetical protein, conserved null null 
unknown 
function k     PM, CS 	  	       
4 Tb927.5.2330 hypothetical protein, conserved binding null 
unknown 
function k     PM, CS 	  	       
4 Tb927.8.6980 hypothetical protein, conserved null null 
unknown 
function c     PM, CS 	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
3 Tb927.3.2230 
succinyl-CoA 
synthetase alpha 
subunit, putative 
binding, 
catalytic 
activity 
metabolic 
process 
carbohy-
drate 
metabolism 
c       x x   
3 Tb927.10.3990 DHH1 (DHH1) 
ATP 
binding, 
ATP-
dependent 
helicase 
activity, 
helicase 
activity, 
nucleic acid 
binding 
null RNA associated c       x     
3 Tb927.4.1080 V-type ATPase, A subunit, putative null 
ATP 
metabolic 
process, ATP 
synthesis 
coupled 
proton 
transport, 
proton 
transport 
transport c       x     
3 Tb927.8.980 
phosphoacetylglucos
amine mutase, 
putative,acetylgluco
saminephosphomuta
se, putative,N-
acetylglucosamine-
phosphate mutase, 
putative 
phosphoace
tylglucosa
mine 
mutase 
activity 
carbohydrate 
metabolic 
process 
carbohy-
drate 
metabolism 
c       x     
3 Tb11.01.8510 
T-complex protein 
1, alpha subunit, 
putative (TCP-1-
alpha) 
ATP 
binding, 
protein 
binding 
cellular 
protein 
metabolic 
process 
protein 
folding c     PM x     
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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
3 Tb927.10.12510 P-type H -ATPase, putative 
ATP 
binding, 
ATPase 
activity, 
catalytic 
activity 
ATP 
biosynthetic 
process, 
cation 
transport, 
metabolic 
process 
transport c     PM x     
3 Tb09.211.1750 
mitochondrial 
carrier protein 
(MCP11) 
binding transport transport c no RXXS/T   PM, CS x x   
3 Tb927.3.1120 
GTP-binding 
nuclear protein rtb2, 
putative (rtb2) 
GTP 
binding, 
GTPase 
activity, 
protein 
binding 
intracellular 
protein 
transport, 
nucleocytopla
smic 
transport, 
protein 
transport, 
signal 
transduction, 
small GTPase 
mediated 
signal 
transduction 
protein 
transport 
and 
maturation 
c     PM, CS x     
3 Tb927.10.14580 
60S ribosomal 
protein L17, 
putative 
structural 
constituent 
of ribosome 
translation 
ribosome 
biogenesis / 
translation 
c     PM, CS x	       
3 Tb927.5.3800 
glutamine 
hydrolysing (not 
ammonia-
dependent) 
carbomoyl 
phosphate synthase, 
putative 
ATP 
binding, 
argininosuc
cinate 
synthase 
activity, 
carbamoyl-
phosphate 
synthase 
activity, 
catalytic 
activity 
arginine 
biosynthetic 
process, 
glutamine 
metabolic 
process, 
metabolic 
process, 
nitrogen 
compound 
metabolic 
process 
other 
metabolism c       	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# of 
peptides gene ID
1 product description1 
predicted 
GO 
function1 
predicted 
GO process1 
functional 
category 
conser-
vation2 
phospho-
RXXS/T 
identified 
NetPhosK 
1.0 
prediction 
PKA3 
detected in 
plasma 
membrane 
(PM) and/or 
cytoskeleton 
(CS) 
proteomes4 
detected 
in 
flagellar 
prote-
omes 5, 6, 
7, 8 
detected in 
glycosomal 
proteomes 
9, 10, 11 
putative 
involve-
ment in 
Ca2+ 
signaling 
3 Tb927.2.380 
retrotransposon hot 
spot protein 2 
(RHS2), putative 
null null unknown function t       	  	       
3 Tb11.01.4370 hypothetical protein, conserved null null 
unknown 
function k     PM, CS 	  	       
          	     
1 www.tritrypdb.org 
2 www.orthomcl.org 
3 www.cbs.dtu.dk/services/NetPhosK/ 
4 Bridges et al., 2007 
5 Broadhead et al., 2006 
6 Zhou et al., 2010 
7 Oberholzer et al., 2011 
8 Subota et al., 2014 
9 Vertommen et al., 2008 
10 Colasante et al., 2006 
11 Güther et al., 2014 
c: conserved; k: kinetoplastid-specific; t: Trypanosoma-specific; PM: plasma membrane; CS: cytoskeleton  
green: phospho-RXXS*/T* identified; orange: no RXXS/T in primary amino acid sequence 
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Table S2: Kinases identified as putative substrates of T. brucei PKA.  	  
gene ID1 description1 kinase group2 putative dual specificity kinase 
phospho-
RXXS/T 
identified 
NetPhosK 
prediction 
PKA3 
Tb927.10.5140 protein kinase, putative,mitogen-activated protein kinase 2, putative  CMGC no   
Tb927.5.800 casein kinase I, isoform 2  CK yes S186 0,7 
Tb11.01.4230 protein kinase, putative  CMGC/CLK maybe   
Tb11.01.1050 hypothetical protein, conserved  unique maybe   
Tb927.10.13780 glycogen synthase kinase 3  CMGC/GSK yes (but only autophosphorylation at Tyr)   
Tb11.02.5050 protein kinase, putative  other/PEK no   
Tb927.2.2720 protein kinase, putative  unique maybe S492, S1427 -- , 0.88 
 
                                 1 www.tritrypdb.org 
         2 Parsons et al., 2005  
3 www.cbs.dtu.dk/services/NetPhosK 
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Supplemental	  Material	  –	  Chapter	  5	  
Supplemental material – Chapter 5 	  	   	  	  	  
 
 
 
Figure S1: PKA-specificity of global RXXS/T site 
phosphorylation. Western blot analysis of lysates 
of T. brucei wild type (wt) cells and a homozygous 
PKAR deletion mutant (∆pkar/∆pkar) with a 
phospho-specific RXXS*/T* antibody. Cells were 
treated (+) or not (-) with 200 µM PKA-specific 
inhibitor peptide myr-PKI(14-22) for 10 minutes. 
PFR-A/C was used as loading control and detected 
by the monoclonal antibody L13D6 (Kohl et al., 
1999). 	  	  	  	  	  	  	  
 
 
Figure S2: Specificity of the anti-PKAR antibody. A Western blot loaded with lysates from T. 
brucei MiTat 1.2 bloodstream parasites (wt), a homozygous deletion mutant of PKAR (∆pkar/∆pkar) 
and an endogenous rescue with L. donovani PKAR (∆pkar/ /LdPKAR) shows that the serum raised 
against T. brucei PKAR (Tb427tmp.02.2210) cross-reacts with L. donovani PKAR 
(LdBPK_130160.1). PFR-A/C detected by the monoclonal antibody L13D6 (Kohl et al., 1999) was 
used as loading control. The endogenous PKAR of both T. brucei and L. donovani (see Figure 4B) 
comes in two molecular mass variants, suggesting allelic polymorphisms. 
 
 
wt ∆p
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/∆p
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∆p
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/Ld
PK
AR
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PKAR
80
46
kDa
wt ∆pk
ar/∆
pka
r
- + - + 
178
80
58
46
30
25
17
kDa
PFR-A/C
Mmyr-PKI(14-22)
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Supplemental material – Discussion 	  
 
Table S1: T. brucei PKA substrate candidates with known or putative role in motility control. 
 
gene ID1 product description1 
annotated/pre-
dicted GO 
function1 
annotated/ 
predicted GO 
process1 
annotated/ 
predicted 
GO 
component
1 
con-
ser-
vation2 
phospho-
RXXS/T 
identi-
fied 
NetPhosK1.0 
prediction 
PKA3 
flagellar 
prote-
ome 4, 5, 6, 
7 
motility 
phenotype 
upon 
RNAi in 
T. brucei 
motility 
phenotype in 
other flagellated 
eukaryotic cells 
or organisms 1, 5 
other 
remarks 
known 
PKA 
substrate 
in other 
organism 
Tb927.1.2340 alpha tubulin 
GTP binding, 
GTPase 
activity, 
structural 
molecule 
activity 
microtubule-based 
movement, 
microtubule-based 
process, protein 
polymerization 
microtu-
bule, 
protein 
complex 
c             
X 
(Boudreau 
et al., 2009) 
Tb927.1.2330 beta tubulin 
GTP binding, 
GTPase 
activity, 
structural 
molecule 
activity 
microtubule-based 
movement, 
microtubule-based 
process, protein 
polymerization 
microtu-
bule, 
protein 
complex 
c     x       
X (Loza-
Huerta et 
al., 2013) 
Tb11.02.0760 
dynein heavy 
chain, 
putative 
ATP binding, 
ATPase 
activity, 
microtubule 
motor activity, 
nucleoside-
triphosphatase 
activity, 
nucleotide 
binding 
bioluminescence, 
microtubule-based 
movement, 
protein-
chromophore 
linkage 
dynein 
complex c     x   
linked to ciliary 
disease in humans     
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gene ID1 product description1 
annotated/pre-
dicted GO 
function1 
annotated/ 
predicted GO 
process1 
annotated/ 
predicted 
GO 
component
1 
con-
ser-
vation2 
phospho-
RXXS/T 
identi-
fied 
NetPhosK1.0 
prediction 
PKA3 
flagellar 
prote-
ome 4, 5, 6, 
7 
motility 
phenotype 
upon 
RNAi in 
T. brucei 
motility 
phenotype in 
other flagellated 
eukaryotic cells 
or organisms 1, 5 
other 
remarks 
known 
PKA 
substrate 
in other 
organism 
Tb927.3.930 
dynein heavy 
chain, 
putative 
ATP binding, 
ATPase 
activity, 
microtubule 
motor activity, 
nucleoside-
triphosphatase 
activity, 
nucleotide 
binding 
microtubule-based 
movement 
dynein 
complex c     x 
motility 
defect in 
BSF and 
PCF 
(Monnerat 
et al., 2009) 
linked to ciliary 
disease in humans     
Tb11.02.0030 
Cytoplasmic 
dynein 2 
heavy chain 
(DYNC2H1), 
putative,Cyto
plasmic 
dynein 2 
heavy chain 
(DYNC2H2), 
putative 
(DHC1b) 
ATP binding, 
ATPase 
activity, 
microtubule 
motor activity, 
nucleotide 
binding 
microtubule-based 
movement 
dynein 
complex c     x   
linked to ciliary 
disease in humans 
predicted to 
be cytoplas-
mic, but 
observed to 
be localized 
in the basal 
bodies and 
the flagellum 
(TriTryp 
DB user 
comment ID 
24800) 
  
Tb927.10.148
90 
C-terminal 
motor 
kinesin, 
putative 
(TBKIFC1) 
ATP binding, 
microtubule 
motor activity 
intracellular 
protein transport, 
microtubule-based 
movement 
null c     x         
Tb927.10.890 kinesin, putative 
ATP binding, 
microtubule 
motor activity, 
nucleotide 
binding 
microtubule-based 
movement null t     x   
linked to ciliary 
disease in humans     
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gene ID1 product description1 
annotated/pre-
dicted GO 
function1 
annotated/ 
predicted GO 
process1 
annotated/ 
predicted 
GO 
component
1 
con-
ser-
vation2 
phospho-
RXXS/T 
identi-
fied 
NetPhosK1.0 
prediction 
PKA3 
flagellar 
prote-
ome 4, 5, 6, 
7 
motility 
phenotype 
upon 
RNAi in 
T. brucei 
motility 
phenotype in 
other flagellated 
eukaryotic cells 
or organisms 1, 5 
other 
remarks 
known 
PKA 
substrate 
in other 
organism 
Tb927.10.124
90 
kinesin, 
putative 
ATP binding, 
microtubule 
motor activity, 
sequence-
specific DNA 
binding 
microtubule-based 
movement null k               
Tb927.10.117
0 
intraflagellar 
transport 
protein 
IFT172, 
putative 
(IFT172) 
null null null c     x         
Tb11.55.0006 
intraflagellar 
transport 
protein IFT88 
(IFT88) 
null null null c               
Tb11.03.0880 
predicted 
WD40 repeat 
protein 
(PIFTF6) 
null null null c               
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gene ID1 product description1 
annotated/pre-
dicted GO 
function1 
annotated/ 
predicted GO 
process1 
annotated/ 
predicted 
GO 
component
1 
con-
ser-
vation2 
phospho-
RXXS/T 
identi-
fied 
NetPhosK1.0 
prediction 
PKA3 
flagellar 
prote-
ome 4, 5, 6, 
7 
motility 
phenotype 
upon 
RNAi in 
T. brucei 
motility 
phenotype in 
other flagellated 
eukaryotic cells 
or organisms 1, 5 
other 
remarks 
known 
PKA 
substrate 
in other 
organism 
Tb927.10.450 
hypothetical 
protein, 
conserved 
(CMF62) 
null null null c     x 
motility 
defect in 
PCFs upon 
RNAi 
(Baron et 
al., 2007) 
homologous to 
Traf3ip1 of other 
eukaryotes (44% 
identity to human 
Traf3ip1); in C. 
elegans, Danio 
rerio, 
Chlamydomonas 
reinhardtii as well 
as in mammalian 
cells (Kunitomo 
and Iino 2008; Li 
et al., 2008; 
Omori et al., 
2008; Berbari et 
al., 2011) 
Traf3ip1 localizes 
to the cilium and 
is required for 
ciliogenesis  
   
Tb927.3.4290 PFR1 (PFR1) calmodulin binding null 
microtubule
-based 
Flagellum 
k     x 
motility 
defect in 
PCFs upon 
RNAi 
(Bastin et 
al., 1998, 
1999; 
Durand-
Dubief et 
al., 2003) 
      
Tb927.8.6660 
paraflagellar 
rod 
component, 
putative 
(PFC1) 
null null null k 
P-peptide 
identified 
(RRQT 
(T477)) 
0,71 x         
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gene ID1 product description1 
annotated/pre-
dicted GO 
function1 
annotated/ 
predicted GO 
process1 
annotated/ 
predicted 
GO 
component
1 
con-
ser-
vation2 
phospho-
RXXS/T 
identi-
fied 
NetPhosK1.0 
prediction 
PKA3 
flagellar 
prote-
ome 4, 5, 6, 
7 
motility 
phenotype 
upon 
RNAi in 
T. brucei 
motility 
phenotype in 
other flagellated 
eukaryotic cells 
or organisms 1, 5 
other 
remarks 
known 
PKA 
substrate 
in other 
organism 
Tb11.01.0680 
leucine rich 
repeat 
(TbLRRP1) 
null null null k 
P-peptide 
identified 
(RPPS 
(S559); 
RSAS 
(S608); 
RRRS 
(S620)) 
0.74; 0.65; 
0.89 x 
motility 
defect in 
PCFs upon 
RNAi 
(Broadhead 
et al., 2006) 
  
interacts with 
Ran (Brasseur 
et al., 2014); 
Ran identified 
as putative 
PKA 
substrate 
devoid of a 
PKA 
phosphoryla-
tion site; Ran 
is involved in 
ciliary protein 
targeting in 
various 
eukaryotes 
  
Tb927.8.8330 
calpain, 
putative,cys-
teine 
peptidase, 
putative 
calcium-
dependent 
cysteine-type 
endopeptidase 
activity 
proteolysis intracellular k 
P-peptide 
identified 
(RRPS 
(S261)) 
0,81 x 
growth and 
CC 
phenotype, 
lethal in 
BSF 
suggested to 
control cell 
motility in human 
cells (reviewed in 
Wells et al., 2005) 
  X 
Tb927.4.2080 
C2 domain 
containing 
protein 
(CC2D) 
null flagellum assembly null k 
P-peptide 
identified 
(RNNS 
(S488)) 
0,76 x     
human 
protein 
CC2D2A 
with similar 
domain 
organization 
implicated in 
ciliogenesis 
and 
ciliopathies 
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gene ID1 product description1 
annotated/pre-
dicted GO 
function1 
annotated/ 
predicted GO 
process1 
annotated/ 
predicted 
GO 
component
1 
con-
ser-
vation2 
phospho-
RXXS/T 
identi-
fied 
NetPhosK1.0 
prediction 
PKA3 
flagellar 
prote-
ome 4, 5, 6, 
7 
motility 
phenotype 
upon 
RNAi in 
T. brucei 
motility 
phenotype in 
other flagellated 
eukaryotic cells 
or organisms 1, 5 
other 
remarks 
known 
PKA 
substrate 
in other 
organism 
Tb927.5.800 
casein kinase 
I, isoform 2 
(CK1.2) 
ATP binding, 
protein kinase 
activity, protein 
serine/threonine 
kinase activity, 
protein tyrosine 
kinase activity 
protein 
phosphorylation null c 
P-peptide 
identified 
(RYCS 
(S186)) 
0,7 x   
important for 
proper motility in 
Chlamydomonas 
(Gokhale et al., 
2009; Boesger et 
al., 2012) or 
Paramecium 
(Walczak and 
Nelson, 1993) 
    
Tb11.02.4700 14-3-3 protein 
protein domain 
specific binding null null c     x 
motility 
defect in 
PCFs upon 
RNAi 
(Inoue et 
al., 2005) 
regulation of cell 
motility in cancer 
cells (Goc et al., 
2012) 
  X 
 
 
 
1 www.tritrypdb.org 
2 www.orthomcl.org 
3 www.cbs.dtu.dk/services/NetPhosK/ 
4 Broadhead et al., 2006 
5 Zhou et al., 2010  
6 Oberholzer et al., 2011 
7 Subota et al., 2014 
c: conserved; k: kinetoplastid-specific; t: Trypanosoma-specific  
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